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General Abstract 
For the past two decades, the development of protein therapeutics has significantly 
expanded with numerous biopharmaceutical and biosimilar products entering the 
medicine market every year, and even more queuing in the pipeline globally. Biologics 
are very complex molecules and therefore extremely sensitive to minor changes in the 
manufacturing process, which can result in heterogeneity and affect the stability, 
potency and immunogenicity of the final product. Public health organisations, such as 
EMA (European Medicines Agency), require that biological products should be 
extensively tested for their similarity to the original drug (in the case of a biosimilar) as 
well as to products from different batches (batch-to-batch comparison). The issued 
guidelines focus, among other tests, on physicochemical characterisation of these 
molecules. The suggested analytical techniques, however, are only vaguely named in 
the specifications, leaving the final decision to the manufacturers. The present work 
focuses on the use of different combinations of analytical techniques with an aim to 
demonstrate similarity or dissimilarity between two or more samples. The selected 
instrumental techniques are characterised by their simplicity and are able to detect 
structural differences and microheterogeneity of the active ingredient in different 
samples, aggregation, degradation and post-translational modifications (PTMs). Seven 
studies were completed in total, each one to a different extent, and these included 
protein therapeutics such as insulin and monoclonal antibodies. The applied techniques 
served for primary (MS),* secondary (far-UV CD, FT-IR) and tertiary structure (near-
UV CD, fluorescence) comparison of the examined samples. Particle size 
comparability and detection of aggregation was achieved with DLS, and higher-order 
structure comparison with 1D 1H-NMR. Coupling of the techniques with temperature-
dependent measurements enabled further comparison on the thermal stability of the 
samples and provided confidence in the observed (at room temperature) results. The 
acquired empirical experience pointed out the advantages and disadvantages of each 
technique compared to the rest of the techniques, possible solutions to the encountered 
challenges, and the cases that one technique can be used instead of another or as 
complementary to it. Finally, a potential SOP is suggested, advising on which 
                                                      
* MS: mass spectrometry, UV: ultraviolet, CD: circular dichroism, FT-IR: Fourier transform 
infrared, DLS: dynamic light scattering, NMR: nuclear magnetic resonance, SOP: standard 
operating procedure. 
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biophysical techniques should be used depending on the structure of the protein that is 
examined and its formulation. 
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Chapter 1 
Introduction 
The work reported in this thesis focuses on methods for structurally characterising 
proteins used as biopharmaceutical drugs. In order to provide a context for this work 
the focus of this chapter is on the products available on the market and how they have 
been reviewed in the United States and Europe. Protein structure and folding is 
overviewed and a brief description of the theoretical concepts of the applied analytical 
techniques for the structural characterisation of the proteins follows. Finally, the reader 
is introduced to the biotherapeutic proteins examined in this work and the case studies 
that are discussed in the next chapters. 
 
1.1. AN INTRODUCTION TO BIOPHARMACEUTICALS AND 
BIOSIMILARS 
Terminology 
The term biopharmaceuticals or else biotechnological or biological products, was first 
introduced in the 1980s with the advent of recombinant DNA technology and refers to 
proteins, polypeptides and their derivatives that are produced from cell-culture 
expression systems. Unlike small molecules, which have a well-defined structure and 
in their vast majority can be chemically synthesised in large quantities and can be fully 
characterised, the manufacturing of biological products is highly complicated 
involving living cells, and therefore these products are required to be highly purified in 
order to meet safety standards. 
In the late 1990s a new term, biosimilar, was introduced for the description of 
biological products that not only consist of the same active ingredient as the already-
licensed one, but also are comparable with it in terms of structure, biological activity, 
immunogenicity, purity and quantity of the drug substance. In simple terms, a 
biosimilar product is the attempt of a company to “copy” the original biological 
product after the expiration of its patent, resulting in a highly similar product with the 
only differences allowed being those pertaining to their clinically inactive ingredients 
(excipients). Thorough testing of the biosimilar against a reference standard (usually 
the original product, also referred to as the innovator product) is required, including 
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structural and functional characterisation of the new product in order to confirm quality 
and consistency of the active substance and safety of its final formulation. 
History 
The advent of recombinant DNA (rDNA) technology in 1972 and monoclonal antibody 
technology1 in 1975 permitted cloning and expression of proteins and peptides, and 
effectively led to the first genetically engineered insulin three years later. In 1982, the 
pharmaceutical company Eli Lilly & Co. launched the first FDA-approved (Food and 
Drug Administration) biopharmaceutical drug, with recombinant human insulin as the 
active ingredient and under the commercial name Humulin.2 The first FDA-approved 
therapeutic monoclonal antibody followed only four years later from Janssen-Cilag (a 
subsidiary of the Johnson & Johnson pharmaceutical company) under the brand name 
Orthoclone.3 This was a murine monoclonal antibody (muromonab), which acted as an 
immunosuppressant in cases of transplant rejection. 
The advent of biomanufacturing and the following and ongoing achievements 
in biological processes such as cell culture and fermentation technologies, and 
engineering, have further accelerated the drug development process and made 
biological products cost-effective and safer than when extracted from tissue sources. 
An idea of the state of the rapidly changing and constantly increasing 
biopharmaceutical and biosimilar market in October 2016, and the “game of patents” is 
given in the next section. 
1.1.1. Biopharmaceuticals and biosimilars in the market 
Biopharmaceutical medicines have attracted the interest of the scientific community 
for more than three decades, with most of the big pharmaceutical companies expanding 
their Research and Development (R&D) strategies to biotechnology and biologics 
development. Biopharmaceuticals constitute currently the most expensive and 
advanced therapies for serious conditions such as cancer, autoimmune disorders (e.g. 
rheumatoid arthritis), blood-related diseases (e.g. anaemia) and neurodegenerative 
diseases (e.g. multiple sclerosis). Due to their high effectiveness and specificity, these 
drugs are safer and present fewer side effects than conventional therapies, with the 
most striking example that of targeted cancer therapies with monoclonal antibodies 
(mAbs) as opposed to traditional chemotherapy with cytotoxic agents. 
Besides vaccines, the majority of proteins and peptides, oligonucleotides, 
blood-derived products and stem cells come under the umbrella of biologics. Examples 
are given in Table 1.1. They can be classified as follows: 
 20 
 
1. Hematopoietic growth factors: a group of proteins that promote blood cell 
growth and bone marrow proliferation—e.g. erythropoietin, indicated for the 
treatment of anaemia (Epogen, Table 1.1). 
2. Monoclonal Antibodies: antibodies produced by a single line of plasma cells, 
able to bind to specific antigens with various mechanisms of action—e.g. 
trastuzumab, indicated for the treatment of HER2-overexpressing breast and 
gastric cancers (Herceptin, Table 1.1). 
3. Vaccines: biological preparations consisting of immunogenic agents 
(attenuated or inactivated microbes, inactivated toxins or segments of the 
pathogen) and providing active immunisation to a specific disease—e.g. 
pneumococcal conjugate vaccine with diphtheria protein, indicated for 
prevention of pneumonia and invasive disease caused by 13 Streptococcus 
pneumoniae strains (commercially available as Prevnar 13). While vaccines 
are better known for their use in a prophylactic manner, therapeutic vaccines 
also exist, and efforts are currently being made for the expansion of this area, 
with the main interest focused on targeted treatments for cancer, STDs (Sexual 
Transmitted Diseases, e.g. HIV and HPV) and hepatitis C. Sipuleucel-T 
(Provenge) is an example of a therapeutic vaccine with an indication for 
castrate resistant prostate cancer.   
4. Thrombolytic agents: enzymes involved in the dissolution of blood clots—e.g. 
alteplase (tPA, tissue plasminogen activator), indicated for the treatment of 
ischemic stroke, myocardial infarction and pulmonary embolism (Activase). 
5. Interferons: a group of signalling proteins produced by the cells of the immune 
system in response to various pathogens such as viruses or cancer cells—e.g. 
Interferon beta-1a, indicated for the treatment of multiple sclerosis (Avonex, 
Table 1.1). 
6. Hormones: a class of signalling molecules of different chemical structures 
(amines, steroids, peptides, proteins) produced in glands and transported to 
specific organs where they express their regulatory activity—e.g. insulin, 
indicated for improvement of the glycemic control in diabetes mellitus (Lantus, 
Table 1.1).  
7. Blood factors: a group of proteins that causes blood to clot in the coagulation 
cascade—e.g. coagulation factor VIIa, indicated for the treatment of bleeding 
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episodes and perioperative management in individuals with haemophilia 
(NovoSeven). 
 
It is important to note though, that from the above-mentioned biological 
products FDA excludes hormones (e.g. insulin, human growth hormone, glucagon), 
which are therefore considered as drugs and are regulated by the FDC Act (Federal 
Food, Drug and Cosmetic Act), rather than by the PHS Act (Public Health Service Act) 
which includes the rest of the products. Biological products (including biosimilars) 
licensed by FDA under the PHS Act have currently reached the total number of 418 
and are categorised in two separate lists, referred to as the “Purple Book”.4 In the 
CBER (Centre for Biologic Evaluation and Research) list,5 297 products are registered 
as vaccines and blood factors, while the remaining 121 biologics can be found in the 
CDER (Centre for Drug Evaluation and Research) list6 and refer to therapeutic proteins 
and antibodies. Out of these 121 products, only 4 are biosimilars with the first (Zarxio) 
approved in June 2015 and the fourth (Amjevita, Table 1.2) in September 2016,7 while 
3 more have been withdrawn from the market. 
The market in Europe is more complicated, as medicines can be granted 
authorisation following either the centralised or a national procedure. This means that 
EMA is responsible only for medicines that have been approved via the centralised 
authorisation procedure and not for all medicines that are available in Europe. National 
competent authorities of the respective EU Member States are responsible for 
medicines that have been approved via the national procedure.8 EMA counts currently 
259 biological products (holding centralised marketing authorisation) in total since 
1995, with 66 of them registered as vaccines and blood factors, 163 as monoclonal 
antibodies and recombinant proteins (including insulin products), and 23 as biosimilar 
products. The first biosimilar was approved in 2006 (Omnitrope),9 and 2 out of the 23 
biosimilars have been withdrawn from the market. 
The top-20 selling biopharmaceutical products for the year 2015, where the 
focus is on antibodies and recombinant proteins, are shown in Table 1.1. In order to be 
in accord with the FDA’s CDER list of licensed biological products, vaccines (e.g. 
Prevnar), peptides (e.g. Copaxone), glucagon products (e.g. Victoza) and blood factors 
(e.g. NovoSeven) have been excluded from the table even if they held high positions in 
the sales ranking. Insulin products, however, have been included despite the fact that 
FDA does not consider these products as biologics since according to the European 
Medicines Agency (EMA), insulin products are still classified as biological medicinal 
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products and form a separate category from the rest of the biologics.10 Monoclonal 
antibodies are now at the centre of attention for the development of both innovator 
products and biosimilars, as they bring considerable financial benefits to 
pharmaceutical companies besides their substantial benefit to public health. Only for 
the year 2015, 7 out of the top 10 drugs by sales were biologics, with 5 of them being 
monoclonal antibodies.11 
 
Table	  1.1:	   Top-­‐20	  biopharmaceutical	  products	   sales	  based	  on	   revenue	   for	   the	  year	  2015.12	  Vaccines,	  
peptides,	  glucagon	  products	  and	  blood	  factors	  have	  been	  excluded	  from	  the	  list,	  while	  insulin	  products	  
are	  included.	  
 
1.1.2. Patents 
In contrast to the EMA, which has been granting approvals for biosimilars for years, 
FDA’s legislation for such products was only recently established under the BPCI Act 
(Biologics Price Competition and Innovation Act of 2009) adopted by the Affordable 
No.$ Product$Name$ Active$Ingredient$
Main$
Therapeutic$
Indication$
Company$Name$
2015$
Revenue$in$
Billions$
(USD)$
1" Humira" Adalimumab$ Immunology"" AbbVie" 14.01"
2" Enbrel" Etanercept$ Immunology"" Amgen/Pfizer"Inc." 8.70"
3" Remicade" Infliximab$ Immunology"" Johnson&Johnson/Merck"&"Co" 8.36"
4" Rituxan"(US)/"MabThera"(EU)" Rituximab$ Oncology" Roche" 7.12"
5" Lantus" Insulin$Glargine$ Diabetes" Sanofi" 7.03"
6" Avastin" Bevacizumab$ Oncology" Roche" 6.75"
7" Herceptin" Trastuzumab$ Oncology" Roche" 6.60"
8" Neulasta" Pegfilgrastim$ Blood"Related"Disorders" Amgen" 4.72"
9" Lucentis" Ranibizumab$ Ophthalmology" Novartis/Roche" 3.60"
10" NovoLog"(US)/"NovoRapid"(EU)" Insulin$aspart$ Diabetes" Novo"Nordisk" 3.11"
11" Humalog" Insulin$lispro$ Diabetes" Eli"Lilly" 2.84"
12" Levemir" Insulin$detemir$ Diabetes" Novo"Nordisk" 2.75"
13" Avonex" Interferon$betaM1a$
Neuroscience/"
Mental"Health" Biogen" 2.63"
14" Soliris" Eculizumab$
Blood"Related"
Disorders"
Alexion"
Pharmaceuticals" 2.59"
15" Stelara" Ustekinumab$ Immunology" Johnson&Johnson" 2.47"
16" Aranesp" Darbepoetin$Alfa$ Blood"Related"Disorders" Amgen" 1.95"
17" Tysabri" Natalizumab$ Neuroscience/"Mental"Health" Biogen" 1.89"
18" Orencia" Abatacept$ Immunology"" BristolZMyers"Squibb" 1.88"
19" Epogen"(US)" Epoetin$Alfa$ Blood"Related"Disorders" Amgen" 1.86"
20" Perjeta" Pertuzumab$ Oncology" Roche" 1.46"
"
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Care Act, which was enacted in 2010 (signed by President Obama). Though some rules 
are yet to be set, the new law clearly states that exclusivity rights for a new drug run 
for 12 years counting from the approval date. Patents, however, are issued by USPTO 
(United States Patent and Trademark Office) with a totally separate procedure, and at 
any time during the development of a drug or after approval. As a general rule, patents 
last for 20 years from the day that the application is filed. This regulation was 
specifically amended in order to avoid cases of drugs with overextended patents such 
as Amgen’s Enbrel, which is protected until 2028, namely for 30 years since its 
approval date (Table 1.2). Despite the fact that Enbrel’s patent was filed in 1995, it was 
only granted in 2011 due to delays in the Patent Office. This incident has so far worked 
in favour of Amgen, providing Enbrel 17 more years without competition counting 
from the date that the patent was issued rather than filed, since the specific patent 
followed the regulations of the old law, which was applicable when the patent was 
initially filed.13,14 
However, this is not an obstacle for competitors, as they have the right to 
challenge the validity of patents. Sandoz’s Erelzi, which is an Enbrel biosimilar (Table 
1.2), gained FDA-approval in August 2016, before the official expiration of Enbrel’s 
patents.15 Launch in the market, though, can be delayed for at least six months from the 
approval date—according to US courts decisions—and up to a few years until the 
protecting patents are resolved, while at the same time the two companies have 
probably reached a confidential agreement.16 Another case is that of Celltrion’s 
Inflectra against its reference product J&J’s Remicade (Table 1.2). Inflectra was the 
first monoclonal antibody biosimilar to get EMA-approval in 2013 and FDA-approval 
in April 2016, before Remicade’s patent expiration. In the US market, one of 
Remicade’s patents17 was invalidated (August 2016) by a court decision, however, 
launching Inflectra would be a risk for Celltrion as another Remicade patent18 case has 
yet to be resolved.19,20 
The above cases are examples of how a biosimilar’s introduction to the market 
can be delayed after its actual approval. The reasons may vary from court regulations 
that protect the reference product’s (innovator’s) rights to publication of new extended 
patents, covering e.g. formulations of the drug, manufacturing methods or additional 
indications and usages or even to hesitation of doctors and patients to switch to a 
therapy with a biosimilar product, especially when they have already seen 
improvement following a therapy with the original product. From the scientific point of 
view, the required tests and procedures might be enough to prove that a biosimilar is 
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highly similar to the innovator product, however, it is always the case that the products 
are not absolutely identical which affects public opinion as to their use. 
Despite the vague aspects of the currently available guidelines for 
demonstrating biosimilarity (see Section 1.1.4), the risk of losses due to reimbursement 
of the originator company and the inevitable delays in biosimilar selling, many 
companies are specialised in developing biosimilars and invest hundreds of millions of 
dollars and 7 to 8 years in R&D. Emerging markets, such as that of India, are ideal for 
debuting a biosimilar as a low cost alternative, monitoring the product and collecting 
data with an ultimate goal of entering larger and more profitable markets, such that of 
the U.S.21 For each reference product, tens of biosimilar medicines are in different 
stages of development or phases of clinical trials or even approved in some countries. 
The major advantage of introducing more than one product with the same active 
ingredient and indications in a market is the increased competition and therefore lower 
prices. Cheaper therapies with a reduced price of 30% on average,22 but without 
discounts in safety and effectiveness compared to the original product, will be 
available and accessible to a wider public, and health care systems will benefit from 
the subsequent savings. Biosimilar developers claim that it is their duty to bring 
biosimilars, manufactured under high quality standards and GMPs (Good 
Manufacturing Practices), to patients as quickly as possible. 
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Table	   1.2:	   Biopharmaceutical	   products	   from	  Table	   1.1	   for	  which	  biosimilars	   in	   Europe	  or	   the	  United	  
States	  have	  been	  approved	  or	  withdrawals	  of	  approved	  products	  have	  been	  recorded.	  Approval	  dates	  
and	  patent	  expiration	  dates	  are	  given,	  and	  the	  reference	  medicine	  where	  available.	  
 
1 Information about approval dates, approved biosimilars and withdrawn products were extracted from the 
EMA and FDA drug databases by manual search of the active ingredient. The links for the search pages 
are following: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01a
c058001d124 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search_Drug_Name  
2 Patent expiration dates were taken from23 and GABI Journal (Generics and Biosimilars Initiative 
Journal)24 and updated by press publications (e.g. Remicade). 
3 Reference medicines were individually extracted from each product’s EPAR (European Public 
Assessment Reports) from the EMA website. 
 
1.1.3. Withdrawals, refusals and discontinuations. What went wrong? 
Regarding cases where approved products were withdrawn from the market, three of 
the withdrawals mentioned in Table 1.2 (Trudexa, Nespo, Neupopeg) were due to 
commercial reasons, with Trudexa (adalimumab) not even making it to the market of 
Product(
Name(
Active(
Ingredient(
Date(
approved1(
Patent(
Expiration(
Date2(
Approved(
Biosimilars1(
Reference(
Medicine3(
Withdrawals(
(approvedD
withdrawn(
date)1(
Humira' Adalimumab( 2002'(US),'2003'(EU)'
2016'(US),'
2018'(EU)'
Amjevita'
(US,'2016)' Humira'
Trudexa'
(EU,'2003<
2007)'
Enbrel' Etanercept( 1998'(US),'2000'(EU)'
2028'(US),'
2015'(EU)'
Erelzi'
(US,'2016),'
Benepali'
(EU,'2016)'
Enbrel' '
Remicade' Infliximab( 1998'(US),'1999'(EU)'
2018'(US,'
invalidated'
in'2016),'
2015'(EU)'
Inflectra'
(US,'2016/'
EU,'2013),'
Remsima'
(EU,'2013),'
Flixabi'
(EU,'2016)'
Remicade' '
Lantus'
Insulin(
Glargine(
2000'
(US/EU)'
2014'(US),'
2014'(EU)'
Basalgar'
(US,'2015),'
Abasalgar'
(EU,'2014)'
Lantus' '
Neulasta' Pegfilgrastim( 2002'(US/EU)'
2015'(US),'
2017'(EU)' ' '
Neupopeg'
(EU,'2002<
2008)'
Aranesp' Darbepoetin(Alfa(
2001'
(US/EU)'
2024'(US),'
2016'(EU)' ' '
Nespo'
(EU,'2001<
2008)'
Tysabri' Natalizumab( 2004'(US),'2006'(EU)'
2020'(US),'
2023'(EU'
potentially)'
' in<house'
Natalizumab'
Elan'Pharma'
(EU,'2008'
refused)'
Epogen'
(US)' Epoetin(alfa( 1989'(US)' 2013'(US)'
Abseamed,'
Binocrit,'
Epoetin'Alfa'
Hexal'
(EU,'2007)'
Eprex/'
Erypo'(EU)'
Eprex'
(US,'1999'
discontinued)'
'
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any member state in the European Economic Area (EEA). Namely, the marketing 
authorisation holder (MAH) has voluntarily decided to withdraw the under additional 
monitoring*25 product for various reasons that presented it as unprofitable, and are 
explained below. Financial reasons is a quite common case of a withdrawal and even 
more common than “forced” withdrawal due to lack of efficacy or safety reasons, yet it 
does not attract public attention as much as the latter. 
Trudexa, after several post-authorisation procedures, was indicated for the 
treatment of rheumatoid arthritis. EMA requested additional monitoring and further 
studies on the product due to uncertainties about the effects of long-term usage. 
Similarly, Nespo (darbepoetin alfa, Table 1.2) a medicine indicated for the treatment of 
anaemia, had to go through additional measures regarding concerns about its safety, 
which were related to unexplained excess mortality in cancer patients. In both cases, 
the provided data from the clinical trials were approved by EMA with a few 
modifications (e.g. in the wording of the package leaflet). For Trudexa, follow-up 
programmes were requested to continue as some of the data were lacking in sampling 
or in statistical significance, while Nespo was concluded to be favourable (with a 
positive benefit/risk profile) for the indicated treatments that were updated in the 
package leaflet to reflect a warning in the case of cancer patients. 
Despite the fact that the data from the clinical trials for both of the above-
mentioned products as well as for Neupopeg (pegfilgrastim, Table 1.2) were good 
enough to provide them with extensions of their marketing authorisations by EMA, the 
actual reasons why the companies (Abbott responsible for Trudexa and Dompé Biotec 
responsible for Neupopeg and Nespo) decided eventually to withdraw the medicines 
still remain unclear. In fact, all three of the here-mentioned withdrawn products 
(Trudexa, Neupopeg and Nespo) received their EMA-approval on very close dates if 
not on the exact same day as their respective (of the same active substances) and 
current “blockbusters” with the tradenames Humira, Neulasta and Aranesp (Table 1.2). 
What made the last three products “blockbusters” is the fact that these were also 
approved by FDA (as well as approved in Europe), while Trudexa, Neupopeg and 
Nespo received approval only in Europe. In all three cases (Trudexa/Humira, 
Neupopeg/Neulasta, Nespo/Aranesp), the post-marketing revisions of the products 
requested by the EMA were taking place in parallel for the eventually withdrawn 
product and its “blockbuster” counterpart, raising the same concerns and questions 
                                                      
* Medicines authorised in the European Union (EU) that are being monitored particularly 
closely by regulatory authorities. 
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about their safety.26-31 It seems possible therefore, that the “European” product could 
not afford to compete with the one that had the extra advantage of being launched in 
the larger U.S. market, or to gather sufficient data from the clinical trials. Having 
estimated wrongly the market’s needs, the companies which were responsible for the 
European versions of the medicines decided to withdraw their marketing authorisations, 
giving place to monopolies. Worth mentioning is also the fact that Dompé Biotec 
(responsible for Neupopeg and Nespo) and Amgen (responsible for Neulasta and 
Aranesp) became co-marketing partners in 2007, just one year before the respective 
withdrawals, while Abbvie (responsible for Humira) originated as a spin-off company 
of Abbott (responsible for Trudexa) in 2013. 
A different case of withdrawal is that of Bexxar (tositumomab Iodine 131) in 
the U.S. market. The answer in that case is probably more complicated than a simple 
reason, and seems to be the outcome of several incidents and coincidences, which were 
extensively followed by Timmerman32 and Prasad.33 In summary, Bexxar was a novel 
radiotherapeutic antibody that received FDA-approval in 2003 and was indicated for 
the treatment of non-Hodgkin’s lymphoma, where the disease was resistant to the 
standard therapy with rituximab and chemotherapy. Bexxar was never indicated as a 
first-line treatment, as its safety and efficacy after long-term usage had not been 
established. In the same way as for the above-mentioned cases, the requested post-
authorisation studies (by FDA) got approved but the data acquired were not of 
statistical significance due to the limited number of the enrolled patients. This resulted 
from the fact that physicians were used to prescribing the already-tested rituximab and 
chemotherapy as a first choice therapy, rather than referring the patients to a radiation 
oncologist expert who could handle the new medicine. Even if Bexxar seemed to be a 
promising drug, the available data did not show a clear advantage over the pre-existing 
therapy (e.g. improvement in response rate or survival time), which in combination 
with the time-consuming clinical trials gave ground for the establishment of the 
standard therapy and the development of more advanced medicines such as ADCs 
(Antibody Drug Conjugates) which are mAbs attached to toxins rather than being 
radiolabeled. GlaxoSmithKline saw a major reduction in Bexxar’s sales after 2006 and 
decided to withdraw the medicine in 2014. 
Refused products as recommended by EMA, are those that have been refused 
marketing authorisation due to safety or efficacy reasons, and Natalizumab Elan 
Pharma (Table 1.2) is an example. In 2004, the company Elan Pharma submitted two 
separate applications for two products with the same active ingredient (natalizumab): 
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Natalizumab Elan Pharma was intended for the treatment of Crohn’s disease when 
treatment with corticosteroids and immunosuppressant drugs was insufficient, and 
Tysabri was indicated for the treatment of multiple sclerosis. While the first was 
refused marketing authorisation (2008)34 due to insufficient evidence of effectiveness 
and safety concerns about the risk of serious infections (such as brain infection), for the 
second the benefit to risk ratio was favourable for the suggested indication and it was 
approved by EMA (2006) even if it raised the same concerns about serious infections. 
Biogen purchased the MAH rights for Tysabri in 2013 with a variable per cent return 
to Elan, depending on the annual sales.35 
According to FDA, products that have been withdrawn from the market for 
reasons other than safety or efficacy (voluntarily withdrawn according to EMA), 
approved products that have never been marketed or have been discontinued from 
marketing, and products that are for military use or for export only, are all named 
discontinued products. Eprex (epoetin alfa, Table 1.2) is one of the most important 
cases and has concerned not only the manufacturing company (J&J), but also academic 
research and national regulatory authorities that investigated different aspects of the 
drug’s safety in the late 1990s to early 2000s. Eprex was the first medicine of the ESA 
class (erythropoiesis-stimulating agent) to receive EMA-approval in 1988 with the 
main indication being the treatment of anaemia due to chronic kidney disease (CKD). 
Epoetin alfa became available in the U.S. in 1989 under the tradenames Epogen (by 
Amgen, Table 1.2) and Procrit (by J&J), while Eprex got FDA-approval in 1999 but 
only for use outside the U.S. 
In 1998, the European authorities requested a change in one of the excipients 
in Eprex’s formulation, which was substitution of HSA (human serum albumin) with 
the stabiliser Tween 80, in the fear that HSA could potentially transmit Creutzfeldt-
Jakob disease (“mad cow” disease) to Europe. Since then, the reported incidents to J&J 
of erythropoietin antibody-mediated PRCA (pure red cell aplasia) in patients with 
chronic renal failure (CRF) who had received Eprex subcutaneously, had significantly 
increased and seemed to be related mostly to Eprex than to other medicines of the same 
class.36 In 2002 the unexpected excess mortality forced the company to impose 
intravenous administration to patients with CRF and ensure that sufficient attention is 
given to storage, handling and shipping under refrigerating conditions (the “cold 
chain”).37 In 2003, it was suspected that the reason for the increased immunogenicity 
of the product and PRCA was the release of leachates due to interaction of Tween 80 
with the stoppers used in the pre-filled syringes, and as a result new rubber stoppers 
 29 
(coated) were manufactured.38 After this modification, the cases of PRCA were 
reduced back to the previously reported numbers of the well-tested formulation with 
HSA as a stabiliser. 
Concerns about the ESA class, though, remained and FDA published a 
reassessment report of the risks of ESAs for the treatment of anaemia in cancer patients 
in 2007.39 The data were insufficient to draw a clear conclusion on the harmful effects 
on survival in patients, and regular reassessments were decided to continue. In order to 
alert patients to the risks, FDA authorities proceeded in adding the “black box” 
warning in the package leaflet, which is the strongest label warning, underscoring the 
risk of blood clots, stroke, heart attack, tumour promotion and death. In addition, the 
prescription of ESAs was restricted under the risk evaluation and mitigation strategy 
(REMS) in 2010, which required that physicians should get additional training in order 
to assess high-risk users and negative side effects. 
1.1.4. The importance of Quality Control (QC) in the development of 
biopharmaceuticals and the ICH guidelines 
All here-mentioned cases of withdrawals remind us of the importance of clinical trials 
in establishing the safety and efficacy of a medicinal product. In order to assess any 
side effects, effects of long-term usage or the impact of a modification in the 
formulation or the administration method, sufficient data should be collected, and for 
that to happen a few years of post-marketing experience are necessary. Clinical trials 
(Phases I−III) and post-marketing studies (Phase IV) have the last word and are the 
most time-consuming “tests” for a medicine, with around 2% of the drugs that enter 
human clinical trials becoming officially approved medicines. Close 
pharmacovigilance control is of utmost significance in that stage, ensuring that the 
same product is used throughout the progress of a therapy, and no switching between 
products is taking place unless these have been evaluated as interchangeable. As a 
general rule, newly-authorised biological or biosimilar medicines are indicated for 
fewer or even different treatments than other authorised products with the same active 
ingredient or reference products, and therefore cannot substitute each other. 
More specifically, Eprex’s case is a striking example of how immunogenicity 
can increase with the slightest modification in the formulation of a product, the 
administration method or the used devices. Biological products are very complex 
molecules and therefore extremely sensitive to any kind of changes, from the 
expression and purification process to formulation and packaging, handling and storage 
conditions, and all of them can play a role in decreasing the stability of the final 
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product. As a consequence, the product becomes more susceptible to stress conditions, 
which could facilitate or accelerate denaturation of the protein or formation of 
aggregates, which in turn can increase immunogenicity and adverse effects. 
Considering these challenges and in order to develop a strategy for predicting and 
reducing immunogenicity of therapeutic proteins, especially when repeated 
administration is required, EMA’s CHMP (committee for medicinal products for 
human use) issued guidelines (2005)40 on how to characterise a proposed biological 
medicinal product and how to demonstrate similarity with the respective reference 
product. Since then, revised versions have been issued, as well as guidelines specific to 
each class of biosimilar products. 
The current specifications as regulated by EMA (ICH Q6B, international 
council on harmonisation)41 focus on determination of physicochemical properties, 
biological activity and purity of the biological product, naming a series of test 
procedures that should be fulfilled, but only vaguely mentioning the required analytical 
techniques. Data should be collected for different batches and in several stages of the 
development process (e.g. during preclinical and/or clinical studies, data for 
demonstration of manufacturing consistency, stability studies), aiming at confirming 
the quality of the product rather than fully characterising it. It is up to manufacturers, 
therefore, to decide on the most suitable techniques that would provide scientific data 
sufficient to support a positive safety and efficacy profile. Subtle differences between 
the biosimilar and the reference product, between biosimilars from different 
manufacturers or between different manufacturing processes are very likely to occur, 
however, the level of variance can be acceptable if cutting-edge analytical, 
manufacturing, clinical and regulatory procedures are adopted. Even though experience 
from the above-mentioned examples has shown that some adverse effects might be 
apparent only during post-authorisation studies and after long-term usage of the 
medicine, quality control and more specifically physicochemical characterisation, 
which is the aim of the present study, can provide a certain amount of confidence and 
filter out the majority of these cases, that otherwise would have had much more serious 
effects. 
Analytical techniques that are reported in this work for the physicochemical 
characterisation of purified proteins or formulated products, are able to detect 
structural differences and microheterogeneity of the active ingredient in different 
samples (batch-to-batch comparison or compared to the reference product), 
aggregation, degradation (e.g. deamidation, oxidation) and post-translational 
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modifications (e.g. glycosylation profile), all of which have been previously blamed in 
the literature for increasing immunogenicity.42 More details on the techniques used and 
the cases that were investigated in this study are given below (Sections 1.3 and 1.4), 
following a brief introduction on protein structure and folding (Section 1.2). 
 
1.2. PROTEIN STRUCTURE AND FOLDING 
A protein’s native structure usually refers to the acquired conformation of the protein 
following correct folding, which is a fundamental requirement for its function and 
stability. The three-dimensional atomic structure of a protein is primarily determined 
by its amino acid sequence. In order for a protein to fold into its native structure, 
essentially the thermodynamically stable structure, all types of intermolecular forces—
covalent and non-covalent—play a role, with the most important of these being 
hydrophobic interactions and hydrogen-bonds. In the early stages of protein folding, 
non-polar amino acids are driven away from water and towards the interior of the 
protein (hydrophobic collapse), while more polar residues are exposed to the aqueous 
environment of the solvent. The side chains of the amino acids are the reason that the 
folding of one protein differs from another and Van der Waals interactions have a large 
contribution during this stage, resulting in tight packing of the protein. In the next stage, 
hydrogen-bonds among backbone amides and carbonyl groups are formed, resulting in 
more compact helical or sheet configurations, which stabilise the secondary structure 
of the protein. The formation of disulfide bridges results in further stability of the 
secondary structure, while the tertiary structure depends mainly on interactions among 
the side chains and finalises the three-dimensional structure of the protein. 
 Since folding is a transition from disorder to order, the occurring 
conformational changes aim at the most energetically minimised structure of the 
protein. The fact, however, that proteins have funnel-shaped energy landscapes, 
namely many high- and few low-energy states, renders protein folding a very 
complicated process to predict or simulate. A funnel describes the conformational 
heterogeneity among the non-native states of a protein, namely the multiple folding 
routes, which also depend on the used conditions (such as solvent, pH and 
glycosylation), as well as the chain entropy of a protein, which increases as the 
structure becomes less stable.43 The balance between the chain entropy and the forces 
of folding leads to denaturation of the protein, which is favoured under progressively 
altered conditions such as high temperatures (thermal denaturation) due to the presence 
of many high- as opposed to fewer low-energy states. During thermal denaturation (i.e. 
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in protein stability studies), the melting temperature (Tm) of the protein is defined as 
the midpoint of the unfolding transition, where the free energy of folding becomes zero, 
while above this temperature the unfolded protein “occupies” a high-energy state. 
Thermal denaturation is often irreversible as it can lead to non-native folds or trapped 
intermediate structures along the folding pathway (local minima in the energy funnel), 
and also due to aggregation of the heat-unfolded polypeptide (see Sections 3.5.1 and 
4.7.2). In many cases misfolding of the protein at high temperature can lead to 
formation of β-sheet rich fibrils that resemble the structure of natural amyloid (see 
Section 2.6). 
 
1.3. USED TECHNIQUES AND COMPLEMENTARITY 
The main goal of this work was to establish the extent to which different techniques 
could be used to evaluate rapidly whether or not different samples had the same 
structure. The selected instrumental techniques are characterised by their simplicity, 
relatively low time consumption, ease of sample preparation, and because they provide 
different and complementary information. 
Mass Spectrometry (MS) is an established technique and most commonly used 
for structural confirmation and characterisation of biopharmaceuticals, covering a wide 
range of information necessary for lot release purposes. Giving answers to fundamental 
questions, such as solving the primary structure, looking into post-translational 
modifications (carbohydrate structure and position, sulfhydryl groups and disulfide 
bridges etc.) and degradation products (e.g. oxidation, deamidation), mass 
spectrometry is the technique of choice for companies offering protein characterisation 
services. Although very small quantities of sample are sufficient for MS analysis, as a 
technique it is more time consuming than the rest (see below) and usually requires 
additional steps in sample preparation (denaturation, reduction, digestion—as 
discussed in Chapter 3), which are moreover irreversibly destructive for the protein. 
Thus, the use of complementary techniques is essential in order to determine 
the spectroscopic profile and examine the higher-order structure of a product. Circular 
dichroism (CD) spectroscopy is the simplest way to estimate the secondary structure of 
proteins in solution (using far-UV data from 260 nm to 190 nm or lower) and to 
acquire a tertiary structure spectroscopic pattern (using near-UV data). Dynamic light 
scattering (DLS) is probably the simplest way to estimate protein size and to detect any 
aggregates or multimers in the intact sample. Nuclear magnetic resonance (NMR) 
spectroscopy of proteins is commonly used to give atomic resolution structures; 
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however, in this comparability work easily accessible 1D 1H NMR was chosen for its 
ability to probe variations in atomic environments and folding of the protein. 
Fluorescence spectroscopy can quickly show any differences in the environment of the 
fluorescent residues. Fourier-transform infrared spectroscopy (FT-IR) is mainly used 
for comparing secondary structures in a qualitative manner and a tentative trial to 
quantitate the results was attempted (discussed in Sections 2.6 and 4.6.3). Ultraviolet-
visible spectroscopy (UV-Vis) is usually used for determination of the extinction 
coefficient; here, it was used for estimating the concentration of a protein based on its 
known extinction coefficient. Finally in the case of insulin (Chapter 2), molecular 
dynamics (MD) simulations complemented these instrumental techniques, by giving 
indications of how structures can change with temperature. As with NMR, MD was 
simply used as an indicator of the effect of heating the protein and not in a 
sophisticated way. 
1.3.1. Mass spectrometry (MS) 
The basic principle of a mass spectrometer is as follows: the sample inlet transfers the 
sample to the mass spectrometer and directs it to the ion source. In the ion source, the 
sample molecules are transformed into gas phase ions, which are accelerated by an 
electromagnetic field and separated by the mass analyser depending on their mass-to-
charge ratio (m/z). The signal of the ions that reach the detector is recorded and 
processed by the data system, usually a PC, which produces the mass spectrum 
(number of ions detected as a function of their m/z ratio). Often, the mass spectrometer 
is connected to a chromatograph (gas or liquid) in order to facilitate separation of 
complex mixtures and, subsequently, determination of the individual mass spectrum of 
each eluted substance. 
Mass spectrometry became a very popular technique for the study of high 
molecular weight biomolecules in the mid-1980s, with the advent of matrix assisted 
laser desorption ionisation (MALDI), which was invented by Hillenkamp et al.,44,45 
and electrospray ionisation (ESI),46 which was developed by John Fenn. Tanaka, who 
further developed MALDI, and Fenn were jointly awarded one half of the Nobel Prize 
in Chemistry in 2002.47 A description of ESI follows, as this method was used in the 
present work for the ionisation of the produced peptides. ESI is a soft ionisation 
method, capable of generating multiple charged ions of intact protein molecules48 with 
very little fragmentation. In brief, the sample (analyte dissolved in volatile 
buffer/solvent) is sprayed through a high-voltage potential capillary into the heated 
ionisation chamber (close to atmospheric pressure). The details of the mechanism for 
 34 
going from solution to ions are still debated, but for large molecules such as proteins, it 
can be thought of as follows. The resulting charged droplets are subjected to a drying 
gas (usually nitrogen), which progressively evaporates the solvent (Figure 1.1, left). As 
the amount of solvent decreases, the charge density of each drop increases and the 
repulsive forces lead to further dissociation into smaller droplets. Complete 
evaporation of the solvent leaves sample ions in the gas phase, bearing a single or 
multiple charges, depending on molecular size and other parameters. The charges are 
often provided by protons, as proteins are usually analysed with the ESI-MS analyser 
in the positive ion mode, with protonation of different sites of the protein or the peptide 
being the reason of the multiple charges. As mentioned above, the sample ions are 
accelerated by an electric field and directed into the mass analyser in order to get 
separated and detected. 
Various mass analysers are available, however, here only the principal 
operations of the time-of-flight (TOF) and the quadrupole analysers are briefly 
explained, since these types were used in the present work. The TOF analyser 
measures the time that ions of different masses need until they hit the detector. 
Effectively this is assuming that all ions are produced at the same time and have the 
same kinetic energy. Therefore light ions will arrive first and heavier ions will follow. 
In order to increase the resolution of this analyser and correct for the slightly different 
kinetic energies, an ion reflector is often used, namely an electric field which acts as a 
mirror by reversing the route of the ions towards the ion source and allowing for longer 
flight times (Figure 1.1, top right). 
The quadrupole mass analyser works as a “mass filter” using a dynamic 
electric field, generated by applying a direct-current voltage (DC) and a radiofrequency 
(RF) to four solid rods with parallel arrangement to the direction of the ion beam. 
Depending on the ratio RF:DC, ions acquire an oscillation in this electrostatic field and 
those with a specific m/z range travel through the device following a stable trajectory 
and reach the detector, while the rest of the ions undergo an unstable oscillation and 
are lost prior to detection (Figure 1.1, bottom right). 
A triple quadrupole tandem mass analyser consists of three quadrupole devices 
arranged in a row (TQ-S), facilitating MS/MS experiments to be carried out. The first 
quadrupole transmits ions of certain m/z value (precursor or parent ions), determined 
by the operator. The second device is used as a collision cell, where fragmentation of 
the parent ions occurs due to their increased internal energy, typically yielding b- and 
y- ions (described below). All ions (parent and fragment) are then transmitted into the 
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third quadrupole, which is scanned to obtain a fragment ion spectrum. Triple 
quadrupole mass spectrometers are necessary in applications that require quantitation 
of both small molecules and biological analytes (see Section 3.3.2). 
 
 
Figure	   1.1:	   Schematic	   representation	   of	   the	   basic	   principle	   of	   a	  mass	   spectrometer	  with	   ESI	   sample	  
introduction.	  Left:	  the	  sample	  is	  sprayed	  through	  a	  capillary	  into	  a	  heated	  chamber.	  Once	  the	  solvent	  
evaporates	  from	  the	  droplets,	  the	  ions	  are	  accelerated	  by	  an	  electromagnetic	  field	  and	  directed	  to	  the	  
mass	   analyser	   for	   separation.	   Top	   right:	   a	   TOF	   analyser	   is	   shown	   with	   a	   reflector.	   Bottom	   right:	   a	  
quadrupole	  analyser	  is	  depicted.	  
A Q-TOF mass spectrometer is a hybrid instrument, consisting of a quadrupole 
and a time-of-flight analyser. It is a very common configuration as it provides data of 
better quality for the time and expense of instrumentation. The front-end (quadrupole) 
is used for selecting the precursor ions, the following collision cell (using only RF) 
generates the fragments, which are then analysed by the TOF section with a reflector, 
offering high-resolution. The detector consists of a counter that produces a current 
proportional to the number of ions that strike it. Since only a few ions make it to the 
detector, electron multiplier circuits are normally used, which essentially produce two 
electrons every time an ion strikes the electron multiplier surface. A series of collisions 
occur all the way until the end of the detector, resulting in a signal amplification of 2n 
(n is number of collisions). The recorder, eventually, produces the mass spectrum, 
which is stored in a computer. 
Fragment ions of biological molecules, and more specifically in proteins, 
usually result from cleavage of a single covalent bond along the backbone. Depending 
on the type of the bond cleaved and whether the fragment ion contains the N- or C-
terminal portion of the peptide, the ion is classified as a-, b-, c- or x-, y-, z-type 
respectively (Figure 1.2). Fragment ion peaks are often found in the mass spectrum of 
the parent ion of the peptide, due to low energy fragmentation, and aid determination 
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of the amino acid sequence of the peptide. In tandem mass spectrometry ion 
dissociation is carried out following isolation of the ion of interest, which is subjected 
to collisional activation (as described above for TQ-S), allowing for the parent-to-
fragment ion transition to be followed. 
 
 
Figure	   1.2:	   Fragment	   ions	   generated	   in	   proteins.	   Depending	   on	   the	   bond	   of	   the	   backbone	   that	   is	  
cleaved	  and	  whether	  the	  resulting	  fragment	  ion	  contains	  the	  N-­‐	  or	  the	  C-­‐terminus	  of	  the	  peptide,	  the	  
ions	   are	   classified	   as	   a-­‐,	   b-­‐,	   c-­‐	   or	   x-­‐,	   y-­‐,	   z-­‐type	   respectively.	   The	   peptide	   structure	   was	   sketched	   in	  
chemspider.com	  (http://www.chemspider.com/StructureSearch.aspx)	  
Biopharmaceutical products are often glycosylated proteins (e.g. monoclonal 
antibodies), and glycosylation is one of the major sources of heterogeneity in such 
molecules, as well as potential immunogenicity of the product (explained in more 
detail in Chapter 3). Determination of the primary structure of the protein (amino acid 
sequence) and identification of the attached glycans (structure and position) are 
therefore among the most fundamental requirements in the ICH guidelines. For protein 
sequencing, the bottom-up approach is usually used, during which the protein is 
enzymatically cleaved, the resulting peptides are separated by liquid chromatography 
(LC) and subsequently analysed by MS and/or MS/MS methods, allowing for great 
sequence coverage in a single experiment. At the same time, structural analysis of the 
carbohydrate moieties of a glycoprotein, and localisation of the glycosylation sites is 
simplified in electron-based ionisation techniques, which most often cleave the peptide 
backbone leaving the carbohydrate chains intact.49 
1.3.2. Absorption spectroscopy 
Ultraviolet-Visible spectroscopy (UV-Vis) 
Electronic excitations 
Light is a rapidly oscillating electromagnetic field that can be described either as a 
wave or a photon. Molecules respond to the interaction with light by absorbing certain 
amounts of electromagnetic radiation and allowing the rest of the light (that is not 
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absorbed) to be transmitted through them, or by scattering light (discussed in Section 
1.3.4). The absorbed energy, in turn, results in transitions of the molecule’s electrons to 
various energy levels of an excited state, while the subsequent return of the electrons to 
the ground state results in the release of this energy in different forms (heat generation, 
fluorescence, etc.). These phenomena, namely the absorbance of light, the emitted 
energy as well as the light that is scattered, are exploited by different spectroscopic 
techniques, such as UV-Vis absorbance (ultraviolet-visible), CD (circular dichroism), 
FT-IR (Fourier transform infrared), NMR (nuclear magnetic resonance), fluorescence 
and DLS (dynamic light scattering), providing information on the analysed molecules 
and more specifically on the conformation and folding of biological macromolecules 
such as proteins. 
To a reasonable approximation the different levels of energy result from the 
formation of different chemical bonds. The paired electrons of a bond occupy the low 
energy bonding orbitals (σ or π), any unshared electrons occupy the nonbonding 
orbital (n), while the antibonding orbitals (π* and σ*), at higher energy, are empty. As 
a result, molecules usually exist in a low energy state (ground state) with their 
electrons located in bonding and nonbonding orbitals, while incident light of suitable 
frequency can cause transition of the molecule to a temporary state of higher energy 
(excited state) as its electrons ascend to the antibonding orbitals (Figure 1.3). The 
relation between the absorbed energy and the frequency (or wavelength) of the incident 
light is described by Planck’s equation: 
 𝐸 = ℎ𝑣 = !!!!  (1.1) 
 
where ℎ is the Planck constant (6.626 × 10−34 J s−1), 𝑣 is the frequency (s−1), 𝑐! is the 
speed of light (3 × 108 m s−1) and 𝜆 is the wavelength (m). 
The most frequent transitions are those that take place from the highest 
occupied molecular orbital (HOMO) to the lowest unoccupied molecular orbital 
(LUMO). In the case of protein molecules, the observed (accessible) absorbance results 
from the π to π* (peptide backbone and aromatic side chains) and n to π* (peptide 
backbone) transitions (Figure 1.3), as discussed below in the UV-Vis and CD sections. 
It is important to mention that the UV absorption occurs over a wide range of 
wavelengths, as each electronic state consists of a large number of vibrational and 
rotational modes, which are energetically very close to each other. As a result, exciting 
electrons from each of these states to the respective higher energy states will result in 
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slightly varying amounts of absorbed energy (at varying wavelengths). Thus, the 
produced UV spectrum will consist of a broad peak that represents the sum of all the 
arising transitions and the different events occurring at each molecule, providing the 
average for the total population. Similarly, the emission spectrum, as the molecules 
return to the ground state, will also result in a broad band. 
 
 
Figure	   1.3:	   Energy	   levels	   of	   the	   ground	   and	   excited	   states	   of	   a	   molecule.	   The	   bonding	   (σ ,	   π),	  
nonbonding	   (n)	   and	   antibonding	   (π*,	   σ*)	   orbitals	   are	   shown	   with	   their	   vibrational	   and	   rotational	  
levels	  (only	  a	  few	  of	  them	  are	  shown	  for	  clarity).	  The	  arrows	  between	  the	  orbitals	  (from	  π	  to	  π*	  and	  
from	  n	  to	  π*)	  refer	  to	  the	  most	  commonly	  observed	  transitions	  in	  protein	  molecules.	  
As described above, biological macromolecules, and more specifically proteins, 
present absorbance in the UV region as their electrons ascend to higher energy levels. 
The bonds or groups of a protein that are able to absorb UV light (chromophores) at 
specific wavelengths are mainly: the carbonyl group of the peptide bond (at ~190 nm 
and 210–230 nm), aromatic amino acid side chains (250–280 nm) and disulfide bonds 
(<260 nm) (described in the CD section).50 The typical absorbance spectrum records 
the amount of light absorbed by the analysed sample in a selected range of 
wavelengths, while for protein quantitation, the most commonly used wavelength is at 
280 nm as contribution of the used buffer excipients is minimised in that region 
compared to lower wavelengths. 
The broad peak at 280 nm results mostly from the contributions of tryptophan 
(~280 nm) and tyrosine (~276 nm) residues and disulfide bonds (<260 nm) and it is 
widely used for determining the concentration of proteins51 by applying the Beer-
Lambert law: 
 𝐴 = 𝑙𝑜𝑔!"( !!!) = 𝜀𝑐𝐿 (1.2) 
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where 𝐴 is the measured absorbance, 𝐼! is the intensity of the incident light, 𝐼 is the 
intensity of the light that is transmitted through the sample, 𝜀  is the extinction 
coefficient (M−1 cm−1), 𝑐 is the molar concentration of the protein (M) and 𝐿: is the 
distance that the light travels through the material (path length, cm). 
The concentration of a protein can therefore be determined, provided that an 
accurate extinction coefficient for the specific protein is obtained. The extinction 
coefficient is the absorbance of a 1 M solution of the contributing chromophores at the 
wavelength maximum (e.g. 280 nm) and can be either theoretically calculated or 
experimentally measured.52 The calculated or measured extinction coefficient is 
usually an approximation as this can vary depending on the environment of the 
chromophores in the protein, namely interactions with nearby amino acids and 
exposure to the solvent, while the wavelength maximum is dependent on the aromatic 
amino acid composition and also the individual environments of the chromophores. 
Finally, the determined concentration might slightly diverge from the actual 
concentration when larger protein aggregates or traces of nucleic acids are present. 
Circular Dichroism (CD) 
Circular dichroism is based on the interaction of an asymmetric (chiral) molecule with 
circularly polarised light and measures the difference in absorption of left- and right-
circularly polarised light by that chiral molecule, resulting in a CD spectrum with 
positive and negative peaks. Biological macromolecules, such as proteins, consist of a 
series of chiral units (backbone and amino acid side chains), which further contribute 
to the formation of asymmetric three-dimensional structures such as helices and 
pleated sheets (secondary structure) depending on the hydrogen bonding patterns. The 
fact that these units and structures interact to a different degree with left- and right-
circularly polarised light gives rise to characteristic CD spectra, representative of the 
dominant secondary structure (far-UV region) or the environment of the aromatic 
amino acid side chains and disulfilde bonds (near-UV). 
A circularly polarised light beam results when two linearly polarised light 
beams incident along the same direction but polarised perpendicular to each other, of 
equal magnitude and out of phase by π/2, are combined (Figure 1.4). Therefore, the 
resulting light beam propagates by following a helical path (either right- or left-
handed) of a constant magnitude. Two circularly polarised beams, one with a 
clockwise (right-handed) and one with an anticlockwise (left-handed) direction, are 
shined onto an isotropic (e.g. solution) sample during a CD experiment. If the sample 
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is symmetric (with no chiral centres) the difference of the two lights will be zero, as 
both lights will be absorbed to a similar extent. A chiral molecule, however, will 
respond differently to each of the light beams, absorbing one more than the other and 
therefore resulting in a positive or negative signal. As a consequence, the remaining 
light for each light beam (light that was not absorbed) will be of different magnitude 
when the beams will be exiting the sample, resulting in an elliptically polarised light 
when subtracted from each other. This elliptical light is recorded by the CD detector 
and translated to a CD spectrum over a wide range of wavelengths. 
 
 
Figure	  1.4:	   	  Left	  and	  centre:	   two	   linearly	  polarised	  beams	  (in	  red	  and	  blue)	  of	  equal	  magnitudes	  and	  
propagating	   in	   perpendicular	   planes	   with	   a	   phase	   difference	   of	   π/2,	   combine	   to	   give	   a	   circularly	  
polarised	  beam	  (right,	  in	  black).	  The	  circularly	  polarised	  beam	  shown	  here	  is	  left-­‐handed,	  following	  an	  
anticlockwise	  helix	  around	  x	  axis.	  
As with UV-Vis absorbance the prerequisite for such a phenomenon is that the 
initial incident light beams are of suitable energy (and therefore wavelength), able to 
cause redistribution of the molecule’s electrons. However, in the case of CD, the 
electrons follow a helical transition (the displacement of electronic charge has a 
circular and a linear component in the direction of the applied field) due to 
combination of the electric and magnetic fields of the radiation as opposed to the linear 
rearrangement that takes place in UV-Vis as a result of interaction predominantly with 
the electric field.53 Protein CD spectra are divided into two regions, the far-UV (180–
250 nm) and the near-UV (250–350 nm), which provide different information on the 
conformation of a protein depending on the interacting chromophores. The CD signal 
in the far-UV region results from the occurring electronic transitions in the peptide 
backbone, namely the π to π* (at ~190 nm)54 and n to π* (210–230 nm)55 transitions, 
which give rise to characteristic CD spectra for different secondary structures (e.g. 
helices, sheets) as they are affected by the respective hydrogen bonding patterns in 
each structure.56-58 Transitions of the side chains of the aromatic amino acids can also 
present CD signals in the far-UV region; however, the magnitude is smaller compared 
with the backbone signals except for some unusual peptides such as gramicidin which 
has a high percentage of tryptophan residues.59 Electronic transitions of the aromatic 
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amino acid side chains and disulfide bonds are significant in the near-UV region.50,56 
More specifically, π to π* transitions occur at: ~280 nm for tryptophans,60 ~276 nm for 
tyrosines,61,62 250–270 nm for phenylalanines63 and <260 nm for disulfide bonds.64 The 
resulting CD spectrum in the near-UV region is affected by the number of aromatic 
amino acids in the protein sequence and the local environments of the individual 
aromatic amino acids (such as interactions with nearby amino acids and polarity). Thus, 
the near-UV CD spectrum is distinct for each protein and characteristic of the folding 
and its tertiary structure.65,66 
Similarly to any spectroscopic technique, a CD spectrum is representative of 
the average of the molecular population and the contributing structures or events that 
take place in solution. CD finds wide application in studying conformational changes 
and unfolding (or folding) of proteins under varying conditions such as temperature, 
pH and protein-ligand interactions, providing valuable qualitative comparative studies 
on the secondary (far-UV CD) and tertiary (near-UV CD) structure of the protein. CD 
data are usually reported in Δε units (mean residue ellipticity), which facilitates 
comparison of the CD spectra of proteins with largely different molecular weights. 
 Δ𝜀 = !×!"#!×!×!"#$%  (1.3) 
 
where Δ𝜀 is molar differential extinction coefficient (M−1 cm−1), 𝜃 is machine units 
(mdeg), C is mass concentration (mg mL−1), P is path length (cm), and MRW (mg 
mmol−1) is mean residue weight, which for the peptide bond is calculated as: MRW = 
molecular mass of protein (Da) / (number of amino acids − 1).67 
Several programs are used for the analysis of far-UV CD spectra and are 
available through various web sites such as DichroWeb68,69 and CDPro70 or as stand-
alone versions, e.g. SSNN (secondary structure neural network).71,72 All of them use 
datasets of CD spectra of proteins, whose secondary structures have been solved by X-
Ray crystallography or NMR experiments, in order to find the contribution of each 
secondary structure component (with a well-defined CD spectrum) to the measured CD 
spectrum and translate it into quantitative percentages. Three of these programs were 
used in this work for the estimation of the secondary structure components of different 
proteins, and on some occasions at different temperatures. SSNN was used in all cases 
(Chapters 2–4), SELCON3 (self-consistent)73,74 was used in Chapters 2 and 4, and 
CDSSTR75,76 was used in Chapter 4. All three are further discussed in Chapter 4. 
 42 
Fourier Transform Infrared spectroscopy (FT-IR) 
Infrared (IR) spectroscopy measures the wavelength and intensity of the infrared light 
that is absorbed by a sample, able to cause transitions in the vibrational state of a 
molecule. IR and therefore excitation of the molecular vibrations to higher energy 
levels requires less energy than the electronic transitions that occur in UV. The 
commonly used IR unit is the wavenumber (cm−1), which is the reciprocal of the 
wavelength in cm, and subsequently directly proportional to the absorbed energy. 
Therefore equation 1.1 becomes: 
 𝐸 = ℎ𝑐!𝑣 (1.4) 
 
where 𝑣 is the wavenumber (m−1) and the rest of the parameters are as described for 
equation 1.1. Incident light of suitable energy, in a wavenumber range of 4000–400 
cm−1, increases the vibrational motions of the chemical bonds (e.g. stretching or 
bending) in a molecule. However, only bonds that have a dipole moment that varies 
over time are able to absorb IR radiation, whereas symmetric bonds (e.g. H2) do not 
interact with infrared light. The strength of the chemical bond, the contributing atoms, 
and the change in the dipole moment determine the intensity and vibrational frequency 
of an IR band, therefore IR spectra give information on the characteristic bonds present 
in a molecule. 
For proteins, the most prominent (and repetitive) bond is the amide bond of the 
peptide backbone, which presents a number of bands in different regions of the FT-IR 
spectrum. The three most important amide bands are: 
 
• the amide I, which is mainly associated with the C=O stretching vibration and 
to a lesser extent with C-N stretching. It depends on the conformation of the 
protein and the H-bonding, and appears at around 1650 cm−1. 
• The amide II band results from in-plane N-H bending and C-N stretching 
vibrations and is also sensitive to the protein conformation. It appears at 
around 1550 cm−1. 
• The amide III bands are more complicated, resulting from C-N stretching and 
C-N-H in-plane bending modes. They appear at around 1200–1350 cm−1. 
 
Out of amide I, II and III, the amide I band is the most sensitive to 
conformational changes and gives information on the secondary structure of a protein, 
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as different secondary structure components have characteristic band frequencies in 
this region (1600–1700 cm−1).77 Antiparallel β-sheet structures, for example, present an 
average frequency of 1633 cm−1 and a second frequency at around 1684 cm−1, α-helix 
appears at ~1654 cm−1 on average, turn structure has an absorption near 1672 cm−1 and 
unordered structure presents a band close to the α-helix frequency, at ~1654 cm−1.78 
Several methods (e.g. second derivative) are often used for resolving the amide I band 
into its individual components, allowing for a quantitative analysis of the secondary 
structure of a protein. These are briefly discussed in Chapter 2 (Section 2.6). 
In this work, attenuated total reflectance Fourier transform IR spectroscopy 
(ATR FT-IR) was used. In Fourier transform IR (FT-IR) spectroscopy, an 
interferogram is produced (time-domain spectrum) by moving mirrors and converted to 
the frequency-domain spectrum by a mathematical operation called Fourier transform. 
When a number of interferograms are accumulated and summed, the signal-to-noise 
ratio increases. In attenuated total reflectance (ATR) FT-IR spectrometry the sample is 
placed in contact with an internal reflection element (IRE) of a higher refractive index, 
e.g. a ZnSe crystal. The radiation is directed into the crystal and towards the sample 
and the method is actually based on the reflection of the infrared beam at the sample-
crystal interface and in the IRE medium, while the number of reflections varies from 
single to multiple, depending on the length of the crystal. A prerequisite for the 
reflection of the beam is that the angle of incidence is equal or greater than the critical 
angle (𝜃!), namely the angle of the incident light (𝜃!) that would theoretically result in 
a refraction angle (𝜃!) of 90°. The critical angle can be calculated from Snell’s law, 
assuming that 𝜃! = 90°: 
 𝑛! sin 𝜃! = 𝑛! sin 𝜃! →   𝜃! = sin!! !!!!  (1.5) 
 
where 𝑛! is the refractive index of the crystal and 𝑛! refractive index of the sample. 
Practically, as the angle of incidence increases up to the 𝜃! value, the refracted beam 
will approach 90° and will be reflected when 𝜃! is reached (Figure 1.5, left). The light 
beam is reflected with an angle equal to the angle of incidence and directed to the 
detector. 
ATR is an advantageous method as a variety of samples can be used (e.g. in 
solution, absorbed on a surface or in solid state) with no sample preparation. However, 
two effects related to the technique, the penetration depth and the anomalous 
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dispersion, result in a somewhat different spectrum compared to a transmission 
spectrum, where the light passes through the sample. As the light beam hits the 
sample-crystal interface, the electrical field of the incident photon extends 
perpendicularly from the surface of the IRE into the sample, resulting in an evanescent 
wave with a frequency similar to that of the incident light, but with an amplitude that 
decays exponentially with distance from the surface of the crystal (Figure 1.5, right). 
The depth of penetration (𝑑!) is the effective distance from the surface, at which the 
evanescent wave can interact effectively with the sample, and is linearly dependent on 
the wavelength. This effect results in distorted relative intensities of the peaks of an 
ATR spectrum, as peaks at high wavenumbers will have smaller intensities than peaks 
at the low-wavenumber end. The effect of the anomalous dispersion results from the 
variation of the refractive index across an absorption band, leading to a shift of the 
absorption bands to lower wavenumbers.79,80 
 
 
Figure	   1.5:	   Crystal	   (in	   orange)	   and	   sample	   (in	   blue)	   arrangement	   in	   an	   ATR	   FT-­‐IR	   experiment.	   Left:	  
incident	  light	  beams	  of	  different	  angles	  are	  shown,	  resulting	  in	  refraction	  (when	  𝜽𝟏<𝜽𝒄,	  dotted	  lines)	  
or	   reflection	   (when	  𝜽𝟏≥𝜽𝒄,	   solid	   and	   dashed	   lines)	   of	   the	   light	   beam.	   Right:	   Zoom	   on	   the	   sample-­‐
crystal	   interface	   at	   the	   point	  where	   the	   incident	   light	   beam	  hits.	  When	  𝜽𝟏≥𝜽𝒄	  the	   light	   is	   reflected,	  
while	  its	  electric	  field	  creates	  an	  evanescent	  wave	  (red)	  that	  expands	  perpendicularly	  from	  the	  sample-­‐
crystal	  interface	  towards	  the	  sample,	  and	  decays	  exponentially	  with	  distance.	  The	  penetration	  depth	  is	  
the	  distance	  from	  the	  surface,	  at	  which	  the	  evanescent	  wave	  can	  still	  interact	  with	  the	  sample.	  
Among its numerous applications, FT-IR spectroscopy is one of the preferred 
techniques for secondary structure characterisation and conformational analysis of 
therapeutic proteins.81,82 Studies on protein folding and stability are quite common, 
allowing for a qualitative comparison by monitoring changes in the secondary structure 
of the molecule induced by various factors (e.g. solution conditions),83-85 while 
deconvolution of the amide I band region to its individual components can provide 
quantitative results on the secondary structure of a protein.77,86 
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Nuclear Magnetic Resonance spectroscopy (NMR) 
In NMR spectroscopy, the use of radiofrequency (RF) radiation combined with a static 
magnetic field cause transitions of the nuclear spins of an atom. Only atomic nuclei 
with odd mass, odd atomic number or both present non-zero nuclear spin, with the 
allowed spin states being quantised and determined by the nuclear spin quantum 
number I. For each nucleus, I is a physical constant and the allowed spin states 
(magnetic quantum number, m) can take values from –I to +I in the following way: –I, 
–I+1, …, I–1, I. For example, 1H (I = ½) can occupy either of the two spin states m = –
½ and m = +½. When a static magnetic field is applied, the allowed spin states become 
energetically distinguishable and transitions between these states can be captured by 
NMR. The frequency of such transitions depends on the strength of the magnetic field 
and the observed nucleus and is determined by the following equation: 
 2𝜋𝑣 = 𝜔 = 𝛾𝐵! (1.6) 
 
where 𝑣 is the transition frequency in s−1 (Hz), 𝜔 is the transition frequency also 
referred to as Larmor frequency (radians s−1), 𝛾 is the gyromagnetic ratio (a constant 
that depends on the identity of the nucleus) and 𝐵! is the strength of the magnetic field 
(Tesla). Due to its high natural abundance and favourable gyromagnetic ratio, the 1H 
isotope is the nucleus of choice in many NMR experiments. 
In order to generate the correct amount of energy for the nuclear spin 
transitions, RF pulses are used, which are defined by their frequency (called the carrier 
frequency, νRF), power, phase and duration. When a pulse of a specific νRF is applied, a 
range of frequencies are also excited on both sides of the carrier frequency. The range 
of these frequencies is determined by the pulse duration, with short pulses leading to a 
wider range of frequencies and longer pulses resulting in more focused excitation 
(narrow spectral region). The pulse power measures the energy intake by the sample 
and the NMR components (e.g. NMR probe) per unit time, with low and high power 
pulses being combined in NMR experiments, but high power pulses of increased length 
being avoided in order to protect the sample and the probe from the destructive 
consequences. Since a pulse has the nature of a wave, the pulse phase is defined by the 
amplitude of the wave at the beginning of the pulse (t = 0). For a sine wave, for 
example, with maximum amplitude at t = 0, the phase shift is π/2. 
Similarly to all the absorption spectroscopic techniques mentioned above, the 
energy of the applied RF pulse is absorbed by nuclear spins in the sample, resulting in 
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a transition from a lower to a higher energy state. In the presence of an external 
magnetic field, a slight majority of the hydrogen nuclei orient in respect to the applied 
magnetic field (B0), adopting the lower energy +½ spin state—as the –½ spin state 
requires higher energy since it is opposed to the magnetic field—while at the same 
time they precess around the applied magnetic field at their transition frequency, called 
the Larmor frequency (Figure 1.6). The sum of magnetic moments for the nuclei with 
spin greater than 0 results in a net magnetisation along the magnetic field direction (+z 
axis), which tilts away from the axis as soon as an RF pulse is applied, resulting in a 
net magnetisation that precesses around z, in the xy plane.87 The precession of the net 
magnetisation around the z axis induces an electric current in the coil of the NMR 
probe, which is actually what is detected as a signal in a pulsed NMR experiment. The 
decay of this signal over time (which is a combination of the two relaxation events 
explained below), as the magnetisation returns to equilibrium (along the z axis), is 
called the free-induction decay signal (FID). Since the FID signal is recorded in the 
time-domain, Fourier transformation is applied, allowing for conversion into the 
frequency-domain spectrum.88 
 
 
Figure	  1.6:	  Left:	  spins	  precessing	  at	  their	  Larmor	  frequency	  at	  both	  spin	  states	  (m	  =	  –½	  and	  m	  =	  +½).	  
The	  sum	  of	  vectors	  from	  the	  individual	  nuclei	  results	  in	  a	  net	  magnetisation	  (in	  red)	  in	  alignment	  with	  
the	  external	  magnetic	   field	   (B0).	  Right:	   the	  applied	   radiofrequency	  pulse	   results	   in	  phasing	   the	   spins	  
(coherence),	  which	  subsequently	  tilts	  the	  net	  magnetisation	  along	  the	  x	  axis,	  while	  at	  the	  same	  time	  
some	  nuclei	  change	  their	  spin	  state	  from	  low	  to	  high	  energy.	  
Since the different spin states of a nucleus are very close energetically, NMR 
uses accordingly small energies to cause transitions (much smaller than what is 
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required in electronic and vibrational excitations). The absorbed RF energy results in a 
transition of the spins from the low to the high energy spin state until the two states are 
equally populated, at which point the transition is saturated and no more energy can be 
absorbed until the spins return to those populations of the upper and lower energy 
levels as predicted by the Boltzmann distribution. The z-magnetisation, therefore, is 
proportional to the population difference between the two spin states, and the constant 
of proportion determines the absolute size of the observed NMR signal. Acquisition of 
successive signals is delayed by the time that is required for the NMR signal to return 
to its equilibrium state, namely for re-establishment of the normal population 
distribution of the two spin states. This process is called spin-lattice relaxation and is 
accompanied by the release of energy to the local environment. The corresponding 
time is called spin-lattice relaxation time (T1). 
A second process related to relaxation is the decay of the transverse 
magnetisation of the spins, called spin-spin relaxation. As mentioned above, the 
applied RF pulse results in a net magnetisation (e.g. on the x axis) that precesses 
around z axis and in the xy plane at the Larmor frequency (Figure 1.6).87 This 
orientation of the magnetisation is disturbed, however, by local spin-spin interactions 
(small magnetic fields from neighbouring nuclei), which lead to fluctuations in the 
local magnetic field and a slightly different precession frequency for each proton. As a 
result, the protons come out of phase (loss of coherence), which is what causes decay 
of the observed signal, namely decrease of the net magnetisation in the xy plane. The 
time required for the decay of the coherence-induced signal (to a certain amplitude) is 
called spin-spin relaxation time (T2) and is an important factor in multi-pulse 
experiments of biological macromolecules, affecting the line widths of the spectrum in 
an inverse manner. The slow tumbling of larger macromolecules in solution leads to 
faster relaxation of transverse magnetisation (short T2), due to enhanced spin-spin 
interactions, and therefore to broad line widths. This problem is often solved by 
recording NMR spectra at elevated temperatures, which result in an increase of the 
overall molecular tumbling rate. Coherences that last longer result in narrower line 
widths, while they can be also transferred to other spins via coupling, which is what 
gives rise to multidimensional NMR experiments. 
The chemical shift is the variation in the resonant frequencies of spins, 
resulting from differences in their chemical environments. Such differences are caused 
by the electron density that surrounds the observed nuclear spin, and by the 
interactions of these electrons with the applied magnetic field. Subsequently, these 
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interactions result in fluctuations in the local magnetic field of the nucleus, and can 
either increase the net magnetic field sensed by the nucleus, moving the resonance to 
higher frequencies (deshielding), or decrease it, leading to lower frequencies 
(shielding).89 The ratio of the difference in resonance frequency of the observed 
nucleus relative to a reference one (usually tetramethylsilane, TMS) is what is reported 
as chemical shift δ in ppm (parts per milion). The chemical shift of 1H is largely 
affected by environmental factors (e.g. temperature, pH, hydrogen bonding, ring 
current effects), to the point that an 1H NMR spectrum can reveal whether a protein is 
folded, presenting dispersed chemical shifts, or unfolded, where resonances for the 
same chemical type of nuclei (e.g. backbone NH protons or nitrogens) are observed in 
a relatively narrow range, due to the decreased local interactions and hence decreased 
differences in the chemical environment of these nuclei.90 
As mentioned above, the generated coherences on one spin during an NMR 
experiment are usually long enough to be transferred to a coupled spin, therefore 
allowing the correlation between coupled spins to be probed. The coherence transfer 
can be achieved via J-coupling (or dipolar coupling, explained below), which is the 
result of the interactions between nuclei coupled through bonds and mediated by the 
electrons of the bond. The energies of the spinning electrons note a slight variation, 
depending on the spin state of the nuclei with which they are interacting, with these 
changes in energy sensed in turn by nuclear spins of the same bonded system. This 
effect results in somewhat different energy levels of the nuclear spin states, which 
depend on the coupled nucleus, and consequently in the separation of the signals with a 
similar “distance” between the signals for both nuclei, called coupling constant. 
Multi-dimensional NMR experiments exploit the effect of coupled nuclei that 
are one or even a few bonds apart. Such experiments (e.g. 2D-, 3D-NMR) are 
nowadays used for the sequential assignments of proteins, with the structure of a 
macromolecule having been determined for the first time by Wüthrich in 1985.91 A 
relatively simple and very commonly used homonuclear 2D-experiment is the TOCSY 
(total correlation spectroscopy),92,93 from which spin systems of different amino acids 
can be identified and correlated. TOCSY is based on the Hartmann-Hahn effect, which 
takes place when a long RF pulse of low power is applied. This pulse results in spin-
locking, namely freezing of the free precession of individual coherences, which 
consequently remain in phase while at the same time energy transfer occurs between 
coupled coherences. At the end of spin-locking, the detected coherences will result in 
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signal amplitudes that will be regulated in accordance with the frequencies of all the 
spins that participated in this energy transfer. 
Heteronuclear 2D-NMR experiments are also extensively used, exploiting 
polarisation transfer from the 1H nucleus to another NMR-active nucleus coupled to 
it, such as 13C or 15N. A heteronuclear experiment is the HSQC (heteronuclear single-
quantum coherence),94 for example, with the resulting spectrum showing correlation 
peaks between the two observed nuclei, when the nuclei in this experiment are 
connected to each other via one or more chemical bond(s). One more homonuclear 
experiment, but exploiting a different mechanism of energy transfer between nuclear 
spins than J-coupling, is the NOESY (nuclear Overhauser effect spectroscopy).95 This 
experiment is based on dipolar relaxation, which is an interaction between spins that 
are close in space (typically with a distance <5 Å) and do not necessarily belong to the 
same spin system or even to the same molecule. The dipolar mechanism is based on 
the fact that each spin has a magnetic moment, resulting in a magnetic field which can 
interact with other spins. This interaction is a property of a pair of nuclei, and its size 
depends strongly on the distance between the two spins and the direction of the vector 
joining the two nuclei. As a molecule tumbles in solution, the direction of this vector 
changes and so does the magnetic field. Changes in the distance between the two 
nuclei also result in a change in the magnetic field, while in general changes in 
orientation are responsible for relaxation. In dipolar relaxation, therefore, energy can 
be transferred between the lattice (molecular motion) and the spins. As a result, dipole-
dipole interaction turns molecular motion into an oscillating magnetic field, which can 
cause transitions of the spins.96 In NOESY the cross-relaxation is responsible for 
exchange of magnetisation between different spins, and this energy exchange takes 
place during the mixing time.*97 Thus, a NOESY spectrum presents cross-peaks of two 
spins (typically referring to 1H-1H correlations) that are experiencing mutual cross-
relaxation and hence are close in space. 
NMR is an extremely useful tool for the investigation of the structure and 
dynamics of biomolecules. Among many applications and advanced experiments, 
sequential assignment, which can be achieved with the acquisition of selected 2D- and 
3D-NMR experiments, forms the basis of three-dimensional structure determination of 
                                                      
* Mixing time (or period) is one of the key parameters in 2D NMR spectroscopy as it allows for 
the transfer of magnetisation or, in other words, transfer of coherence among spins (through one 
of the two mechanisms described above) prior to acquisition. Depending on the type of the 
experiment, the mixing period consists of one or more pulses and delays. 
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biomolecules. However, one of the most significant limitations of the technique is the 
size of the protein molecule, with proteins larger than 30 kDa rendering challenging 
the acquisition of 2D (or of higher dimension) NMR spectra. Large proteins can be 
tackled, nowadays, with the use of sophisticated experiments such as methyl-TROSY 
(transverse relaxation optimised spectroscopy)98 or FROSTY-MAS (Freezing 
Rotational diffusion Of protein Solutions at low Temperature and high viscositY 
Magic-Angle-Spinning spectroscopy),99,100 in combination with optimised labeling 
methods and/or highly deuterated proteins. Although the use of 2D NMR experiments 
has been reported in the literature for the comparison of biosimilars with the 
corresponding reference products,101 such complicated NMR experiments and protein 
labeling (15N, 13C) are very labour- and time-consuming processes, and therefore are 
not yet fully established for the purpose of quality control of formulated therapeutic 
proteins. Compared with 2D experiments, which are more complicated to set and 
interpret, 1D 1H-NMR experiments provide a simple fingerprint of the analysed sample. 
1D 1H-NMR experiments were mostly used in this work in order to provide 
information on the qualitative comparison of the spectra of different samples of a 
peptide (insulin, Chapter 2) and a monoclonal antibody (Chapter 4). 
1.3.3. Emission spectroscopy 
Fluorescence 
As mentioned above (UV-Vis in Section 1.3.2), absorption spectroscopy measures the 
energy that is absorbed by a molecule during its excitation from the ground state to an 
excited state. Fluorescence, however, is an emission spectroscopic method and is based 
on the measurement of the reverse process, namely the energy that is radiated as the 
electron returns to the ground state. The emitted light, in such cases, is of lower energy 
than the light that was absorbed during excitation as an amount of energy is lost by 
non-radiative processes. As a result, the emission spectrum is observed at longer 
wavelengths. According to Jablonski,102 loss of energy is the result of internal 
conversion processes, which occur prior to emission. In other words, the molecules 
initially relax to the lowest vibrational level of the excited state and then return to a 
higher vibrational level of the ground state by the emission of photons, which is what 
causes the fluorescence phenomenon. The shift of the emitted light to longer 
wavelengths, compared to the incident light, was first observed by Stokes (Stokes 
shift).103 
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Proteins have intrinsic fluorescence, due to the fluorescence of the aromatic 
amino acids tryptophan, tyrosine and phenylalanine, with tryptophan presenting the 
most dominant fluorescence signal in most of the cases.104-106 Similarly to the 
absorption spectrum, the released energy (emission spectrum) is also affected by 
interactions between the molecular dipole and the surrounding environment, namely 
interactions with nearby amino acids and solvent exposure. The high sensitivity of 
tryptophan, in particular, makes fluorescence valuable in monitoring conformational 
changes in proteins, as its fluorescence signal can be almost entirely isolated by the 
contribution of other aromatic amino acids when the absorption wavelength is set at 
295 nm. The emission maximum of tryptophan usually provides information on protein 
folding, as the hydrophobic environment of a folded protein limits solvent exposure, 
resulting in a shift towards lower wavelengths (blue-shift) compared to the maximum 
of free tryptophan in water (353 nm). Consequently, unfolding and increased solvent 
exposure shifts the maximum towards longer wavelengths (red-shift). 
Intensity of the fluorescence signal also depends on the local environment. 
Non-radiative processes are inhibited in the hydrophobic environment of a folded 
protein, therefore generally resulting in increased emitted energy (higher intensity) 
compared to the unfolded protein,107 while in other cases Trp fluorescence is quenched 
by nearby amino acids in the folded protein, therefore showing lower intensity 
compared to the unfolded protein.108 Fluorescence intensity is also affected by high 
protein concentrations, where an inner filter effect takes place due to the high density 
of the protein, resulting in decreased intensity compared to a diluted solution. Finally, 
the width of the band reflects the number of Trp residues and the heterogeneity of their 
environments in the folded protein.50 
Due to its sensitivity as a technique and among other more advanced 
applications, fluorescence is largely used for studies on protein conformation, stability 
and folding or unfolding kinetics, providing information on the average environment of 
tertiary structures in the analysed sample. In combination with other spectroscopic 
techniques (CD, FT-IR, NMR etc.) it offers valuable information on protein structure, 
as discussed in Chapter 4. 
1.3.4. Scattering spectroscopy 
Dynamic Light Scattering (DLS) 
Light scattering occurs when an incident photon induces a dipole moment in the 
electron cloud of a molecule, which in turn leads to the energy being radiated or 
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scattered in all directions.50,109 Scattering can follow either Rayleigh or Mie theory, 
depending on the size of the molecule.110 When the particle is much smaller than the 
wavelength of the incident light (<λ/10), it is assumed that all sides of the interacting 
particle are equally subject to the electric field, therefore resulting in isotropically 
scattered waves, of equal intensities in all directions (Rayleigh theory). For larger 
particles, the interactions become more complex with the scattered waves being 
distorted from the front (the side facing the incident beam) to the back of the particle 
(Mie theory). 
DLS (dynamic light scattering) measures the intensity fluctuations of the 
scattered light from a collection of particles in a sample as a function of time. These 
fluctuations result from the motion of the particles in solution (Brownian motion) and 
intermolecular interactions.111 As a result, a fast moving particle will cause rapid 
intensity fluctuations as opposed to a slow moving particle. The velocities of the 
molecules are related to their size, with small particles moving faster than larger 
particles, so particle size affects the DLS signals. In order to extract information about 
the particle size from DLS, the instrument produces an autocorrelation function of the 
fluctuating light intensity with respect to time. This function is then fit using two 
different algorithms in order to provide the weighted mean hydrodynamic size of the 
particles (Z-average) and polydispersity index (PDI)112 or the particle size 
distribution.113 The size distribution shows the relative intensity of light scattered by 
particles of different size classes (intensity distribution). The polydispersity index is 
related to the width of the size distribution and is a way of describing the uniformity of 
a sample. A PDI value <0.1 indicates an almost ideal, monodisperse sample with 
particles of one only size class present (a single exponential decay is fitted to the 
autocorrelation curve), while values >0.4 originate from broad distributions, indicating 
a highly polydisperse sample (the sum of multiple exponential decays is used). 
In the case that there is more than one peak present (more than one particle 
population), the generated intensity distribution will be largely affected by the larger 
particle size, as large particles scatter more light than smaller particles and the intensity 
of the scattered light is proportional to the sixth power of the particle’s diameter 
(Rayleigh approximation). Mie theory is then applied in order to convert the intensity 
distribution to a number distribution, assuming that the particles are of spherical 
shape.114 The number distribution shows the number of particles in each population 
and is useful for comparative purposes in the case of polydisperse samples, but should 
not be used for reporting the absolute size of the particles. 
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As mentioned above, the detected fluctuations in the intensity of the light 
result from the random movement of the particles in solution and their bombardment 
by the solvent molecules (Brownian motion). The velocity of this motion is defined by 
the diffusion coefficient (D) of the particle in a particular solvent environment, thus 
depending on the size of the particle, the surface structure, concentration and the ions 
present. The diffusion coefficient is calculated from the autocorrelation function, since 
it is proportional to the lifetime of the exponential decay, and the hydrodynamic radius 
(𝑅!) is calculated using the Stokes-Einstein115 equation: 
 𝐷 = !"!!"!! (1.7) 
 
where 𝑘 is the Boltzmann constant, 𝑇 is the absolute temperature and 𝜂 is the viscosity 
of the solution. The temperature should be accurately set, as any changes in the 
temperature will result in variation in the viscosity of the sample and therefore in 
miscalculation of the particle size. The final value of the particle size reported by the 
DLS instrument is the hydrodynamic diameter, which refers to the diameter of a 
spherical particle (including the hydration layer) that diffuses with the same speed as 
the measured molecule. 
DLS finds use in the determination of the particle size of macromolecules, in 
aggregation studies and in forced degradation studies (e.g. as a function of 
temperature), where conformational changes and unfolding of the protein are followed 
via the detected changes in its diffusion. DLS is a nondestructive technique and 
particularly useful in probing the effects of solution conditions and formulation 
excipients on the stability of a therapeutic protein, while the polydispersity index gives 
information on the homogeneity of a sample. An increased PDI in the case that a single 
population is detected suggests either the presence of trace amounts of larger species or 
the presence of differently shaped molecules (e.g. due to unfolding). The sensitivity of 
DLS in detecting very small amounts of larger particles makes it a valuable tool for 
qualitative comparison of samples of biotherapeutic molecules, particularly indicating 
early onset of aggregation as discussed in Chapter 2 (Section 2.4). 
 
1.4. CASE STUDIES AND CHALLENGES 
The above-described techniques were applied in different combinations on several 
protein samples and various case studies, which are reported in detail in Chapters 2, 3 
and 4. The examined protein therapeutics include: insulin, trastuzumab, somatropin, 
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etanercept and a monoclonal antibody. The common goal in all studies was to 
demonstrate similarity or dissimilarity between two or more samples in particular to 
spot differences in their structure and detect aggregates or degradation products that if 
significant could potentially result in loss of activity or increased immunogenicity. 
All samples, except insulin, were provided already formulated by the 
manufacturing company for comparability assessment, and were tested under normal 
(room temperature) conditions and in some cases under the induced stress of increased 
temperatures. Comparison of the samples at elevated temperatures allowed the 
detection of structural (and consequently stability) differences that were not obvious or 
might have been overlooked if the comparison had only taken place at room 
temperature. 
The use of already formulated products in these tests is usually preferred to 
reconstitution for various reasons such as ensuring consistency in concentration and 
solvent environment, maintaining stability of the active substance, minimising sample 
preparation and human error. Furthermore, the formulation of a product with 
appropriate and compatible excipients usually requires specific knowledge116-118 and 
several trials119 in order to achieve solubility, reduce intermolecular interactions such 
as adsorption and aggregation, prevent microbe growth, avoid changes in pH, ionic 
strength and viscosity, situations that if not properly addressed could affect the 
product’s stability and consequently safety and efficacy. 
All examined cases were targeted at one common purpose: finding the 
combination of techniques that are able to demonstrate (or not) similarity between 
samples with confidence; what makes each case distinct is the reason why the 
examined samples might vary. In Chapter 2 for example, a comparison of insulin 
samples under different conditions is discussed. Exploiting insulin’s ability to exist in 
various oligomerisation states depending on the environmental conditions, a study was 
conducted that focused on investigating how stability and secondary structure are 
affected by oligomerisation state. Chapter 3 comprises a detailed comparison between 
two mAbs (trastuzumab) and their respective ADCs that came from different 
conjugation processes. The main question was how and to what extent an alternative 
conjugation method could affect the structure of the antibody and the number of the 
conjugates attached to it. Chapter 4 consists of various cases that include: structure 
determination of somatropin and batch-to-batch and/or biosimilar to reference product 
comparability studies (etanercept, mAb in phase III of clinical trials). The additional 
objective of these short studies of Chapter 4 was to suggest solutions to challenges, 
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technique-related or associated with the formulation or sample preparation, someone 
may come across when performing such analyses. 
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Abstract 
Although protein structure has been studied for many decades, it remains the case that 
we cannot state with confidence whether two samples have the same molecular 
structure, particularly in solution. The increasing number of biosimilar 
biopharmaceutical drugs that are being tested means this is not an academic exercise. 
In this work we consider how five well-established techniques: dynamic light 
scattering (DLS), circular dichroism (CD), Fourier transform infrared spectroscopy 
(FT-IR), nuclear magnetic resonance spectroscopy (NMR), and molecular modelling 
can be combined to provide information about the supposedly well-understood protein 
insulin. A goal of this work was to establish a systematic means of detecting 
differences between insulin samples as a function of pH, temperature, and the presence 
or absence of zinc, all of which are known to change the oligomerisation state and to 
affect molecular structure. We used the recently developed Secondary Structure Neural 
Network (SSNN) circular dichroism algorithm to facilitate analysis of the CD spectra 
as well as a retrained version for analysis of the FT-IR spectra. 
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Chapter 2 
Biophysical Characterisation of 
Insulin for Structure Comparison 
2.1. INTRODUCTION 
Since 1921 when insulin was first extracted from dogs and purified, the advances in 
insulin’s history were slow in pace but tremendous in importance leading to the award 
of several Nobel Prizes to the respective discoverers.1,2 In 1955 insulin was the first 
protein to be fully sequenced, and subsequently it was the first human protein to be 
chemically synthesised in 1963. With the developments in X-Ray crystallography, 
Dorothy Hodgkin and her team solved the three-dimensional structure of insulin in 
1969.3 In 1978, insulin was the first human protein to be genetically engineered by 
Genentech, and launch of recombinant human insulin as the first biopharmaceutical 
drug (Eli Lilly & Co.’s Humulin) followed in 1982.4 
 Despite the fact that insulin has been extensively studied since the 1920s, a lot 
has to be explored and it is still under research. Insulin products have recently lost their 
patent protection and several biosimilar products as well as new drugs have been 
developed or are under development for diabetes treatment.5 The main focus is on 
ultra-rapid acting insulins, new formulations with prolonged duration of action (such as 
insulin degludec),6 innovative administration methods (oral or inhaled) and new 
devices for insulin delivery (infusion pumps).7 The case where Marvel Ltd withdrew 
its application for a marketing authorisation for a biosimilar insulin renders even more 
significant the need for high standards of quality control.8 
 In this chapter we focus on bovine insulin as a case study, considering what 
information can be extracted from five of the well-established techniques (CD, NMR, 
DLS, FT-IR and molecular modelling) often used to characterise protein structure. We 
have complemented room temperature data collection with temperature dependence 
which enables us to probe subtle differences in structure that may not be apparent in 
room temperature data. We chose insulin as our model system for this study since it 
plays a key role in the regulation of blood glucose levels, exists in different forms, and 
many of the studies in the past years have used circular dichroism (CD),9-11 nuclear 
magnetic resonance (NMR)12-18 and Fourier transform infrared spectroscopies (FT-
IR),19-24 dynamic light scattering (DLS),25-29 X-Ray crystallography,30-33 mass 
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spectrometry (MS)34,35 and other techniques. Insulin is often described as a peptide 
hormone since it consists of two polypeptide chains A and B, with 21 and 30 amino 
acids respectively, held together by two disulfide bridges Cys (A7)–Cys (B7) and Cys 
(A20)–Cys (B19), while a third intrachain disulfide bond links cysteines A6 and 
A11.36-42 Usually, chain A folds into two α-helical segments A2–A8 and A13–A19 
connected by an extended section, while chain B folds into two extended segments 
connected by a central α-helical segment at B9–B2231,43 (Figure 2.1). Bovine insulin 
differs in sequence from human insulin at A8 (human: Thr; bovine: Ala), A10 (human: 
Ile; bovine: Val) and B30 (human: Thr; bovine: Ala), resulting in a slightly more 
compact structure for the first.30 
 
 
Figure	  2.1:	  Sequence	  and	  secondary	  structure	  of	  bovine	   insulin.	  The	  disulfide	  bridges	  are	  shown	  and	  
the	  amino	  acids	  that	  belong	  to	  helices	  are	  annotated	  in	  red.	  H	  =	  α -­‐helix,	  G	  =	  3/10-­‐helix,	  S	  =	  bend,	  B	  =	  
β -­‐bridge,	  T	  =	  turn,	  E	  =	  β -­‐strand.	  The	  secondary	  structure	  is	  according	  to	  the	  DSSP	  annotation	  for	  the	  
entry	  with	  PDB	  ID	  4E7T.	  	  
One of the main characteristics of insulin is its ability, under different 
conditions, to exist as: 
• monomers (pH 10–11) or 
• dimers (acidic pH, with the C-terminal portions of two adjacent B 
chains forming anti-parallel strands)44 or 
• tetramers and hexamers (neutral pH, with the hexamer being three 
dimers assembled around 2 Zn2+ ions to bury hydrophobic 
surfaces).16,27,45-48 
In hexamer formation (Figure 2.2), three identical dimers assemble around 2 Zn2+ ions, 
with each metal ion coordinated in an octahedral arrangement to three His (B10) side 
chains and three water molecules.49,50 In this way, more hydrophobic surface areas are 
buried in the hexamer’s interior and therefore, in the organism, the hexamer serves for 
storage of insulin molecules in membrane enclosed vesicles rich in zinc, where they 
are protected from physical and chemical degradation.51,52 During transfer from 
vesicles into the blood stream, the Zn2+-insulin hexamers rapidly break down to 
chain&A& 1& 2& 3& 4& 5& 6& 7& 8& 9& 10& 11& 12& 13& 14& 15& 16& 17& 18& 19& 20& 21&
bovine& G" I" V" E" Q" C" C" A" S" V" C" S" L" Y" Q" L" E" N" Y" C" N"
DSSP& H& H& H& H& H& H& H& S& B& H& H& H& H& G& G& G& B&
chain&B& 1& 2& 3& 4& 5& 6& 7& 8& 9& 10& 11& 12& 13& 14& 15& 16& 17& 18& 19& 20& 21& 22& 23& 24& 25& 26& 27& 28& 29& 30&
bovine& F" V" N" Q" H" L" C" G" S" H" L" V" E" A" L" Y" L" V" C" G" E" R" G" F" F" Y" T" P" K" A"
DSSP& B& T& H& H& H& H& H& H& H& H& H& H& H& G& G& G& E& E& E& T& T&
S&S&
S&
S&
S&
S&
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monomers (the active form),53,54 favoured by the significant dilution that takes place 
(insulin concentration in vesicles is ~21 mM; in circulation 57–280 pM), by the change 
in pH from 5.5 to 7.4, which results in strong repulsion of the six Glu (B13) 
carboxylates, and also by the limited availability of zinc ions which show higher 
affinity to albumin in serum.52,55 Monomeric units within the different oligomerisation 
states have similar but not identical structures, with the hexamer being the most stable 
and slightly more helical than any other oligomerisation state.56 In the present study, 
EDTA was used to remove Zn-binding in the case of neutral and basic pH,55 while at 
acidic pH, the His (B10) side chains are protonated and therefore unable to coordinate 
metal ions.57 
 
 
Figure	  2.2:	  Left:	   Three	  dimers	  assemble	  around	  2	  Zn2+	   ions	   in	  hexamer	   formation.	   Each	   chain	  of	   the	  
insulin	   hexamer	   is	   represented	  with	   a	   different	   colour.	  Right:	   Coordination	   between	   a	   Zn2+	  ion	   and	  
three	  His	  (B10)	  side	  chains.	  For	  the	  representation	  the	  structure	  with	  PDB	  ID	  code	  4E7T	  was	  used	  and	  
PyMOL.58	  
Insulin is also one of the proteins that are known to be involved in amyloidosis. 
Such proteins lead to the formation of intermolecular β-sheets that result from 
aggregation of the unfolded protein under stressful conditions (e.g. increased 
temperature). These structures gradually evolve resulting in the formation of fibrils 
(amyloid-like fibrils), which are responsible for many neurodegenerative diseases such 
as Parkinson’s and Alzheimer’s,19 while insulin aggregates have been found 
responsible for cutaneous allergy.59 Aggregation and fibrillation studies are therefore 
important in order to understand the mechanism and conditions under which it occurs. 
Bovine insulin, which was used in the present study, is more prone to form fibrils than 
human insulin.60 
The variation of structure with conditions (monomer, dimer, hexamer 
depending on pH and presence or absence of zinc) is important in the formulation of 
 66 
commercial insulin products, as insulin’s oligomerisation state is directly connected 
with its biological activity (see commercial formulations).51-55 In the present study, our 
focus is on the relationship between oligomerisation state, stability, secondary structure 
and aggregation or fibrillation (when apparent from the data) and the simplest 
analytical methodologies that can be used to probe this. The behaviour of the monomer, 
dimer and hexamer as a function of temperature was measured by four well-established 
experimental techniques—DLS, CD, NMR and FT-IR spectroscopy—and was 
simulated through molecular dynamics (MD) simulations to aid interpretation of the 
experimental data. 
Commercial formulations 
In the same way that a change in the substitution of a small molecule can affect its 
specific action (e.g. vinblastine/vincristine), a mutation in the amino acid sequence of a 
biological molecule can affect its structure and in consequence its action. Different 
products (analogues) are often found under the same name of the native protein, and a 
well-known example is that of insulin. Changes such as replacement, addition of 
specific amino acids or attachment of a fatty acid chain on the insulin molecule (Figure 
2.3) have led to numerous products that differ in their pharmacokinetics. The resulting 
analogues therefore are separated into four types (rapid-, short-, intermediate- and 
long-acting) depending on their onset, peak and duration of action (Table 2.1).  
 
 
Figure	  2.3:	  Sequences	  of	  native	  human	   insulin	  and	   its	  analogues.	  For	   the	  analogues	  only	   the	  sites	  of	  
the	  altered	  amino	  acids	  are	  shown,	  while	  the	  rest	  of	  the	  sequence	  (blank)	  remains	  the	  same	  as	  in	  the	  
native	  protein.	  
 A key property in order to achieve rapid or prolonged action is the 
oligomerisation state of insulin. As can be easily observed from Table 2.1, the majority 
of the formulations contain a source of Zn ions (ZnCl2 or ZnO) and are kept in neutral 
pH, conditions that would favour the formation of hexamers in the case of native 
human insulin at the used concentration (~3.5 mg/mL). However, insulin analogues in 
fast-acting formulations (such as insulin glulisine, lispro and aspart) have a reduced 
tendency to form hexamers61 and therefore are more rapidly absorbed compared to 
chain&A& 1" 2" 3" 4" 5" 6" 7" 8" 9" 10" 11" 12" 13" 14" 15" 16" 17" 18" 19" 20" 21"
human" G& I& V& E& Q& C& C& T& S& I& C& S& L& Y& Q& L& E& N& Y& C& N&
glargine" G"
chain&B& 1" 2" 3" 4" 5" 6" 7" 8" 9" 10" 11" 12" 13" 14" 15" 16" 17" 18" 19" 20" 21" 22" 23" 24" 25" 26" 27" 28" 29" 30" 31" 32"
human" F& V& N& Q& H& L& C& G& S& H& L& V& E& A& L& Y& L& V& C& G& E& R& G& F& F& Y& T& P& K& T&
glulisine" K" E"
lispro" K" P"
aspart" D"
glargine" R" R"
detemir" C14"faCy"acid"chain"
degludec" sideFchain"of"E"+"C16"faCy"acid"
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regular insulin. On the opposite end, the addition of a fatty acid at the C-terminal of 
chain B (insulin detemir, degludec) increases self-association of the drug molecules 
resulting in a slow systematic absorption. Similarly, insulin glargine leads to the 
formation of microprecipitates when neutralised after injection, leading to a slow 
release of insulin molecules.62 Finally, the duration of action of formulations 
containing recombinant human insulin (short) and protamine (intermediate action) 
largely depends on several factors (e.g. dose, site of injection, physical activity) and 
varies in different individuals or at different times in the same individual. Thus, 
combination of a short- and intermediate- acting insulin in fixed ratios is quite common 
(pre-mixed formulations) offering more effective coverage in basal (fasting control) 
and bolus (mealtime carbohydrate control) insulin needs.63 
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Table	  2.1:	  Commercial	  formulations	  of	  insulin.	  The	  mentioned	  quantities	  for	  the	  active	  substance	  and	  
the	   inactive	   ingredients	  concern	  preparations	  with	  strength	  of	  100	  units/mL.	  According	  to	  WHO	  1	   IU	  
(International	   Unit)	   of	   human	   insulin	   is	   the	   activity	   contained	   in	   0.03846	   mg	   of	   the	   international	  
standard	  for	  human	  insulin.64	  NPH	  =	  Neutral	  Protamine	  Hagedorn.	  
 
Information for the types of insulin were collected from65-68 
Information about the ingredients were collected from the products’ labels. The following links were 
accessed on 17 Jan, 2017: 
1https://www.drugs.com/pro/apidra.html 
2http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020563s115lbl.pdf 
3http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000258/WC500030372.pdf 
4http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018780s120lbl.pdf 
5http://pi.lilly.com/us/HUMULIN-N-USPI.pdf 
6http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021081s034lbl.pdf 
7http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021536s037lbl.pdf 
8http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203314lbl.pdf 
Type%(acting) Brand Recombinant%human%analogue Appearance mg/mL% Inactive%ingredients%per%mL pH
Rapid Apidra1 insulin,glulisine clear,,colourless,solution 3.49 3.15,mg,m9cresol 7.3
6,mg,tromethamine
5,mg,NaCl
0.01,mg,Tween,20
water,for,injection
HCl,,NaOH,for,pH,adjustment
Humalog2 insulin,lispro clear,,colourless,solution 3.47 0.0197,mg,Zn 7.097.8
3.15,mg,m9cresol
16,mg,glycerin
1.88,mg,Sodium,Phosphate,dibasic
NovoRapid3 insulin,aspart clear,,colourless,solution 3.50 Zinc,chloride
glycerol
phenol
m9cresol
NaCl
Disodium,phosphate,dihydrate
water,for,injection
HCl,,NaOH,for,pH,adjustment
Short%(Regular) Humulin,R4 identical,to,human,insulin clear,,colourless,solution 9 0.015,mg,Zn 7.097.8
(Novolin,R) 2.5,mg,m9cresol
(Actrapid) 16,mg,glycerin
(Insuman) water,for,injection
HCl,,NaOH,for,pH,adjustment
Intermediate%(NPH) Humulin,N5 regular,insulin,+,protamine cloudy,suspension 9 0.025,mg,Zn 7.097.5
(Novolin,N) (human,isophane,suspension) 0.35,mg,protamine,sulfate
(Insulatard) 16,mg,glycerin,
(Protaphane) 3.78,mg,dibasic,sodium,Phosphate
1.6,mg,m9cresol
0.65,mg,phenol
water,for,injection
HCl,,NaOH,for,pH,adjustment
Long Lantus6 insulin,glargine, clear,aqueous,solution 3.64 0.03,mg,Zn 4.0
(Abasalgar) insulin,glargine,(Biosimilar) 2.7,mg,m9cresol
20,mg,glycerol,85%
0.020,mg,Tween,20
water,for,injection
HCl,,NaOH,for,pH,adjustment
Levemir7 insulin,detemir clear,,colourless,solution 14.20 0.0654,mg,Zn 7.4
2.06,mg,m9cresol
16,mg,glycerin
1.80,mg,phenol
0.89,mg,disodium,phosphate,dihydrate
1.17,mg,NaCl
HCl,,NaOH,for,pH,adjustment
Tresiba8 insulin,degludec clear,,colourless,solution 9 0.0327,mg,Zn 7.6
19.6,mg,glycerol
1.50,mg,phenol
1.72,mg,m9cresol
water,for,injection
HCl,,NaOH,for,pH,adjustment
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2.2. MATERIALS AND METHODS 
2.2.1. Materials 
Insulin from bovine pancreas (I6634) and ethylenediamine tetraacetic acid disodium 
salt dihydrate (E5134) (Na2EDTA) were purchased from Sigma-Aldrich. Hydrochloric 
acid (36%; BDH) was purchased from VWR International, sodium hydroxide pellets 
and sodium dihydrogen orthophosphate dihydrate were purchased from Fisher 
Scientific, and disodium hydrogen orthophosphate (71643) was from Fluka 
Biochemika. Latex spheres (3100A) were from Thermo Fisher scientific. Deuterium 
oxide was from Sigma-Aldrich (151882), and ultrapure water was used (18 ΜΩ·cm at 
25 °C) in all cases. The 0.1 M HNO3 for ICP-OES sample preparation was purified in-
house by sub-boiling point distillation, and for calibration, zinc ICP/DCP 356743 and 
sulfur ICP/DCP 356603 standards (Fluka) were used. 
2.2.2. Spectroscopic data collection 
A Jasco V-660 UV-Vis or a NanoPhotometer P300 UV-Vis Spectrophotometer was 
used for measuring insulin concentrations using a molar absorptivity value of ε278 = 
6080 M–1cm–1.69 For the UV-Vis calibration curve, the concentration of the prepared by 
weight sample was determined by its absorbance as 1.75 mg/mL, which was used as 
the starting point. Insulin was subjected to consecutive dilutions and each spectrum 
was acquired following its respective blank with the instrument set to automatic 
baseline correction. All data were recorded in a 1 cm quartz cell, from 250–310 nm, 
with a data interval of 0.2 nm, bandwidth 2.0 nm and scanning speed 100 nm/min. In 
Figure 2.4, the marker points represent the expected concentrations (following 
dilutions of the 1.75 mg/mL sample) and a straight line was fit to the data. 
DLS data were collected on a Malvern Zetasizer Nano-series with a laser 
wavelength of 633 nm and a detection angle of 173˚. A quartz cuvette (ZEN2112) QS 
3.00 mm from Malvern Instruments was used for the measurements. Averages over 6 
measurements at each temperature for each sample were taken and are presented in 
terms of intensity and number values. Number values present the number of particles 
of each size, thus emphasizing smaller particles, whereas intensity values scale by the 
volume, thus emphasizing the presence of larger particles. 
CD spectra were collected on a JASCO J-1500 CD spectropolarimeter using a 
PTC-510 Peltier thermostatted cell holder. The CD spectra (mdeg) were baseline-
corrected by subtracting the corresponding buffer blank from each spectrum at all 
temperatures. The baseline-corrected spectra were zeroed by subtracting the averaged 
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value from 260–250 nm (mdeg) from the whole spectrum. The data were converted 
into Δε per amino acid residue units, the wavelength step was changed to 1 nm and 
data from 240 nm to 190 nm were used as the input format required for the secondary 
structure analysis by SSNN70 and SELCON.71 The CD spectra with high concentration 
(~1 mM) were normalised according to the negative peak at ~208.0 nm of the low 
concentration (~17 µM) spectra in order to facilitate qualitative comparison of the CD 
spectra at the two different concentrations. 
IR spectra were collected on a single reflection ZnSe Attenuated Total 
Reflectance (ATR) accessory, PIKE MIRacle with a high-pressure clamp, on a JASCO 
FT/IR-4200 spectrometer. The sample was heated in the water bath of a Hei-VAP 
rotary evaporator and the temperature was checked with a Digi-Thermo thermometer 
(−55°C to +148°C). Air was recorded as a background. The IR spectra (Absorbance 
units) of the dried sample layers were manually corrected by subtracting a water 
vapour spectrum. The corrected spectra were zeroed in the region of 1800 cm−1 and 
normalised by dividing by the maximum absorbance value between 1600 to 1700 cm−1. 
The SSNN software was retrained with a reference FT-IR data set of 47 proteins with 
known secondary structures from crystallography data, provided by Rina Dukor 
(private communication), and the Amide I band was tested for its secondary structure 
content. The second derivative was calculated for the area 1400–1800 cm−1 in order to 
show the exact positions of the peaks, with a five data point window and without 
smoothing. 
Protein (via Sulfur) and zinc concentrations were determined using an 
Inductively Coupled Plasma Optical Emission Spectrometer (ICP-OES; PerkinElmer 
Optima 5300 DV, model S10) by measuring S at 180.669 and 181.975 nm and Zn at 
206.200 and 213.857 nm. The measurements were conducted by Dr. Hasan Tanvir 
Imam. Plasma operating conditions were: Argon (Ar) flow rate 13.0 L/min, auxiliary 
gas flow rate 0.2 L/min, nebulizer flow rate 0.8 L/min and RF power 1300 W. For 
calibration, 6 Zn and S standards of 0.2, 0.5, 0.7, 1.0, 2.0 and 5.0 ppm were prepared 
gravimetrically in ultra-pure 0.1 M HNO3. Samples were prepared using the same 0.1 
M HNO3, which was also used as a blank. Typically, correlation coefficients of better 
than 0.9998 were obtained. 
For all NMR experiments, the water peak was suppressed using double pulsed 
field gradient spin echo for excitation sculpting (DPFGSE).72 All spectra were Fourier-
transformed, phased and baseline-corrected in Topspin 1.3. 1D 1H-NMR experiments 
were carried out on a Bruker AV III-600 spectrometer operating at 600.13 MHz for 1H. 
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Exponential multiplication was used for apodisation and line broadening 0.5 Hz; no 
zero-filling was applied. The chemical shift of the residual HDO was corrected for its 
temperature-dependence and used as internal reference.73 The line widths of selected 
peaks, which could be easily followed across the increasing temperature, were 
measured in Topspin 1.3 at half height of the peaks. 2D-NMR experiments were 
recorded on a Bruker AV II-700 spectrometer operating at a 1H frequency of 700.24 
MHz and a 13C frequency of 176.08 MHz. Data matrices of 4096 (t2 dimension) by 
440 (t1 dimension) with acquisition times of 0.18 s and 0.02 s (in the respective 
dimensions) were collected as a sum of 32 scans for the 1H–1H chemical shift-
correlated spectra (NOESY and TOCSY), and the spectra were processed with 2048 
points in each dimension of the frequency domain. For the TOCSY spectrum, 
homonuclear Hartman-Hahn transfer using the MLEV17 sequence74 with a mixing 
time of 65 ms was used. For the NOESY experiment, a mixing time of 125 ms was 
used. The 1H–13C correlated spectrum (HSQC) was a sum of 192 scans over data 
matrices of 2048 (t2) by 128 (t1), using 2D H-1/X correlation via double inept transfer 
and Echo/Antiecho-TPPI (time-proportional phase incrementation) acquisition with 
heteronuclear decoupling during acquisition.75-77 The spectral widths were 16 ppm and 
166 ppm and relaxation delay was 1 s. The spectra were processed with 2048 (f2 
dimension) and 1024 (f1 dimension) points. The squared shifted sinebell function was 
used for apodisation of all 2D spectra. 
The balance used was a Mettler Toledo XP2U and the pH meter Mettler 
Toledo Seven Compact pH/Ion S220 InLab Nano Sensors. Refractive indices were 
measured on a Bellingham+Stanley Abbe60/DR Refractometer. The centrifuges were a 
Fisher Scientific microcentrifuge 7200g and a SIGMA 1–14K. A Merck Millipore 
Direct-Q system was used for water purification. 
2.2.3. Temperature dependent measurements 
For all CD temperature-dependent experiments, the same parameters were used: 
wavelength range 260–180 nm, 1 s data integration time (DIT), 2 nm band width, data 
pitch 0.2 nm, 100 nm/min continuous scanning speed. Data were obtained every 5 °C 
from 20 °C to 110 °C, at a ramp rate of 2.5 °C/min with 300 s equilibration time once 
the desired temperature was reached. CD spectra were also recorded at the conclusion 
of the temperature experiment, 5–8 hours after the samples had been cooled down to 
20 °C. Each spectrum is the average of 12 accumulations. A 0.1 cm path length cuvette 
was used for 0.1 mg/mL insulin solutions. For the high concentration solutions (~1 
mM) a 0.01 cm fixed path length round cuvette and a demountable cuvette with a 
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nominal path length of 0.001 cm were used. The path length of the demountable 
cuvette was measured by using the absorbance of 0.2 M potassium chromate and the 
Beer-Lambert Law with an extinction co-efficient of 4830 M−1cm−1 at 372 nm. The 
length was determined to be 0.00208 ± 0.00008 cm, and the value 0.00208 was used in 
the analysis. 
For the 1D 1H-NMR temperature-dependent experiments the acquisition time 
was either 0.7 or 1.2 seconds, a relaxation delay of 1 s, and a 90˚ pulse width of 8.05 
µs were used. The final spectra were the sum of 128 scans. An equilibration time of 5 
minutes was allowed after the desired temperature was reached. The chemical shift of 
the water resonance was determined at each temperature and the excitation frequency 
(centred on the water resonance) was adjusted accordingly. Spectra were acquired from 
20–75 °C, with a 5 °C temperature interval. 
For the DLS experiments, the viscosity was estimated as described by Gilroy 
et al.78 For the neutral and basic samples (Table 2.2), measurements of solutions 
consisting of 1 µL of polystyrene latex spheres of known size (100 nm) in 99 µL of 
blank solution at each temperature were run, while for the acidic sample the viscosity 
of water was used, as latex spheres appeared to aggregate in these conditions due to 
increased hydrophobicity.79 In a temperature range from 20–75 °C with a 5 °C 
temperature interval, 6 measurements were recorded for each temperature. 300 s were 
allowed as the equilibration time after the desired temperature was reached. Each 
measurement consisted of 6 runs, with 60 s total duration. In the case of the hexamer 
control sample, the viscosity was estimated by measuring a solution consisting of 1 µL 
of latex spheres in 25 µL of blank at each temperature. Each measurement consisted of 
10 runs, with 200 s total duration time, and 180 s were allowed as the equilibration 
time. 
For the FT-IR temperature experiment, the instrument was purged with N2 for 
at least 1 hour before recording the first spectrum and continuously throughout the 
measurements. The sample was heated for 20 minutes at each temperature, in a range 
from 20–95 °C with a 5 °C interval. Spectra were recorded at 25 °C, after being heated 
for 20 minutes at 75 °C and for one hour at 95 °C. For the data collection, 5 µL of 
sample were applied on the crystal and dried with CO2-free air. The procedure was 
repeated 4 times for each sample resulting in a 4-layer solid. A spectrum of solid fibres 
was also recorded for a sample that was prepared and treated in the same way and was 
left at room temperature for 5 months. All data were collected at room temperature, 
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using the TGS (triglycine sulfate) detector and in a wavelength range from 400–4000 
cm−1. For each spectrum 1000 scans with 4 cm−1 resolution were co-added. 
 
Table	  2.2:	  Corrected	  values	  for	  viscosity	  at	  each	  temperature	  and	  refractive	  indices	  for	  each	  one	  of	  the	  
blank	  solutions,	  obtained	  as	  described	  in	  the	  text.	  The	  values	  presented	  for	  the	  blank	  at	  pH	  2.5	  are	  the	  
same	  as	  water	  values.	  
 
2.2.4. Sample preparation 
For the UV-Vis calibration, 2.151 mg of insulin were weighed and dissolved in 1.076 
mL of 0.3 M NH4OH. The pH was measured as 10.5. 
For the CD experiments, the different samples were prepared as follows: 
⇒ Low pH sample: insulin was initially dissolved in HCl (0.1 M). Sodium 
phosphate buffer (100 mM, pH 7.0) and water were added. The pH was further 
adjusted with HCl (0.1 M) and the final volume was adjusted with the addition of 
water, resulting in an insulin solution of ~0.1 mg/mL in 10 mM sodium phosphate 
buffer and pH 2.8.  
⇒ Neutral pH samples: insulin was dissolved in 0.1 M NaOH; sodium phosphate 
buffer was added and the solution was split into two parts. EDTA (1 mM) was added to 
one of the aliquots (to complex zinc), aiming at a concentration 1.5 times that of the 
concentration of insulin in the sample. Water was added resulting in insulin solutions 
of ~0.1 mg/mL in 10 mM sodium phosphate buffer. The pH of both samples was 7.3. 
⇒ Basic pH samples: two samples were prepared as for the neutral samples 
except that pH was adjusted with 0.1 M NaOH to pH 10.6 in 10 mM sodium phosphate 
buffer. 
Temperature 
(°C) 
Blank 
pH 2.5 
Blank 
pH 7.7 
Blank 
pH 7.6, 
EDTA 
Blank 
pH 10.9 
Blank 
pH 10.5, 
EDTA 
Blank 
pH 8.0, 
100 mM NaCl 
20 1.003 1.018 0.991 1.075 1.038 0.988 
25 0.887 0.936 0.906 0.945 0.939 0.874 
30 0.792 0.852 0.776 0.790 0.831 0.785 
35 0.714 0.759 0.683 0.724 0.710 0.701 
40 0.649 0.675 0.648 0.673 0.683 0.637 
45 0.595 0.616 0.592 0.621 0.631 0.593 
50 0.548 0.580 0.533 0.566 0.556 0.552 
55 0.508 0.522 0.491 0.520 0.527 0.514 
60 0.471 0.533 0.455 0.476 0.479 0.479 
65 0.438 0.477 0.433 0.478 0.461 0.440 
70 0.407 0.453 0.398 0.444 0.410 0.414 
75 0.378 0.456 0.375 0.425 0.400 0.385 
Refractive 
Index 1.3330 1.3334 1.3332 1.3345 1.3335 1.3340 
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For the high concentration solutions the preparation was the same as for the 
respective EDTA-free samples, resulting in insulin solutions of 1.18 mM at pH 2.3, 
0.90 mM at pH 7.5 and 0.92 mM at pH 10.9. 
All samples were left to equilibrate for 30 mins and the pH was checked again 
before starting the experiment. For all samples, identical control solutions omitting the 
protein (blank) were prepared for baseline correction of CD spectra. 
Samples for DLS were prepared in the same way as samples for CD 
spectroscopy, but with a 50-fold increase in all concentrations. The resulting pH values 
were: 2.5, 7.7 and 10.9 for the EDTA-free basic sample and 10.5 for the EDTA-
containing basic sample. The hexamer control sample25 was prepared in the same way 
as the neutral EDTA-free sample, with the only difference being the addition of NaCl 
(1 M), resulting in an insulin solution of ~8 mg/mL in 10 mM sodium phosphate buffer, 
100 mM NaCl and pH 8.0. The refractive indices of the blank samples were measured. 
All samples and blanks were centrifuged with a centrifugal force of 6,000 rpm for 10 
minutes and filtered through 0.2 µm syringe filters (Thermo Scientific) directly into a 
Quartz cuvette prior to the measurement. 
For the 1H-NMR experiments, the samples were prepared as for the DLS 
experiments, but solutions contained 10% D2O for the field-frequency lock.48 The 
resulting pH values (determined with the pH meter calibrated using buffers in pure 
H2O solutions) were: 2.5, 7.4 and 10.8 for the EDTA-free basic sample and 10.7 for 
the EDTA-containing basic sample. The 2D-NMR experiments (NOESY, TOCSY, 
13C-HSQC) were recorded for an acidic sample (pH 2.5) prepared in the same way, and 
at a temperature of 25 °C. 
For the FT-IR temperature experiment the sample was prepared in the same 
way as the hexamer control sample for the DLS experiment, differing slightly in 
insulin and buffer concentration (10 mg/mL and 50 mM respectively) and a pH of 8.2. 
Solid fibres were obtained from a similar sample that was left at room temperature for 
5 months. 
For the ICP-OES sample preparation, insulin was initially dissolved in 1 M 
NH4OH. 20 mM ammonium bicarbonate buffer (pH 8.0) and water were added, 
resulting in a final insulin solution of 1 mg/mL (theoretical concentration) in 10 mM 
ammonium bicarbonate and 0.1 M NH4OH. The sample was separated into 100, 200, 
300 and 500 µL aliquots, and each was diluted to a final volume of 3 mL using ultra-
pure 0.1 M HNO3. 
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2.2.5. Simulated Annealing (SA) 
Simulated annealing molecular dynamics (SA-MD) simulations were performed 
using the AMBER 12.0 package. Each system was prepared by using the Generalised 
Born implicit solvent model.80 The Particle Mesh Ewald (PME) method was employed 
in all of the simulations.81 During each simulation, all bonds to H atoms were fixed and 
all other bonds were constrained to their equilibrium values by applying the SHAKE 
algorithm.82 A cut-off radius of 9 Å was used. The minimisations were performed for 
10000 cycles. The temperature was controlled by applying the Langevin algorithm, 
while the pressure was controlled by the isotropic position scaling protocol used in 
AMBER.83 Three separate simulations of insulin monomer, dimer and hexamer were 
performed. The initial PDB (Protein Data Bank) structures for monomer, dimer and 
hexamer were extracted from the PDB ID code 4E7T. The pH was set to 10.8, 2.5 and 
7.5 for insulin monomer, dimer and hexamer systems respectively with appropriate 
states of protonation, deprotonation and neutralisation of the amino acid residues 
present in each insulin system, as established using Accelrys discovery studio 2.5. The 
temperature range used was 293–383 K. At the first step after minimisation, the 
systems were heated to 293 K and allowed to relax slightly. A total run of 1.68 ns of 
MD simulated annealing with the time and temperature profile given in Table 2.3 was 
performed for all insulin systems. 
For the secondary structure determination, the DSSP (Dictionary of protein 
Secondary Structure)84 module of AMBER was used and three snapshots of the 
annealing trajectories at 20, 50, 65, 75 and 110 °C were analysed for each system. The 
results presented are the average over three snapshots at 1/3, 2/3 and last trajectory of 
each temperature. α-helix and 3/10-helix were combined to give the total α-helix 
content; β-strand was used for the total β-sheet content; turns were given by addition 
of turns and bends; and “other” is the sum of β-bridge, π-helix and other, according to 
Micsonai et al. and Sreerama et al.85,86 The images from the simulations were 
generated using Swiss-PdbViewer.87 
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Table	  2.3:	  Time	  and	  temperature	  profile	  of	  the	  SA-­‐MD	  simulations	  for	  all	  insulin	  systems.	  
 
  
Steps Temperature (K) Time (fs) 
Annealing Step 1 0–293 500 
Annealing Step 2 293 60000 
Annealing Step 3 293–323 60000 
Annealing Step 4 323 240000 
Annealing Step 5 323–338 30000 
Annealing Step 6 338 120000 
Annealing Step 7 338–348 20000 
Annealing Step 8 348 80000 
Annealing Step 9 348–383 70000 
Annealing Step 10 383 800000 
Annealing Step 11 383–293 100000 
Annealing Step 12 293 100000 
Total Time  1680500 fs = 168 ps = 1.68 ns 
 
 77 
Results and Discussion 
2.3. CONCENTRATION DETERMINATION 
2.3.1. ICP-OES measurements 
According to the manufacturer’s specification sheet, the Zn content in the product is 
≤1.0 % (on a dry basis). ICP-OES was conducted in order to verify the protein 
concentration and the amount of Zn present. The measured sulfur content was divided 
by the number of cysteines in the monomer resulting in 0.80 mg/mL insulin 
concentration, [P]. The ratio of the measured zinc content to the protein’s 
concentration was found to be [Zn]/[P]=0.65 (0.7 % on a dry basis). The sample was 
also checked by UV-Visible absorbance spectroscopy (UV-Vis); this gave the same 
result. The significant and consistent difference observed between the weighed 
theoretical concentration (1 mg/mL) and the experimentally measured concentration 
(0.80 mg/mL) of the tested sample is probably due to the amount of water that solid 
insulin might contain. After confirming that the two methods were in agreement, we 
decided to use UV-Vis as the main method for estimating the protein’s concentration 
and to make that easier, the following calibration curve was measured. 
2.3.2. UV-Vis spectroscopy 
As mentioned above, the experimentally measured concentration (1.75 mg/mL) is 
persistently lower than the theoretical concentration of the originally weighed insulin 
(2 mg/mL) by a factor of ~0.85 on average. The calibration curve (Figure 2.4) provided 
data on the empirical relationship between insulin’s concentration and absorbance, and 
allowed for a quick estimation of the protein’s concentrations in solution. Although the 
used solvent was different than the conditions used in the rest of the experiments (see 
sample preparation)—which can potentially affect the instrumental response and 
subsequently the derived equation for the protein’s concentration—the curve can still 
give a good approximation and the equation is very close to the Beer-Lambert Law 
when 𝜀278 = 6080 M–1cm–1, for 1 cm path length and after conversion from molar to 
mass concentration for insulin (5733.49 g mol−1) is applied: 
 𝐴 = 𝜀𝑐𝐿 ⇒ 𝐴 = 𝜀 𝜌Μ 𝐿 ⇒ 𝐴 =   1.0604𝜌 
 
where 𝛢: absorbance, 𝜀: extinction coefficient, 𝑐: concentration (M), 𝐿: path length 
(cm), 𝜌: concentration (g L−1) and Μ: molecular weight (g mol−1). 
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Figure	  2.4:	  The	  concentration	  of	  insulin	  in	  0.3	  M	  NH4OH	  at	  pH	  10.5	  was	  calibrated	  in	  relation	  to	  the	  UV-­‐
Vis	  absorbance	  at	  278	  nm	  in	  a	  1	  cm	  cuvette.	  The	  equation	  and	  the	  R-­‐squared	  value	  are	  shown	  in	  the	  
chart.	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2.4. DLS SPECTROSCOPY 
Insulin assembly and aggregation is pH and concentration dependent.27,88 Based on the 
X-ray structure,36 the monomer, dimer, tetramer and hexamer diameters with one layer 
of water have been calculated previously (in the literature) as 3.1, 3.7, 4.5, and 5.7 nm, 
respectively.25,88,89 In our dynamic light scattering (DLS) experiments at 1 mM protein, 
three main populations (Figure 2.5i,ii, Table 2.4) were observed below 40 °C. At 20 °C 
(Figure 2.5i), an equilibrium of monomers and dimers (intensity values 3.2–3.3 nm) is 
dominant at acidic and basic pH, whereas tetramers (4.8 nm) are predominant at 
neutral pH in the presence of EDTA (no Zn), and hexamers (5.3 nm) are favoured at 
neutral pH in the presence of Zn, possibly in equilibrium with smaller oligomers as 
judged by the relatively small size value. The acidic and neutral samples presented 
mid-range polydispersity (polydispersity index >0.1), while the basic samples appeared 
to be highly polydisperse (polydispersity index >0.4). All solutions also contained very 
high molecular weight species (data not shown). The hexamer control sample was 
prepared in conditions that strongly favoured the hexamer formation (1.4 mM insulin, 
100 mM NaCl, pH 8.0).25 In the temperature range from 35–65 °C it appeared to be 
nearly monodisperse, showing one main population to be present below 70 °C with 
hydrodynamic diameter (intensity values) of 5.5–6.1 nm. Larger aggregates appeared 
at 75 °C, while the sample had probably evaporated as the intensity decreased 
significantly (Figure 2.5iii, bottom right). The size distributions at 20 °C and from 60–
75 °C are shown in Figure 2.5iii for all six samples. Intensity values were used due to 
their sensitivity in detecting larger particles and multiple populations, which was 
especially useful at higher temperatures, and in order to aid interpretation of the line 
widths in the following 1D NMR experiments (Section 2.7.1). Table 2.4 shows the 
sizes for all six samples in number values from 20–75 °C, which allows for 
comparison among samples of the size of the most prominent population. 
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Figure	   2.5:	   Hydrodynamic	   diameter	   (nm)	   of	   insulin	   (1	   mM)	   in	   acidic,	   neutral	   (EDTA-­‐free,	   EDTA-­‐
containing)	  and	  basic	   (EDTA-­‐free,	  EDTA-­‐containing)	  pH	   in	  10	  mM	  sodium	  phosphate	  buffer	   solutions	  
shown	   by	   DLS.	   i.	   Dynamic	   light	   scattering	   temperature	   experiment.	   The	   size	   of	   insulin	   particles	   in	  
terms	  of	  intensity	  values	  (nm)	  is	  shown.	  ii.	  Size	  distribution	  of	  the	  five	  samples	  at	  25	  °C.	  The	  number	  of	  
particles	  (percent)	  of	  each	  population	  is	  shown.	  iii.	  Size	  distributions	  for	  all	  six	  insulin	  samples	  at	  20	  °C	  
and	  from	  60–75	  °C.	  The	  particle	  sizes	  are	  shown	  in	  intensity	  values.	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Table	  2.4:	  DLS	  temperature	  experiment	  showing	  the	  size	  (hydrodynamic	  diameter)	  of	  insulin	  particles	  
in	   terms	   of	   number	   values	   (in	   nm).	   Insulin	   solutions	   are	   1	  mM	   at	   acidic,	   neutral	   (EDTA-­‐free,	   EDTA-­‐
containing)	  and	  basic	  (EDTA-­‐free,	  EDTA-­‐containing)	  pH	  in	  10	  mM	  sodium	  phosphate	  buffer	  and	  1.4	  mM	  
protein	  solution	  of	  pH	  8.0	  in	  100	  mM	  NaCl,	  10	  mM	  sodium	  phosphate	  buffer.	  The	  percentages,	  where	  
mentioned,	  describe	  the	  population	  of	  each	  size	  in	  the	  sample.	  100%	  population	  is	  implied	  where	  no	  
percentages	  are	  mentioned.	  
 
  
! 20#°C# 25#°C# 30#°C# 35#°C# 40#°C# 45#°C# 50#°C# 55#°C# 60#°C# 65#°C# 70#°C# 75#°C#
pH#2.5# 2.3! 2.4! 2.3! 2.3! 2.3! 2.4! 2.1! 2.0! 2.1! 2.1! 2.0! 2.2!
pH#7.7# 3.7! 3.7! 3.4! 3.4! 3.5! 3.4! 3.2! 3.4! 3.2!
3.7!
(87%)!
1.7!
(13%)!
5.3!
2.6!
(50%)!
8.7!
(12%)!
pH#7.7#
EDTA#
3.4! 3.2! 3.2! 3.3! 3.0! 2.9! 2.9! 2.7! 2.6! 2.6! 3.3!
2.5!
(62%)!
8.5!
(38%)!
pH#10.9# 2.5! 2.3! 2.8! 2.6!
2.5!
(73%)!
1.2!
(27%)!
2.9!
3.4!
(74%)!
1.6!
(26%)!
3.1!
(59%)!
1.6!
(41%)!
2.4! 2.8! 2.7!
2.8!
(51%)!
1.1!
(49%)!
pH#10.5#
EDTA# 2.8! 2.3! 2.4! 2.4! 2.4! 2.4! 2.6! 2.5!
3.3!
(83%)!
0.9!
(17%)!
2.2!
(83%)!
6.4!
(17%)!
5.1!
2.0!
(14%)!
3.1!
(19%)!
7.6!
(67%)!
pH#8.0,#
100#mM#
NaCl!
4.1! 4.0! 3.7! 3.8! 3.8! 3.7! 3.7! 3.6! 3.4! 3.5! 3.7! 2.9!
(33%)!
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2.5. CD SPECTROSCOPY AND SECONDARY STRUCTURE ANALYSIS 
The CD spectra for different insulin samples at 20 °C (Figure 2.6) all have obvious α-
helical content, but differ somewhat from the characteristic α-helix spectrum90 with 
1−2 nm shifts to longer wavelength compared to the typical bands at 195 nm/208 
nm/222 nm of an all α-helical protein. These shifts reflect the relatively high β-sheet 
content of insulin, as the classic β-sheet spectrum has a positive peak between 195 nm 
and 202 nm and a single negative signal between 215 nm and 219 nm. The relative 
intensities of the peaks are consistent with the previously reported pH dependence of 
the insulin CD spectra.91 The most significant variation concerns the 222 nm band, 
which increases in magnitude according to: basic pH < acidic pH, neutral-EDTA < 
neutral EDTA-free (Zn available) sample following the change from predominance of 
monomer, to dimer, to hexamer.10 The largely monomeric basic samples present the 
lowest intensities of the ~195 nm positive peak and the ~222 nm negative peak in 
accord with an increase in random coil content (usually a negative signal at 200 nm 
and little, perhaps positive intensity at 222 nm)92 consistent with the increased 
flexibility of the N- and C-termini of the B chain of the monomer.57,93 In the neutral 
EDTA-free sample, the 222:208 nm ratio is almost 1:1 which is generally accepted to 
reflect increased hydrophobicity of the environment for the respective helices as would 
occur in the hexamer where surfaces are protected from the polar aqueous 
environment.90 The ~195 nm peak increases are a result of the stabilisation of β-sheets 
between chains in the oligomeric complexes. 
 
 
Figure	   2.6:	   CD	   spectra	   in	  Δε	  units	   for	   insulin	   at	   0.1	  mg/mL,	   10	  mM	  sodium	  phosphate	  buffer	   at	   the	  
indicated	  pH	  conditions	  at	  20	  °C.	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The differences between the samples were more apparent when we measured 
the CD as a function of temperature. As described in Section 1.2, thermal denaturation 
leads to activation of the energy barriers and to high-energy unfolded states of the 
protein due to loss of the native interactions. In the effort of the protein to reach an 
alternative conformation, located in one of the neighbouring minima in the energy 
funnel, multiple off-pathway events can take place resulting in partially unfolded, 
misfolded structures and aggregated forms. All samples showed a gradual reduction in 
α-helical character (222 and 208 nm signals, Figure 2.7i), but the temperature at which 
this occurred and the degree of shift towards the 200 nm negative band of the random 
coil differed. The negative maximum for each one of the samples at 110 °C (bold line) 
is shown in Figure 2.7i: the basic samples presented the lowest wavelength (~201–202 
nm), perhaps indicating that they are closer to the completely unfolded conformation; 
the neutral samples shifted down to ~204–205 nm, perhaps due to the presence of more 
than one oligomerisation state, while the acidic sample presented the highest 
wavelength (207.6 nm), probably suggesting that a partially unfolded conformation 
was reached. We quantified these changes using SSNN70,94 (a neural network algorithm 
which uses a self-organising map for protein secondary structure assignment from CD 
spectra and is based on reference set 7 protein database92 enhanced by 5 denatured and 
helical proteins) and SELCON3 using the same reference set 7 (Figure 2.8).71,86 
Reference set 7 has been annotated by DSSP. All five samples showed similar, but not 
identical, trends (Figure 2.7ii), namely gradual decrease in their helical content (of the 
order of 20–40%), increase in unordered content (15–25%), and a relatively abrupt 
increase in β-sheet content (10–20%) at different temperatures. In general, the data 
reflect the higher stability of the oligomers relative to the monomers. The formation of 
β-structure with temperature increase is intriguing and discussed below in the context 
of the molecular modelling. 
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Figure	  2.7:	  i.	  Changes	  in	  the	  CD	  spectra	  of	  insulin	  with	  increasing	  temperature.	  The	  red	  arrows	  in	  the	  
plot	  of	  the	  acidic	  sample	  (pH	  2.8)	  show	  the	  direction	  of	  the	  decreasing	  signal	  intensities	  at	  195	  nm,	  208	  
nm	  and	  222	  nm	  with	  increasing	  temperature,	  which	  was	  observed	  for	  all	  five	  samples.	  For	  each	  sample,	  
the	  spectrum	  at	  110	  °C	  is	  shown	  as	  a	  bold	  line,	  and	  the	  wavelength	  of	  the	  negative	  maximum	  is	  given.	  
ii.	  Changes	  in	  secondary	  structure	  content	  (fraction	  values)	  of	  the	  five	  different	  samples	  of	  insulin	  with	  
increasing	  temperature.	  The	  CD	  spectra	  were	  analysed	  with	  SSNN.	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Figure	   2.8:	   Secondary	   structure	   content	   of	   the	   five	   different	   samples	   of	   insulin	   at	   20	   °C,	   75	   °C	   and	  
110	  °C.	  The	  CD	  spectra	  were	  analysed	  with	  SSNN	  and	  SELCON3.	   Insulin	  solutions	  were	  0.1	  mg/mL	  at	  
acidic,	   neutral	   (EDTA-­‐free,	   EDTA-­‐containing)	   and	   basic	   (EDTA-­‐free,	   EDTA-­‐containing)	   pH	   in	   10	   mM	  
sodium	  phosphate	  buffer.	  
Finally, spectra were recorded at the end of each experiment after cooling 
down to 20 °C. Partial reversibility was apparent only at acidic pH (Figure 2.9i). The 
spectra of the neutral and basic samples suggest that irreversible unfolding took place 
in both cases, due to arrangement of the molecules in trapped intermediate 
conformations in the folding funnel. None of the samples presented clear signs of 
aggregation—perhaps due to the low concentration of the samples (~0.1 mg/mL) used 
for the CD experiments—as visual inspection at the end of the experiment did not 
show presence of any solid particles or turbidity. Comparison of the HT spectra at 
20 °C and after the samples were cooled down to 20 °C (Figure 2.9iii) suggested the 
appearance of some scattering particles only in the case of the neutral EDTA-free 
sample at the end of the experiment, as the HT spectrum showed higher values after 
the sample was cooled down (cooled to 20 °C) compared to the initial spectrum (at 
20 °C). The consistent difference in the wavelength of the minima between basic 
(199.6 nm for both samples) and neutral pH (~203–205 nm) is believed to indicate the 
presence of the completely unfolded monomer at basic pH, and an equilibrium of 
partially unfolded hexamers, dimers that have not completely dissociated and unfolded 
dissociated monomers at neutral pH95 (also discussed in the molecular modelling, 
Section 2.8). The higher wavelength shift in the case of the neutral EDTA-free sample 
(205.0 nm) is due to the presence of the more stable Zn2-hexamer as the predominant 
assembly, which is more resistant to dissociation. In contrast, the EDTA-containing 
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sample (minimum at 202.8 nm) would dissociate more easily, as it is believed to be a 
mixture of dimers, tetramers and possibly Zn-free hexamers. 
The highly helical spectrum at pH 2.8 after cooling down shows that refolding 
to a partially folded structure occurred, as the spectrum is very similar to that at 45 °C 
(Figure 2.9ii). This is in agreement with previous studies suggesting the presence of a 
common partially unfolded intermediate during fibrillation and random coil 
generation.96-98 We assume therefore that this intermediate conformation is shown by 
the spectrum at 110 °C (with a minimum at 207.6 nm). A possible explanation could 
be that the dissociation of the dimer (predominant at acidic pH) results in two 
monomers with different flexibility (discussed in molecular modelling, Section 2.8). 
Monomer 1 represents the completely unfolded conformation, while monomer 2 is 
likely to represent the partially unfolded intermediate, which can potentially lead to 
any of the three pathways, namely refold back to a partially folded state (represented 
by the 45 °C spectrum here), fibril formation or random coil. 
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Figure	  2.9:	  i.	  CD	  spectra	  for	  insulin	  0.1	  mg/mL	  at	  acidic,	  neutral	  (EDTA-­‐containing,	  EDTA-­‐free)	  and	  basic	  
(EDTA-­‐containing,	   EDTA-­‐free)	   pH	   in	   10	  mM	   sodium	   phosphate	   buffer	   after	   having	   been	   heated	   and	  
cooled	  down	  to	  20	  °C.	  Unfolding	  of	  the	  protein	  at	  neutral	  and	  basic	  pH	  seems	  to	  be	  irreversible,	  while	  
refolding	   to	   a	   partially	   folded	   conformation	   is	   apparent	   in	   acidic	   conditions.	   ii.	   Comparison	   of	   CD	  
spectra	  for	  insulin	  at	  pH	  2.8	  at	  20	  °C,	  45	  °C,	  110	  °C	  and	  after	  being	  cooled	  down	  to	  20	  °C.	  Upon	  cooling,	  
the	  partially	  unfolded	   intermediate	  appearing	  at	  110	   °C	   seems	   to	   refold	   to	  a	   structure	  very	   close	   to	  
that	  observed	  at	  45	  °C.	  iii.	  Comparison	  of	  the	  HT	  spectra	  of	  the	  five	  insulin	  samples	  at	  20	  °C	  and	  at	  the	  
end	  of	  the	  experiment,	  after	  the	  samples	  were	  cooled	  down	  to	  20	  °C.	  
Figure 2.10 shows the CD spectra for all five samples at the temperature where 
the partially unfolded intermediate is observed for the first time. As described above 
and as expected from the stability order, the intermediate structure is first observed at 
65 °C for the two basic samples, at 80 °C for the acidic sample and at 90 °C for both 
neutral samples. 
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Figure	  2.10:	  CD	  spectra	  for	  each	  one	  of	  the	  five	  samples	  at	  the	  temperature	  where	  they	  first	  present	  a	  
minimum	  at	  207.0	  or	  207.6	  nm.	  This	  structure	   is	  believed	  to	  represent	  that	  of	   the	  partially	  unfolded	  
intermediate	  and	  is	  observed	  at	  an	  earlier	  temperature	  for	  the	  two	  basic	  samples	  (65	  °C),	  at	  80	  °C	  for	  
the	  acidic	  sample	  and	  at	  90	  °C	  for	  the	  two	  neutral	  samples,	  following	  their	  expected	  stability	  order	  as	  
mentioned	  in	  the	  text.	  
CD uses a significantly lower protein concentration in comparison to DLS and 
NMR. In order to match the DLS and NMR experiments, CD spectra of the EDTA-free 
samples were obtained at a concentration of ~1 mM and compared with the respective 
data at the usual concentration of 0.1 mg/mL (~17 µM). The comparison is shown in 
Figure 2.11. Data below 200 nm were excluded as too noisy due to high HT (High 
Tension) values.99,100 In all three cases (acidic, neutral and basic pH), higher 
concentration results in increase of the intensity of the negative peak at 222 nm, which 
as mentioned above is a sign of increased hydrophobicity. At acidic pH, the dimeric 
unit is probably moving towards the formation of tetramers but with the dimer 
dominant as shown by the DLS results. At neutral pH the two spectra are almost 
identical with the tetramer/hexamer equilibrium slightly moving towards the hexamer 
formation at the higher concentration, while at basic pH the predominant monomer at 
lower concentration seems to move towards a monomer/dimer equilibrium at higher 
concentration (see also DLS and 1H-NMR results). The above data are therefore 
confirming that the oligomerisation equibria in the case of insulin are concentration-
dependent, as expected. 
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Figure	  2.11:	  CD	  spectra	  of	  EDTA-­‐free	   insulin	  samples	  at	  acidic	   (left),	  neutral	   (centre)	  and	  basic	   (right)	  
pH.	  The	  used	  concentration	  of	  ~1	  mM	  (in	  red)	  is	  in	  accordance	  with	  the	  concentration	  used	  for	  the	  DLS	  
and	  NMR	  experiments	  and	  the	  spectra	  are	  compared	  with	  their	  respective	  at	  a	  concentration	  of	  ~17	  
μM	  (0.1	  mg/mL,	  in	  blue).	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2.6. FT-IR SPECTROSCOPY AND SECONDARY STRUCTURE 
ANALYSIS 
Fourier transform infrared spectroscopy (FT-IR) has been largely used to track changes 
in the secondary structure of proteins as a function of solvent, pH, concentration and 
temperature. In the case of insulin, numerous studies have focused on monitoring the 
aggregation and fibrillation process by following characteristic changes on the amide I 
band, as usually there is a difference in the band shape between native and thermally 
denatured states. The majority of the insulin aggregation studies in the literature have 
been conducted at acidic pH (conditions that promote dimers and monomers), and 
fibril formation was initiated by heating at 65 °C for several hours.19-24  
In protein FT-IR spectroscopy, the use of heavy water (D2O) is very common 
in order to minimise the H2O bending vibration band at 1645 cm−1, which overlaps 
with the amide I vibration band of the protein, and spectra are often acquired using a 
CaF2 transmission window. Analysis of the secondary structure content is mainly 
based on band fitting19 or the use of neural networks.101-103 In brief, band fitting 
involves deconvolution of the amide I peak into specific components corresponding to 
secondary structure elements. Fourier deconvolution or second derivative analysis60,104 
is used for enhancement of peak positioning, and the peaks are fitted with a Gaussian 
or Lorentzian function. Integration of the resulting peaks gives the relative amounts of 
each secondary structure element. Neural networks (NN) are algorithms trained to infer 
the secondary structure of proteins (pattern recognition). The training involves a 
reference set containing protein spectra with known secondary structures, and the 
analysis (fitting) is largely affected by the band shape of the tested peak. 
In this experiment insulin was used at higher pH (8.2) than usual, under the 
hexamer promoting conditions,25 which is believed to protect insulin from 
fibrillation.98 Water-based buffer was preferred, as this represents better the protein’s 
native environment in comparison to D2O, and the ATR technique was used. Our 
neural network (SSNN) was retrained70 with an FT-IR reference set consisting of 47 
protein spectra recorded in the transmission mode. Comparing ATR to transmission 
spectra might affect the analysis somewhat due to the effect of the anomalous 
dispersion, which is induced by the use of ATR and results in shifting the peak 
positions (see Section 1.3.2 for FT-IR). The shape of the band though is not expected 
to change much, thanks to the large amount of protein that was deposited on the crystal 
(4 solid layers of the 10 mg/mL protein solution). The depth of penetration is also an 
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effect specific to ATR, which changes the relative peak heights. However, since we 
only use the normalised amide I peak, our analysis will not be affected by this effect. 
In the present study, insulin fibrils were obtained as described in materials and 
methods (Section 2.2.3), and a comparison between insulin as powder from the 
purchased bottle and the formed fibrils is shown in Figure 2.12. Figure 2.13 shows the 
ATR FT-IR spectra of insulin at 25 °C, after being heated at 75 °C, 95 °C and of 
insulin fibrils in absolute absorbance units (i) and normalised absorbance (ii). As the 
temperature increases the amide I peak becomes wider (Figure 2.13 and Figure 2.14) 
which is typical of unfolded structures,22 while also a decrease in intensity is observed, 
perhaps denoting a decrease in concentration in the supernatant solution which was 
used for the spectra (as the protein precipitated in the form of aggregates or fibrils). As 
a consequence of the reduced concentration, the amide I/amide II peak ratio is affected 
by the penetration depth effect at higher temperatures, and is therefore distorted 
(Figure 2.13, the two peaks are almost of equal height at 95 °C and the fibres 
spectrum). 
 
 
Figure	  2.12:	  Aluminium	  weighing	  boats	  containing	  insulin	  from	  the	  purchased	  bottle	  as	  white	  powder	  
(left),	  and	  the	  fibrils	  that	  were	  left	  at	  room	  temperature	  for	  five	  months	  as	  pale	  yellow	  solid	  (right)	  are	  
shown.	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Figure	  2.13:	  ATR-­‐FTIR	  spectra	  of	  insulin	  at	  25	  °C,	  after	  being	  heated	  at	  75	  °C,	  95	  °C	  and	  of	  insulin	  fibres	  
after	  being	  left	  at	  room	  temperature	  for	  five	  months.	  i.	  The	  spectra	  are	  shown	  in	  absolute	  absorbance	  
units.	  ii.	  The	  amide	  I	  band	  is	  normalised	  to	  unity.	  
At 25 °C the amide I peak appears at 1650.8 cm−1 while resolving the peak 
with the second derivative (Figure 2.14) reveals its positions at 1656.6 cm−1 
(characteristic band frequency of proteins with high α-helix content), 1648.8 cm−1 
(usually referred to as random coil) and a shoulder at ~1642.0 cm−1 (β-sheet in native 
proteins).105,106 Heating the sample at 75 °C results in shifting the amide I peak to lower 
frequency (1647.9 cm−1) evidencing an increase in the random coil content, while at 
the same time a shoulder appears at ~1627 cm−1 which is typical for the formation of 
parallel β-sheets resulting from aggregation of unfolded proteins. The second 
derivative locates a wide peak at 1652.7 cm−1 with a shoulder at ~1642 cm−1 and a peak 
at 1625.7 cm−1 (fibril formation). The 95 °C and the fibrils spectra are quite similar, 
presenting the amide I peak at 1647.9 cm−1 and a prominent feature at 1625.7 cm−1 (the 
observed shoulder at the 75 °C spectrum). The second derivative resolves the peak 
giving maxima at 1660.4 cm−1 (turns or 310 helix), 1652.7 cm−1 (disordered) and 1624.7 
cm−1 (parallel β-sheet in fibrils). 
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Figure	  2.14:	  The	  amide	  I	  peaks	  for	  the	  spectra	  at	  25	  °C,	  75	  °C,	  95	  °C	  and	  for	  insulin	  fibrils	  are	  normalised	  
to	   unity	   (bottom).	   Second	   derivative	   amide	   I	   spectra	   (top)	   are	   used	   to	   aid	   peak	   positioning.	   The	  
resolved	  band	  positions	   (within	  ±1	  cm−1)	  are	  given	   in	   the	   table	   (top	   right).	  The	   respective	  secondary	  
structures	  were	  assigned	  according	  to	  Kong	  et	  al.107	  
Quantification of the secondary structure elements using SSNN showed a total 
decrease of 22% in the α-helix content and 17% increase in the β-sheet content for the 
fibres spectrum (Table 2.5). Although the assignment is good enough for helices and 
sheets, random coil content does not seem to be affected which is clearly in 
disagreement with what happens in reality. As explained in Section 1.2, thermal 
experiments can lead to a variety of off-pathway events in the folding funnel (high-
energy states), including non-native conformations of the protein (thermal unfolding), 
trapped intermediates between the denatured and the native state, and aggregation of 
misfolded structures. In the case of insulin, aggregation is initiated by a partially 
unfolded intermediate of the monomer,21,97 and therefore transition from the hexamer 
to the monomer results in loss of ordered structure due to the loose termini, as does 
partial unfolding of the monomer at high temperatures prior to aggregation. 
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Table	  2.5:	  Secondary	  structure	  assignment	  for	  the	  ATR	  FT-­‐IR	  spectra	  of	  insulin	  at	  25	  °C,	  75	  °C,	  95	  °C	  and	  
for	  insulin	  fibrils	  using	  the	  IR	  trained	  version	  of	  SSNN.	  
 
 
By inspecting outputs from the analysis of the FT-IR spectra with SSNN, a 
poor spectral fit and an increased error (NRMSD value, normalised root mean squared 
deviation) were observed at higher temperatures. Figure 2.15 shows a comparison of 
the original and the fitted (predicted) spectra, and the resulting residual. Indeed SSNN 
seems to fail in recognising the new feature at 1625.7 cm−1 and probably this is due to 
the absence of any spectra of denatured proteins forming aggregates or fibrils from the 
reference set. Therefore the occurring change in the shape of the amide I band (an 
additional maximum between 1620–1640 cm−1, characteristic of intermolecular β-sheet 
resulting from fibril formation of unfolded proteins) is not represented in the reference 
set. Hence, caution has to be exercised when interpreting the results, and the use of 
SSNN in the estimation of secondary structure from ATR FT-IR spectra should be 
regarded as an approximation, as different conditions (e.g. comparing ATR to 
transmission spectra) make precise assignment of the secondary structure and 
frequency challenging. 
 
Sample' α)helix' β)sheet' bend' turn' coil'
25°C% 0.47% 0.10% 0.08% 0.12% 0.23%
75°C% 0.33% 0.18% 0.11% 0.15% 0.24%
95°C%1hr% 0.32% 0.18% 0.11% 0.15% 0.24%
ﬁbres%5%
months%old% 0.25% 0.27% 0.11% 0.14% 0.23%
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Figure	  2.15:	  SSNN	  output	  from	  the	  analysis	  of	  the	  ATR	  FT-­‐IR	  spectra	  at	  25	  °C	  (i),	  75	  °C	  (ii),	  95	  °C	  (iii)	  and	  
for	   insulin	   fibrils	   (iv).	   The	   spectral	   fit	   of	   the	   original	   (black)	   to	   the	   predicted	   spectrum	   (blue	   dashed	  
line),	  their	  residual	  (red)	  and	  the	  NRMSD	  value	  are	  shown	  in	  each	  case.	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2.7. 1D 1H- AND 2D-NMR SPECTROSCOPY 
2.7.1. 1D 1H-NMR results 
Applications of NMR spectroscopy to study protein structure and dynamics in solution 
typically involve an impressive arsenal of state-of-the-art multi-nuclear multi-
dimensional techniques such as nuclear Overhauser effect spectroscopy (NOESY), 
hetero-correlated (1H, 13C, 15N) experiments and their hyphenated equivalents, 15N-
NMR-based relaxation measurements to study protein dynamics, and diffusion-ordered 
spectroscopy (DOSY) for estimating molecular size and oligomer speciation.108 In the 
case of insulin especially, specific 1H-NMR experiments have been used for detection 
of aggregation.109,110 However, as our goal was to detect (as simply as possible) 
qualitative differences between two samples, we chose to exploit the information-
rich,111 but often hard to interpret, 1-dimensional 1H-NMR spectroscopy as a simple 
and relatively fast approach. The time required to record each spectrum did not exceed 
5 mins and approximately 4 hours were needed in total for the temperature-dependent 
measurements. Key diagnostic variations were observed in line widths (measured 
values are given where possible), chemical shifts and peak dispersion as a function of 
solution conditions. 
Line widths and peak dispersion (Figure 2.16): The aromatic and backbone 
HN signals between 6 and 10 ppm show clear differences in line widths (Figure 2.16i) 
between samples at room temperature. At basic pH, most of the backbone HN signals 
have disappeared due to exchange with the water protons on an intermediate timescale, 
and the narrow line widths of the signals for aromatic and aliphatic protons suggest 
that mono- and dimeric states are favoured.112 The broadening of the aromatic peaks 
above 40 °C (Figure 2.16ii C, D) is probably an indication of the onset of aggregation, 
which is also supported by the appearance of larger particles in the DLS data especially 
at temperatures from 60 °C onwards (Figure 2.5iii).  
At acidic pH, the backbone HN peaks are widely dispersed (Figure 2.16i), 
indicating that the protein is in a well-folded state, and sharp enough to confirm that 
smaller oligomers, such as dimers, are predominant in these conditions.48  
The broader peaks throughout the neutral-EDTA spectra (up to 55 °C, Figure 
2.16ii B) are a sign of shorter relaxation times, which are, amongst other parameters, 
the result of the presence of larger oligomers (i.e. tetramers and hexamers) with longer 
rotational correlation times (τc). Above 55 °C the decrease in line width of the aromatic 
peaks around 6.4–7.6 ppm (Figure 2.16ii B) can either result from faster tumbling of 
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the present molecules at higher temperatures or indicate that dissociation to smaller 
oligomers (e.g. dimers) occurs. Aggregation seems to start at 70 °C as the lines become 
broad again. As shown above, in the DLS data (Section 2.4, Figure 2.5iii and Table 
2.4), the neutral EDTA-containing sample presented particles that decreased in size 
with increasing temperature. Particles with a diameter of 2.6–2.7 nm (number values in 
Table 2.4, close to the size of monomers and dimers that were observed in the basic 
samples) were detected at 55–65 °C, and 2.5 nm and 8.5 nm (number values) at 75 °C, 
further supporitng the case of dissociation of larger to smaller oligomers from 55 °C 
onwards, and onset of aggregation at 70 °C (as can be seen in Figure 2.5iii). 
The pronounced broadness of all peaks in the spectrum of the neutral EDTA-
free sample is indicative of the dominance of the hexamer12 (Figure 2.16ii A), while at 
higher temperatures (60–70 °C) the aromatic peaks (6.4–7.6 ppm) become 
progressively sharper. Similarly to what was described for the neutral EDTA-
containing sample, sharper lines can either result from faster tumbling of the present 
molecules or suggest an increase in the presence of dimeric or monomeric units.34 In 
this case, DLS data (Figure 2.5iii and Table 2.4) were less clear. However, a decrease 
in the particle diameter was observed at 60 °C (3.2 nm, number values as presented in 
Table 2.4), which probably indicates an equilibrium of larger and smaller oligomers, 
while smaller particles (2.6 nm, close to the size of monomers and dimers) were 
detected at 75 °C, as well as multiple populations of larger particles (Figure 2.5iii). The 
additional hexamer control sample, at pH 8.0, presented similar behaviour in DLS to 
the neutral EDTA-free sample, namely gradual decrease in particle size with increasing 
temperature and smaller particles (2.9 nm, Table 2.4) as well as larger particles at 
75 °C (Figure 2.5iii). The line widths for the peak at 6.71 ppm were measured over the 
increasing temperature (Figure 2.16ii A) to give an example of how this feature can be 
exploited in a quantitative manner for quality control of proteins where molecular size 
or oligomerisation state is relevant, and to complement DLS data. 
Aromatic region (6.4–7.6 ppm) (Figure 2.16ii): Insulin has Tyr and Phe 
residues, which have protons that can be monitored to report on their environment. 
Qualitatively, it is evident that the two basic samples have a high degree of similarity 
in this region, whilst the two neutral samples are significantly different. The Tyr (B26) 
Hδ proton signal at 6.63 ppm, characteristic for the monomeric state,15 shows a gradual 
decrease and eventual disappearance at 50 °C for the two basic samples (Figure 2.16ii 
C, D) indicating the transition from the monomeric to an aggregated state. 
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Figure	   2.16:	   i.	   Comparison	   of	   line	  widths	   and	   overall	   dispersion	   in	   the	   1H-­‐NMR	   spectra	   of	   insulin	   (1	  
mM)	   in	   acidic,	   neutral	   (EDTA-­‐free,	   EDTA-­‐containing)	   and	   basic	   (EDTA-­‐free,	   EDTA-­‐containing)	   pH,	   10	  
mM	   sodium	   phosphate	   buffer	   solutions	   at	   25	   °C.	   In	   the	   aliphatic	   region,	   at	   0.16	   and	   0.45	   ppm	   the	  
characteristic	   peaks	   for	   the	   monomer	   and	   the	   dimeric	   unit	   respectively	   are	   indicated.	   ii.	   Aromatic	  
region	   (6.4–7.6	   ppm)	   of	   the	   1H-­‐NMR	   spectra	   of	   insulin	   at	   neutral	   and	   basic	   pH	   at	   increasing	  
temperature.	   The	   sharpness	   of	   the	   peaks	   at	   70	   °C	   for	   the	   pH	   7.4	   EDTA-­‐free	   sample	   (tetramers	   and	  
hexamers	   predominant	   at	   room	   temperature)	   (A),	   and	   at	   60–65	   °C	   for	   the	   pH	   7.4	   EDTA-­‐containing	  
sample	   (tetramers	   predominant	   at	   room	   temperature)	   (B),	   suggests	   an	   increase	   in	   the	   presence	   of	  
dimeric	  or	  monomeric	  units.	  The	  line	  widths	  for	  the	  peak	  at	  6.71	  ppm	  for	  the	  neutral	  EDTA-­‐free	  sample	  
(A)	  were	  measured	  at	  half	  height	  of	  the	  peak,	  indicating	  transition	  towards	  smaller	  oligomers	  with	  the	  
increase	  of	  temperature.	  The	  peak	  at	  6.63	  ppm	  up	  to	  45	  °C	  for	  both	  basic	  samples	  pH	  10.8	  EDTA-­‐free	  
sample	  (C)	  and	  the	  pH	  10.7	  EDTA-­‐containing	  sample	  (D)	  (monomers	  and	  dimers	  predominant	  at	  room	  
temperature)	  refers	  to	  a	  Tyr	  (B26)	  Hδ	  proton	  signal	  characteristic	  for	  the	  monomeric	  state.	  
Histidine Hε1 region (7.45–8.70 ppm) chemical shifts and line widths 
(Figure 2.17i): Histidine NMR signals are particularly sensitive to pH as their 
imidazole rings gain/lose a proton between pH 6–7, unless they are buried, hydrogen-
bonded, or metal-bound (Figure 2.17i B). Basic samples (Figure 2.17i D, E) have two 
strong signals at 7.51 and 7.66 ppm at room temperature, with measured line widths 4–
6 Hz (representing the monomer), which have been assigned to the Hε1 protons of His 
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(B5) and His (B10) respectively14,16 and decrease in intensity when the temperature 
increases. At 60 °C, a broader peak at 7.61 ppm which has been assigned to a 
denatured form of insulin replaces these signals. At acidic pH (Figure 2.17i A), the 
histidine Hε1 protons appear at 8.53 ppm for His (B5) and 8.61 ppm for His (B10) 
(line widths 6–7 Hz, representing the dimer), as the imidazole ring is protonated under 
these conditions.12,48,113,114 At neutral pH (Figure 2.17i B, C), the histidine Hε1 peaks 
(~7.5–7.6 ppm) appear very broad at 20 °C (34–39 Hz for the EDTA-free sample with 
the hexamer as the predominant form and 27–31 Hz for the EDTA-containing sample 
at which the tetramer is favoured), but become progressively sharper as the 
temperature increases (e.g. at 60 °C, the line width is 4 Hz indicating dissociation to 
monomer). A more detailed discussion about the neutral samples is following. The 
measured line widths of the histidine peaks give a representation of the oligomerisation 
state in each sample (Figure 2.17i, Table 2.6). 
The presence of the peak at 7.43 ppm in the case of the two neutral samples 
(Figure 2.17i B, C), has been previously reported in the literature to refer to the Hε1 
proton of the Zn-free His (B10) signal in higher oligomers (hexamer and half part of 
the tetramer), where a shielding effect is caused by the histidine rings from the 
opposite dimeric units.17 Alhough both of these conformations (tetramers and possibly 
Zn-free hexamers due to their high association constant)45 are favoured in the case of 
the EDTA-containing sample (complexed Zn), in the presence of Zn (EDTA-free 
sample) the formation of the Zn2-hexamer is preferred to the Zn-free molecule,115 thus 
the 7.43 ppm peak is believed to represent only the Zn-free tetramer (half part). In the 
other half of each tetramer and in dimers, the same proton of His (B10) is exposed and 
deshielded at 7.71 ppm as previously reported.17 The broad peak at 7.58 ppm, more 
obvious in the case of the neutral sample containing Zn (EDTA-free), is believed to 
represent both the His (B5) Hε1 proton—in the hexamer due to its upfield shift—and 
the Zn-coordinated His (B10) resonance in the hexamer where the downfield effect 
from the Zn-binding is balanced by the upfield-shifting effect from the opposite 
rings.12,14,17 The peak at 7.66 ppm in the EDTA-containing neutral sample represents 
the His (B5) Hε1 proton of smaller oligomers such as dimers and tetramers. Therefore, 
the above evidence suggests the presence of tetramers and hexamers as predominant 
species at neutral pH in the presence of Zn (EDTA-free sample) and the presence of 
dimers, tetramers and probably Zn-free hexamers in the case of the EDTA-containing 
neutral sample. The progressive sharpening of the His (B5) and His (B10) Hε1 proton 
peaks with the increase of temperature is perhaps a sign that the Zn is not bound to 
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insulin anymore as a consequence of the hexamer dissociation (e.g. EDTA-free neutral 
sample at 70–75 °C, Figure 2.17i B), as seems to be the case in acidic conditions 
(Figure 2.17i A) in which His (B10) is unable to coordinate metal ions. 
The sharpening of the Histidine Hε1 peaks was followed with the increase of 
temperature for all five samples and the line widths measured at half height of the 
peaks (FWHH) are reported in Table 2.6. The FWHH values increase from the 
monomer (basic pH, ~4 Hz) to the dimer (acidic pH, ~7 Hz) and tetramer/hexamer 
(neutral EDTA-containing, ~27 Hz/neutral EDTA-free sample, ~35 Hz) and decrease 
to ~4 Hz at higher temperatures for all samples. The latter observation indicates the 
transition to smaller oligomers (probably monomers) that subsequently will start 
aggregating before fibrillation takes place. The line width of the histidine peak that 
corresponds to the denatured species is also given for the basic samples and those of 
the characteristic for the dimeric unit and the monomer (at ~0.45 and 0.16 ppm 
respectively) for the basic samples and the neutral EDTA-free sample, representing the 
oligomerisation state in each case. 
Shifting: At pH 2.5, the upfield shift of a doublet peak from 8.48 ppm (in the 
25 °C spectrum) to 8.15 ppm at 65 °C (Figure 2.17i A) is remarkable. This signal is 
believed to represent the backbone amide proton of Asn (B3)48 with a coupling 
constant 3JHNHα of 6.7 Hz, and the −0.37 ppm shift can probably be attributed to 
temperature dependence of the amide proton due to its participation in hydrogen 
bonding.116 The flexibility of the N-terminus of chain B, where Asn (B3) belongs, 
could also support participation of the residue in hydrogen bonding. 
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Figure	  2.17:	   Selected	   regions	   from	   the	   1H-­‐NMR	  spectra	  of	   insulin	  at	  acidic	   (A),	  neutral	  EDTA-­‐free	   (B)	  
and	  EDTA-­‐containing	  (C),	  basic	  EDTA-­‐free	  (D)	  and	  EDTA-­‐containing	  (E)	  pH	  at	  increasing	  temperature.	  i.	  
Histidine	  Hε1	  region:	  A.	   (8.1–8.7	  ppm),	  B–E.	   (7.48–7.72	  ppm).	  The	  His	   (B5)	  and	  His	   (B10)	  Hε1	  proton	  
signals	   are	   shown.	   The	   noted	   line	  widths	   of	   the	   histidine	   peaks	   are	   an	   indication	   of	   the	   size	   of	   the	  
dominant	   species	   in	   each	   sample.	   For	   the	   acidic	   sample	   the	   increasing	   shielding	   effect	   on	   the	   two	  
indicated	  doublet	  peaks	  (dotted	  lines;	  the	  peak	  at	  8.48	  ppm	  probably	  corresponds	  to	  the	  backbone	  HN	  
of	  Asn	  (B3),	  while	  the	  signal	  at	  8.66	  ppm	  has	  not	  been	  assigned	  to	  any	  residue)	   is	  suggested	  to	  be	  a	  
temperature	  dependence	  effect	  due	  to	  participation	  of	  the	  protons	  in	  hydrogen	  bonding.	  For	  the	  two	  
basic	  samples	  the	  appearance	  and	  increase	  in	  the	  population	  of	  a	  new	  species,	  probably	  corresponding	  
to	   denatured	   forms,	   is	   indicated.	   ii.	   Methyl	   region	   (0.0–0.8	   ppm).	   The	   disappearance	   of	   the	   peaks	  
characteristic	  of	  the	  monomer	  (0.16	  ppm)	  and	  dimeric	  unit	  (0.45	  ppm)	  is	  shown,	  indicating	  unfolding	  
of	  the	  protein	  with	  increasing	  temperature.	  The	  shown	  line	  widths	  indicate	  the	  presence	  of	  small	  units	  
at	  basic	  pH	  (D,	  E)	  and	  higher	  oligomers	  at	  pH	  7.4	  EDTA-­‐free	  sample	  (B).	   iii.	  Hα 	   region	  (3.5–7.0	  ppm).	  
The	   downfield	   shift	   of	   peaks	   reveals	   a	   gradual	   increase	   in	   the	   β -­‐sheet	   content,	   indicating	   the	  
formation	  of	  aggregates.	  The	  peaks	  at	  5.04	  ppm	  and	  5.37	  ppm	  belong	  to	  Hα 	  protons,	  while	  the	  peaks	  
at	  6.28	  and	  6.60	  ppm	  are	  side	  chain	  NH	  protons	  (see	  2D-­‐NMR	  results,	  Figures	  2.19–2.22).	  
Methyl region (0–1 ppm) (Figure 2.17ii): Insulin has an extremely high-field 
shifted signal for the Leu (B15) Hδ methyl protons in the monomer that is present at 
basic pH117-119 (0.16 ppm, Figure 2.17ii D, E). This signal moves downfield for the 
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dimer and higher assemblies15,120 (~0.45 ppm at 20 °C) where shielding of this methyl 
group by Phe (B24) and Tyr (B26) (Figure 2.18) is less effective, though still present.15 
The acidic pH and neutral EDTA-free samples do not show the resonance at 0.16 ppm, 
confirming the absence of monomers (Figure 2.17ii A, B), while the addition of EDTA 
at neutral pH led to a high level of heterogeneity in the methyl region, consistent with 
the presence of several species (Figure 2.17ii C). In all cases, disappearance of all 
high-field shifted peaks in the methyl region indicates unfolding of the protein. The 
high stability of the hexamer is thus reflected in the persistence of such high-field 
shifted signals up to a temperature of 70 °C for the most stable neutral (pH 7.4) EDTA-
free sample (Figure 2.17ii B).34,50 The line widths of these methyl signals are given 
where possible (Figure 2.17ii, Table 2.6). 
Hα  resonances (3.5–7.0 ppm) (Figure 2.17iii): For all samples, the downfield 
shift of peaks in the Hα proton area, from 3.5–4.5 ppm to 4.6–5.8 ppm at increased 
temperatures (≥50 °C), is thought to reveal gradual increase in the β-sheet content,121 
which is in agreement with our CD and FT-IR results and usually accompanies the 
formation of aggregates. Based on the knowledge that the chemical shifts of Hα 
protons are dependent on secondary structure, it has been suggested that integration of 
1-D 1H-NMR spectra from 4.85–5.90 ppm (largely Hα resonances from residues in β-
conformation) may give estimates of the β-strand content of a protein without the need 
of prior resonance assignment.122 Amyloid-like fibrils are composed of arrays of β-
strands;123 it is therefore possible that the increase in low-field shifted Hα proton 
resonances is an indication for the onset of fibril formation, although the sharpness of 
the peaks indicates that the species are not highly aggregated. Loss of NMR signal 
intensity for the acidic sample at 75 °C (Figure 2.17i–iii A) is also a consequence of 
aggregation which may be observed by visual inspection of the sample at the end of the 
experiment. Differences in the location of these peaks between the neutral and acidic 
(at 4.6–5.0 ppm) (Figure 2.17iii A–C) and the basic samples (at 4.6–4.9 ppm and 5.6–
5.8 ppm) (Figure 2.17iii D, E) suggest the presence of different misfolded 
conformations and aggregates in each case, in accord with our DLS data. The peaks 
with chemical shifts at 5.04, 5.37, 6.28 and 6.60 ppm are discussed below. 
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Figure	  2.18:	  The	  distance	  between	  the	  Leu	  (B15)	  Hδ	  methyl	  group	  and	  the	  aromatic	  residue	  Phe	  (B24)	  
is	  shown.	  Left:	   in	  the	  case	  of	  the	  monomer	  the	  distance	  was	  measured	  as	  3.4	  Å.	  Right:	  for	  the	  dimer	  
the	  distance	  was	  measured	  as	  3.8	  Å.	  
 
Table	   2.6:	   The	   changes	   on	   line	   widths	   (in	   Hz)	   with	   temperature	   are	   shown.	   The	   line	   widths	   were	  
measured	   at	   half	   height	   of	   the	   peaks.	   The	   selected	   peaks	   are:	   the	   Histidine	   Hε1	   peaks	   of	   the	   five	  
samples,	   the	   Leu	   (B15)	  Hδ 	  methyl	   peaks	   for	   the	   dimeric	   unit	   (~0.45	   ppm)	   and	   the	  monomer	   (~0.16	  
ppm)	  for	  the	  basic	  samples	  and	  the	  neutral	  EDTA-­‐free	  sample	  (dimeric	  unit	  only),	  and	  the	  His	  peak	  for	  
the	   denatured	   species	   for	   the	   basic	   samples.	   The	   measured	   line	   widths	   are	   indicative	   of	   the	  
oligomerisation	  state	  and	  the	  predominant	  species	  in	  each	  sample,	  namely	  dimer	  at	  pH	  2.5,	  hexamer	  
at	   pH	   7.4	   EDTA-­‐free,	   tetramer	   at	   pH	   7.4	   and	   presence	   of	   EDTA,	   monomer	   at	   basic	   pH	   (at	   20	   °C).	  
Similarly,	   changes	   in	   the	   line	   widths	   with	   the	   increase	   of	   temperature	   denote	   changes	   in	   the	  
oligomerisation	  state.	  
 
! ! Width&(Hz)&at&T&(°C)&
Characteristic&peaks& peaks&(ppm)& 20&°C& 25&°C& 30&°C& 35&°C& 40&°C& 45&°C& 50&°C& 55&°C& 60&°C& 65&°C& 70&°C& 75&°C&
!
pH&2.5& !! !! !! !! !! !! !! !! !! !! !! !!
His!(B10)! 8.58! 6.40! 7.97! 8.13! 9.58! 6.13! 3.75! 3.47! 3.16! 2.91! 3.00! !! !!
His!(B5)! 8.53! 7.24! 6.61! 5.27! 4.59! 5.85! !! 5.76! 5.01! 3.95! 3.15! !! !!
!
pH&7.4& !! !! !! !! !! !! !! !! !! !! !! !!
His!(B10)! 7.71! 33.54! 33.50! 32.03! 35.19! !! !! !! !! 20.25! 12.99! 6.20! 3.76!
His!(B5)! 7.56! 38.72! 42.31! 41.59! 30.71! !! !! !! !! 17.05! 8.51! 5.39! 4.19!
Leu!(B15)!Hδ!methyl!
(dimeric!unit)! 0.42! 47.60! 55.03! 59.22! 43.93! 42.44! 42.45! 43.72! 41.95! 41.54! 41.19! 40.36! !!
!
pH&7.4&EDTA& !! !! !! !! !! !! !! !! !! !! !! !!
His!(B10)! 7.70! !! !! !! !! !! !! 30.65! 16.18! 4.46! 3.12! 4.05! !!
His!(B5)! 7.66! 27.25! 26.54! 27.92! 36.71! 34.23! 20.10! 9.02! 4.99! 4.01! 3.98! 3.96! 4.36!
!
pH&10.8& !! !! !! !! !! !! !! !! !! !! !! !!
His!(B10)! 7.67! 3.85! 3.88! 3.95! 3.91! 3.51! 3.43! !! !! !! !! !! !!
His!(denatured!
species)! 7.66! !! !! !! !! !! 11.36! 10.54! 10.63! 9.58! 8.22! 8.82! 10.29!
His!(B5)! 7.53! 6.12! 6.39! 5.91! 5.25! 4.09! 3.76! !! !! !! !! !! !!
Leu!(B15)!Hδ!methyl!
(dimeric!unit)! 0.42! 33.75! 29.25! 19.33! !! !! !! !! !! !! !! !! !!
Leu!(B15)!Hδ!methyl!
(monomer)! 0.16! 20.12! 19.31! 18.06! 18.40! 15.60! 14.03! !! !! !! !! !! !!
!
pH&10.7&EDTA& !! !! !! !! !! !! !! !! !! !! !! !!
His!(B10)! 7.65! 4.33! 4.01! 3.78! 3.36! 3.22! 3.04! !! !! !! !! !! !!
His!(denatured!
species)! 7.64! !! !! !! !! !! !! !! !! 7.28! 6.65! 6.93! 7.67!
His!(B5)! 7.51! 5.12! 4.24! 3.88! 3.52! 4.48! 3.60! !! !! !! !! !! !!
Leu!(B15)!Hδ!methyl!
(dimeric!unit)! 0.39! 30.65! 25.07! 20.41! !! !! !! !! !! !! !! !! !!
Leu!(B15)!Hδ!methyl!
(monomer)! 0.13! 19.73! 19.00! 17.91! 17.61! 15.81! 16.36! !! !! !! !! !! !!
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2.7.2. 2D-NMR results 
Interesting is the fact that different peaks appear for each sample in the region from 
5.0–6.6 ppm (Figure 2.17iii), with the only common peak for all samples being the one 
at 5.04 ppm. In an attempt to determine the identity of the residue to which this proton 
refers, 2D 1H experiments were carried out. The 2D-TOCSY spectrum at pH 2.5 at 
25 °C (Figure 2.19) showed a correlation of this resonance with resonances at 8.53 
ppm and 2.97 ppm. As discussed above, the Hε1 proton of the protonated His (B5) 
residue appears at 8.53 ppm, therefore the 5.04 ppm is likely to represent the Hα 
proton of His (B5), whilst the resonance at 2.97 ppm may refer to the Hβ protons. 
The peak at 5.37 ppm is also a Hα proton and presents correlations with two 
spin systems, one of which probably belongs to an aromatic residue as it correlates 
with two aliphatic peaks at 2.81 and 3.35 ppm and an aromatic peak at 7.22 ppm 
(Figure 2.19).16 This peak is tentatively assigned to Phe (B24) on the C-terminus of 
chain B on the monomer-monomer interface, due to its further NOESY correlations 
(Figure 2.20, in green). The two neutral samples present peaks at 5.04 and 5.37 ppm, 
which have also been reported in the literature for the 1H-NMR spectrum of the native 
Zn2-hexamer in the Zn(II)-T6 state,43,124,125 while in the two basic samples only the peak 
at 5.04 ppm appears. 
 
 
Figure	  2.19:	  A	  portion	  of	  a	  2D-­‐TOCSY	  spectrum	  at	  pH	  2.5	  25	  °C,	  showing	  the	  correlations	  of	  the	  protons	  
at	  5.04	  and	  5.37	  ppm.	  
ppm
5.05.56.06.57.07.58.08.59.09.510.0 ppm
10
9
8
7
6
5
4
3
2
1
0
 
 
 
 
 
 
 
 
 
 
 
 
 
Insulin no treatment TOCSY 
1H#(ppm)#
1 H
#(p
pm
)#
 105 
 
Figure	  2.20:	  Left:	  2D-­‐NOESY	  spectrum	  at	  pH	  2.5	  25	  °C,	  showing	  the	  correlation	  peaks	  of	  the	  Hα 	  proton	  
at	  5.37	  ppm	  (green	   line).	  Their	   through	  correlation	  peaks	   (not	   indicated)	   led	  us	   to	   tentatively	  assign	  
the	  Hα 	   proton	   to	  Phe	   (B24).	   The	   correlation	  of	   the	  peaks	  at	   6.6	   and	  7.09	  ppm	   (blue	   lines)	  with	   the	  
protons	  at	  2.55	  and	  3.95	  ppm	  probably	   refer	   to	   the	  signals	  of	  an	  asparagine	  residue.	  Right:	   zoom	   in	  
image	  of	  the	  selected	  area.	  
At acidic pH, the peak at 6.28 ppm has a correlation with a peak at 7.49 ppm 
(Figure 2.21, in red). Given the combination of chemical shifts, the fact that no cross-
peak was present in the 13C-HSQC spectrum (Figure 2.22, red) and the exclusive 
presence at acidic pH, this likely corresponds to an arginine side-chain NH proton. 
From the peak at 7.49 ppm and its through-bond correlations we found that these peaks 
are related to protons at 2.96 (δ-CH2), 1.66, 1.41 (γ-CH2), 1.76, 1.86 (β-CH2), 4.3 (Hα), 
8.26 ppm (backbone HN) (Figure 2.21, red lines). Thus the signal at 6.28 ppm is likely 
to refer to the side chain NH2 protons of Arg (B22). 
The peak at 6.60 ppm exhibits a cross-peak that correlates with the peak at 
7.09 ppm in the 2D-TOCSY spectrum (Figure 2.21, blue). The absence of correlation 
peaks in the 13C-HSQC spectrum (Figure 2.22, blue) indicates that both peaks also 
refer to side-chain NH protons, while both the 6.60 ppm and 7.09 ppm signals further 
correlate with the protons at 3.95 and 2.55 ppm in the 2D-NOESY spectrum (Figure 
2.20, blue). Therefore they are likely to be signals of an asparagine residue. 
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Figure	  2.21:	  Full	  2D-­‐TOCSY	  spectrum	  at	  pH	  2.5	  25	  °C,	  showing	  the	  correlation	  of	  the	  peak	  at	  6.28	  ppm	  
with	  the	  peak	  at	  7.49	  ppm	  and	  the	  through-­‐bond	  correlations	  of	  the	  peak	  at	  7.49	  ppm	  with	  the	  peaks	  
at	   1.41,	   1.66	   (γ-­‐CH2),	   1.76,	   1.86	   (β -­‐CH2),	   2.96	   (δ-­‐CH2),	   4.3	   (Hα)	   and	   8.26	   ppm	   (backbone	  H
N)	   in	   red,	  
probably	  matching	  an	  arginine	  residue.	  The	  correlation	  of	  the	  peak	  at	  6.6	  ppm	  with	  the	  peak	  at	  7.09	  
ppm	  is	  shown	  in	  blue.	  
 
 
Figure	  2.22:	  2D-­‐HSQC	  (13C	  and	  1H)	  spectrum	  at	  pH	  2.5	  25	  °C,	  showing	  the	  absence	  of	  cross-­‐peaks	  for	  the	  
peaks	  at	  6.28,	  7.49	  (red)	  and	  6.6,	  7.09	  (blue)	  therefore	  indicating	  that	  these	  peaks	  refer	  to	  side	  chain	  
NH	  protons.	  
  
ppm
−110 9 8 7 6 5 4 3 2 1 0 ppm
−1
11
10
9
8
7
6
5
4
3
2
1
0
 
 
 
 
 
 
 
 
 
 
 
 
 
Insulin no treatment TOCSY 
1H#(ppm)#
1 H
#(p
pm
)#
ppm
5.56.06.57.07.58.08.59.09.5 ppm
105
110
115
120
125
130
135
140
1H−13C HSQC with SI & adiabatic inversion − hsqcetgpsisp2
6.28%6.6%7.09%7.49%
1H%(ppm)%
13
C%
(p
pm
)%
 107 
2.8. MOLECULAR MODELLING 
The molecular modelling simulations were carried out by Dr. Shirin Jamshidi. In the 
molecular dynamics simulations, the monomer, dimer and hexamer were separately 
investigated for their dynamical behaviour as a function of increasing temperature. We 
used higher temperatures than in the laboratory to compensate for the shorter time 
scale of the simulations. 
Monomer: The overlaid structures at 20, 50, 65, 75 and 110 °C (Figure 2.23i) 
illustrate increasing flexibility and progressive displacement of the B chain C-
terminus,126 and increasingly flexible N-termini for both A and B chains, while the α-
helix content seems to be significantly reduced and the turn content increased at the 
end of the simulation (Table 2.7). 
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Figure	  2.23:	  Overlaid	  structures	  from	  the	  SA-­‐MD	  simulations	  at	  increasing	  temperature.	  From	  black	  to	  
light	  grey	  with	  decreasing	  brightness,	   the	   frames	  are	  at	  20,	  50,	  65	  and	  75	   °C.	  The	   frame	  at	  110	   °C	   is	  
shown	  in	  yellow.	  i.	  The	  monomer	   is	  depicted.	  Left:	  A	  chain,	  centre:	  B	  chain,	  right:	  A	  and	  B	  chains.	   	   ii.	  
Dimer:	  A.	  The	  frames	  are	  at	  20	  °C	  (black)	  and	  110	  °C	  (yellow).	  Leu	  (B15)	  and	  the	  aromatic	  residues	  at	  
the	  C-­‐terminus	  of	  B	  chain	  are	  shown	  in	  both	  structures,	  indicating	  the	  increased	  distance	  at	  110	  °C.	  B.	  
Comparison	   between	   monomer	   1	   from	   the	   dimer	   simulation	   at	   110	   °C	   (yellow)	   and	   the	   monomer	  
simulation	  at	  110	  °C	  (white).	  The	  similarity	  of	  the	  two	  unfolded	  structures	  is	  apparent.	  C.	  Monomer	  2	  
at	  110	  °C	  ended	  up	  in	  a	  differently	  unfolded	  conformation.	  iii.	  Hexamer:	  The	  expansion	  of	  the	  structure	  
and	  the	  tendency	  towards	  dissociation	  with	  increasing	  temperature	  is	  shown.	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Dimer: Figure 2.23ii A shows the overlaid structures at 20 and 110 °C. The 
dimer appears to dissociate at 110 °C, resulting in two differently misfolded monomers. 
The overlay of the 110 °C monomer structure with monomer 1 from the dimer 
simulation (Figure 2.23ii B) shows that the final structures are similar. The extended B 
chain C-terminus (which turns the Leu (B15) methyl group away from the aromatic 
residues Phe (B24), Phe (B25) and Tyr (B26)) leads us to the conclusion that this 
structure represents the completely unfolded conformation, while monomer 2 appears 
in a differently unfolded conformation (Figure 2.23ii C) probably referring to the 
partially unfolded intermediate. Figure 2.24 shows monomer 2 at 20, 50, 65, 75 and 
110 °C. For both chains (A on the left and B on the right), which are depicted 
separately for clarity, the flexibility of the N-termini throughout the simulation is 
apparent. The displacement of the two chains at 110 °C (in yellow) is indicative of the 
high tendency for dissociation of the dimer to the two misfolded monomers. 
 
 
Figure	  2.24:	  Overlaid	  structures	  from	  the	  dimer	  simulation	  (monomer	  2)	  as	  a	  function	  of	  temperature	  
for	  chain	  A	  (Left)	  and	  chain	  B	  (Right).	  From	  black	  to	  light	  gray	  with	  decreasing	  brightness,	  the	  frames	  
are	  at	  20,	  50,	  65	  and	  75	  °C.	  The	  frame	  at	  110	  °C	  is	  shown	  in	  yellow.	  
Hexamer: Figure 2.23iii depicts the overlaid structures at 20, 50, 65, 75 and 
110 °C. The structure gradually expands as the temperature increases, suggesting a 
tendency towards dissociation. At 110 °C the interactions between the antiparallel β-
strands of the B chain C-terminal portions are weakened and the B chain N-terminus is 
completely extended. Each one of the three dimers is separately depicted in Figure 
2.25, suggesting that each dimer can potentially follow a different unfolding pattern. 
Both A (left) and B (right) chains of dimer 1 appear to be more stable and compact in 
contrast to the increased flexibility of dimers 2 and 3, which gradually diverge leading 
to more expanded structures and to a complete extension of the N-termini of the B 
chains in the case of dimer 3. However, dimer 3 appears to preserve its antiparallel β-
strand character in the same way as dimer 1, while dimer 2 appears prone to further 
 110 
dissociation to monomers as the antiparallel β-strand character has disappeared. At the 
end of this simulation, a significant amount of helix content is still maintained (Table 
2.7) which indicates that despite the evident onset of dissociation into monomers, the 
latter do not completely unfold on the short timescale of the simulations. 
 
 
Figure	  2.25:	  Structures	  from	  the	  hexamer	  simulation	  as	  a	  function	  of	  increasing	  temperature.	  Chains	  A	  
(left)	  and	  B	  (right)	  are	  depicted	  separately	  for	  each	  of	  the	  three	  dimers.	  From	  black	  to	  light	  grey	  with	  
decreasing	  brightness,	  the	  frames	  are	  at	  20,	  50,	  65	  and	  75	  °C.	  The	  frame	  at	  110	  °C	  is	  shown	  in	  yellow.	  
The	   three	   dimers	   present	   differences	   in	   their	   unfolding	   patterns,	   therefore	   contributing	   to	   the	  
increased	   stability	  of	   the	  hexamer,	  which	  needs	   significantly	   longer	   time	  and	  higher	   temperature	   in	  
order	  to	  dissociate	  and	  unfold	  compared	  to	  the	  dimer.	  
 The results from the secondary structure analysis for the monomer, dimer and 
hexamer simulations at 20, 50, 65, 75 and 110 °C, using the DSSP algorithm, are 
presented in Table 2.7. As mentioned above, the monomer and the dimer show a 
decrease in the α-helix content, while the hexamer seems to maintain a significant 
amount of its helical content at the end of the simulation. In all three cases the β-sheet 
content is hardly changing, which is contradicting the results from the rest of the 
techniques. This inaccuracy perhaps results from the fact that the simulations depict 
only one molecule in each case, while β-sheet formation is an intermolecular event 
caused by the aggregation of several molecules. 
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Table	   2.7:	   Secondary	   structure	   analysis	   results	   from	   the	   simulations	   of	   insulin	  monomer,	   dimer	   and	  
hexamer	   using	   the	   DSSP	   algorithm	   of	   the	   AMBER	   package.	   The	   results	   were	   averaged	   over	   three	  
snapshots	  at	  each	  one	  of	  the	  shown	  temperatures.	  The	  abbreviations	  stand	  for:	  (h)	  helix,	  (s)	  strand,	  (t)	  
turn,	  (o)	  other.	  
 
  
! ! 20!°C! 50!°C! 65!°C! 75!°C! 110!°C!
Monomer!
(h)!
(s)!
(t)!
(o)!
0.45!
0.00!
0.13!
0.42!
0.46!
0.05!
0.18!
0.31!
0.36!
0.08!
0.20!
0.36!
0.41!
0.03!
0.17!
0.39!
0.20!
0.03!
0.37!
0.40!
Dimer!
(h)!
(s)!
(t)!
(o)!
0.40!
0.05!
0.17!
0.38!
0.38!
0.07!
0.18!
0.37!
0.38!
0.04!
0.21!
0.37!
0.34!
0.09!
0.24!
0.33!
0.27!
0.05!
0.31!
0.37!
Hexamer!
(h)!
(s)!
(t)!
(o)!
0.42!
0.02!
0.16!
0.41!
0.43!
0.03!
0.17!
0.38!
0.37!
0.07!
0.21!
0.35!
0.42!
0.03!
0.18!
0.38!
0.36!
0.05!
0.22!
0.37!
!
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2.9. CONCLUSION 
The main conclusion from this work is that empirical comparisons of data collected 
with the complementary techniques of DLS, CD, FT-IR, NMR and molecular 
modelling coupled with innovative use of temperature dependence can be used to 
identify the occurrences of differences in structure in solution even when the samples 
are heterogeneous. This is therefore the beginning of the development of a batch-to-
batch comparison methodology for comparing the similarity of a new formulation to 
the original product as part of the Quality Control procedure, which will ensure the 
safety and efficacy of a biopharmaceutical product.127 DLS gives a simple indication of 
particle size which helps understanding of line-width variations in NMR spectra. 
Chemical shifts in different regions of the NMR spectrum give evidence for structural 
changes but more detailed analysis of methyl protons, histidines, or other aromatic 
protons (particularly when coupled with temperature dependence) enabled us to 
monitor the presence or loss of intermolecular interactions as well as stabilities of 
samples. CD gave a picture of structural differences and the relative stabilities of 
different samples which could be plotted as percentage changes of different secondary 
structure motifs as a function of temperature. Along with CD spectroscopy, FT-IR can 
look into the secondary structure of globular proteins, showing a promising use in 
combination with our retrained SSNN software, and probably is the first choice 
technique in studying aggregation and fibrillation phenomena. Although the 
simulations were only run for a very short time (ns), they provided a useful 
complement to the experiments when considered over a greater temperature range than 
the experiments, letting us visualise which parts of the molecules were likely to unfold 
first. 
The significance of temperature as a variable is that we were able to observe 
quite subtle differences in structure and/or stability by seeing the different temperatures 
at which the structural motifs were lost and β-strand structure appeared. There was no 
evidence of increased β-strand structure in the molecular dynamics simulations at 
higher temperatures, so we conclude that the β-strand formation is an intermolecular 
event that reflects the early stages of the process that later leads to fibril formation and 
is favoured at higher concentrations such as those used for DLS, FT-IR and NMR. 
Thus combining temperature dependent DLS, CD (with structure analysis), and 
molecular modelling where possible should be explored for probing early aggregate 
formation. Although most of our data confirmed and consolidated existing literature 
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data for insulin, we are not aware of any combined use of these techniques in 
conjunction with temperature variation to probe the early stages of fibre formation. 
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Abstract 
Monoclonal antibodies and antibody-drug conjugates are state-of-the-art 
biotherapeutics against various types of cancer. However, the complexity of their 
structure induces high lot-to-lot heterogeneity depending on the manufacturing 
conditions, and can affect the stability, function and immunogenicity of the final 
product. EMA guidelines require that homogeneity between samples should be 
demonstrated in cases where biosimilar-to-innovator and batch-to-batch comparison is 
pursued. In this work, two native samples of trastuzumab (mAbs) were compared with 
two conjugated samples (ADCs), while at the same time comparison of the used 
conjugation methods was carried out. Mass spectrometry (MS), circular dichroism 
(CD) and dynamic light scattering (DLS) in combination, and coupled with 
temperature dependence, were able to cover the primary structure, post-translational 
modifications (PTMs), relative drug-conjugation, secondary structure, stability, purity 
and aggregation of the samples. Overall, all four samples appeared stable at least up to 
54 °C; ADCs presented reduced stability compared to the mAbs because of their more 
flexible hinge region, while the new patented conjugation method appeared more 
controlled and yielded products of higher purity in comparison to the traditional 
technique. 
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Chapter 3 
Monoclonal Antibodies (mAbs) and 
Antibody-Drug Conjugates (ADCs) 
3.1. INTRODUCTION 
Antibodies are glycoproteins secreted by B cells as a response to substances that are 
recognised as foreign by the organism (antigens). The antibody-antigen interaction is 
characterised by high specificity (lock and key concept), which makes antibodies ideal 
molecules for targeted therapies. In the early 1900s, Paul Ehrlich was the first to 
express the idea of molecules that would be able to deliver the drug directly to the 
disease site,1 receiving a Nobel Prize in Physiology or Medicine in 1908. However, the 
“magic bullets” concept did not see much progress due to difficulties in isolating and 
purifying antibodies from animal or human serum. Milstein and Köhler were the first 
to successfully produce a monoclonal* antibody (mAb) in 1975,2 while Muromonab-
CD3 (OKT3) was the first antibody to receive FDA approval in 1986 as 
immunosuppressive agent for kidney transplantation.3 Murine mAbs, however, had the 
disadvantage of causing allergic reactions followed by triggering of anti-drug 
antibodies (ADAs). With the advent of recombinant technology, the production of 
humanlike antibodies became possible, initially as chimeric4 (65% human) and later as 
humanised5 (95% human). Fully human mAbs followed with the development of in 
vitro phage-display technology6-8 and the generation of mouse strains capable of 
expressing human variable domains.9,10 Both humanised and fully human mAbs act 
similarly to endogenous immunoglobulin G (IgG), and have significantly reduced 
immunogenicity. 
Nowadays, “magic bullets” refer to antibody-mediated targeted therapy using 
structures such as antibody-drug conjugates (ADCs), which combine the specificity of 
mAbs with enhanced potency, due to the attached cytotoxic agents. Unlike 
conventional anticancer therapeutics that can also attack healthy cells, usually resulting 
in increased toxicity, side effects and development of drug resistance, ADCs exploit 
the property of endocytosis and are designed to be inactive in the bloodstream. The 
antibodies recognise and bind to antigens that are specifically expressed by tumour 
                                                      
* Produced by a single cell line, in contrast with polyclonal antibodies, which are secreted by 
different B cell lines. 
 121 
cells and are found on the target cells’ surface. In that way the ADCs enter the cells 
(through endocytosis) and, after being processed, they release the attached drugs 
(toxins), which act either as antimitotic agents by inhibiting microtubule 
polymerisation11-13 or by targeting DNA, cleaving the double-strand at specific sites,14 
and eventually lead to cell apoptosis. Gemtuzumab ozogamicin (Mylotarg) was the 
first ADC that received FDA approval in 2000 for acute myeloid leukemia,15 however 
marketing authorisation was refused by EMA in 200816 and the drug was withdrawn 
from the U.S. market in 2010.17 EMA has so far approved two ADCs: brentuximab 
vedotin (Adcetris) for Hodgkin lymphoma,18,19 and trastuzumab emtansine (Kadcyla) 
for breast cancer.20 Kadcyla is the recommended therapy to patients who have 
previously received the related mAb, trastuzumab—commercially available in the 
European market since 2000, under the name Herceptin.21 
Such complex molecules, as biotherapeutics or more specifically monoclonal 
antibodies, require a series of tests in order to support comparability between a follow-
on version (biosimilar) and the original innovator’s product, as well as batch-to-batch 
similarity. That is because heterogeneity in biologics can occur in any stage of the 
production, from expression to purification, conjugation (when the molecule under 
question is an ADC) and storage. Changes in the conditions used in any of the above-
mentioned steps might induce heterogeneity due to glycosylation variants, lysine-
clipping variants22,23 (both of which are referred to as post-translational modifications, 
PTMs), drug load variants (displaying different drug-to-antibody ratios), and 
modifications caused by degradation of the protein molecule such as deamidation, 
oxidation and aggregation. All mentioned modifications (PTMs, drug load variants and 
modifications resulting from degradation) can affect the stability, potency and 
immunogenicity of the final product. Full control of the manufacturing process is 
therefore of utmost importance, and accordingly significant is inspection of the 
structural similarity and the amount of impurities or degradation products among 
samples. 
This chapter is a comparability study on the stability of four trastuzumab 
molecules, two of which are the native antibodies (mAbs) and the other two are 
conjugated to an antimitotic agent (ADCs). The two conjugates were produced using 
two different techniques: ADC (S) was produced with the traditional “in-solution” 
method,24 while for ADC (LR) a patented “lock-release” method25 was adopted. The 
sample called mAb (LR) went through the patented process including binding to a 
resin and release. The selected analytical techniques in this chapter follow the ICH 
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Guidelines for structural characterisation and confirmation of the molecule.26 As in 
Chapter 2, the room temperature data were complemented with temperature 
dependence, which emphasises subtle differences that might be overlooked at room 
temperature. 
Mass spectrometry (MS) was used as a tool to confirm the primary structure 
(amino acid sequence) of the antibody samples and also in order to look at post-
translational modifications, such as carbohydrate structure and position, and 
degradation products (asparagine deamidation and methionine oxidation). Relative 
quantitation of the toxin molecules on each one of the conjugated samples was also 
applied. Dynamic light scattering (DLS) was chosen for its ability to show any 
impurities in the samples or formation of aggregates (especially at higher temperatures), 
and circular dichroism (CD) provides information on the secondary structure of the 
molecules and the loss of stability with the increase of temperature. 
Commercial products of trastuzumab 
As mentioned above, two products have been authorised—in both the EU and U.S. 
markets—based on the monoclonal antibody trastuzumab and are distributed by Roche. 
Herceptin (trastuzumab) is a recombinant DNA-derived humanised IgG1 monoclonal 
antibody produced by mammalian (Chinese hamster ovary) cell suspension culture and 
purified by affinity and ion exchange chromatography. Trastuzumab selectively binds 
to the human epidermal growth factor receptor 2 protein (HER2), inhibiting signalling 
and preventing proteolytic cleavage of its extracellular domain, which activates the 
receptor under normal conditions. As a result, proliferation of human tumour cells that 
overexpress HER2 is inhibited and Herceptin acts as an antineoplastic agent, indicated 
for breast and gastric cancer. The list of excipients, in the vial that is provided as a 
lyophilised powder* for reconstitution, includes L-histidine HCl, L-histidine, D-(+)-
trehalose dihydrate and Tween 20 (similar to the samples provided for analysis in this 
study, see Materials). The mixture is reconstituted with 20 mL of bacteriostatic water 
for injection containing 1.1% benzyl alcohol as a preservative, yielding a ~21 mg/mL 
solution of trastuzumab at a pH of ~6. The solution is further diluted with 250 mL of 
0.9% NaCl solution in order to be intravenously administered in personalised doses of 
4 mg/kg body weight.27 
                                                      
* A concentrated solution for injection is also available, and in addition to the above-mentioned 
excipients it contains recombinant human hyaluronidase (rHuPH20) and L-methionine. It is 
administered subcutaneously after dilution with 0.9% or 0.45% NaCl solution. 
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Kadcyla (trastuzumab emtansine), is an antibody-drug conjugate of 
trastuzumab, covalently linked to a maytansine derivative (DM1), which is a 
microtubule inhibitor, via a stable thioether linker (MCC, 4-[N-
maleimidomethyl]cyclohexane-1-carboxylate).28 An average of 3.5 DM1 molecules are 
conjugated to each molecule of trastuzumab, and Kadcyla combines the action of both 
trastuzumab—as was described above—and the cytotoxic agent DM1. Selectivity of 
the antibody for the HER2-overexpressing tumour cells increases intracellular delivery 
of DM1 directly to the malignant cells. Upon internalisation, the ADC undergoes 
subsequent lysosomal degradation, resulting in release of DM1-containing cytotoxic 
catabolites and cell apoptosis. The list of excipients contains succinic acid, sodium 
hydroxide, sucrose and Tween 20, and the mixture is reconstituted with sterile water 
yielding a 20 mg/mL solution. The reconstituted solution is further diluted with 250 
mL of 0.9% NaCl solution and is administered intravenously in personalised doses of 
3.6 mg/kg body weight.29 According to EMA, this medicine is subject to additional 
monitoring, and intensive studies are still in progress due to limited data on its long-
term use. 
3.1.1. Antibody structure 
Antibodies are symmetric glycoproteins of the Immunoglobulin (Ig) superfamily, 
consisting of two identical heavy chains, of approximately 50 kDa each, and two equal 
light chains of 25 kDa each, held together by disulfide bonds (Figure 3.1). Each chain 
is divided in variable (VL, VH) and constant domains (CL, CH), with the variable 
domains determining the antigen-recognising part of the molecule and the constant 
domains determining the classes and subclasses of the antibody. While for the light 
chain there are only two types, defining an antibody as kappa or lambda, for the heavy 
chain there are five varieties that classify the antibody as Ig G, M, A, D and E. IgG 
constitutes 75% of the total immunoglobulins in the plasma of healthy individuals, 
therefore therapeutic monoclonal antibodies are typically of the IgG class. Depending 
on the heavy chain, IgG subclasses (or isotypes) can be defined as 1, 2, 3 and 4, with 
IgG1 being the most common (66%) and IgG2 following (23%). All four subclasses 
present >95% homology in the amino acid sequences of the constant domains of the 
heavy chains (CH1, CH2, CH3), but differ in the hinge region both in amino acid 
composition and structure (length, and number of inter-heavy chain disulfide bridges). 
The variable regions for both the heavy and light chains consist of the complementary-
determining regions (CDRs), which bind to the antigen, and the framework regions, 
which aid the CDR to contact the antigen. The variable and the attached to them 
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constant regions of both the light and heavy chains (VL, CL, VH, CH1) combine to form 
the fragment antigen binding domain (Fab), while the fragment crystallisable (Fc) 
domain responsible for triggering cell lysis is composed of the heavy chain CH2 and 
CH3 constant domains. 
 
 
Figure	   3.1:	   Representation	   of	   trastuzumab	   structure	   (or	   an	   IgG1	   antibody),	   showing	   the	   variable	  
domains	   (VH,	   VL)	  with	   the	   CDRs	   and	   the	   constant	   domains	   (CH1–3,	   CL)	   of	   the	   heavy	   (H)	   and	   light	   (L)	  
chains.	   The	   intra-­‐chain	   disulfide	   bonds	   are	   indicated	   with	   black	   lines	   for	   each	   domain,	   while	   the	  
cysteine	  (Cys)	  residues	  forming	  inter-­‐chain	  disulfide	  bonds	  are	  labelled	  and	  the	  bonds	  are	  shown	  as	  S-­‐S.	  
As	  discussed	  below,	  glycosylation	  in	  trastuzumab	  takes	  place	  on	  the	  asparagine	  residue	  Asn	  (300)	  (only	  
one	  of	  the	  present	  glycan	  structures	  is	  shown	  here).	  
Trastuzumab is an IgG1 kappa monoclonal antibody and its primary sequence 
is shown in Figure 3.2. As can be also seen in Figure 3.1 and Figure 3.3, covalent intra- 
and inter-chain disulfide bonds stabilise the structure. Each heavy chain presents 4 
intra-disufide bridges at the cysteine (Cys) sites 22–96, 147–203, 264–324, 370–428 
and the two heavy chains are connected with two inter-chain disulfide bridges formed 
in the hinge region at Cys (229) and Cys (232). Each light chain presents two intra-
chain disulfide bonds, at the sites 23–88 and 134–194, and connects to the respective 
heavy chain with an inter-chain disulfide bridge at L214–H223. In addition to covalent 
disulfide bonds, non-covalent interactions between pairs of domains hold the chains 
together, further stabilising the overall structure. Therefore, even if the inter-chain 
disulfide bonds are broken, the antibody structure may still be maintained. Similarly, 
each one of the regions is folded into a compact, globular domain—mainly composed 
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of antiparallel β-sheet secondary structure motifs—linked to one another by short 
stretches of extended polypeptide chain (Figure 3.3). This domain conformation is, as 
well, stabilised by the internal disulfide bond and powerful non-covalent forces, which 
define the secondary structure of the molecule. 
 
 
Figure	   3.2:	   Amino	   acid	   sequence	   of	   the	   heavy	   (450	   amino	   acids)	   and	   light	   (214	   aa)	   chain	   of	  
trastuzumab.	  The	  heavy	  chain	  is	  approximately	  49	  kDa,	  while	  the	  light	  chain	  almost	  23.5	  kDa,	  resulting	  
in	   a	   total	  mass	   of	   ~148	   kDa	   including	   the	   glycan	   structures	   (Figure	   3.6).	   The	   cysteine	   residues	   that	  
contribute	   to	   the	   formation	  of	  disulfide	  bonds	  are	  highlighted	   in	  yellow	  and	   the	  glycosylation	  site	   is	  
highlighted	  in	  orange.	  
 
 
Figure	   3.3:	   Cartoon	   representation	   of	   an	   IgG2	   antibody	   with	   PDB	   ID	   1IGT.30	   The	   heavy	   chains	   are	  
shown	   in	  blue,	   light	  chains	  are	   in	  orange,	   inter-­‐	  and	   intra-­‐chain	  disulfide	  bonds	  are	  shown	   in	  yellow	  
and	   the	   attached	   glycans	   are	   shown	   in	   ball-­‐and-­‐stick	   representation.	   The	   image	   is	   not	   an	   accurate	  
representation	   of	   trastuzumab,	   but	   serves	   as	   an	   example	   of	   a	   complete	   immunoglobulin	   structure.	  
Swiss-­‐PDB	  viewer	  was	  used	  for	  generating	  the	  image.31	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The antibody-antigen binding is mainly based on steric complementarity 
between the antibody’s CDRs and the antigen’s epitope, while a variety of non-
covalent interactions (Van der Waals, hydrophobic interactions, hydrogen bonds and 
ionic interactions) are also involved. The degree of complementarity determines the 
strength of the binding, and very slight changes in the shape of either can lead to 
weaker binding or no binding at all. It is therefore of major importance that the 
antibody maintains its structure after conjugation with the drug-molecule, and the 
simplest way to investigate such changes is by comparing the secondary structure of 
the samples. 
3.1.2. Toxins 
There are several types of drug molecules that are currently used for antibody 
conjugation. Maytansins (such as DM1 on trastuzumab, used in the commercial 
product Kadcyla) and auristatins (e.g. MMAE on brentuximab, used in Adcetris) act by 
blocking the polymerisation of tubulin, while calicheamicins target DNA. In the 
present study, MMAE (monomethyl auristatin E) was the cytotoxic agent attached to 
trastuzumab. However, in order to achieve stability of the ADC during formulation, 
storage and in the bloodstream after administration, and efficient release of the 
pharmacologically active molecule once the ADC enters the tumour cell, various 
linkers have been designed, which covalently bind the antibody and the cytotoxin. 
Linkers are divided in noncleavable and cleavable. As their name declares, 
noncleavable linkers remain intact during intracellular metabolism and the cytotoxic 
agent is released after lysosomal degradation of the antibody. Cleavable linkers are 
metabolised in the cell and release the drug either after hydrolysis (for acid-labile 
hydrazine linkers) or enzymatic cleavage (peptide-based linkers) or reduction 
(disulfide linkers). Conjugation of the linker/drug molecule takes place on either the 
lysine amines (e.g. Kadcyla) or the cysteine sulfhydryl groups (e.g. Adcetris) of the 
antibody. Lysines are usually highly available and exposed on the antibody molecule 
compared to cysteines (e.g. for trastuzumab there are 90 lysines and 32 cysteines), and 
form stable amide bonds after direct reaction with the linkers used. Cysteines are 
normally involved in the formation of disulfide bridges and therefore partial reduction 
is a necessary intermediate step in order to form the active sulfhydryl groups. As a 
result, lysine-based conjugation leads to greater heterogeneity with different drug-to-
antibody ratio species, while in the case of cysteine-conjugation the four inter-chain 
disulfide bonds are typically targeted, producing up to eight possible sites for 
conjugation after they are partially reduced (Figure 3.4). 
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Figure	   3.4:	   Schematic	   representation	   of	   conjugation	   of	   the	   native	   trastuzumab	  with	   the	   linker/drug	  
vcMMAE.	  Partial	  reduction	  of	  the	  inter-­‐chain	  disulfide	  bonds	  leads	  to	  six	  different	  combinations	  of	  the	  
available	  sulfhydryl	  groups.	  Subsequent	  conjugation	  can	  lead	  to	  a	  respective	  heterogeneous	  mixture	  of	  
trastuzumab	  with	  the	  number	  of	  attached	  toxins	  varying	  from	  0–8.	  
The whole structure (toxin, spacer and linker) used in the present study is 
vedotin (vcMMAE). It consists of the toxin MMAE, the PABC spacer (p-
aminobenzoylcarbamate) and the valine-citrulline peptide (cleavable linker), while 6-
maleimidohexanoic acid is directly attached to the antibody via a cysteine residue 
(Figure 3.5). The peptide linker of vcMMAE allows easy and fast release of the 
cytotoxic molecule after hydrolysis of the valine-citrulline peptide by cathepsin B and 
loss of the PABC molecule. The noncharged MMAE can further diffuse into 
neighbouring cells exerting its cytotoxicity.32 The potency of the ADC can be adjusted 
by regulating the number of the attached cytotoxic molecules. Previously published 
studies have shown that the best therapeutic window is achieved with 2–4 drug 
molecules per antibody, while a higher DAR (drug to antibody ratio) might be 
recognised by the organism as a damaged form and therefore cleared out.33,34 
Ideally the partial reduction and the subsequent conjugation should be highly 
controlled processes in order to avoid production of a heterogeneous mixture with 
varying numbers of cytotoxic molecules per antibody. The targeted residues are 
usually located on the Fc or constant region, or else interference in antigen-binding 
might be risked. The conjugation sites and the number of the cytotoxins attached to the 
antibody should be investigated, so that batch-to-batch reproducibility can be 
confirmed. 
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Figure	   3.5:	   Monoclonal	   antibody	   linked	   to	   the	   vcMMAE	   structure	   via	   6-­‐maleimidohexanoic	   acid	  
(attachment	   group).	   Vedotin	   (vcMMAE)	   consists	   of	   the	   toxin	   MMAE	   (monomethyl	   auristatin	   E),	   a	  
spacer	  (PABC)	  and	  the	  peptide-­‐based	  linker	  valine-­‐citrulline.	  6-­‐maleimidohexanoic	  acid	  is	  attached	  to	  
the	   cysteines	   of	   the	   antibody.	   The	   vcMMAE	   structure	   was	   sketched	   in	   chemspider.com	  
(http://www.chemspider.com/StructureSearch.aspx).	  
3.1.3. Glycosylation 
One of the most important post-translational modifications on antibodies is 
glycosylation. Although glycosylation is a very consistent and reproducible process 
under physiological conditions, production of glycotherapeutic agents is characterised 
by great heterogeneity depending on the culture conditions and usually results in 
protein preparations that contain more than one glycoforms, which as a consequence 
can affect the potency and safety of the product. The current regulatory guidelines, 
therefore, require that the manufacturers should assure that a consistent human 
glycoform profile is maintained for recombinant mAbs and among different lots. 
The most common types of glycosylation are the N- and O-glycans. N-type is 
linked to the amino group of asparagine, when the sequence pattern Asn-X-Ser or Asn-
X-Thr is met, with X being any amino acid except proline. O-glycans are attached to 
the hydroxyl group of serine or threonine. IgG monoclonal antibodies have at least one 
N-glycosylation site located at asparagine 297 of each heavy-chain CH2 domain of the 
Fc portion,35 while the glycosylation site of recombinant IgG isotypes might vary 
slightly, depending on the manufacturing process. Such is the case of trastuzumab, in 
which the glycosylation site is located on Asn (300). In eukaryotes, protein 
glycosylation takes place in the endoplasmic reticulum (ER) and the Golgi apparatus. 
During the initial stage, which is common for all proteins, a block of 3 glucoses (Glc), 
9 mannoses (Man) and 2 N-acetylglucosamines (GlcNAc) is attached to the protein 
(Glc3Man9GlcNAc2) in the ER. A cycle of addition and removal of glycans is achieved 
with the help of transferases and glycosidases, until the protein is correctly folded.36 
Further processing follows in the Golgi apparatus, which aims to diversify the glycans, 
leading to the final glycoforms.37 
a"achment)group) linker) spacer) MMAE))
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In the case of IgG antibodies, sugars usually belong to the bi-antennary 
complex type, presenting a conserved heptasaccharide core, which is composed of two 
N-acetylglucosamine (GlcNAc), three mannose (Man) and two more GlcNAc residues. 
Additional residues might be present, such as fucose, galactose, and N-
acetylneuraminic acid (NANA). Despite the considerable heterogeneity,38 the most 
abundant structures of N-linked glycans in mAbs—also observed in the present 
study—are usually G0F, G1F and G2F, according to the number of galactose residues 
on the two branches (Figure 3.6). Due to their position in the hydrophobic surface of 
the CH2 domain of the antibody molecule (Figure 3.3) and their subsequent 
noncovalent interactions with the protein surface, glycans play a major role in protein 
conformation and stabilisation, maintaining and regulating binding to the Fc 
receptors.39,40 Deviation in the glycosylation of immunoglobulins is linked to several 
diseases (such as rheumatoid arthritis),41 while the presence of certain saccharides (e.g. 
α1,3-fucose) is related with high immunogenicity.42 Conclusively, both the present 
glycoforms and the glycosylation sites need to be well characterised in mAbs, 
confirming consistency in glycan composition among different samples and providing 
an additional evidence of the product’s stability and potency and the manufacturer’s 
control over the whole process. In the case of trastuzumab, G0F, G1F and G2F were 
observed, accounting for ~1.5% of the antibody’s mass. 
 
 
Figure	   3.6:	   Structures	   of	   the	   three	  most	   abundant	   N-­‐glycans	   found	   in	   recombinant	   antibodies.	   The	  
monoisotopic*	  masses	  are	  given	  for	  the	  free	  non-­‐conjugated	  monosaccharides	  and	  for	  the	  non-­‐protein	  
bound	   oligosaccharides	   G0F,	   G1F	   and	   G2F.	   The	   respective	   masses	   are	   18	   Da	   lower	   within	   the	  
                                                      
* The monoisotopic mass is calculated based on contributions only from the lightest isotope for 
each element. 
G0F$
mass:%1462.54%
G1F$
mass:%1624.60%
G2F$
mass:%1786.65%
GlcNAc%
mass:%221.09%
Mannose%
mass:%180.06%
Fucose%
mass:%164.07%
Galactose%
mass:%180.06%
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glycopeptide	  as	  shown	   in	  Figure	  3.11.	  The	  representation	   follows	  the	  symbol	  nomenclature	  outlined	  
by	   the	   Consortium	   for	   Functional	   Glycomics	  
(http://www.functionalglycomics.org/static/consortium/Nomenclature.shtml).	  
3.1.4. Deamidation 
Deamidation is one of the most common amino acid modifications and can be 
observed on asparagine (N) and less frequently on glutamine residues of a protein 
sequence. Previous studies have shown the heavy chain N255 residue as one of the 
modification hotspots observed on the trastuzumab molecule,43,44 while N387 has also 
been shown to be susceptible.45 Deamidation is usually favoured on asparagine 
residues that are solvent accessible and are often found in flexible regions of the 
molecule, while the most common case is when glycine (G) is the following amino 
acid as its short side chain further increases accessibility to the asparagine side chain. 
Asparagine sites followed by amino acids with larger side chains are somewhat 
protected due to steric hindrance. Exposure to high pH (~8) and temperature can 
further promote deamidation. The focus in this study was mainly on the asparagine 
residues, which constitute 3.76% of the sequence (19 residues on HC and 6 on LC), 
and more specifically in cases where these are followed by glycine. In the trastuzumab 
sequence three NG sites can be found (N55, N318 and N387 on HC) and deamidation 
was observed on all three of them (see MS results, Section 3.3.1). 
The mechanism of deamidation is shown in Figure 3.7. The reaction proceeds 
via formation of an L-succinimide intermediate with loss of ammonia (17 Da), which 
is in equilibrium with its D-enantiomeric form. The succinimide intermediate was 
present in most of the cases that deamidation was observed in the present study. 
Hydrolysis (gain of 18 Da) of any of the enantiomers, results in a mixture of aspartate 
(D) and isoaspartate, with the last leading to a significant change in the backbone of 
the protein by introducing a methylene. As a consequence, deamidation causes charge 
heterogeneity in proteins and often results in reduction or loss of biological activity,46 
with some exceptions where the protein remains unaffected.47 Isomerisation of 
aspartate to isoaspartate has been found to play a role in aging, autoimmune response, 
cancer and neurodegeneration (such as Alzheimer’s disease),48 while in the case of 
recombinant monoclonal antibodies it can potentially affect the clinical efficacy 
depending on the location. The importance of identifying the sites and amount of 
deamidation is therefore crucial, in order to evaluate the possible outcomes. However, 
the fact that aspartic and isoaspartic acid have identical masses and similar chemical 
properties (with isoaspartate eluting only slightly earlier), makes it hard to differentiate 
between the two unless specific experiments are conducted.48,49 
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Figure	  3.7:	  Mechanism	  of	  deamidation	   reaction	  on	  asparagine.	  Formation	  of	   the	  cyclic	   L-­‐succinimide	  
with	  loss	  of	  ammonia	  and	  subsequent	  hydrolysis	  to	  aspartic	  or	  isoaspartic	  acid	  happens,	  resulting	  in	  a	  
total	  mass	  increase	  of	  1	  Da	  for	  the	  modified	  peptide.	  The	  structures	  were	  sketched	  in	  chemspider.com	  
(http://www.chemspider.com/StructureSearch.aspx).	  
3.1.5. Oxidation 
Oxidation is the protein modification that results in the addition of one or more oxygen 
atoms to a susceptible side chain, after reacting with atmospheric oxygen or oxygen 
radicals in solution. On monoclonal antibodies, it is most frequently observed on 
methionine and tryptophan residues,50-52 it has been reported on histidine under light 
stress (photooxidation),53 while unpaired cysteines can also be potential sites of 
oxidation.54 The hotspot for methionine oxidation on trastuzumab has been previously 
reported to be the M255 residue.52,55 Since methionine is one of the most hydrophobic 
amino acids, exposure to aqueous environments can promote modification. As a result, 
the presence of polar amino acids in the surrounding environment of a methionine 
residue favours oxidation on the specific site.56 Like most proteins, trastuzumab has a 
low content of methionine residues (0.90%) with five of them located on the heavy 
chain and one on the light chain, while oxidation was observed on two of them (one on 
the heavy and one on the light chain). 
Figure 3.8 shows the steps of oxidation for methionine. Addition of one atom 
of oxygen leads to methionine sulfoxide (Mso), increasing the molecular mass of the 
peptide by 16 Da, while further oxidation results in the addition of an extra oxygen and 
the formation of methionine sulfone (Msn) (increase of 32 Da). Methionine oxidation 
has been found to decrease structural stability and accelerate aggregation,57 it can cause 
−NH3%
+H2O% +H2O%
L*Asparagine% L*Succinimide% D*Succinimide%
L*Aspar:c%acid% L*Isoaspar:c%acid%
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protein misfolding, which disrupts the function,58 while in the case of antibodies it has 
been found to affect interaction with receptors and binding.59 As with deamidation, it is 
therefore important to identify the sites and the extent to which oxidation occurs in 
order to assess the possible consequences on potency and immunogenicity. In the 
present study, only methionine sulfoxide was observed, mainly on M255 (heavy chain), 
and an insignificant amount on M4 (≤ 1%, on the light chain).  
  
Figure	  3.8:	  Oxidation	   steps	  on	  methionine.	  Addition	  of	  one	  oxygen	  atom	  results	   in	   the	   formation	  of	  
methionine	  sulfoxide	  (Mso),	  while	  the	  second	  oxygen	  atom	  leads	  to	  methionine	  sulfone	  (Msn)	  and	  a	  
total	  molecular	  mass	  increase	  of	  32	  Da.	  
  
O" O"
Methionine" Methionine"sulfoxide"(Mso)" Methionine"sulfone"(Msn)"
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3.2. MATERIALS AND METHODS 
3.2.1. Materials 
L-Histidine (H8000), L-Histidine monohydrochloride monohydrate (H5659), Tween 
20 (P9416) and D-(+)-trehalose dihydrate (T9531) were purchased from Sigma-
Aldrich. Ultrapure water was used (18 ΜΩ·cm at 25 °C) in all cases. The latex spheres 
(3100A) were from ThermoFisher Scientific. For the CD calibration a Neodymium and 
Holmium filter from Starna were used. The ammonium D-10-camphorsulfonate was 
from Katayama chemical Co. 05-1251, ammonia solution 35% w/w was purchased 
from Scientific Laboratory Supplies (CHE1136), benzene from Aldrich (401765), and 
the Na[Co(S,S-EDDS)], Na[Co(R,R-EDDS)] standards (CD0038) were synthesized at 
the University of Warwick.60,61 Potassium chromate was purchased from Aldrich 
(216615) and potassium hydroxide pellets AnalaR from BDH (102104V). All 
samples—the native monoclonal antibody prior to conjugation 
(Herceptin/Trastuzumab), the ADC (Her vcE) made using the traditional solution 
method and the ADC made using ADC Biotechnology’s proprietary lock-release 
method—were kindly provided by ADC Biotechnology as follows: 
 
Table	   3.1:	   The	   native	   monoclonal	   antibody	   (Herceptin)	   and	   the	   antibody	   drug	   conjugate	   (Her	   vcE)	  
samples	   as	   received	  by	  ADC	  Biotechnology.	   vcE	   is	   the	   conjugated	   toxin	   used	   as	   the	   anticancer	   drug	  
(MMAE)	  with	   the	   linking	   to	   the	   antibody	   structure	   (altogether	   named	   as	   vedotin	   or	   vcMMAE),	   and	  
Formulation	  A	  is	  a	  solution	  of	  5	  mM	  histidine-­‐HCl	  buffer,	  50	  mM	  trehalose,	  0.01%	  w/v	  Tween	  20	  and	  
pH	   6.0.	   The	   names	   and	   the	   colours	   (blue,	   green,	   red,	   orange)	   of	   the	   samples	   (left	   column)	   are	  
according	  to	  the	  figures	  in	  the	  results	  section.	  
 
3.2.2. Spectroscopic data collection 
Peptide mapping analysis was performed using an Acquity ultra-performance liquid 
chromatography (UPLC) PDA (Photodiode array) detector (Waters) coupled to a Xevo 
G2 Q-TOF (quadrupole time-of-flight) mass spectrometer with ES and Nanospray 
(Waters). The analytical column was an Acquity UPLC BEH C18, 1.7µm, 1.0 x 50 
mm. Mass spectra were processed with MassLynx 4.1, and BiopharmaLynx was used 
Sample'ID' Sample'Reference'No'
Protein'
Concentra5on'
(mg/mL)'
Volume'
supplied'(mL)' Formula5on'
Hercep&n(
(Solu&on)( 038(151( 1.11( 5(x(1(mL( A(
Hercep&n(
(Lock:Release)( 053(113( 1.07( 5(x(1(mL( A(
Her(vcE(
(Solu&on)( 045(016( 1.09( 5(x(1(mL( A(
Her(vcE((Lock:
Release)( 045(007( 0.98( 5(x(1(mL( A(
Sample'name'
in'text'
mAb'(S)'
mAb'(LR)'
ADC'(S)'
ADC'(LR)'
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for confirmation and to aid further interpretation. The light and heavy chain sequences 
of trastuzumab were entered in each software, where the masses of the tryptic 
digestion-generated peptides were computed allowing for up to 5 missed cleavages. 
Carboxymethylation of cysteine residues was set as a fixed modification, while lysine 
clipping at the C-terminus was set as variable modification. Identification of the 
glycopeptides—yielding the glycan and peptide structures—and the glycosylation site 
was allowed with BiopharmaLynx. The data were also manually searched for 
methionine oxidation, asparagine deamidation and the succinimidyl intermediate. The 
areas of the modified and unmodified peptides were calculated by integration of the 
respective peaks in the extracted chromatograms. The amount of modification on each 
site is expressed as a percentage of the total sum of the modified and unmodified areas. 
The quantitative LC-MS/MS analysis was performed using an Acquity UPLC 
PDA detector (Waters) in-line with a Xevo TQ-S Triple Quadrupole tandem mass 
spectrometer with ES (Waters). The analytical column was an Acquity UPLC BEH 
C18, 1.7µm. For each of the conjugated samples (ADC (S) and ADC (LR)), sample 
treatment—with the necessary reactions prior to MS analysis—was conducted in 
triplicate. Eight replicate measurements in total were acquired for each conjugated 
sample, from which two were excluded in each case. All data were analysed using 
MassLynx 4.1, and the quantification was performed using the integrated areas of the 
peaks of interest in the MRM plot (multiple reaction monitoring plot). The mass 
fragment corresponding to m/z 359.20 was used as the marker peptide, and the ions 
with m/z 686.50 and m/z 718.50 were fragments resulting from the drug molecule of 
the drug-conjugated peptides of the light (LC) and heavy (HC) chain as shown in Table 
3.4. The sum of the integrated areas from the two transitions for each drug-conjugated 
peptide was normalised by dividing by the integrated area of the marker peptide. 
 The DLS and CD data were collected on the instruments as mentioned in 
Chapter 2 (Section 2.2.2). The data were collected in six replicates and processed as 
discussed in Chapter 2, with a few differences that are described below. The high 
concentration (1 mg/mL) CD data were collected on a JASCO J-815 
spectropolarimeter. 
For the DLS data 6 measurements at each temperature were averaged for each 
replicate. For each sample, the data are presented in terms of intensity and number 
values as an overall mean of the averaged values over the 6 replicates. The standard 
deviation was calculated over six values in each case, using the averaged 
measurements of each replicate. 
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For the CD spectra, the same spectrum of the formulation was subtracted from 
each replicate in the case of the first three replicates, while for the last three replicates 
spectra of the formulation were recorded on the same day and cuvette as their 
respective samples and used for the baseline-correction. The data were zeroed by 
subtracting the averaged value from 250–240 nm from the whole spectrum (mdeg) and 
converted to Δε units. The data were averaged over the 6 replicates (as presented in the 
text) and the wavelength step was changed to 1 nm. For the secondary structure 
analysis the truncated spectra and SSNN were used.62 For the high concentration (1 
mg/mL) CD spectra, 5 replicates were recorded for each sample and baseline-corrected 
by subtracting the same formulation spectrum. Zeroing, conversion to Δε units and 
averaging followed, and the data were shifted by −3 nm to correct for the difference in 
the calibration between the two instruments. 
The balance, pH meter, refractometer, centrifuges and water purification 
system were as described in the spectroscopic data collection of Chapter 2 (Section 
2.2.2). 
3.2.3. Measurements 
For the peptide mapping experiments, the peptide mixture was infused onto the 
column at a flow rate of 10 µL/min and a total volume of 15 µL was injected. The 
column temperature was 50.0 °C, elution was performed at 0.350 mL/min and a 
gradient as shown in Table 3.2, and electrospray ionisation (ESI) in the positive ion 
mode was used. The spectrometer was calibrated (for mass correction) prior to analysis 
using [Glu1]-Fibrinopeptide B. MS spectra were recorded over an m/z range of 50-
2000 with a scan duration of 0.5 sec, capillary voltage was 2.5 kV, cone voltage 40.0 V, 
source temperature 120 °C and desolvation temperature was 400 °C. The cone gas flow 
was set to 50 L/h and the desolvation gas flow was 550 L/h. 
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Table	  3.2:	  Liquid	  chromatography	  gradient	  table	  for	  the	  peptide	  mapping	  Q-­‐TOF	  experiments.	  Solvent	  
A:	  0.1%	  formic	  acid	  in	  water,	  solvent	  B:	  0.1%	  formic	  acid	  in	  acetonitrile.	  The	  total	  run	  time	  was	  45	  min.	  
 
 
For the mass spectrometric quantitation, the peptide mixture was infused onto 
the column at a flow rate of 5 µL/min and a total volume of 5 µL was injected. The 
column temperature was 60.0 °C, elution was performed at 0.400 mL/min and a 
gradient as shown in Table 3.3. The mass spectrometer was operated in the positive ion 
electrospray ionisation (ESI) mode and calibrated prior to analysis using 0.1% ortho-
phosphoric acid. The capillary voltage, cone voltage and collision energy were set to 
2.4 kV, 30.0 V and 25.0 eV, respectively. The source temperature was set to 150 °C and 
the desolvation temperature was 550 °C with a desolvation gas flow of 1100 L/h. The 
MRM (multiple reaction monitoring) acquisition mode was used, following the parent-
to-daughter ion transitions for a marker peptide and the peptides attached to the drug 
molecule as shown in Table 3.4. 
 
Time%(min)% Flow%rate%(mL/min)% %A% %B% Curve%
Ini$al' 0.350' 100.0' 0.0' Ini$al'
0.30' 0.350' 100.0' 0.0' 6'
34.00' 0.350' 55.0' 45.0' 6'
35.00' 0.350' 15.0' 85.0' 6'
37.00' 0.350' 15.0' 85.0' 6'
38.00' 0.350' 100.0' 0.0' 6'
39.00' 0.350' 0.0' 100.0' 6'
40.00' 0.350' 100.0' 0.0' 6'
41.00' 0.350' 0.0' 100.0' 6'
42.00' 0.350' 100.0' 0.0' 6'
43.00' 0.350' 0.0' 100.0' 6'
44.00' 0.350' 100.0' 0.0' 6'
45.00' 0.350' 100.0' 0.0' 6'
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Table	  3.3:	   Liquid	  chromatography	  gradient	   table	   for	   the	  mass	   spectrometric	  quantitative	  analysis	  on	  
the	  TQ-­‐S	  spectrometer.	  Solvent	  A:	  water,	  solvent	  B:	  acetonitrile.	  The	  total	  run	  time	  was	  45	  min.	  
 
 
Table	   3.4:	   Transitions	   of	   parent	   to	   fragment	   ions	  monitored	   in	   the	  MRM	  mode	   for	   the	   quantitative	  
analysis	  of	  drug	  molecules	   in	  the	  antibody	  structure.	  The	  marker	  peptide,	   the	  drug	  peptides	  and	  the	  
retention	  time	  (RT)	  at	  which	  they	  are	  eluted	  are	  shown.	  MMAE	  is	  the	  drug	  molecule	  without	  the	  linker	  
and	  monoisotopic	  mass	  718.50	  Da.	  LC:	  light	  chain,	  HC:	  heavy	  chain.	  
 
3.2.4. Temperature dependent measurements 
For all CD temperature-dependent experiments, the same parameters were used: 
wavelength range 250–180 nm, 1 s data integration time (DIT), 2 nm band width, data 
pitch 0.2 nm, 100 nm/min continuous scanning speed. Data were obtained every 1 °C 
from 20 °C to 100 °C, at a ramp rate of 1.0 °C/min. 30 s were allowed as equilibration 
time once the desired temperature was kept within ± 0.1 °C for 5 seconds. For the last 
three replicates, CD spectra were also recorded at the conclusion of the temperature 
experiment, at least 30 min after the samples had been cooled down to 20 °C. Each 
spectrum is the average of 4 accumulations, while 16 accumulations spectra were 
collected for each sample before the temperature experiment, at 20 °C. The total 
duration time of the temperature experiment was ~ 8 h. A 0.1 cm path length cuvette 
Time%(min)% Flow%rate%(mL/min)% %A% %B% Curve%
Ini$al' 0.400' 100.0' 0.0' Ini$al'
0.50' 0.400' 100.0' 0.0' 6'
37.50' 0.400' 55.0' 45.0' 6'
40.00' 0.400' 3.0' 97.0' 6'
41.00' 0.400' 3.0' 97.0' 6'
41.50' 0.400' 100.0' 0.0' 6'
42.00' 0.400' 0.0' 100.0' 6'
42.50' 0.400' 100.0' 0.0' 6'
43.00' 0.400' 0.0' 100.0' 6'
43.50' 0.400' 100.0' 0.0' 6'
44.00' 0.400' 0.0' 100.0' 6'
44.50' 0.400' 100.0' 0.0' 6'
45.00' 0.400' 100.0' 0.0' 6'
Transi'on)(m/z)) RT)(min)) Pep'de)(parent)ion)) Fragment)ion)
Pep'de)
property)
886.99%>%359.20% 22.24%±%0.16% LC46–61% y’’3% Marker%
812.44%>%686.50% 32.66%±%0.17% LC212–214% MMAE%fragment% Drug%
%%%%%%%%%%%%%>%718.50% MMAE% Drug%
884.48%>%686.50% 30.27%±%0.18% HC222–225% MMAE%fragment% Drug%
%%%%%%%%%%%%%>%718.50% MMAE% Drug%
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was used for ~0.1 mg/mL trastuzumab solutions. For the high concentration solutions 
(~1 mg/mL) and for the excipients of the formulation a demountable cuvette with a 
nominal path length of 0.01 cm was used. The path length of the cuvette was measured 
by using the absorbance of 0.02 M potassium chromate and the Beer-Lambert Law 
with an extinction co-efficient of 4830 M−1cm−1 at 372 nm, and was determined to be 
0.01071 ± 0.00003 cm. The value 0.01071 was used in the analysis. The J-1500 CD 
spectrophotometer was calibrated according to SOP 48.3 (attached in Appendix C) at 
the beginning and at the end of the temperature-dependent experiments, in order to 
confirm that its operation was within the accepted criteria (see below, CD calibration, 
Section 3.2.6). 
For the DLS experiments, the viscosity was estimated63 for the used 
formulation (Table 3.5), by running measurements of solutions consisting of 1 µL of 
polystyrene latex spheres of known size (100 nm) in 99 µL of blank solution at each 
temperature. The Z-average64 sizes were used, as the blank was monodisperse 
(polydispersity index < 0.1). In a temperature range from 20–75 °C with a 5 °C 
temperature interval, 6 measurements were recorded for each temperature. 300 s were 
allowed as the equilibration time after the desired temperature was reached and each 
measurement consisted of 10 runs, with 200 s total duration. Six replicates were 
recorded for each one of the four samples. 
 
Table	  3.5:	  Corrected	  values	  for	  viscosity	  at	  each	  temperature	  and	  refractive	   index	  for	  the	  used	  blank	  
solution	  (Formulation	  A).	  
 
3.2.5. Sample preparation 
All protocols for the reactions, sample treatment and standard operating procedures 
(SOPs) used for the MS experiments are proprietary of BioPharmaSpec and therefore 
cannot be published herein. 
Formulation A was prepared as a blank for the CD and DLS experiments. A 
30 mM histidine buffer was prepared by mixing 530 µL of 60 mM L-histidine 
monohydrochloride solution with 470 µL of 60 mM L-histidine free base solution and 
1 mL of water. The 30 mM Histidine-HCl buffer was mixed with 0.2% w/v Tween 20, 
100 mM trehalose and water in suitable ratios, resulting in a final formulation of 5 mM 
histidine buffer, 50 mM trehalose, 0.01% w/v Tween 20 and pH 6.01. 
Temperature 
(°C) 20 25 30 35 40 45 50 55 60 65 70 75 
Refractive 
Index 
Formula(on*A* 1.029 0.909 0.805 0.717 0.652 0.601 0.555 0.515 0.476 0.440 0.409 0.379 1.335 
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For the CD temperature dependent measurements the samples and the 
formulation were diluted by a factor of 10 with water. CD data of the samples in their 
original concentration (~1 mg/mL) were also recorded at 20 °C, using a 0.01 cm 
cuvette. 
For the DLS experiments samples and formulation (blank) were used in their 
original concentrations. The formulation solution with the latex spheres was sonicated 
for 2–3 min, and all solutions (samples and formulation) were filtered through 0.2 µm 
syringe filters (Thermo Scientific) directly into the Quartz cuvette prior to the 
measurement. The refractive index of the blank was measured (Table 3.5). 
3.2.6. CD calibration 
The target values and the measured values from the CD spectrophotometer calibration 
before and after the temperature-dependent experiments are shown in Table 3.6 and 
Table 3.7 for each one of the performed tests. For the calibration of the wavelength 
accuracy, the neodymium and holmium filters, ammonia65,66 and benzene67,68 vapour 
were used (Table 3.6). Ammonia vapour was used only at the end of the experiments. 
To determine the scaling factor for the CD intensity, a 0.06% (w/v) aqueous 
ammonium D-10-camphorsulfonate (ACS)69 solution and the enantiomeric forms 
(R,R)- and (S,S)-Na[CoIII(EDDS)] (ethylenediaminedisuccinate)61,70 were used (Table 
3.7). 
The measured values from the wavelength accuracy tests (Table 3.6) are 
within the accepted limits in the region 240–640 nm for both calibrations—before and 
after the experiments. At lower wavelengths (194-209 nm), the accuracy presents a 
deviation of ~−0.3 nm from the accepted values. From the intensity performance tests 
(Table 3.7), the maximum of the ACS solution peak at 291 nm appeared to be 5.3–
5.6% lower than the target value, while the deviation for the (R,R)-Na[CoIII(EDDS)] 
enantiomer was 3.0–4.6% at 211.5 nm. The maxima for the two enantiomeric forms 
appeared at 210.5 nm rather than at 211.5 nm, which is in agreement with the noticed 
wavelength deviation at this region. The ratio of the signals at 193 nm and 291 nm for 
the ACS solution was calculated as 2.02 and 2.06 before and after the experiments 
respectively, with the last value meeting the acceptance criteria, as this is normally 
expected to be 2.05-2.10. 
The observed wavelength deviation and the intensity variation at the far-UV 
region—where the protein spectra are analysed—could potentially affect the secondary 
structure prediction and the spectral fit with the used algorithm. In order to adjust for 
these differences the spectra can be artificially shifted by +1 nm and a scaling factor of 
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~1.04 can be applied for the intensity.71,72 However, no effect from the calibration was 
observed on the secondary structure prediction, and therefore the corrections were 
considered unnecessary. 
 
Table	   3.6:	   Target	   wavelengths	   for	   the	   HT	   maxima	   for	   each	   one	   of	   the	   calibration	   tests,	   measured	  
wavelengths	   at	   the	   beginning	   and	   at	   the	   end	   of	   the	   experiments	   and	   the	   respective	   deviations	   are	  
presented.	  The	  measured	  values	  should	  be	  ±	  0.8	  nm	  from	  the	  target	  values.	  Values	  that	  do	  not	  meet	  
the	  criterion	  are	  noted	  in	  red.	  
 
 
Table	   3.7:	   The	   maximum	   target	   intensity	   values	   at	   the	   specific	   wavelengths	   and	   the	   measured	  
intensities	   before	   and	   after	   the	   temperature	   experiments	   are	   shown	   for	   the	   performed	   tests.	   The	  
measured	  values	  should	  be	  ±	  1	  mdeg	  from	  the	  target	  values.	  Values	  that	  do	  not	  meet	  the	  criterion	  are	  
noted	  in	  red.	  
 
  
Test% Target%Wavelength%(nm)%
Wavelength%before%
experiment%(nm)% Devia8on%(nm)%
Wavelength%a9er%
experiment%(nm)% Devia8on%(nm)%
Neodymium)ﬁlter) 586.0) 585.5) −0.5) 585.4) −0.6)
Holmium)ﬁlter)
637.5) 638.4) 0.9) 638.2) 0.7)
536.6) 536.2) −0.4) 536.0) −0.6)
460.2) 459.6) −0.6) 459.6) −0.6)
453.7) 453.4) −0.3) 453.2) −0.5)
445.7) 445.2) −0.5) 445.2) −0.5)
360.9) 360.4) −0.5) 360.2) −0.7)
333.9) 333.4) −0.5) 333.4) −0.5)
287.6) 287.2) −0.4) 287.2) −0.4)
279.4) 279.0) −0.4) 278.8) −0.6)
Benzene)vapour)
259.0) 258.7) −0.3) 258.6) −0.4)
253.0) 252.6) −0.4) 252.6) −0.4)
247.2) 246.8) −0.4) 246.8) −0.4)
241.7) 241.3) −0.4) 241.2) −0.5)
Ammonia)vapour)
208.6) B) B) 207.6) −1.0)
204.8) B) B) 203.7) −1.1)
201.1) B) B) 200.0) −1.1)
197.5) B) B) 196.4) −1.1)
194.0) B) B) 193.1) −0.9)
190.6) B) B) 189.8) −0.8)
187.2) B) B) 186.4) −0.8)
Test% Wavelength%(nm)%
Target%Intensity%
(mdeg)%
Intensity%before%
experiment%(mdeg)%
Intensity%a:er%
experiment%(mdeg)%
ACS$solu)on$(1$cm$
cuve1e)$ 291$ 188.0$
179.9$ 180.6$
ACS$solu)on$(1$mm$
cuve1e)$
291$ 18.8$ 18.5$ 18.4$
193$ −39.1$ −37.5$ −37.9$
(R,R)>Na[CoIII(EDDS)]$ 211.5$ −50.0$ −48.5$ −47.7$
(S,S)>Na[CoIII(EDDS)]$ 211.5$ 50.0$ 49.3$ 49.5$
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Results and Discussion 
3.3. MASS SPECTROMETRY 
Mass spectrometry has been widely used for the characterisation of biotherapeutic 
proteins73-75 and for distinguishing the lot-to-lot heterogeneity in glycosylation 
profiles,76 and is one of the first choice techniques required by the ICH guidelines. 
Acquiring data of the intact structure is usually the initial step. However, in order to 
qualitatively identify and quantify any modifications in the primary structure, large 
proteins should be cleaved into smaller peptides, which will facilitate the analysis 
within the mass resolution limits. 
3.3.1. Q-TOF results 
Protein cleavage is accomplished with the use of sequence specific enzymes 
(proteases), such as Trypsin, Chymotrypsin and Glu-C, either in separate or sequential 
digestions when improved sequence coverage is required. In the present study, tryptic 
digestion was applied on trastuzumab resulting in sufficient coverage of 94.90% for the 
heavy chain and 100.00% for the light chain (see overall coverage map in Appendix A, 
Figure A1). 
Trypsin cleaves at the C-terminal end of lysine (K) and arginine (R) (primary 
cleavage), while at later stages of the proteolytic process it presents chymotryptic 
activity and also cleaves at the C-terminal end of tyrosine (Y), phenylalanine (F) and 
tryptophan (W) (secondary cleavage). A few steps usually precede the tryptic 
digestion: denaturation is applied in order to make the peptide bonds more accessible 
to the enzyme, the disulfide bonds are reduced and the free cysteines are protected by 
carboxymethylation. The resulting peptide mixture from the protein digestion is 
separated by reversed-phase UPLC where the elution time of each peptide fragment 
depends on its hydrophobicity, therefore providing a “fingerprint” chromatographic 
pattern (TIC plot, total ion current) characteristic of the protein under analysis. In 
conjunction with a mass spectrometer, the effluent enters the electrospray system 
allowing identification of the expected peptides and modified—due to post-
translational modifications (PTMs) or degradation—peptides. 
The peptide mapping tables for each sample can be found in Appendix A 
(Table A1–Table A4), where apart from primary and secondary cleavage, missed 
cleavage sites were also observed (trypsin cleaves at the second or third K/R in turn, 
e.g. peptide LC36–45). The TIC plots (Figure 3.9) for the four samples look quite 
similar on a first inspection, confirming consistency in identity, homogeneity and 
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purity of the samples. The most prominent difference appears at RT 23.0–27.0 min, 
with the two ADCs presenting some peaks due to elution of the drug-conjugated 
peptides in this region. A closer look at the overlaid plots (Figure 3.10) discloses some 
more variations, namely at RT 15.93 min the two native antibodies (mAb (S) and 
(LR)) differ significantly from the conjugated samples due to elution of the non-
conjugated version of the peptide HC222–244 at that time. At RT 16.52 min the 
peptide HC305–323 elutes, and the observed differences are probably due to the 
varying amounts of deamidation on the asparagine residue N318 (see below for 
deamidation). Intensity differences in the chromatographic patterns can also result 
from variations in the tryptic digestion that might occur from sample to sample or 
varying response to MS. A common heavy chain C-terminal modification, lysine-
clipping, was observed in three of the samples on the HC443–450 peptide. 
 
 
Figure	  3.9:	  TIC	  (total	  ion	  current)	  plots	  for	  the	  four	  samples	  resulting	  from	  digestion	  with	  trypsin.	  The	  
chromatographic	  patterns	  were	  obtained	  by	  reversed-­‐phase	  liquid	  chromatography.	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Figure	  3.10:	  Overlaid	   TIC	   (total	   ion	   current)	   plots	   for	   the	   four	   samples	   resulting	   from	  digestion	  with	  
trypsin.	  The	  chromatographic	  patterns	  were	  obtained	  by	  reversed-­‐phase	   liquid	  chromatography.	  The	  
retention	  times	  (RT)	  at	  which	  the	  samples	  differ	  are	  indicated	  with	  the	  eluted	  peptides	  assigned.	  
After confirming the primary structure for all four samples, the glycan 
structures and the site of glycosylation were identified. The spectrum of the ADC (S) 
sample in Figure 3.11 proves the presence of three different glycans (G0F, G1F and 
G2F) attached to the peptide. The respective peaks were found in the second charge 
state at m/z 1317.51, 1398.55 and 1479.58, while smaller glycan fragments were also 
observed and G0F as a detached fragment. The same peaks were found for all four 
samples (Appendix A, Figure A2) confirming consistency. Figure 3.12 presents the 
chromatogram peaks, at RT ~4.30 min, corresponding to the three different forms of 
the glycosylated peptide for the four samples. The similarity of the peaks (G0F, G1F 
and G2F glycosylation) and the fact that all three forms are observed in the same 
spectrum is an indication that the glycan structures exist as parental forms of 
glycosylation, rather than G0F or G1F occurred as fragments from either G1F/G2F or 
G2F respectively due to loss of galactose residues. The significantly lower intensity of 
the peak corresponding to the G2F glycosylated peptide—consistent among the four 
samples—declares the different populations of each structure (inset tables in Figure 
3.12). However, a separate analysis would be required in order to confirm the exact 
populations, which was not necessary in this study as the intention was to obtain an 
overall image and to confirm the absence of immunogenic glycan structures. 
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Figure	  3.11:	  The	  peaks	  for	  the	  glycosylated	  peptide	  HC296–304	  are	  shown	  for	  the	  ADC	  (S)	  sample.	  The	  
glycan	  structures	  of	  G0F,	  G1F	  and	  G2F	  were	  found	  attached	  to	  the	  peptide	  at	  the	  [M+2H]2+	  state	  with	  
m/z	  1317.51,	  1398.55	  and	  1479.58,	  respectively.	  G0F	  is	  also	  present	  as	  a	  fragment	  (m/z	  723.26)	  as	  well	  
as	   smaller	   glycan	   fragments	   at	   the	   lower	   end	   of	   the	   spectrum	   (m/z	   366.14,	   528.19,	   690.25,	   731.26,	  
893.32)	  as	  the	  assigned	  structures	  indicate.	  A	  comparison	  of	  the	  respective	  spectra	  for	  all	  four	  samples	  
can	  be	  found	  in	  Appendix	  A	  (Figure	  A2).	  
 
 
Figure	  3.12:	  Chromatogram	  peaks	  corresponding	   to	   the	  glycosylated	  peptide	  HC296–304	  attached	  to	  
G2F	  (blue),	  G1F	  (green)	  and	  G0F	  (brown)	  for	  each	  one	  of	  the	  four	  samples.	  The	  G2F	  peak	  was	  shifted	  by	  
−0.02	  min	  in	  order	  to	  align	  with	  the	  other	  peaks.	  The	  similar	  shape	  of	  the	  three	  peaks	  indicates	  that	  all	  
three	   glycan	   structures	   are	   observed	   as	   parental	   glycosylation	   forms.	   The	   respective	   intensities	  
indicate	  different	  populations	  of	  the	  three	  structures.	  
All cysteine residues were assumed to be carboxymethylated and the 
respective peptides were identified as such. The same peptides were also searched for 
the cysteine residues on which conjugation occurred. The total masses of the peptides 
with the unmodified cysteines and the vcMMAE molecule were calculated and 
identified, while the presence of vcMMAE signature fragment ions further confirmed 
the conjugation sites. The two most abundant signature fragment ions in our spectra 
had m/z 506.36 and 718.51 (MMAE molecule) and the cleavage sites are shown in 
Figure 3.13. The conjugation sites were revealed to be on the cysteines that contribute 
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to the inter-chain disulfide bond between the heavy and the light chain, namely on Cys 
(223) and Cys (214) respectively (Figure 3.14). 
 
 
Figure	   3.13:	   The	   two	   most	   abundant	   signature	   fragment	   ions	   for	   vcMMAE	   linker-­‐drug	   that	   were	  
observed	  in	  the	  under-­‐analysis	  samples	  (following	  figures).	  
 
 
Figure	   3.14:	   The	   antibody	   drug	   conjugates	   provided	   by	   ADC	   Biotechnology	   presented	   the	   above	  
structure.	  The	  glycans	  are	  attached	  on	  the	  residue	  Asn	  (300)	  and	  the	  linker-­‐drug	  molecules	  (vcMMAE)	  
on	   Cys	   (214)	   and	   Cys	   (223)	   of	   the	   light	   and	   heavy	   chain	   respectively.	   Each	   antibody,	   therefore,	   can	  
bring	  up	  to	  4	  drug	  molecules	  (here,	  only	  2	  are	  shown	  for	  clarity).	  
The identified drug-peptides were HC222–225, HC222–244, LC208–214 and 
LC212–214. While the peptides HC222–225 and LC212–214 were identified only in 
their drug-conjugated form (Appendix A, Figure A3, Figure A4), the peptides HC222–
244 and LC208–214 appeared both as conjugated and non-conjugated. Figure 3.15 
shows the spectrum of the non-conjugated peptide HC222–244 with m/z 844.04 for the 
ADC (S) sample, where all three cysteines are carboxymethylated (Cmc) and the b and 
y’’ fragment ions are assigned. The respective spectra for all four samples seem quite 
similar qualitatively, and can be found in Appendix A (Figure A5). In Figure 3.16, the 
ADC spectra for the same peptide—but drug-conjugated—and the extracted 
vcMMAE&
mass:&1315.78&
m/z:&506.36&
m/z:&718.51&
VH#
VL# VL#
VH#
CL# CL#
CH1# CH1#
CH2# CH2#
CH3# CH3#
NH
2#
COOH# COOH#
NH
2# NH
2#
NH
2#
Fab#
region#
Fc#
region#
5S5S5#
5S5S5#
5S5S5#
Hinge#
region#
Asn300#
Cys214#
Cys223#
Cy
s2
32
#
Cy
s2
29
#
ADC$
=#Heavy#chain#(50#kDa)#
=#Light#chain#(25#kDa)#
 146 
chromatograms for all four samples are shown. In this case two 
carboxymethylcysteines were identified, and one more cysteine (Cys (223)) that was 
linked to vcMMAE, resulting in m/z 1263.29. Only two y’’ fragment ions were 
assigned, as the remaining energy from the electrospray ionisation is probably not 
sufficient to cause further fragmentation. The comparison of the four extracted ion 
chromatograms makes apparent the absence of such a peptide from the mAb samples. 
The non-conjugated peptide LC208–214 with m/z 870.34 and the assigned fragment 
ions are shown in Figure 3.17 for the ADC (S), while all four samples present a high 
degree of similarity as far as quality is concerned (Appendix A, Figure A6). The same 
peptide but with vcMMAE attached to Cys (214) (m/z 1064.56) is shown in Figure 
3.18 for the ADC samples. As expected, the peak at ~23.4 min—where LC208–214 
elutes—is absent from the extracted chromatograms of the mAb samples. 
 
 
Figure	  3.15:	  Spectrum	  of	  the	  non-­‐conjugated	  peptide	  HC222–244	  (RT	  16.01	  min)	  for	  the	  ADC	  (S)	  sample.	  
All	   cysteines	   are	   carboxymethylated	   (Cmc)	   resulting	   in	   m/z	   844.04	   for	   the	   [M+3H]3+	   state.	   The	  
observed	  b	   (blue)	  and	  y’’	   (red)	   fragment	   ions	  are	  assigned.	  A	  comparison	  of	  all	   four	   samples	   can	  be	  
found	  in	  Appendix	  A	  (Figure	  A5).	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Figure	  3.16:	  Spectrum	  of	  the	  drug-­‐conjugated	  peptide	  HC222–244	  (RT	  25.67	  min)	  for	  the	  ADC	  (S)	  (top,	  
red)	  and	  ADC	  (LR)	  (bottom,	  orange)	  samples.	  One	  of	  the	  three	  cysteine	  residues	  (Cys	  (223))	  is	  attached	  
to	   the	  drug	  molecule	   resulting	   in	  m/z	  1263.29	   for	   the	   [M+3H]3+	   state.	   Signature	   fragment	   ions	   from	  
vcMMAE	   are	   present	   as	   [M+H]+,	   with	   m/z	   718.51	   (MMAE	   molecule)	   and	   506.36.	   The	   extracted	  
chromatograms	  on	  the	   left	   show	  the	  absence	  of	   the	  peak	  at	  ~25.60	  min	   for	   the	  mAb	  samples	   (blue,	  
green)	   in	   contrast	   to	   the	   ADC	   samples	   (red,	   orange).	   Only	   y’’	   fragment	   ions	   were	   observed	   and	  
assigned	  to	  y’’4	  and	  y’’6.	  
 
 
Figure	  3.17:	  Spectrum	  of	  the	  non-­‐conjugated	  peptide	  LC208–214	  (RT	  3.04	  min)	  for	  the	  ADC	  (S)	  sample.	  
Cys	   (214)	   is	   carboxymethylated	   (Cmc)	   resulting	   in	  m/z	   870.34	   for	   the	   [M+H]+	   state.	   The	   observed	   b	  
(blue)	   and	   y’’	   (red)	   fragment	   ions	   are	   assigned.	   A	   comparison	   of	   all	   four	   samples	   can	   be	   found	   in	  
Appendix	  A	  (Figure	  A6).	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Figure	  3.18:	  Spectrum	  of	  the	  drug-­‐conjugated	  peptide	  LC208–214	  (RT	  23.45	  min)	  for	  the	  ADC	  (S)	  (top,	  
red)	   and	  ADC	   (LR)	   (bottom,	  orange)	   samples.	   The	   cysteine	   residue	  Cys	   (214)	   is	   attached	   to	   the	  drug	  
molecule	  resulting	  in	  m/z	  1064.56	  for	  the	  [M+2H]2+	  state.	  Signature	  fragment	  ions	  from	  vcMMAE	  are	  
present	  as	  [M+H]+,	  with	  m/z	  718.51	  (MMAE	  molecule)	  and	  506.36.	  The	  extracted	  chromatograms	  on	  
the	  left	  show	  the	  absence	  of	  the	  peak	  at	  ~23.45	  min	  for	  the	  mAb	  samples	  (blue,	  green)	  in	  contrast	  to	  
the	  ADC	  samples	  (red,	  orange).	  Only	  the	  b6	  fragment	  ion	  was	  observed.	  
In order to identify sites that are prone to modifications such as deamidation 
and oxidation, the respective residues were changed to the modified forms, and signals 
from the modified peptides were manually searched. For the deamidation sites, all 
asparagines (N) followed by a glycine residue were converted to aspartic acid (D) 
resulting in a mass increase of 1 Da, as explained above (Section 3.1.4), and all three 
of them were found on the heavy chain (N55, N318, N387). The identified peptides, 
found both in the native and modified form, were HC51–59, HC305–320, HC305–323 
and HC374–395, with the native peptides eluting earlier, as asparagine is more 
hydrophilic than aspartic acid.77 Figure 3.19 shows peptide HC51–59 and the observed 
fragment ions for ADC (S), while the spectra for all four samples and their extracted 
chromatograms can be found in Appendix A (Figure A7). As can be seen from the 
extracted chromatograms the native peptide eluted at ~5.9 min while the deamidated 
peptide appeared at ~6.1 min and ~6.4 min probably corresponding to the Asp and 
isoAsp forms. The weak intensities though do not allow for further confirmation 
through the fragment ions (Appendix A, Figure A8). The modified peptide HC305–320 
was found at ~17.7 min with m/z 905.00 (Figure 3.20 and Appendix A, Figure A9). 
The glutamine residue Q314 is also a potential deamidation site. However, the 
presence of the fragment ions y’’7 and y’’8 are a proof that glutamine is intact in this 
case. The modified N318 was also identified in the peptide HC305–323 and can be 
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found in Appendix A (Figure A10 for the ADC (S) with the assigned fragment ions 
and Figure A11 for all four samples and their extracted chromatograms). The fragment 
ions y’’10 or b10 were too large in this case to be identified and confirm for the native 
form of Q314. The modified form of HC374–395 was found at ~15.1 min with m/z 
1273.06, showing the occurring deamidation on N387 (Figure 3.21 and Appendix A, 
Figure A12). For the same deamidated peptides, the succinimidyl intermediate was 
observed at a later RT than the aspartic acid form and with a mass decrease of 18 Da 
(Table 3.8 and Appendix A, Table A5–Table A8).  
 
 
Figure	  3.19:	  Spectra	  of	  the	  native	  (bottom)	  and	  deamidated	  (top)	  peptide	  HC51–59	  with	  RT	  5.94	  min	  
and	  6.12	  min	  respectively	  are	  shown	  for	  the	  ADC	  (S)	  sample.	  N55	  is	  modified	  to	  aspartic	  acid	  resulting	  
in	  a	  mass	  increase	  of	  1	  Da	  and	  m/z	  1085.53	  for	  the	  [M+H]+	  state.	  The	  observed	  y’’	  fragment	  ions	  are	  
assigned.	  A	  comparison	  of	  all	  four	  samples	  can	  be	  found	  in	  Appendix	  A	  (Figure	  A7).	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Figure	  3.20:	  Spectra	  of	   the	  native	   (bottom)	  and	  deamidated	   (top)	  peptide	  HC305–320	  with	  RT	  17.42	  
min	  and	  17.72	  min	  respectively	  are	  shown	  for	   the	  ADC	  (S)	  sample.	  N318	   is	  modified	  to	  aspartic	  acid	  
resulting	  in	  a	  mass	  increase	  of	  1	  Da	  and	  m/z	  905.00	  for	  the	  [M+2H]2+	  state.	  The	  observed	  y’’	  fragment	  
ions	  are	  assigned.	  A	  comparison	  of	  all	  four	  samples	  can	  be	  found	  in	  Appendix	  A	  (Figure	  A9).	  
 
 
Figure	  3.21:	  Spectra	  of	   the	  native	   (bottom)	  and	  deamidated	   (top)	  peptide	  HC374–395	  with	  RT	  14.89	  
min	  and	  15.09	  min	  respectively	  are	  shown	  for	   the	  ADC	  (S)	  sample.	  N387	   is	  modified	  to	  aspartic	  acid	  
resulting	  in	  a	  mass	  increase	  of	  1	  Da	  and	  m/z	  1273.06	  for	  the	  [M+2H]2+	  state.	  The	  observed	  b	  (blue)	  and	  
y’’	   (red)	   fragment	   ions	   are	   assigned.	   A	   comparison	   of	   all	   four	   samples	   can	   be	   found	   in	   Appendix	   A	  
(Figure	  A12).	  
For the identification of the oxidation sites, all methionines (M) were 
converted to methionine sulfoxide (M*) in the used software, resulting in a mass 
increase of 16 Da, and one of them was found on each chain (M4 on the light chain and 
M255 on the heavy chain). The identified peptides—present both in the native and 
modified form—were LC1–18 and HC252–258, with the native peptides eluting later, 
due to the higher hydrophobicity of methionine compared to methionine sulfoxide.78 
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Figure 3.22 shows peptide LC1–18 and the observed fragment ions for the ADC (S), 
while the spectra for all four samples and their extracted chromatograms can be found 
in Appendix A (Figure A13). The elution time for the modified peptide was ~8.1 min 
with m/z 947.93, while the native peptide appeared ~2.6 min later (RT 10.7 min). The 
fragment ion b4 in the spectrum of the oxidised peptide confirms the presence of the 
modified M*4. Peptide HC252–258 eluted at ~5.9 min with m/z 851.45 (Figure 3.23 
and Appendix A, Figure A14) showing the occurring modification on M255, while the 
native form had an elution time of ~6.9 min. The presence of the fragment ions b4, 
y’’4 and y’’5 in the spectrum of the oxidised peptide further confirms the modification. 
 
 
Figure	  3.22:	  Spectra	  of	  the	  native	  (bottom)	  and	  oxidised	  (top)	  peptide	  LC1–18	  with	  RT	  10.72	  min	  and	  
8.19	   min	   respectively	   are	   shown	   for	   the	   ADC	   (S)	   sample.	   M4	   is	   modified	   to	   methionine	   sulfoxide	  
resulting	  in	  a	  mass	  increase	  of	  16	  Da	  and	  m/z	  947.93	  for	  the	  [M+2H]2+	  state.	  The	  observed	  b	  (blue)	  and	  
y’’	   (red)	   fragment	   ions	   are	   assigned.	   The	   fragment	   ion	   b4	   in	   the	   oxidised	   spectrum	   confirms	   the	  
modification.	  A	  comparison	  of	  all	  four	  samples	  can	  be	  found	  in	  Appendix	  A	  (Figure	  A13).	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Figure	  3.23:	   Spectra	  of	   the	  native	   (bottom)	  and	  oxidised	   (top)	  peptide	  HC252–258	  with	  RT	  6.99	  min	  
and	  5.94	  min	  respectively	  are	  shown	  for	  the	  ADC	  (S)	  sample.	  M255	  is	  modified	  to	  methionine	  sulfoxide	  
resulting	  in	  a	  mass	  increase	  of	  16	  Da	  and	  m/z	  851.45	  for	  the	  [M+H]+	  state.	  The	  observed	  b	  (blue)	  and	  y’’	  
(red)	  fragment	  ions	  are	  assigned.	  The	  fragment	  ions	  b4,	  y’’4	  and	  y’’5	  in	  the	  oxidised	  spectrum	  confirm	  
the	  modification.	  A	  comparison	  of	  all	  four	  samples	  can	  be	  found	  in	  Appendix	  A	  (Figure	  A14).	  
The relative amounts of oxidation, deamidation and the succinimidyl 
intermediate were calculated for each sample and are presented in Table 3.8, while a 
more detailed description of the integrated areas of the chromatogram peaks for the 
modified and native peptides is provided in Appendix A (Table A5–Table A8). The 
amount of oxidation on M4 was calculated as ~1%, while M255 appeared to be more 
susceptible (~3%).55,74 Deamidation on N55 and the succinimidyl intermediate varied 
among the four samples from 17–27% and 5–9% respectively. For N318 the average 
deamidation resulting from the two peptides was calculated as ~13% and the presence 
of the succinimidyl intermediate was estimated as 2%. Only the mAb (LR) presented a 
higher amount of deamidation on N318 (17% on average), which resulted from peptide 
HC305–323. Finally deamidation on N387 varied from 7% (for mAb (S)) to ~12% (for 
the rest of the samples) and the succinimidyl intermediate was only identified in the 
mAb (S) as 9%. 
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Table	  3.8:	  The	  amount	  of	  oxidation,	  deamidation	  and	  the	  succinimidyl	  intermediate	  is	  presented	  as	  a	  
percentage	  (%)	  of	  the	  total	  area	  (sum	  of	  the	  modified	  and	  native	  form).	  
 
3.3.2. TQ-S results 
As described above (Q-TOF results, Section 3.3.1), for peptide mass analyses, the 
protein should be subjected to a treatment that would render its structure more 
accessible to enzyme digestion. In this case, the ADC samples were treated with CNBr, 
which cleaves at the C-terminal end of methionine (M) while the disulfide bonds 
remain intact. The reaction was performed in darkness, in order to prevent 
modification of the methionines, as exposure to aqueous environment increases the 
possibility of oxidation. Tryptic digestion followed and the resulting peptide mixture 
was separated by reversed-phase UPLC. The selected peptides were directed into the 
tandem quadrupole mass spectrometer (MS/MS) and the transitions to their fragment 
ions were monitored in order to facilitate the quantitative analysis. The TIC plots from 
the eight repetitions for each sample (Appendix A, Figure A15, Figure A16) showed 
that LC46–61 (RT ~22.3 min) was the most abundant and reproducible peptide and 
was therefore chosen as the marker peptide. The drug-conjugated peptides HC222–225 
(RT ~30.3 min) and LC212–214 (RT ~32.7 min) were monitored in two transitions. 
The integrated areas for each one of the monitored transitions are given in Appendix A 
(Table A9) and the relative abundance of the drug-conjugated peptides for each sample 
is shown in Figure 3.24. Conjugation on the light chain seems to be comparable for the 
two samples with a ratio to the marker peptide of  ~2.5 for the ADC (S) and ~2.2 for 
the ADC (LR) on average. The heavy chain for the ADC (S) presents approximately 
2.5 times the conjugation of the ADC (LR) and the calculated ratios are ~1.0 and ~0.4 
respectively. For both chains, conjugation on the ADC (LR) presents better precision 
perhaps indicating that the lock-release method is more controlled. The light chain 
Site% Pep(de% Comment% mAb%(S)% mAb%(LR)% ADC%(S)% ADC%(LR)%
M4% LC1–18& Oxida,on& 0.7& 0.4& 1.0& 0.4&
M255% HC252–258% Oxida,on& 1.9& 3.3& 3.4& 2.0&
N55% HC51–59& Deamida,on& 16.9& 20.3& 26.9& 19.2&
Succinimidyl& 4.9& 5.8& 8.6& 6.4&
N318% HC305–320& Deamida,on& 5.8& 6.9& 6.4& 5.9&
Succinimidyl& 1.1& 1.2& 1.1& 0.9&
HC305–323& Deamida,on& 17.6& 29.2& 18.9& 18.6&
Succinimidyl& 2.6& 2.7& 2.9& 2.6&
N387% HC374–395& Deamida,on& 6.7& 11.7& 11.4& 12.3&
Succinimidyl& 8.9& N/A& N/A& N/A&
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responds better to MS, therefore resulting in a significant difference between the two 
chains and preventing direct comparison. 
Data acquired by ADC Biotechnology showed a DAR (drug-to-antibody ratio) 
of 3.6 for the ADC (S) and 3.7 for the ADC (LR). In addition, the lock-release method 
appeared to be of higher purity resulting in <0.5% of free drug, while in the solution 
method 4.5% of free drug was present. The amount of free drug in antibody-drug 
conjugate preparations is important to be maintained at low levels, as due to its high 
toxicity it can potentially affect the safety of the final product. 
 
 
Figure	  3.24:	  Relative	  abundance	  of	  the	  drug-­‐conjugated	  peptides,	  calculated	  by	  dividing	  the	  sum	  of	  the	  
areas	  from	  the	  two	  transitions	  by	  the	  marker	  peptide	  area.	  LC	  and	  HC	  are	  the	  light	  and	  heavy	  chains	  
respectively.	  (S)	  and	  (LR)	  are	  the	  ADC	  samples	  produced	  with	  the	  solution	  and	  the	  lock-­‐release	  method.	  
The	  6	  presented	  measurements	  were	  acquired	  from	  three	  replicates	  for	  each	  sample	  (ADC	  (S)	  and	  ADC	  
(LR)).	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3.4. DLS SPECTROSCOPY 
Previous studies on the stability of trastuzumab, using DLS spectroscopy among other 
techniques, have shown a hydrodynamic diameter of 11.2–11.6 nm for the native 
antibody.79,80 In this study, the hydrodynamic diameter was measured as 10.8–11.7 nm 
(intensity values), with the mAb (S) presenting the lowest value and the ADC (S) the 
highest, while mAb (LR) and ADC (LR) were both measured as 11.5 nm (Figure 3.25, 
left). This variation in the measured values between the mAb (S) and the rest of the 
samples is probably the result of higher inherent stability and/or purity of the first. The 
right image in Figure 3.25 shows the size distributions at the end of the temperature 
experiment, after the samples were heated up to 100 °C and subsequently cooled down 
to 20°C. As can be easily observed, mAb (S) was the only sample that has retained 
particles of the initially detected size, indicating higher structural stability than the rest 
of the samples, and especially than the ADC (S), which presented particles of larger 
size and lower intensity, indicative of its decreased stability. All four samples 
presented wider peaks when cooled down to 20°C, suggesting the appearance of larger 
particles, which affect the shape of the distribution. As described in Section 1.2, and 
also discussed below in the CD Section (3.5.1), application of high temperatures leads 
to activation of the energy barriers between the native and the denatured states. 
However, only partial unfolding of the antibodies took place here, since the DLS 
temperature-dependent experiment was conducted up to 75 °C, namely below the 
temperature that the completely unfolded structure was observed in the CD results 
(83 °C). As explained in Section 3.5, the different domains of trastuzumab unfold in 
two stages (at two different temperatures). It seems, therefore, that only the first stage 
was satisfied during the DLS experiment (especially for the conjugated samples that 
presented an earlier conformational change), and the partially unfolded structure ended 
up to a misfolded intermediate (expanded structure) in one of the local minima in the 
energy funnel after the samples were cooled down. In the case of the conjugated 
samples, intermolecular interactions (aggregation) might have also taken place, 
however to a limited extent, since the size of the particles for the two ADCs at the end 
of the experiment was relatively small (close to the initial value) and therefore not 
sufficient to suggest with certainty that aggregation occurred. The intensity 
distributions of the samples at each temperature can be found in Appendix A (Figure 
A17–Figure A20). 
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Figure	  3.25:	  Size	  distributions	  presented	  in	  intensity	  values	  (nm)	  for	  the	  four	  samples	  at	  20°C	  (left),	  and	  
after	  the	  samples	  were	  cooled	  down	  to	  20°C	  (right).	  The	  distributions	  become	  wider	  at	  the	  end	  of	  the	  
experiment	  and	  the	  ADC	  samples	  shift	  to	  larger	  values.	  Both	  observations	  indicate	  the	  appearance	  of	  
larger	  particles.	  The	  presented	  data	  are	  averaged	  over	  6	  replicates.	  
Intensity values are highly affected by the presence of larger particles and 
impurities, shifting the distribution to higher values. Since the samples presented 
moderate uniformity in the majority of the measurements, with polydispersity indices 
(PDI) between 0.1 and 0.4, the results are henceforth presented in number values as 
more representative of the most abundant species in the sample. Figure 3.26 (left) 
shows the mean size of the particles observed in each sample (averaged over six 
replicates) and how this is changing over the temperature range 20–75°C and when the 
sample is cooled down to 20°C. The mAb samples seem to follow a common path 
throughout the experiment, showing a slight increase in size from ~6.8 nm at 20 °C to 
7.1 nm when cooled down to 20°C. The ADC samples also present very similar trends 
to each other, but different from that of their native relatives. The size of the ADC 
(LR) was measured as 6.6 nm at 20°C, while ADC (S) presented the largest value of all 
four with a mean particle size of 7.2 nm. Both conjugated samples appear to be more 
prone to the appearance of larger particles with sizes between 8.5–8.9 nm at the end of 
the experiment (cooled to 20°C), perhaps indicating expansion of the structure rather 
than prominent aggregation, as aggregation would be expected to lead to much larger 
values. 
The standard deviations with a 95% confidence interval were calculated over 
the averaged number values of the six replicates and are shown as error bars in Figure 
3.26 (right). The sample mAb (LR) presented a large deviation from 30–45°C, due to a 
faulty replicate that presented particles up to 10.8 nm. This effect is also reflected in 
the mean particle sizes at the specific temperatures. The rest of the samples also 
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presented larger particles than the given mean sizes, occasionally, in the order of 9.4–
10.2 nm. Since this was only observed in one of the replicates in each case, the effect is 
considered insignificant and the mean particle sizes are a good approximation. 
However, the effect is reflected in the calculated standard deviations. The mean 
particle size values with their standard deviations at each temperature can be found in 
Appendix A (Table A10). Finally, very small particles (~3.0 nm) appeared in one of 
the replicates of mAb (LR) and two of the replicates of ADC (S) at temperatures above 
40°C. Again these observations were not consistent—as the particles appeared at one 
or two temperatures only—and therefore they were not included in the analysis. 
 
 
Figure	   3.26:	   Hydrodynamic	   diameter	   (nm)	   of	   the	   four	   trastuzumab	   samples	   over	   a	   range	   of	  
temperatures	  from	  20–75°C	  and	  after	  the	  samples	  were	  cooled	  down	  to	  20°C.	  Left:	  the	  averaged	  sizes	  
over	   6	   replicates	   are	   shown.	   Right:	   overall	   mean	   particle	   diameters	   (solid	   circles)	   and	   standard	  
deviation	  with	  a	  95%	  confidence	   interval	   (error	  bars).	  The	   results	  are	  presented	   in	   terms	  of	  number	  
values.	  
In conclusion, the DLS data showed that native trastuzumab molecules (mAb 
samples) have an inherently high structural stability at temperatures up to 75°C, 
presenting only a small increase in their size. The ADC samples were less stable than 
the native antibodies, showing a significant and irreversible expansion of their 
structure at temperatures from 60°C onwards. This structural instability is probably 
acquired during the stage of reduction of the inter-chain disulfide bonds, which 
precedes the conjugation process. However, the whole structure is still held together by 
noncovalent bonds, which prevent the structure from collapsing into smaller molecules 
(e.g. fragments composed of different combinations of the heavy and light chains as 
implied by Figure 3.4). Furthermore, the ADC (S) sample presented a wider 
distribution in comparison to that of the ADC (LR) perhaps indicating the presence of 
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impurities that affect the measured intensity values. As a result, lock-release seems to 
have an advantage over the solution method, providing a final product of higher purity. 
Finally, neither of the samples presented any prominent aggregation, which could 
potentially be explained by the protective effect of the formulation excipients. 
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3.5. CD SPECTROSCOPY AND SECONDARY STRUCTURE 
ESTIMATION 
Previously published studies on the thermal stability of IgG antibodies and more 
specifically on trastuzumab have used CD spectroscopy79 and differential scanning 
calorimetry (DSC).81,82 These studies have shown that IgG antibodies present two (or 
more) transition states of unfolding, which correspond to unfolding of different 
domains or groups of domains. The melting temperatures however vary significantly 
between murine and humanised antibodies, among different isotypes—as flexibility of 
the hinge region differs—and even among changing variable domains of the same 
isotype. Trastuzumab has appeared to unfold in two stages, with the first occurring at 
~70 °C due to the CH2 domain and the second at ~82 °C due to unfolding of the Fab 
and CH3 domain of the Fc fragment.82 
3.5.1. CD spectra of trastuzumab 
In the present study, spectra were obtained for the trastuzumab samples at their original 
concentrations (~1 mg/mL) using a ~0.01 cm path length demountable cuvette (Figure 
3.27, left), and following 10-fold dilution using a 0.1 cm path length fixed cuvette 
(Figure 3.27, right). The data were obtained at 20 °C and are the average of 5 and 6 
replicates respectively. The normalised data look almost identical at the two different 
concentrations, presenting the typical β-sheet spectrum with a positive peak at ~201 
nm and a negative peak at ~217 nm, characteristic of the antibody. The “shoulder” at 
~232 nm is probably a contribution from the turns spectrum (usually negative at ~190 
nm, positive at ~208 nm and a low negative signal at ~228 nm). The distortion of the 
spectra below 200 nm for the 1 mg/mL samples is due to the distorted HT signal 
(flattened, data not shown) at lower wavelengths. At both concentrations, mAb (S) 
presented a slightly stronger signal at 217 nm, while ADC (S) was somewhat weaker 
than the rest of the samples in the same area, which could probably be a first sign of 
the difference in inherent stability among the samples. A more detailed comparison 
between the two concentrations for each sample is provided in Appendix A (Figure 
A21). The high concentration spectra were recorded on a J-815 spectrophotometer, 
while the 0.1 mg/mL data were recorded on a J-1500 model. In order to correct for the 
variance in the calibration between the two instruments, the 1 mg/mL spectra were 
shifted by −3 nm. The similarity of the spectra at the two concentrations confirms that 
there are no significant differences in the structure of any of the four samples after 
dilution. Therefore, the following temperature experiments were performed with the 
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diluted forms, due to the convenience of a fixed path length cuvette. Table A11 
(Appendix A) shows the maximum, minimum and zero-crossing points for the 6 
replicates of the 0.1 mg/mL data at 20 °C. 
 
 
Figure	   3.27:	   CD	   spectra	   of	   the	   four	   trastuzumab	   samples	   at	   their	   original	   concentration	   (~1	  mg/mL)	  
using	  a	  0.01	  cm	  demountable	  cuvette	  (left)	  and	  after	  10-­‐fold	  dilution	  (0.1	  mg/mL)	  using	  a	  0.1	  cm	  fixed	  
cuvette	   (right).	  All	  data	  were	  acquired	  at	  20	   °C.	  The	  high	  concentration	  spectra	  are	   the	  average	  of	  5	  
replicates	  (16	  scans	  each),	  and	  the	  diluted	  spectra	  are	  averaged	  over	  6	  replicates	  (16	  scans	  each).	  
The used formulation has a relatively strong CD signal, which originates from 
the His-Cl buffer in the wavelength region from ~198 nm onwards, and from trehalose 
at lower wavelengths (Figure 3.28, left). The formulation spectrum was also checked 
for any changes at higher temperatures (up to 100 °C) and a gradually decreasing 
intensity was observed, while the shape of the spectrum remained exactly the same 
(Appendix A, Figure A22, left). At the end of the temperature experiment, and after the 
cuvette was cooled down to 20 °C, the formulation spectrum was identical with the 
initial one at 20 °C (Appendix A, Figure A22, right). For the baseline correction of the 
trastuzumab spectra at different temperatures, the blank (formulation only) spectra at 
20 °C were used (Figure 3.28, right). Recording the blank in replicates showed a 
variance, which is probably the result of a combination of reasons such as different 
cuvettes, noise from the instrument and different days of acquiring the data. For the 
first three replicates the same blank spectrum (Bl1) was used in all cases, while for the 
last three replicates a blank spectrum recorded on the same cuvette and on the same 
day as its respective sample was used (Bl2* replicates) in order to correct for the 
                                                      
* Replicates with 4 scans were used for the spectra at different temperatures and replicates with 
16 scans were used for the spectra at 20 °C, according to the spectra of the samples. 
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variation. However, the total averages of the Bl2 replicates seem to eliminate the 
observation and the Bl1 and Bl2 (total average) spectra seem to overlay sufficiently in 
the region from 200-220 nm, where the samples differ the most. 
 
 
Figure	   3.28:	   Left:	   CD	   spectra	   of	   the	   formulation	   and	   for	   each	   one	   of	   the	   excipients	   at	   their	   original	  
concentrations	  (5	  mM	  His-­‐Cl	  buffer	  pH	  5.95,	  50	  mM	  trehalose,	  0.01%	  w/v	  Tween	  20).	  The	  spectra	  were	  
recorded	  on	  a	  J-­‐815	  spectrophotometer,	  using	  a	  demountable	  cuvette	  with	  a	  nominal	  path	   length	  of	  
0.01	   cm.	   Right:	   CD	   spectra	   of	   the	   formulation	   replicates	   after	   10-­‐fold	   dilution.	   The	   spectra	   were	  
recorded	  on	  a	   J-­‐1500	   spectrophotometer,	   using	   a	   0.1	   cm	   fixed	  path	   length	   cuvette	   according	   to	   the	  
following	  temperature	  experiment.	  Bl1	  (=Blank	  1)	  was	  only	  recorded	  once	  (with	  4	  and	  16	  scans)	  and	  
was	  used	  for	  correcting	  the	  spectra	  of	  the	  first	  three	  replicates.	  Bl2	  (=Blank	  2)	  spectra	  were	  recorded	  in	  
replicates,	   on	   the	   same	  day	   and	   cuvette	   as	   the	  matching	   sample	   spectrum,	   and	   they	  were	  used	   for	  
correction	  of	  the	  last	  three	  replicates.	  The	  total	  averages	  of	  the	  spectra	  for	  the	  Bl2	  replicates	  are	  also	  
given.	   The	   16	   and	   4	   scans	   spectra	  were	   used	   for	   correction	  of	   the	   spectra	   at	   20	   °C	   and	   at	   different	  
temperatures	  respectively,	  in	  accordance	  with	  the	  spectra	  recorded	  for	  the	  samples.	  
The averaged CD spectra of the samples at increasing temperature from 
20 °C to 100 °C, per 1 °C, are shown in Figure 3.29. As the temperature increases, the 
characteristic β-sheet spectrum of the antibody is gradually changing towards a 
spectrum with a negative peak at ~204 nm, indicating that the structure is dominated 
by random coil character (usually negative at ~198 nm and a weak positive signal at 
~212 nm). All four samples seem to be quite stable up to a temperature of 54 °C, when 
the conjugated antibodies start to differentiate from the native antibodies (see below, 
Figure 3.30), while the native antibodies start to diverge from their initial spectrum at 
~65 °C (see below, melting curve Figure 3.31). The spectrum that corresponds to the 
first unfolded structure in each case is emphasised by a bold line and occurs at different 
temperatures for the native and the conjugated antibodies, revealing a difference in 
their inherent stability. Both mAb (S) and mAb (LR) seem to reach their unfolded 
structure at 82 °C (grey), while the ADC samples appear to be slightly less stable with 
an unfolding temperature at 80 °C (purple). From the unfolding temperature onwards, 
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the spectra are hardly changing. A table with the specific unfolding temperatures for 
each replicate is given in Appendix A (Table A12). 
 
 
Figure	  3.29:	  CD	  spectra	  of	   the	   trastuzumab	  samples	  after	  10-­‐fold	  dilution	  at	  a	   temperature	   range	  of	  
20–100	  °C,	  per	  1	  °C.	  The	  spectra	  were	  recorded	  on	  a	  J-­‐1500	  spectrophotometer,	  using	  a	  0.1	  cm	  fixed	  
path	   length	   cuvette.	   The	   red	   arrows	   in	   the	   plot	   of	   the	   mAb	   (S)	   sample	   show	   the	   direction	   of	   the	  
decreasing	   and	   increasing	   signal	   intensities	   at	   201	   nm	   and	   217	   nm	   respectively	   with	   increasing	  
temperature,	  which	  was	  observed	  for	  all	  four	  samples.	  The	  first	  unfolded	  spectrum	  for	  each	  sample	  is	  
emphasised,	   showing	   the	   different	   temperatures	   that	   unfolding	   takes	   place	   between	   the	   native	   (at	  
82	   °C,	   grey)	   and	   the	   conjugated	   (at	   80	   °C,	   purple)	   antibodies.	   The	   spectra	   are	   averaged	   over	   6	  
replicates.	  
Figure 3.30 provides a comparison of how unfolding is progressing for the 
four samples at selected temperatures. As mentioned above, the CD spectra of the two 
conjugated antibodies start to differentiate from the native antibodies at ~54 °C, with 
the ADC samples gradually losing intensity at 201 nm. After the remaining shoulder at 
201 nm is completely lost (at ~72 °C for the ADC and ~78 °C for the mAb samples), 
the negative peak increases in intensity and at the same time shifts from 217 nm to 204 
nm. The spectra remain different until 83 °C, when all samples are unfolded and 
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appear very similar in shape, but different in intensity. As with the 20 °C spectra, mAb 
(S) presents a stronger signal while ADC (S) has the weakest signal of all four. From 
83 °C to 100 °C there is hardly any change in the CD spectra of the trastuzumab 
samples, perhaps indicating that the completely unfolded state is reached after 
activation of the energy barriers between the native and the denatured state. Some 
variability was observed in one of the mAb (S) replicates in the temperature range 76–
80 °C (data not shown), though not significant enough to affect the final conclusion. 
 
 
Figure	   3.30:	   Comparison	   of	   the	   CD	   spectra	   of	   the	   trastuzumab	   samples	   at	   selected	   temperatures,	  
showing	   the	   differentiation	   of	   the	   conjugated	   from	   the	   native	   antibodies.	   All	   four	   samples	   are	  
unfolded	   at	   83	   °C,	   therefore	   presenting	   very	   similar	   spectra	   but	   different	   intensities.	   The	   data	   are	  
averaged	  over	  6	  replicates.	  
The signal at 201 nm was followed throughout the temperature experiment for 
all four samples and the extracted melting curves are shown in Figure 3.31 (left) as an 
average of 6 replicates. As discussed above and becoming more obvious from the 
melting curves, the ADC samples start changing at ~54 °C, while the mAb samples 
seem to diverge from their initial spectrum at ~64 °C. The conjugated samples obtain 
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their unfolded structure at ~82 °C, while the native antibodies follow later, at ~83 °C. 
At the end of the experiment, and after the samples were cooled down to 20 °C (right), 
the negative peak appears much wider and shifted at ~210 nm perhaps denoting a 
combination of random coil and β-sheet structure or even aggregation. As described in 
Section 1.2, thermal denaturation leads to a high-energy unfolded state of the protein 
due to loss of the native interactions. Cooling of the samples (restoring the folding 
conditions) results in lowering the energy state to local minima, by folding of the 
protein towards misfolded intermediates or by utilising intermolecular interactions 
(aggregation). Both of these events are irreversible, especially in the case of large 
multidomain proteins such as monoclonal antibodies. The respective HT spectra, at 
20 °C and after the samples were cooled down to 20 °C, are shown in Figure A23. The 
higher HT values of the samples after they returned to the initial temperature (cooled to 
20 °C) denote the presence of scattering particles and further support the observation 
that aggregation occurred upon cooling of the samples. However, no solid particles 
were visible to the naked eye at inspection of the samples at the end of the experiment. 
Though the two transition states are not that obvious in the present study, the 
point where 201 nm crosses zero (at 72 °C for the ADCs and 78 °C for the mAbs) 
could be regarded as the first state, and the completely unfolded spectrum (80 °C for 
the ADCs and 82 °C for the mAbs) as the second. Therefore in the case of the ADCs, 
the first state, at which CH2 is supposed to unfold according to the literature, is 
probably affected by the increased flexibility of the hinge region due to the reduced 
inter-disulfide bonds, while the second transition state, at which Fab and CH3 domains 
unfold, is probably affected by the presence of the toxin on the Fab region. In both 
cases the conjugated samples present reduced stability compared to the mAbs, and 
earlier unfolding of their distinct domains. 
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Figure	  3.31:	   Left:	  Melting	   curves	  of	   the	   trastuzumab	   samples	   at	   201	  nm.	   The	   curves	  were	   extracted	  
from	   the	   normalised	   data	   (Δε	   units)	   and	   averaged	   over	   6	   replicates.	   Right:	   Comparison	   of	   the	   CD	  
spectra	  of	  the	  four	  samples	  at	  20	  °C	  and	  at	  the	  end	  of	  the	  experiment,	  after	  the	  samples	  were	  cooled	  
down	  to	  20	  °C.	  Only	  the	  last	  3	  replicates	  were	  used	  for	  calculating	  the	  average.	  
3.5.2. Secondary structure estimation 
The averaged spectra of the four samples were analysed for their secondary structure 
content at each temperature using SSNN. Figure 3.32 shows the estimated changes that 
occur in each sample, focusing on the main four structure types (α-helix, β-sheet, turns 
and other*). For all four samples the initial and the final estimations are almost 
identical (at 20–57 °C and 82–100 °C respectively), while from 58–81 °C some 
variability is observed—especially in β-sheet and other—between the conjugated and 
the native antibodies. The overall change in the antibodies’ structure appears to be in 
the order of 20%, originating from a decrease in the β-sheet content (from 44% to 
24%), and shared as an increase between other (30% to 37%) and α-helix (6% to 19%), 
while turns remain almost unaffected (20%). The increase in the α-helix content is 
probably an artefact which is reflected in the relatively small increase of “other”, due 
to a misfit of the predicted to the original spectra from ~80 °C onwards. A false feature 
at ~228 nm is incorrectly estimated for all four samples (Appendix A, Figure A24). 
The SSNN predicted results for the spectra at 20 °C were compared to the crystal 
structure of an IgG2a antibody (PDB ID: 1IGT),30 for which the structures were 
assigned as: α-helix 6%, β-sheet 45%, turns 9% and other 40%. Conclusively, the 
results for α-helix and β-sheet seem to be in good agreement with the crystal structure, 
while turns and other present a 10% difference. 
 
                                                      
* Other can refer either to unordered structure or to unassigned secondary structure. 
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Figure	  3.32:	  Results	   from	  the	   secondary	   structure	  analysis	  of	   the	  averaged	   trastuzumab	  spectra	  at	  a	  
temperature	   range	   from	   20–100	   °C,	   per	   1	   °C.	   SSNN	   was	   used	   for	   the	   analysis,	   and	   the	   assigned	  
structures	  are	  α -­‐helix,	  β -­‐sheet,	  turns	  and	  other,	  presented	  in	  fraction	  values.	  
3.6. CONCLUSION 
MS, CD and DLS are three of the most useful techniques for physicochemical and 
structural characterisation of biotherapeutic molecules. Due to the distinct information 
that each one of them produces regarding the structure of the protein molecule, 
combination of all three is necessary in order to carry out a more complete study, when 
a biosimilar-to-innovator or batch-to-batch comparison is required. CD and DLS were 
coupled with the use of temperature dependence in order to aid interpretation and 
further confirm observations that were made at room temperature. Comparison of four 
trastuzumab samples—two in the native state and two conjugated with a toxic agent 
using different conjugation methods—showed differences in the inherent stability and 
some variation in purity. 
MS showed some variability in homogeneity and purity in certain regions of 
the TIC plot of the four samples. However, glycosylation appeared homogeneous 
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among the samples and the relative amounts of modifications such as deamidation and 
oxidation presented comparable values, with the exceptions of ADC (S) and mAb (LR) 
that exhibited higher deamidation on N55 and N318 respectively. For both ADCs, drug 
conjugation took place on the heavy-light chain inter-disulfide bond presenting 
qualitative homogeneity, while quantitative analysis suggested that the lock-release 
method offers more control over the conjugation process. DLS revealed differences in 
stability between the native and the conjugated samples at increased temperatures, with 
the first presenting minor changes in size and greater inherent stability. ADCs 
displayed irreversible structure expansion, due to partial reduction of their inter-chain 
disulfide bonds prior to conjugation, while the narrower distribution of the ADC (LR) 
at the end of the experiment is probably indicative of the lock-release method resulting 
in higher purity compared to the solution method. mAb (S) appeared to be the purest of 
all four due to its smallest size both at the beginning and at the end of the experiment. 
Aggregation was not evident up to 75 °C, the highest temperature at which DLS was 
conducted. Similarly, CD indicated differences in structure at 20 °C with mAb (S) 
presenting slightly stronger intensity and ADC (S) weaker signal compared to the rest. 
However all samples appeared unchanged at least up to 54 °C, while stability 
differences were emphasised at increased temperatures, as the ADCs started changing 
much earlier than the mAbs (Figure 3.31) and unfolded at 80 °C, while the mAbs 
unfolded at 82 °C. During the temperature experiment, a decrease in the β-sheet 
content was noted and an increase in random coil (other). The spectra after cooling 
down to 20 °C indicated a mixture of irreversible unfolding and aggregation. 
In conclusion, temperature dependence measurements are of major help in 
comparability studies and especially in the case of antibodies, where despite the 
absence of inter-chain disulfide bonds, noncovalent interactions between opposing 
domains are still sufficient to maintain the compact structure under normal conditions. 
However, at increased temperatures, ADCs presented larger flexibility of the hinge 
region and unfolded earlier than mAbs, while the presence of the toxin might have also 
contributed to decreased stability. 
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Abstract 
For the past 20 years, the imminent patent expiration for many marketed 
biopharmaceutical products has led to substantial investments, of pharmaceutical 
companies, in the development of biosimilar products. However, such products need to 
be extensively tested for their similarity to the original drug before they are granted 
approval by medicine organisations. Physicochemical characterisation is one of the 
required tests, using a variety of analytical methods in order to provide sufficient data 
on the biosimilar compared to the reference product as well as on batch-to-batch 
comparison. In the present work, real cases of five therapeutic proteins were examined 
and are presented as short studies: protein H, somatropin, protein A, etanercept and a 
monoclonal antibody. The main purpose of all studies was comparability assessment of 
the secondary structure of the provided samples using far-UV CD spectroscopy. In 
most cases, the CD spectra were analysed for their secondary structure content using 
SELCON3 and CDSSTR with various reference sets, and SSNN. A variety of 
analytical techniques were used in different combinations in each study in order to 
further complement far-UV CD data. FT-IR provided supporting information on 
secondary structure, DLS served for size comparability, Near-UV CD and fluorescence 
depends on tertiary structure and orientation of the aromatic amino acids of the under-
analysis protein, and 1D 1H-NMR provided higher-order structure comparison. 
Coupling of CD and/or DLS with temperature-dependent measurements provided 
information on the thermal stability of the samples. The encountered challenges, 
resulting mostly from high concentration of the samples and the formulation buffer, 
were addressed in the best possible way given the limited amount of time in which the 
studies had to be completed. 
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Chapter 4 
Real Cases of Biotherapeutic 
Proteins: Short Studies and 
Challenges 
4.1. INTRODUCTION 
The examined cases reported in this chapter concern protein therapeutics that have 
long been available in the market, namely protein H,* somatropin (hGH), protein A, 
etanercept (TNFR2:Fc) and a monoclonal antibody (mAb). They are short studies on 
real cases of biosimilar products which are currently under development. Our aim was 
to provide a comparability assessment between different batches (for protein A, 
etanercept, mAb), between the biosimilar and the reference product (for etanercept) or 
between the native and the conjugated antibody (for protein H). Samples were 
provided by BioPharmaSpec and assessed for their particle size, secondary/tertiary 
structure, aromatic amino acids environment and higher-order structure similarity 
according to the manufacturer's requests, or out of additional research interest. For 
these purposes, the applied techniques were DLS, far-UV CD and FT-IR, near-UV CD, 
fluorescence and 1D 1H-NMR respectively, used in different combinations for each 
study. In some cases, thermal stability was also tested by coupling CD and/or DLS 
with temperature-dependent measurements (etanercept and mAb). 
Far-UV CD was the common technique in all studies, as secondary structure 
comparability was the main request in all examined cases. For the secondary structure 
analysis of the far-UV CD spectra, several of the available algorithms were used and 
their results were compared with the DSSP assignment for the crystal structure (from 
suitable PDB entries). However, several challenges were encountered, mostly 
occurring due to high viscosity of the concentrated samples. Dilution of the provided 
samples was necessary in certain cases (e.g. mAb study), where the protein 
concentration was extremely high and the formulation buffer was not suitable for a 
particular technique (such as CD and NMR). Dilution is not optimal as this might 
induce changes in the secondary structure of the examined molecule (as was the case 
                                                      
* Data on protein H and protein A are confidential and therefore excluded from the present 
Volume. A separate Volume (Vol. 2) is provided for the examiners to review. 
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with protein A). The best possible solutions were provided, given the limited amount 
of time in which these studies had to be completed. In most of the cases measurements 
were conducted in three replicates in order to ensure reproducibility of the results. 
4.1.1. Protein H 
Protein H concerns confidential material, therefore any information regarding the 
protein name and structure has been excluded from the main thesis (Vol. 1). The 
protein is introduced and discussed in a separate Volume (Vol. 2), which is provided 
for the examiners to review. 
4.1.2. Somatropin (human growth hormone, hGH) 
Human growth hormone is responsible for growth-promoting effects in the body, and 
its secretion from the anterior pituitary gland is controlled by the hypothalamus.1 The 
synthetic form of the protein is called somatropin (recombinant human growth 
hormone rhGH; here referred to as hGH for simplicity).2,3 Human growth hormone is 
essential for normal growth in children, by acting directly on the growth plates or by 
production of insulin-like growth factors (e.g. IGF-1) mainly in the liver.4 It also plays 
an important role in the metabolism of proteins, lipids and carbohydrates during 
childhood and throughout adult life. Humatrope (by Lilly) was the first somatropin 
product to receive FDA approval in 1987 for treatment of children with growth failure 
associated with a number of causes such as inadequate endogenous growth hormone 
secretion (growth hormone deficiency, GHD) and Turner syndrome (TS), and for 
replacement of endogenous growth hormone in adults with GHD. Numerous 
commercial products of somatropin have become available since, with slight 
differences in the indications, while Omnitrope (by Sandoz GmbH) was the first 
biosimilar to gain marketing-authorisation approval by EMA in 2006. 
However, the fact that most of the currently established products require a 
once daily subcutaneous injection makes adherence to the treatment troublesome, 
especially for paediatric patients. Efforts are being made to develop long-acting, 
sustained-release and prolonged half-life preparations that will allow for reduced 
injection frequency and decreased inconvenience of a daily therapy. Such technologies 
include microencapsulation of rhGH in microparticles and protein fusion/conjugation 
as follows: 
 
1. Microparticles consisting of growth hormone incorporated into a hyaluronidate 
matrix (LG Life Sciences and BioPartners)5 result in sustained-release of rhGH. 
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2. Fusion of a sequence of hydrophilic amino acids as head and tail to both C- 
and N-termini of rhGH results in a MW of 119 kDa, >5 times rhGH’s mass 
(XTEN by Amunix).6 Increase of the hydrodynamic size of the molecule 
results in reduced clearance by filtration in the kidneys (glomerular filtration), 
therefore extending the half-life of rhGH. 
3. Conjugation of a carboxyl-terminus peptide (CTP) from human chorionic 
gonadotropin (hCG) to rhGH (Prolor Biotech Inc.)7 prolongs half-life. 
4. The inactive prodrug consisting of PEGylated rhGH (PEG = 
polyethyleneglycol) linked to a carrier (TransCon by Ascendis Pharma)8 
releases GH in its native form through hydrolysis of the linker depending on 
pH and temperature conditions, resulting in a sustained-release prodrug. 
5. Fusion of human serum albumin with the N-terminus of rhGH (Albutropin by 
TEVA)9 or via a terminal fatty acid, which is attached to the rhGH backbone 
and exhibits noncovalent albumin-binding properties (reversible albumin 
binding by Novo Nordisk),10 both extend half-life of the product. 
6. A hybrid consisting of rhGH fused with a hybrid Fc fragment containing 
partial Fc domains of human IgD and IgG4 produces a long-acting fusion 
protein (LAPSCOVERY by Hanmi).11 
 
These novel formulations aim at once per week or less frequent injections, 
maintaining effective drug levels, equivalent to those obtained with daily hGH therapy, 
throughout the dosing interval. Moreover, the levels of both hGH and IGF-1 should 
neither exceed nor fall below the “normal” ones, as both excess (acromegaly) and 
deficiency (GHD) are related with increased rates of morbidity and mortality due to 
consequences in the cardiovascular system.12,13 Tolerability of the induced 
modifications and maintaining the original activity and biodistribution of hGH are 
essential for achieving optimal efficacy and safety, while at the same time the 
manufacturing and distribution costs need to be kept within affordable levels. Nutropin 
Depot (Genentech) was the first long-acting formulation to receive FDA-approval in 
1999, using zinc-stabilised rhGH embedded in PLGA (polylactic-co-glycolic acid) 
microspheres (ProLease by Alkermes Inc.),14 however, it was withdrawn from the 
market in 2004 due to the high cost of its production.15 
Structure 
Human growth hormone consists of a single polypeptide chain of 191 amino acids 
resulting in a molecular mass of ~22 kDa (Figure 4.1). Two intra-molecular disulfide 
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bonds are formed between Cys53–Cys165 and Cys182–Cys189 (Figure 4.2 in yellow). 
Previous studies have shown that hGH is a globular protein in solution,16,17 compactly 
folded and presenting a hydrophobic interior. X-Ray crystallography has revealed a 
mainly α-helical conformation of approximately 52%18 which is distributed into four 
helical segments, while the helix content from CD spectra has been calculated as 
55±5%.19 The rigid helices are believed to be somewhat conserved among different 
species, while the surrounding loops are probably more flexible and responsible for 
species-specific properties.20 
 
 
Figure	  4.1:	  Primary	   structure	  of	  human	  growth	  hormone,	   consisting	  of	   a	   single	  polypeptide	   chain	  of	  
191	  amino	  acids	  and	  a	  total	  mass	  of	  ~22	  kDa.	  The	  cysteine	  residues	  which	  contribute	  to	  the	  formation	  
of	  the	  intra-­‐chain	  disulfide	  bonds	  are	  highlighted	  in	  yellow.	  
 
 
Figure	  4.2:	  Three-­‐dimensional	  structure	  of	  hGH	  (PDB	  ID	  1HGU)21	  in	  ribbon	  representation.	  The	  shown	  
model	   has	   12	  mutations	   and	   therefore	  might	   vary	   slightly	   from	   the	   native	   hGH.	   The	   side	   chains	   of	  
cysteine	   residues,	   which	   contribute	   to	   the	   formation	   of	   the	   intra-­‐molecular	   disulfide	   bridges,	   are	  
shown	  in	  ball-­‐and-­‐stick	  mode	  (in	  yellow).	  
4.1.3. Protein A 
Protein A concerns confidential material, therefore any information regarding the 
protein name and structure has been excluded from the main thesis (Vol. 1). The 
protein is introduced and discussed in a separate Volume (Vol. 2), which is provided 
for the examiners to review. 
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4.1.4. Etanercept 
Etanercept is a therapeutic protein for regulation of various inflammatory and 
autoimmune diseases, and finds medical use in the treatment of rheumatoid arthritis 
(RA).22 It is a dimeric fusion protein produced by recombinant DNA engineering and 
consists of the extracellular portion of the human 75 kDa (p75) tumour necrosis factor 
receptor (TNFR2) linked to the Fc component of human immunoglobulin G1 (IgG1). 
Etanercept belongs to the wider class of tumour necrosis factor antagonists that are 
commercially available, along with the anti-TNF mAbs adalimumab and infliximab. Its 
mechanism of action comprises neutralisation of the tumour necrosis factor (a soluble 
inflammatory cytokine) by inhibiting binding of TNFα to cell surface TNF receptors 
and therefore by disrupting inflammatory pathways driven by TNF.23 Etanercept was 
the first anti-TNF biological agent to receive approval by FDA in 1998 and by EMA in 
2000 under the trade name Enbrel, and was indicated for reduction in symptoms of 
active rheumatoid arthritis in patients who have had an inadequate response to disease-
modifying antirheumatic drugs (DMARDs).24,25 
Antibody-based therapeutic proteins have the advantage of binding to the 
target with high specificity, and therefore being more effective and presenting fewer 
side effects compared to conventional DMARDs. Moreover, their extended half-life in 
the blood circulation allows for less frequent administration. In the case of etanercept, 
the half-life of TNFR (30 min–2 h)26 is extended to 70–132 h27 due to the Fc portion of 
IgG.28 Enbrel is administered by subcutaneous injection and is provided as prefilled 
syringes containing 50 mg/mL solution of etanercept and formulated with: sucrose (10 
mg/mL), sodium chloride NaCl (5.8 mg/mL), L-arginine HCl (5.3 mg/mL), sodium 
phosphate monobasic monohydrate (2.6 mg/mL) and sodium phosphate dibasic 
anhydrous (0.9 mg/mL) at pH 6.3. Vials containing 25 mg of etanercept powder for 
reconstitution are formulated with: sucrose (10 mg), mannitol (40 mg) and 
tromethamine (1.2 mg) at pH 7.4. 
Biopharmaceutical companies have been making efforts to develop Enbrel 
biosimilars in order to reduce the cost of RA therapy.29 However, the complexity of the 
molecule and especially glycosylation patterns render biosimilar development 
challenging.30 Among other biosimilars that have been approved for inflammatory 
diseases,31 two biosimilars of Enbrel were approved in 2016: Benepali by EMA32 and 
Erelzi by FDA,33 and one more in 2017: Lifmior by EMA.34 The present study 
investigates the similarity between 3 biosimilar and 3 innovator products of etanercept, 
from 3 different batches in each case. DLS was used in order to provide a size and 
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stability comparability assessment of the provided samples, far-UV CD and FT-IR 
provided information on secondary structure similarity and stability, near-UV CD 
assessed the tertiary structure of the products and fluorescence evaluated similarity in 
the environment of the aromatic amino acids. 
Structure 
As described above, etanercept is a homodimer and each monomer (or chain) contains 
the TNFR2 molecule linked to the Fc portion of IgG1 by an O-glycosylated peptide.35 
Each chain consists of 467 amino acids and has a molecular mass of ~51 kDa (Figure 
4.3), while the two chains are held covalently via 3 inter-chain disulfide bonds at Cys 
(240), Cys (246) and Cys (249), resulting in a total molecular mass of ~102 kDa. The 
rest of the cysteine residues contribute to the formation of 13 intra-chain disulfide 
bonds (on each chain), 11 of which are in the TNFR2 region, and 2 in the Fc region.36 
Etanercept presents extensive glycosylation, which is the main cause for its 
heterogeneity, especially for the O-linked glycans. Each chain has 3 N-glycosylation 
sites: Asn (149), Asn (171) on the TNFR2 and Asn (317) in the Fc region, and 10–13 
potential O-glycosylation sites, resulting in a mass of up to 130 kDa for the 
glycosylated molecule (65 kDa for each chain).30,37 Figure 4.3 shows the TNFR2 
region, the O-glycosylated linker and the Fc portion underlined in green, red and blue 
respectively. The cysteine residues that form inter-chain disulfide bridges are 
highlighted in yellow and the glycosylation sites are highlighted in orange. It has been 
reported that one more O-glycosylation site exists in the region 121–185 of the 
sequence.35 
 
 
Figure	  4.3:	  Primary	  structure	  of	  a	  single	  chain	  of	  etanercept.	  The	  sequence	  of	  the	  TNFR2	  molecule	   is	  
underlined	   in	   green,	   the	   O-­‐glycosylated	   linker	   with	   red	   and	   the	   Fc	   portion	   of	   IgG1	   with	   blue.	   The	  
cysteine	   residues	   that	   contribute	   to	   the	   formation	  of	   inter-­‐chain	  disulfide	  bridges	   are	  highlighted	   in	  
yellow	  and	  the	  potential	  N-­‐	  and	  O-­‐glycosylation	  sites	  in	  orange.	  
Since there is no crystal structure available for the whole molecule in the PDB, 
the secondary structure of etanercept was calculated by combination of the PDB entries 
for TNFR2 (PDB ID: 3ALQ)38 and the Fc fragment of IgG1 (PDB ID: 3AVE),39 and 
1 L P A Q V A F T P Y A P E P G S T C R L R E Y Y D Q T A Q M C C S K C S P G Q H A K V F C T K T S D 
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101 G WY C A L S K Q E G C R L C A P L R K C R P G F G V A R P G T E T S D V V C K P C A P G T F S N T 
151 T S S T D I C R P H Q I C N V V A I P G N A S MD A V C T S T S P T R S MA P G A V H L P Q P V S T 
201 R S Q H T Q P T P E P S T A P S T S F L L P MG P S P P A E G S T G D E P K S C D K T H T C P P C P 
251 A P E L L G G P S V F L F P P K P K D T L M I S R T P E V T C V V V D V S H E D P E V K F N WY V D 
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401 WE S N G Q P E N N Y K T T P P V L D S D G S F F L Y S K L T V D K S R WQ Q G N V F S C S V MH E 
451 A L H N H Y T Q K S L S L S P G K 
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showed ~33% β-sheet, ~17% turns, ~5% α-helix, while structure was not assigned for 
~45% of the amino acids in the protein. The structure in Figure 4.4 shows the 4 
cysteine-rich domains of TNFR2 (orange) and the Fc fragment of IgG1 consisting of 
the hinge region with the 3 inter-chain disulfide bonds, CH2 and CH3 domains (blue) 
and the intermediate O-glycosylated peptide. 
 
 
Figure	   4.4:	   Schematic	   representation	   of	   etanercept	   structure	   showing	   the	   four	   domains	   of	   TNFR2	  
(orange)	  and	  the	  CH2	  and	  CH3	  domains	  of	  the	  Fc	  fragment	  of	   IgG1	  (blue).	  Glycosylation	  in	  etanercept	  
takes	  place	  on	  the	  asparagine	  residues	  Asn	   (149),	  Asn	   (171)	  and	  Asn	   (317),	  while	  10–13	  potential	  O-­‐
glycosylation	  sites	  have	  been	  reported	  (here	  only	  a	  few	  of	  them	  are	  shown	  in	  the	  O-­‐glycosylated	  linker	  
region).	   Only	   the	   inter-­‐chain	   disulfide	   bridges	   of	   the	   hinge	   region	   are	   shown	   (-­‐S-­‐S-­‐).	   The	   glycan	  
structures	  were	  built	  with	  GlycanBuilder40,41	  
4.1.5. Monoclonal antibody (mAb) 
Development of suitable formulations for protein therapeutics aims at providing long-
term storage stability by protecting the protein from degradation (such as oxidation and 
deamidation) and minimising protein-protein interactions, which could potentially 
result in formation of immunogenic aggregates. More specifically, therapeutic 
monoclonal antibodies are often required to be formulated in high concentrations 
(~100 mg/mL or even more)42 in order to facilitate administration and reduce the 
injected volume of the usually high dosage administered. However, aggregation and 
high viscosity are two of the major concerns in concentrated antibody formulations. In 
order to tackle these complications and to minimise aggregation, addition of excipients 
Asn171&
Asn149&
CH2& CH2&
CH3& CH3&
COOH& COOH&
NH2& NH2&
TNFR2&
Fc&
Asn317&
Cys240&
Cys246&
6S6S6&
Cys249&
6S6S6&
6S6S6&
Ser/Thr&
Hinge&
region&
O6glycosylated&
pepDde&
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such as surfactants and stabilisers, and adjustment of the pH conditions in a range far 
from the isoelectric point (pI) of the protein are fundamental actions during 
formulation development.43,44 Moreover, such high protein concentrations induce 
analytical challenges, as most of the quality control tests normally require lower 
concentrations and therefore dilution of the product is necessary, though not ideal as 
the dilution process may not be reproducible and can affect the protein structure. 
Different concentrations can presumably result in structural and stability changes, 
however given that all samples are treated in a similar way, this work is predicated on 
the assumption that a comparability assessment is still allowed within each one of the 
used analytical methods. 
In this study, four monoclonal antibody samples were provided in their final 
formulation, at a concentration of ~100 mg/mL, with the objective of investigating 
their similarity. The excipients used in this case were Tween 80 as surfactant, arginine 
as stabiliser and the pH was adjusted to 5.0 as usually recommended for antibodies, 
which are stable at pH 4.5–5.5. Dilution or buffer exchange of the samples was 
necessary prior to the chracacterisation experiments, due to their high concentration. 
DLS was used in order to provide a size comparability assessment of the samples, far-
UV CD provided information on secondary structure similarity and thermal stability 
and 1D 1H-NMR assessed similarity in the higher-order structure of the products. 
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4.2. MATERIALS AND METHODS 
4.2.1. Materials 
All materials used for the following studies were as described in Chapter 2. For the CD 
calibration and path length assignment the same apply as described in materials of 
Chapter 3. All samples and buffers were provided by BioPharmaSpec Ltd. as follows: 
 
Table	  4.1:	  Somatropin	  (hGH)	  sample	  and	  formulation	  buffer	  as	  received	  from	  BioPharmaSpec	  Ltd.	  The	  
buffer	  was	  20	  mM	  ammonium	  bicarbonate,	  pH	  8.3.	  
  
 
Table	  4.2:	  Etanercept	  (TNFR2:Fc)	  samples	  and	  buffer	  as	  received	  from	  BioPharmaSpec	  Ltd.	  The	  colours	  
are	  according	  to	  the	  figures	   in	  the	  results	  section	  (Section	  4.6).	  For	  the	  1st	  analysis	  the	  samples	  were	  
provided	  as	  buffer	  exchanged	  into	  50	  mM	  ammonium	  bicarbonate	  buffer	  pH	  7.07.	  For	  the	  2nd	  analysis	  
(requested	  repeat	  analysis	  for	  the	  fluorescence	  data,	  Section	  4.6.4)	  the	  samples	  were	  in	  a	  formulation	  
consisting	   of:	   sucrose	   10	   mg/mL,	   NaCl	   5.84	   mg/mL,	   L-­‐Arginine	   HCl	   5.3	   mg/mL,	   sodium	   phosphate	  
monobasic	  monohydrate	  2.4	  mg/mL	  and	  sodium	  phosphate	  dibasic	  anhydrous	  2.03	  mg/mL;	  PBS	  buffer	  
(Sigma	  P4417)	  was	  supplied	  as	  a	  diluent.	  
  
 
Sample'ID'
Protein'
Concentra2on'
(mg/mL)'
Volume'
supplied'(mL)'
Buﬀer& –& 5&
Somatropin& 3.56& 0.250&
Sample'name'
in'text'
Buﬀer&
hGH&
1st$Analysis$ 2nd$Analysis$
Sample$ID$
Protein$
Concentra8on$
(mg/mL)$
Volume$
supplied$
(mL)$
Protein$
Concentra8on$
(mg/mL)$
Volume$
supplied$
(mL)$
Etanercept) 0.88) 2) 50) 0.050)
Etanercept) 0.97) 2) 50) 0.050)
Etanercept) 0.89) 2) 50) 0.050)
Etanercept) 0.88) 2) 25) 0.100)
Etanercept) 0.97) 2) 25) 0.100)
Etanercept) 0.95) 2) 25) 0.100)
Buﬀer) –) 50) –) 100)
Sample$name$
in$text$
TNFR2:Fc)1)
TNFR2:Fc)2)
TNFR2:Fc)3)
TNFR2:Fc)4)
TNFR2:Fc)5)
TNFR2:Fc)6)
Buﬀer)
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Table	  4.3:	  Monoclonal	  antibody	  (mAb)	  samples	  and	  buffers	  as	  received	  from	  BioPharmaSpec	  Ltd.	  The	  
colours	   are	   according	   to	   the	   figures	   in	   the	   results	   section	   (Section	   4.7).	   The	   samples	   were	   in	   a	  
formulation	  consisting	  of:	  50	  mM	  citric	  acid	  monohydrate,	  0.05%	  w/v	  Tween	  80,	  110	  mM	  L-­‐Arginine,	  
240	  mM	  L-­‐Arginine	  HCl,	  at	  pH	  5.0;	  a	  similar	  buffer	  but	  without	  Tween	  80	  was	  supplied	  as	  a	  diluent.	  
 
4.2.2. Spectroscopic data collection 
The CD, DLS and FT-IR data were collected on the instruments as described in 
Chapter 2 (Section 2.2.2). 
For the CD data, the spectrum of the reference buffer or the averaged spectrum 
(when the buffer was recorded in triplicate) was subtracted from each replicate. The 
data were zeroed by subtracting the averaged value from 260–250 nm (mdeg) or 250–
240 nm (for the monoclonal antibody) for the far-UV data, and 350–340 nm (for 
protein A) or 330–320 nm (for etanercept) for the near-UV data from the whole 
spectrum. The far-UV spectra were converted to Δε units and averaged over 3 
replicates (as presented in the text). The wavelength step was changed to 1 nm and the 
truncated spectra were tested using SELCON3, CDSSTR and SSNN for the secondary 
structure analysis, as described in Section 4.2.7. 
Fluorescence spectra were recorded using a Jasco FP-6500 spectrofluorometer. 
For both analyses, 1st and 2nd (repeat analysis for the fluorescence data), data for 
etanercept were collected with an excitation wavelength of 280 nm and with an 
excitation wavelength of 295 nm.	   At an excitation wavelength of 280 nm, aromatic 
amino acids tryptophan and tyrosine fluoresce. At an excitation wavelength of 295 nm, 
the fluorescence intensity is dominated by tryptophan fluorescence. Samples and buffer 
were measured in triplicate. The mean fluorescence intensity was calculated at each 
wavelength for the respective buffer and subtracted from each replicate. The three 
subtracted replicates were averaged for each sample. There may be an element of inner 
filter effect reducing signals at the concentrations used in these experiments.45,46 
Sample'ID'
Protein'
Concentra2on'
(mg/mL)'
Volume'
supplied'
(mL)'
Monoclonal'An)body' 102.2' 0.200'
Monoclonal'An)body' 103.0' 0.200'
Monoclonal'An)body' 103.1' 0.200'
Monoclonal'An)body' 96.7' 0.200'
Buﬀer'with'PS80' –' 50'
Buﬀer'without'PS80' –' 50'
Sample'name'
in'text'
mAb'1'
mAb'2'
mAb'3'
mAb'4'
Buﬀer'
Buﬀer'
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For the DLS data of etanercept (samples from the 2nd analysis were used), the 
refractive index of the PBS buffer was measured as 1.334 and the viscosity of the 
solution was determined by using latex spheres of known diameter suspended in 10 
mM sodium chloride solution and in PBS buffer, as described in Chapter 3. The size 
distributions are shown in Appendix B (Figure B3, Figure B4), for all measurements 
and averaged measurements/replicates respectively. For the particle diameters in NaCl 
and PBS, the Z-Average values as calculated by the Zetasizer software were used for 
the viscosity calculation (106.6 nm for the NaCl solution, and 107.3 nm the average 
value of the three replicates in PBS), resulting in a viscosity value of 1.009. Samples 
and buffer were measured in triplicate, and 6 measurements were averaged for each 
replicate. For each sample, the data are presented in terms of intensity and number 
values as an average over 3 replicates. The standard deviations were calculated from 
the three replicates of each sample, using the mean number values as calculated by the 
software. 
For the monoclonal antibody samples, the refractive index of each buffer 
solution was measured as shown in Table 4.5 and the viscosity was determined as 
described in Chapter 3, by using latex spheres in 10 mM sodium chloride and in each 
one of the four buffer solutions. The size distributions of the latex spheres in all five 
solutions are shown in Appendix B (Figure B20, Figure B21) for all measurements and 
averaged measurements respectively. For the viscosity calculation the Z-Average 
values were used for the particle diameters, as shown in Appendix B (Figure B20), and 
the resulting viscosity values are given in Table 4.5. For each sample, the data are 
presented in terms of intensity and number values as an average over 8 measurements. 
The standard deviations were calculated from 8 measurements for each sample, using 
the mean number values as calculated by the software. 
 FT-IR spectra of etanercept (samples from the 1st analysis were used) were 
recorded in triplicate and the buffer was recorded once using a 6-bounce ZnSe 
Attenuated Total Reflectance flat plate with lid. The spectra were corrected by 
applying a factor to the buffer subtraction in order to minimise the water association 
peak at 2130 cm−1, while a second factor was applied to the water vapour spectrum in 
order to minimise its contribution at 1700–1800 cm−1. The spectra were zeroed in the 
region of 1800 cm−1 and averaged over the 3 replicates. The data were normalized by 
dividing by the maximum absorbance value between 1600 and 1800 cm−1 for each 
spectrum, and the normalised spectra were analysed for their secondary structure 
content in the region of the amide I band (1600–1700 cm−1) using the retrained version 
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of SSNN (as discussed in Chapter 2). The second derivative was calculated for the area 
1400–1800 cm−1, using a five data point window and without smoothing. 
1D 1H-NMR experiments for the monoclonal antibody samples were carried 
out on a Bruker AV III-600 spectrometer operating at 600.13 MHz for 1H. The water 
peak was suppressed using double pulsed field gradient spin echo for excitation 
sculpting (DPFGSE).47 All spectra were Fourier-transformed, phased and baseline-
corrected in Topspin 3.2. Exponential multiplication was used for apodisation and line 
broadening was 1.0 Hz. Spectra were recorded with 15624 points in the time domain 
and processed with 32768 points in the frequency domain. Spectral width was 13 ppm. 
The balance, pH meter, refractometer, centrifuges and water purification 
system were as described in the spectroscopic data collection of Chapter 2. 
4.2.3. Measurements 
For all far-UV CD experiments, the same parameters were used: wavelength range 
260–180 nm, 1 s data integration time (DIT), 2 nm bandwidth (unless otherwise stated), 
0.2 nm data pitch, 100 nm/min continuous scanning speed. Each spectrum was the 
average of 16 accumulations (unless otherwise stated), at room temperature. 
⇒ Protein H samples: Spectra of the samples (nominally 1 mg/mL) and 
buffer were measured in triplicate using a demountable cuvette with a nominal path 
length of 0.01 cm. The path length of the cuvette was measured by using the 
absorbance of 0.02 M potassium chromate and the Beer-Lambert Law with an 
extinction co-efficient of 4830 M−1cm−1 at 372 nm, and was determined to be 0.0058 ± 
0.0002 cm. The value 0.0058 was used in the analysis and the mean residue weight 
(MRW, described in Section 1.3.2 in the CD part) was 109.6 (without accounting for 
the attached glycans, and for the toxin molecules in the case of the ADC). 
⇒ Somatropin (hGH) sample: Spectra were measured in triplicate for the 
samples and once for the buffer. For the original concentration (nominally 3.56 
mg/mL) a demountable cuvette with nominal path length of 0.001 cm was used, while 
spectra for the 2- and 4-fold diluted samples (df2 and df4) were obtained using a 
nominally 0.01 cm demountable cuvette. A cuvette with a fixed path length of 0.1 cm 
was used for the sample that was diluted by a factor of 30 (df30). The path lengths of 
the demountable cuvettes were measured by using 0.20 M and 0.02 M solutions of 
potassium chromate, as described above, for the 0.001 cm and 0.01 cm cuvettes 
respectively. The path lengths were determined as 0.000726 ± 0.000009 cm and 
0.00584 ± 0.00009 cm, and the values 0.000726 and 0.00584 were used for conversion 
of data to Δε units. MRW was 116.5. 
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⇒ Protein A samples: For the samples in their original concentration (~2 
mg/mL), spectra were measured in triplicate using a demountable cuvette with nominal 
path length of 0.01 cm; a 0.1 cm fixed path length cuvette was used for the 10-fold 
diluted samples (df10), which were recorded once. The respective buffers (in the 
original concentration and after 10-fold dilution) were recorded once in the appropriate 
cuvettes. The path length of the demountable cuvette was measured as described for 
protein H, and was determined to be 0.00628 ± 0.00003 cm. MRW was 123.6, using 
the MW of the glycosylated protein (65,000 Da) as provided with the samples. For the 
fixed 0.01 cm cuvette, a wavelength range of 350–180 nm was used and 8 
accumulations. The path length of the fixed cuvette was accurately measured using the 
interference fringe method and gave a value of 0.0099 cm. This method uses 
interference between the incident light beam and light that has been double reflected 
between the two surfaces of the cuvette as described by Hennessey and Johnson.48 
⇒ Etanercept (TNFR2:Fc) samples: Spectra were recorded for the 1st 
analysis samples at the received concentration (~0.9 mg/mL), using a demountable 
cuvette with a nominal path length of 0.01 cm. Both the buffer and the samples were 
recorded in triplicate, and each spectrum was the average of 12 accumulations. The 
path length of the demountable cuvette was measured as described for protein H, and 
was determined to be 0.0060 ± 0.0001 cm. The value 0.0060 was used for conversion 
to Δε units and MRW was calculated as 109.9, without taking into account 
glycosylation, as the purpose of the study was comparability among samples and not 
extracting quantitative results of the secondary structure. 
⇒ Monoclonal antibody (mAb) samples: Spectra were recorded before (at 
25 °C) and after (cooled to 25 °C) the melting curves for the 1000-fold diluted samples 
(~0.1 mg/mL). The buffer with Tween 80 was diluted accordingly (see sample 
preparation) and a 0.1 cm fixed path length cuvette was used. The same parameters 
were used, as described above and a wavelength range 250–180 nm. 
For the near-UV CD experiments, a wavelength range of 350–250 nm was 
used and the DIT was set to 2 s for protein A, while the rest of the parameters were the 
same as for the far-UV data. Protein A spectra were recorded once, at 37 °C. For 
etanercept (1st analysis samples) a wavelength range of 330–250 nm was used, 1.0 nm 
bandwidth, 16 accumulations and the rest of the parameters were as described for far-
UV. Etanercept spectra were recorded in triplicate. A 1 cm path length masked black 
quartz cuvette was used in all cases. 
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Fluorescence data for etanercept (1st analysis samples) were recorded with 
emission wavelength range 280−500 nm at excitation wavelength 280 nm, and 
295−500 nm at excitation wavelength 295 nm. The DIT was set to 1 s, data pitch was 
0.2 nm, scanning speed was 200 nm/min and excitation and emission bandwidths were 
set to 3 nm.	  A fixed path length fluorescence, nominal 3 mm, cuvette was used. For the 
2nd analysis samples, spectra were recorded with the same parameters, but 0.1 nm data 
pitch. 
DLS measurements for etanercept (2nd analysis samples) were obtained as 6 
measurements for each replicate, with 10 runs per measurement and a run duration of 
20 s. An equilibration time of 60 s was allowed before the measurements started. For 
the sample measurements, material was set to protein (RI 1.450), and viscosity and 
refractive index of the dispersant were 1.009 and 1.334 respectively. For the latex 
measurements, material was set to polystyrene latex (RI 1.590) and the viscosity and 
refractive index of water were used. The measurements for the monoclonal antibody 
samples were obtained as 8 measurements, with 12 runs per measurement and a run 
duration time of 10 s. The viscosity and refractive index of the dispersant for each 
sample were set as shown in Table 4.5. For the buffers, the same parameters were used, 
but with 5 measurements and the refractive index and viscosity of water. As described 
for etanercept, the material was set accordingly for sample and buffer measurements. 
For all data a 3 mm quartz cuvette (small volume) was used. 
For the FT-IR experiments for etanercept (1st analysis samples), the 
instrument was purged with N2 for at least 1 hour before recording the first spectrum 
and continuously throughout the measurements. All data were collected in a 
wavelength range from 400–4000 cm−1 and for each spectrum 1000 scans with 4 cm−1 
resolution were summed. 
For the 1D 1H-NMR spectra the acquisition time was 1.0 s. A relaxation delay 
of 1.7 s, and a 90˚ pulse width of 16.00 µs were used. All data were collected at a 
temperature of 45 °C and the final spectra were the sum of 2560 scans. 
4.2.4. Temperature dependent measurements 
Far-UV CD data for the temperature-dependent measurements of etanercept were 
recorded at a concentration of 0.1 mg/ml, using a 0.1 cm fixed path length cuvette. 
Spectra for etanercept sample 1 (sample from the 1st analysis) were recorded in a 
temperature range 20–100 °C, with a 5 °C step, and a ramp rate of 2.5 °C/min, and 
after cooling down to 20 °C with the rest of the parameters set as described above. 
Melting curves were recorded for all six etanercept samples (2nd analysis) at two 
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different fixed wavelengths: 195.4 nm and 202.0 nm, with data points obtained from 
25–90 °C, every 0.1 °C, at a ramp rate of 0.5 °C/min. The temperature was kept within 
±0.1 °C from the desired temperature for 3 s before the measurement was recorded. 
Spectra were also collected at the beginning (25 °C) and at the end of the melting 
curves, after the samples were cooled down to 25 °C (parameters were same as above 
with the exception of a wavelength range 260–185 nm). The curves were smoothed by 
averaging 10 points for each temperature e.g. 25 °C was the average of the intensities 
from 25.0–25.9 °C etc. The average intensity of the smoothed melting curves from 25–
29 °C was adjusted to the Δε values (at the respective wavelengths 195.4 nm and 200.0 
nm) of the 25 °C spectra that were recorded at the beginning of each experiment. 
Melting curves for the monoclonal antibody samples were recorded at 200.0 
and 217.0 nm, with data points recorded from 25–100 °C, every 0.1 °C. The ramp rate 
was 0.5 °C/min and the temperature was kept within ±0.1 °C from the desired 
temperature for 5 s before the measurement was recorded. DIT and bandwidth were set 
as described in Section 4.2.3. The curves were smoothed as described for etanercept, 
and each curve was offset for visibility by using as a starting point the average value 
from 25–29 °C, averaged over the four samples. 
For the DLS temperature experiments, etanercept samples (2nd analysis) were 
measured from 25–75 °C with a 5 °C temperature interval. For each temperature, 
number of measurements, runs and run duration were as described above. An 
equilibration time of 180 s was allowed after the desired temperature was reached. The 
viscosity of the PBS buffer was estimated at each temperature as described above, and 
the corrected viscosity values are given in Table 4.4: 
 
Table	  4.4:	  Corrected	  values	  for	  viscosity	  at	  each	  temperature	  and	  refractive	   index	  for	  the	  used	  blank	  
solution	  (PBS	  buffer)	  for	  the	  etanercept	  DLS	  study.	  
 
4.2.5. Sample preparation 
For the far-UV CD spectra, the protein H samples were used in their received 
concentrations. Somatropin was used in its original concentration (nominally 3.56 
mg/mL) and in 2-, 4- and 30-fold dilutions with water. Protein A was used in its 
original concentration (~1.9 mg/mL) and in a 10-fold dilution with water. Etanercept 
samples were used in their received concentrations (~0.9 mg/mL) for the 1st analysis. 
For the melting curves (2nd analysis), the samples were diluted down to 1 mg/mL with 
Temperature 
(°C) 25 30 35 40 45 50 55 60 65 70 75 
Refractive 
Index 
PBS$buﬀer$ 0.924 0.806 0.746 0.700 0.683 0.642 0.611 0.583 0.563 0.551 0.520 1.334 
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PBS and a further 10-fold dilution (0.1 mg/mL) with water followed, as PBS is not 
suitable for far-UV CD measurements due to the Cl− absorption. Monoclonal antibody 
samples were used after dilution with water and 100 mM sodium phosphate buffer (pH 
7.04), resulting in a final solution of ~0.1 mg/mL protein in 10 mM sodium phosphate 
buffer. The buffer with Tween 80 was diluted in the same way. 
For the near-UV CD spectra, protein A samples were used in their original 
concentrations (~1.9 mg/mL). Etanercept samples and buffer were recorded as 
received (1st analysis, ~0.9 mg/mL). 
Fluorescence data for etanercept were recorded in the received concentrations 
of the samples for the 1st analysis (~0.9 mg/mL), while for the repeat (2nd) analysis 50- 
or 25-fold dilution with PBS was applied, depending on the original concentration of 
the samples, in order to reach a final concentration of 1 mg/mL. 
For the DLS measurements of etanercept (2nd analysis) the samples were 
diluted with PBS to a final concentration of 1 mg/mL. All solutions were filtered 
through 0.2 µM syringe filters (Thermo Scientific) directly into the quartz cuvette prior 
to the measurement. The monoclonal antibody samples were diluted to 5 mg/mL using 
the buffer without Tween 80. The buffer with Tween 80 was diluted similarly and the 
specific volumes of samples and buffers are shown in Table 4.5. 
 
Table	  4.5:	  Dilution	  of	  the	  monoclonal	  antibody	  samples	  to	  5	  mg/mL	  using	  the	  buffer	  without	  Tween	  80.	  
The	   buffer	   with	   Tween	   80	   was	   diluted	   according	   to	   the	   respective	   sample.	   Refractive	   indices	   were	  
measured	  for	  each	  buffer	  using	  a	  refractometer,	  and	  viscosity	  values	  were	  calculated	  by	  suspension	  of	  
latex	  spheres	  of	  known	  diameter	  in	  10	  mM	  NaCl	  solution	  and	  each	  of	  the	  buffers.	  
 
 
FT-IR data for etanercept samples (1st analysis) were recorded in their 
received concentrations (~0.9 mg/mL). 
1D 1H-NMR spectra for the monoclonal antibody samples were recorded after 
buffer exchange into 20 mM sodium phosphate buffer using Amicon filters with a 30 
kDa MWCO (molecular weight cut-off) and addition of 10% D2O for the field-
Buﬀer& Refrac+ve&Index&
Viscosity&
(mPa)&
Volume&of&sample/
buﬀer&with&
Tween&80&(μL)&
Volume&of&
buﬀer&without&
Tween&80&(μL)&
Buﬀer&1& 1.348& 1.240& 9.8& 190.2&
Buﬀer&2& 1.348& 1.236& 9.7& 190.3&
Buﬀer&3& 1.348& 1.242& 9.7& 190.3&
Buﬀer&4& 1.349& 1.246& 10.3& 189.7&
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frequency lock.49 The pH of the sodium phosphate buffer was adjusted to 5.4 using 1 
M hydrochloric acid solution. The data were recorded at sample concentrations of 
approximately 30 mg/mL (mAb 1), 48 mg/mL (mAb 2), 43 mg/mL (mAb 3) and 36 
mg/mL (mAb 4). 
4.2.6. CD calibration 
For each study the J-1500 CD spectrophotometer intensity was calibrated according to 
SOP 48.3 (attached in Appendix C) at the beginning of the experiment, in order to 
confirm that its operation was within the accepted criteria. The calibration protocol is 
summarised in Chapter 3. For the calibration of the wavelength and intensity accuracy 
similar tests were performed as described in Chapter 3. The target values and the 
measured values are shown in Appendix B for each one of the performed tests. 
⇒ Protein H: The measured values from the wavelength accuracy tests 
(Appendix B, Table B1) were within the accepted limits for the region 187–586 nm. 
From the intensity performance tests (Appendix B, Table B2), the maximum of the 
ACS solution appeared to deviate by +0.8% from the target value at 291 nm, while the 
ratio of the signals at 193 nm and 291 nm was within the acceptance criteria and 
calculated as 2.08. The deviation for the (R,R)- and (S,S)-Na[CoIII(EDDS)] enantiomers 
was +3.8–4.6% at 211.5 nm. 
⇒ Somatropin (hGH): The wavelength accuracy criterion was met for the 
region 187–460 nm (Appendix B, Table B3), while at longer wavelengths (536–586 
nm) a shift of −1.0 nm was observed. The intensity signal was within calibration at 291 
nm (Appendix B, Table B4), while at lower wavelengths a deviation of +3.6% was 
observed for the ACS solution (at 193 nm) and +2.8% for the (S,S)-Na[CoIII(EDDS)] 
enantiomer (at 211.5 nm). The ratio of the signals at 193 nm and 291 nm for the ACS 
solution was calculated as 2.11, which is slightly higher than the accepted value 
(within 2.05–2.10). 
⇒ Protein A: The wavelength accuracy criterion was met for the region 
187–586 nm (Appendix B, Table B7). The intensity signal presented a deviation of 
−4.3% and −5.0% for the ACS solution at 193 nm and 291 nm respectively (Appendix 
B, Table B8), while the ratio of the two signals was calculated as 2.1 (within the 
accepted values). The intensity signal for the (R,R)-Na[CoIII(EDDS)] enantiomer (at 
211.5 nm) presented a deviation of −4.2%. 
⇒ Etanercept (TNFR2:Fc): A wavelength shift of −0.9–1.6 nm  was 
observed for the region 445–586 nm (Appendix B, Table B9). For the near-UV area 
(240–361 nm) the wavelength accuracy criterion was met, while for part of the far-UV 
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region (190–209 nm) a −1.0 nm shift was observed. The intensity signal presented a 
small deviation of +2.4% for the ACS solution at 291 nm (Appendix B, Table B10), 
and the ratio of the signals at 193 and 291 nm was calculated as 2.05 (within the 
accepted values). Intensity at 211.5 nm presented a deviation of +6.6 and +8.2% from 
the target value for the (R,R)- and (S,S)-Na[CoIII(EDDS)] enantiomers respectively. 
4.2.7. Secondary structure analysis 
SELCON3 and CDSSTR from CDPro (a suite of programs for protein CD analysis),50 
and SSNN were used for inferring the secondary structure of the tested proteins. For 
SELCON3 and CDSSTR the analysis was applied based on seven different reference 
sets (1–7), while for SSNN only reference set 7 enhanced by 5 more proteins was used 
(http://www2.warwick.ac.uk/fac/sci/chemistry/research/arodger/arodgergroup/research
_intro/instrumentation/ssnn/). The reference sets contain CD spectra and secondary 
structures of soluble and denatured proteins, and differ in the number of proteins and 
wavelength range that they use in the analysis 
(http://sites.bmb.colostate.edu/sreeram/CDPro/). 
For the studies of Protein H, Somatropin (hGH), Protein A and Etanercept 
(TNFR2:Fc), the analysed wavelength range was 180–260 nm, 185–240 nm or 190–
240 nm, depending on each reference set’s requirements as specified in the CDPro 
website. The secondary structure results are classified in different fractions according 
to each reference set. Reference sets 1, 3, 4, 6 and 7 use the same six classes: α-helix 
regular and distorted, β-sheet regular and distorted, turns and unordered; therefore, 
they are expected to give comparable results.50,51 The regular and distorted fractions 
were summed up in order to give the helix and sheet content. Reference set 2 estimates 
α-helix, 310-helix, β-sheet, turns, poly(Pro)II structure and unordered.52,53 In this case, 
the sum of α-helix and 310-helix resulted in the total helix content, while poly(Pro)II 
structure was added to unordered. For reference set 5 the same assignments apply as in 
reference set 2, but without the 310-helix fraction.54 
  
 192 
Results and Discussion 
4.3. PROTEIN H 
The produced data for protein H are confidential and therefore have been excluded 
from the main thesis (Vol. 1). A separate Volume (Vol. 2) is provided for the 
examiners to review. 
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4.4. SOMATROPIN (RECOMBINANT HUMAN GROWTH HORMONE) 
4.4.1. CD spectra of somatropin 
CD spectra of somatropin (hGH) were recorded at the provided concentration (~3.56 
mg/mL) using a demountable cuvette with a nominal path length of 0.001 cm, and after 
2- and 4-fold dilution using a demountable cuvette nominally of 0.01 cm path length. 
Amino acid analysis, conducted by BioPharmaSpec, showed a concentration of 3.30 
mg/mL for the original sample and therefore the values 3.30, 1.65 and 0.82 were used 
as the respective concentrations for conversion to Δε units, while the path lengths of 
the demountable cuvettes were assigned as described in materials and methods 
(Section 4.2.3). The processed data are shown in Figure 4.5 (left), with all three spectra 
presenting identical shapes, namely a maximum at 192.0 nm and two minima at 208.4 
nm and 219.6 nm, typical of α-helical proteins and similar to previously reported 
studies of hGH.55 
However, the spectra present different intensities which is unusual as Δε shows 
the per residue intensity and therefore is expected to be of similar levels for the same 
protein at different concentrations. Moreover, the theoretical negative maximum at 222 
nm of a hypothetical protein with 100% α-helix content should not exceed −(12–13) 
M−1cm−1,56-58 which is clearly not the case here, as hGH displays values of −14.2, 
−11.0 and −10.7 M−1cm−1 (minima at ~220 nm) for the initial, the 2- and 4-fold diluted 
samples respectively. Considering that the CD magnitudes were consistent among the 
three replicates in each case (see raw data in Appendix B, Figure B1), the above 
inaccuracy was a strong indication that an error was induced during conversion to Δε; 
from equation 1.3 it was concluded that this was caused by the assigned path length 
values. In order to confirm this suspicion, an additional spectrum was recorded 
following 30-fold dilution, using a 0.1 cm fixed path length cuvette (raw data in 
Appendix B, Figure B1). Indeed, the final processed spectrum (Figure 4.5, right) 
displayed a Δε value of approximately −6.25 M−1cm−1 at 208 nm, implying a 50–60% 
error in the previous calculations. The only explanation for such a large and consistent 
error in the assembly of the demountable cuvettes is that the high viscosity of the 
concentrated samples of hGH resulted in a path length increase, which was only 
obvious after converting the data to Δε units. 
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Figure	  4.5:	  Normalised	  CD	  spectra	   (Δε	  units)	  of	  hGH	  at	  different	  concentrations	  averaged	  over	   three	  
replicates.	  Left:	  hGH	  at	   its	  original	  concentration	  (nominally	  3.56	  mg/mL,	  black),	  after	  2-­‐	  (red)	  and	  4-­‐
fold	  dilution	  (blue),	  using	  demountable	  cuvettes.	  Right:	  hGH	  after	  30-­‐fold	  dilution	  (green)	  using	  a	  fixed	  
path	  length	  cuvette.	  For	  the	  conversion	  to	  Δε	  units,	  MRW	  116.5	  Da,	  path	  lengths	  of	  0.000726	  cm	  (for	  
the	  original	  concentration),	  0.00584	  cm	  (for	  df2	  and	  df4)	  and	  0.1	  cm	  (for	  df30)	  and	  concentrations	  of	  
3.30	  mg/mL,	  1.65	  mg/mL,	  0.82	  mg/mL	  and	  0.11	  mg/mL	  were	  used	  respectively.	  
Given that the shape of the spectra does not change at different concentrations, 
indicating that the secondary structure of hGH is not affected after dilution, the path 
lengths of the demountable cuvettes were recalculated, by assuming equal Δε values 
for all four concentrations at 220 nm, based on the spectrum of the 30-fold diluted 
sample which presented a value of −5.68 M−1cm−1. This led to the following equation: 
 P! = !×!!×!"!!×!"   (4.1) 
 
where P!: is the path length of the demountable cuvette 𝑥 (cm), 𝜃!: is the CD spectrum 
(mdeg) of the sample with a dilution factor df! recorded in the demountable cuvette,  𝜃: 
is the spectrum (mdeg) of the  df-fold diluted sample recorded in the fixed cuvette with 
a path length of P (cm). 
The average of the region 210–230 nm was used for the calculation and gave 
0.001815 cm for the 0.001 cm cuvette and 0.01114 cm for the 0.01 cm cuvette, with 
the last being the average of the 2- and 4-fold diluted samples. The new values were 
used for conversion to Δε and the corrected spectra are shown in Figure 4.6. The CD 
spectra for all four samples look almost identical suggesting that the secondary 
structure of hGH does not change upon dilution. The slight variation at lower 
wavelength (192 nm) is perhaps due to the reduced resolution of the instrument at 
these wavelengths and increase of the noise level, as observed by the melting curves of 
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etanercept (Figure B10, Appendix B). The maximum, zero-crossing and minima points 
and values of the corrected normalised spectra (Δε units) are given in Appendix B, 
Table B5 for all three replicates of each sample. 
 
 
Figure	   4.6:	   Corrected	   normalised	   CD	   spectra	   (Δε	   units)	   of	   hGH	   in	   different	   concentrations	   averaged	  
over	  three	  replicates.	  Path	  lengths	  of	  0.001815	  cm	  (for	  the	  original	  concentration,	  black),	  0.01114	  cm	  
(for	  df2	  in	  red	  and	  df4	  in	  blue)	  and	  0.1	  cm	  (for	  df30	  in	  green)	  were	  used	  for	  conversion	  to	  Δε	  units.	  
Secondary structure estimation for somatropin 
Similarly to the case of protein H, SELCON3, CDSSTR and SSNN were used in order 
to obtain secondary structure estimates of hGH from analysis of its CD spectra. The 
results from the 7 reference sets (for SELCON3 and CDSSTR) and 1 reference set for 
SSNN were compared and are presented with their NRMSD values in Appendix B, 
Table B6. The performed analyses with the different sets and programs were consistent 
for all four samples, and the average value and standard deviation with a 95% 
confidence interval of the 15 estimates were calculated for each sample and are shown 
in Table 4.6. The α-helix content of hGH at all four different concentrations was 
estimated as approximately 60% with a deviation of ±6%. This value is relatively close 
to previously reported estimates, which have been calculated from the hGH CD 
spectrum as 55±5%16,19 and is also not very far from the X-Ray crystal structure which 
has shown that 100 amino acids in total are spread in four helical segments, resulting in 
52% of α-helix.18 The remaining 40% was spread among β-sheet conformation (~10%), 
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turns (~15%) and other (~15%), relatively close to the previously calculated with 
SELCON values of 2%, 12% and 20% respectively for a commercial formulation of 
hGH.59 The random coil (or other) content presented the largest deviation of ±19% on 
average, perhaps due the difference of the CD spectra at lower wavelength (~192 
nm)—the random coil spectrum normally presents a negative peak below 200 nm. This 
variation between the spectra at ~192 nm might also result from the higher noise levels 
of the instrument at lower wavelengths. 
 
Table	  4.6:	  Averaged	  values	  and	  standard	  deviations	  (with	  a	  95%	  confidence	  interval)	  of	  the	  secondary	  
structure	   estimates	   over	   the	   15	   analyses	   performed	   for	   hGH	   at	   different	   concentrations.	   SELCON3,	  
CDSSTR	  (7	  reference	  sets	  each)	  and	  SSNN	  were	  used	  for	  the	  CD	  spectra	  analysis.	  
 
 
The original spectra and the calculated spectra from all analyses performed for 
hGH at the concentration provided and after 30-fold dilution are shown in Figure 4.7, 
while the data for the 2- and 4-fold diluted samples are shown in Appendix B, Figure 
B2. The spectral fits from all different programs and reference sets were very similar 
and in agreement with the original (experimentally measured) spectra, which is a good 
sign of an overall accurate estimation of the secondary structure of the protein. As 
expected and also seen in the previous study, SELCON3 presents slightly worse 
spectral fits, without this meaning that the actual results are of poorer quality. 
 
Helix& Sheet& Turns& Other&
hGH& 0.60±0.06% 0.08±0.07% 0.13±0.09% 0.19±0.16%
hGH&df2& 0.62±0.05% 0.10±0.10% 0.15±0.13% 0.13±0.20%
hGH&df4& 0.59±0.06% 0.10±0.10% 0.16±0.12% 0.14±0.20%
hGH&df30& 0.61±0.05% 0.11±0.09% 0.15±0.13% 0.14±0.20%
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Figure	  4.7:	  Original	  and	  calculated	  CD	  spectra	  of	  hGH	  at	   its	  original	  concentration	  (left)	  and	  after	  30-­‐
fold	   dilution	   (right)	   from	   analysis	   with	   different	   software	   and	   reference	   sets.	   Spectral	   fits	   of	   the	  
calculated	  spectra	  are	   in	  agreement	  with	  each	  other	  and	  with	  the	  experimentally	  measured	  spectra,	  
suggesting	  an	  overall	  accurate	  secondary	  structure	  analysis.	  
In conclusion, correction of concentration errors—or path length errors, as was 
the case here—is very crucial, particularly in the case of proteins with high α-helix 
content, as it is generally accepted that α-helix estimates from most fitting programs 
are mostly affected by intensity errors. Cross-checking the secondary structure of hGH 
at different concentrations by analysis of its CD spectra (after these were corrected for 
the path length error) using different programs and reference sets, showed very close 
estimates and similar values in all cases, especially for the most important α-helix 
content. Therefore, the secondary structure of hGH is considered to be similar to 
previously reported studies and unaffected by changes in the concentration. 
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4.5. PROTEIN A 
The produced data for protein A are confidential and therefore have been excluded 
from the main thesis (Vol. 1). A separate Volume (Vol. 2) is provided for the 
examiners to review. 
  
 199 
4.6. ETANERCEPT 
4.6.1. DLS spectroscopy of etanercept 
Previous studies on the characterisation and stability of etanercept using DLS as one of 
the main techniques have shown hydrodynamic radii of 6.0–7.5 nm (or diameter of 
12.0–15.0 nm) depending on concentration60 and 7.0–8.3 nm (diameter of 14.0–16.6 
nm),61 while the theoretical value has been reported as 7.1 nm (diameter of 14.2 nm).62 
In this study, the hydrodynamic diameter of etanercept was measured as 14.1–15.1 nm 
(Z-average value as calculated by the Zetasizer software, based on intensity values),63 
which was in agreement with the values reported in the literature. However, this value 
was obtained only for the innovator samples (4–6), as they appeared to be nearly 
monodisperse (PDI < 0.1) presenting narrow distributions Figure 4.8 (left). The three 
biosimilar samples (1–3) presented wider peaks with a PDI of 0.4, indicative of 
moderate polydispersity, due to the presence of some larger particles of approximately 
140 nm, which resulted in a Z-average value of ~20 nm. The distributions of all 
measurements and replicates for each sample are given in Appendix B (Figure B5) in 
intensity values in order to speculate for the presence of impurities, since intensity 
values are more sensitive to the presence of larger particles. 
 
 
Figure	  4.8:	   Left:	   Size	  distributions	   (nm)	  presented	   in	   intensity	  values	   for	   the	   six	  etanercept	   samples.	  
The	   three	   innovator	   samples	   appeared	   to	   be	   of	   higher	   purity,	   presenting	   narrower	   peaks	   and	   an	  
absence	  of	   the	  peak	  at	  ~140	  nm,	  which	  was	  observed	   in	   the	  distributions	  of	   the	  biosimilar	   samples.	  
Right:	  The	  size	  distributions	  in	  number	  values	  showed	  that	  the	  population	  of	  the	  140	  nm	  particles	  was	  
insignificant.	  The	  presented	  data	  are	  averaged	  over	  3	  replicates	  (18	  measurements	  in	  total).	  
The distributions of the samples in number values showed that the population 
of these large particles was not significant (Figure 4.8, right hand side panel), and all 
six samples presented identical peaks. The following mean sizes and the standard 
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deviations were calculated by the mean number values of each measurement (as 
calculated by the Zetasizer software), as these results are not affected by the presence 
of larger particles and represent better the most abundant species in the sample. For all 
six samples the overall mean diameters (over 18 measurements) were similar and 
calculated as 10.3–10.6 nm, while the standard deviations differed, with samples 3, 5 
and 6 presenting more widely spread sizes (Figure 4.9), perhaps due to the relatively 
short equilibration time (60 s) that was allowed before the measurements started. The 
DLS of the biosimilars does suggest the presence of some large particles. 
 
 
Figure	  4.9:	  Left:	  Overall	  mean	  particle	  diameters	  (nm)	  of	  etanercept	  indicated	  as	  solid	  circles.	  For	  each	  
sample,	   the	   overall	  mean	  was	   calculated	   over	   18	  measurements	   using	   the	   number	  mean	   values	   as	  
estimated	   by	   the	   Zetasizer	   software.	   The	   error	   bars	   indicate	   the	   standard	   deviation	   with	   a	   95%	  
confidence	  interval.	  The	  values	  of	  the	  overall	  means	  and	  the	  standard	  deviations	  for	  each	  sample	  are	  
shown	  in	  the	  attached	  table	  (right).	  
Temperature experiment 
The six etanercept samples were heated gradually in a temperature range from 25 to 
75 °C and the intensity distributions throughout and at the end of the temperature 
experiments, when the samples were cooled down to 20 °C, are shown in Appendix B, 
Figure B6. In this case all samples presented impurities of larger sizes than the 
monomeric protein, however the number distributions confirmed that the population of 
these particles was small (inset). Figure B7 in Appendix B shows the size distributions 
at the beginning (at 25 °C, left) and at the end of the temperature experiment (cooled to 
20 °C, right). All samples presented wider peaks and a shift to larger sizes than the 
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original measurement when cooled back down to 20 °C, suggesting the appearance of 
larger particles, which affected the shape of the distribution. These particles (when 
cooling down to 20 °C), were likely to represent partially unfolded etanercept 
molecules, while loss in intensity was probably a sign of a mixture of particles with 
different sizes. 
Figure 4.10 (left) shows the mean size of the particles (number values 
averaged over six measurements) observed in each sample from 25–75 °C and when 
the samples were cooled down to 20°C. All six samples seemed to follow a common 
path throughout the experiment, showing initially a decrease to a size of 6.7–7.7 nm at 
70 °C, while a slight increase in size was observed at 75 °C (7.0–8.4 nm) and a “jump” 
towards larger values (11.0–11.9 nm) after the samples were cooled back down to 
20 °C. The observed size decrease represents a more compact conformation of the 
protein, which probably resulted from gradual loss of the interactions between the 
protein and arginine HCl—which was one of the excipients in the provided samples for 
the repeat analysis for the fluorescence data (2nd analysis, Section 4.2.1)—as the 
temperature increased. A study by Arakawa et al. on the effect of arginine HCl on 
suppression of protein interactions has shown that the molecule acts by increasing the 
surface tension of water, and interacts with most amino acid side chains and peptide 
bonds, but presents limited binding to the outer surface of the protein; therefore, with a 
diameter of 0.76 nm, arginine HCl is expected to cause a significant expansion in the 
size of the protein.64 Another study has shown that the concentration-dependence of the 
hydrodynamic diameter of etanercept is suppressed by addition of arginine HCl in the 
protein solution, resulting in a size of 13.0–13.7 nm (Z-average value), namely a size 
increase in the order of 16% and 37% for high (50 mg/mL) and low (5 mg/mL) 
concentration samples respectively.65 These findings are in agreement with the size 
decrease that was observed in the present study, which was in the order of 40% at 
70 °C. Furthermore, the three innovator samples appeared slightly larger than the 
biosimilar samples consistently throughout the temperature experiment, which was 
also attributed to arginine. Since the innovator samples were subjected to 2-fold less 
dilution than the biosimilar samples—the first were provided at a concentration of 25 
mg/mL while the second at 50 mg/mL, and all samples were diluted to 1 mg/mL—they 
contained twice as much arginine HCl, which probably resulted in a somewhat larger 
size. Interestingly, all six samples presented very similar sizes at 55 °C (8.1–8.4 nm), 
which seems to be a key temperature. The increase in size at 75 °C was probably due 
to partial unfolding of the structure, while the “jump” at the end of the experiment 
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(cooled to 20 °C) showed size values relatively close to the initial ones but of larger 
particles, perhaps due to combination of two events: restoration of the interactions 
between arginine and etanercept and partial unfolding of the protein. The standard 
deviations—calculated over the averaged number values of six measurements and 
shown as error bars in Figure 4.10 (right)—were smaller compared to the above-
discussed measurements at room temperature, perhaps due to the longer equilibration 
time (180 s) that was allowed before each set of measurements. Larger deviations were 
evident at 75 °C and at the end of the temperature experiment (cooled to 20 °C), 
indicating a mixture of protein particles with varying sizes. 
A limitation of the DLS instrumentation is that the temperature maximum is 
75 °C, which is a critical point for the case of etanercept, as according to previously 
published studies it presents 3 transition melting temperatures due to independent 
unfolding of the different domains (TNFR and CH2, CH3 of the Fc component). While 
TNFR and CH2 are expected to unfold at 57.0 °C and 69.6 °C respectively, the CH3 
domain presents a higher melting temperature, at 82.8 °C.37,60 Consequently, complete 
unfolding of the protein was precluded in the DLS temperature experiment, resulting in 
mixed particle sizes and large standard deviations at its closure. The average sizes and 
the standard deviations at each temperature can be found in Appendix B (Table B11). 
 
 
Figure	  4.10:	  Hydrodynamic	  diameter	  (nm)	  of	  the	  six	  etanercept	  samples	  over	  a	  range	  of	  temperatures	  
from	  25–75	  °C	  and	  after	  the	  samples	  were	  cooled	  back	  down	  to	  20°C.	  Left:	  the	  averaged	  sizes	  over	  6	  
measurements	  are	  shown.	  Right:	  mean	  particle	  diameters	  (solid	  circles)	  and	  standard	  deviation	  with	  a	  
95%	  confidence	  interval	  (error	  bars).	  The	  results	  are	  presented	  in	  terms	  of	  number	  values.	  
In conclusion, the DLS data showed similarity in size and thermal stability 
among the biosimilar and the innovator samples. The innovator samples, however, 
appeared to be of higher monomeric purity compared to the biosimilars, which 
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presented larger particles with a size of ~140 nm—affecting the intensity 
distributions—and wider peaks. The temperature experiment showed common trends 
in size changes for all 6 samples and expansion of the structure at the end of the 
experiment, after cooling down to 20 °C. The concomitant widening of the peaks 
indicated the presence of particles with mixed sizes, which probably indicates that 
unfolding was not fully completed. No prominent aggregation was evident for any of 
the samples, perhaps due to the relatively low concentration of the protein and the 
protective effect of arginine HCl against aggregation.60,65 
4.6.2. CD spectra of etanercept 
Far-UV 
CD spectra of etanercept were recorded at the provided concentrations (~0.9 mg/mL) 
using a demountable cuvette with a nominal path length of 0.01 cm. Raw data of the 
buffer and samples are shown in Appendix B, Figure B8 (replicates and averages). The 
processed data (converted to Δε units) are shown in Figure 4.11 (left). All samples 
presented identical shapes, namely a negative maximum at around 193 nm and a 
second negative peak of lower intensity at 230 nm, similarly to previously reported far-
UV CD spectra of etanercept.60,66 This kind of CD spectrum is unusual, dominated by 
random coil structure and β-sheet conformation perhaps of type II (as described for 
protein A, Section 4.5.1 in Vol. 2). The variation in intensity of the six samples 
probably results from a concentration error or can be partly attributed to the observed 
variation among replicates in the raw data (see for example replicates for samples 3 
and 6, Appendix B, Figure B8). The minima and the Δε values for each sample 
(averaged over three replicates) are given in Appendix B (Table B12), and these 
spectra were used for the secondary structure analysis as discussed below. In order to 
eliminate the intensity variation due to concentration error and to aid visual inspection 
of the shape of the spectra, the data were further normalised based on the minimum Δε 
value of sample 1 (Figure 4.11, right). Similar shape for all 6 samples was evident, 
indicating similarity in their secondary structure and implying that the intensity 
variation was induced during conversion to Δε, both due to inaccuracy in concentration 
estimation and human error in the assembly of the demountable cuvette. 
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Figure	  4.11:	  CD	   spectra	   (Δε	  units)	  of	   the	   six	  etanercept	   samples	  at	   their	  original	   concentration	   (~0.9	  
mg/mL)	   in	   ammonium	   bicarbonate	   buffer	   using	   a	   0.01	   cm	   demountable	   cuvette	   (left).	   Right:	   The	  
spectra	  were	  normalised	  to	  the	  intensity	  of	  the	  negative	  maximum	  at	  193	  nm	  of	  sample	  1,	  in	  order	  to	  
aid	  visual	  inspection	  of	  their	  shape.	  Data	  were	  acquired	  at	  room	  temperature	  and	  are	  presented	  as	  an	  
average	  over	  3	  replicates	  (12	  scans	  each).	  
Melting curves 
In order to inspect the effect of temperature in the CD spectrum of etanercept, sample 1 
was recorded as an example in a range from 20 °C to 100 °C and after cooling the 
sample down to 20 °C (Appendix B, Figure B9). The onset of the protein unfolding 
was observed at 50 °C, while the structure was fully unfolded at 80 °C with the 
negative maximum presenting a shift from 193 nm to 202 nm, suggesting an increase 
in the random coil content. Upon cooling, the peak shifted slightly to shorter 
wavelengths (~199 nm), accompanied by a change in its shape perhaps suggesting 
partial refolding of the protein. Refolding of etanercept has been reported to be 
favoured by arginine HCl,65 which was one of the excipients in the samples from the 
2nd analysis used for the melting curves. Furthermore, the CD spectra cross in more 
than one point, at around 195 nm (isodichroic points), indicating that etanercept 
undergoes more than one transitions.67 
The signals of the crossing-point at 195.4 nm and of the ending (at high 
temperatures, ≥80 °C) negative maximum at 202 nm were followed for all 6 samples 
throughout a range of temperatures from 25 °C to 90 °C resulting in the melting curves 
shown in Figure 4.12 (left and right respectively). The two wavelengths presented 
similar transitions for all six samples, indicating that the biosimilar products are of 
equal thermal stability to the innovator ones. The intensity of the signal at 195.4 nm 
was almost stable up to ~57 °C, when it started increasing, while at 75 °C it presented 
a decrease towards more negative values. The signal at 202 nm started decreasing at 
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~43 °C and was constant from ~82 °C onwards. As discussed above (in the DLS 
results, Section 4.6.1), etanercept presents three melting temperatures, which vary 
depending on the concentration of the sample. The results from two published studies 
that have used differential scanning calorimetry (DSC) varied significantly, showing 
melting temperatures at: Tm1 = 51.2/57.0 °C, Tm2 = 60.2/69.6 °C and Tm3 = 
85.5/82.8 °C for the first/second study respectively, at a protein concentration of 1 
mg/mL, while at 0.25 mg/mL etanercept was less stable with Tm1 = 42.9 °C, Tm2 = 
57.0 °C and Tm3 = 85.6 °C.37,60 In the present study, however, a tentative attempt was 
made to assign the melting temperatures from the melting curves, and these were found 
approximately as: Tm1 = 53 °C, Tm2 = 70 °C (as the average of 68 °C and 72 °C) and 
Tm3 = 82 °C. The raw melting curves, with data points every 0.1 °C, are shown in 
Figure B10 (top, Appendix B), illustrating the levels of noise from the instrument and 
the deterioration of the resolution especially at lower wavelength. The respective HT 
spectra are also included (Figure B10, bottom) showing that aggregation might have 
occurred for some of the samples (e.g. samples 2, 3, 4 and 6), however to a very 
limited extent due to the minor changes in the HT values. No solid particles were 
observed in any of the samples at the end of the experiment. 
CD spectra and the respective HT spectra of the six samples recorded at the 
beginning (25 °C) and at the end of the melting curves (cooled to 25 °C) are presented 
in Appendix B, Figure B11 and Figure B12. For all six samples, the HT spectra at 
25 °C and after the samples were cooled down to 25 °C are identical (Figure B12), 
suggesting that no significant aggregation took place. All six samples present CD 
spectra of similar shape both at the beginning and at the end of the experiment (Figure 
B11), but samples 2 and 5 differ somewhat in intensity at the end of the experiment, 
perhaps due to buffer evaporation. The spectra at 25 °C suggest a Δε value of 
approximately −2.4 for the minimum at 192 nm, revealing a +50% error in the 
calculated Δε spectra for the above-described high concentrated samples (~0.9 mg/mL) 
at room temperature, which presented a value of approximately −4.8 (Figure 4.11, left). 
As shown in the preceding studies, this error results from the path length assignment of 
the demountable cuvette and seems to be quite common in cases of concentrated 
samples, where increased viscosity affects assembly of the cuvette. More specifically, 
high viscosity seems to be related to the absence of excipients such as surfactants (e.g. 
Tween 20), amino acids (e.g. histidine or arginine), and carbohydrates (e.g. sucrose or 
trehalose), which are usually added to biopharmaceutical formulations in order to 
reduce viscosity and increase stability of the preparation.43,44,65 Absence of excipients 
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was the case for all proteins presented so far in this chapter and also for etanercept, as 
its CD spectra were collected in ammonium bicarbonate buffer (samples provided for 
the 1st analysis for which spectra were recorded at room temperature), while the path 
length error was not observed for the trastuzumab samples in Chapter 3, as these were 
properly formulated, containing Tween 20, histidine and trehalose (see Figure 3.27). 
However, the purpose of this study was comparison of the similarity between 
biosimilar and innovator samples, rather than estimation of the actual secondary 
structure contents. Therefore, the Δε spectra in this case were used without applying 
any correction of the path length. 
 
 
Figure	  4.12:	  Melting	  curves	   (Δε	  units)	  of	   the	  etanercept	  samples	  at	  one	  of	   the	  crossing	  points	  of	   the	  
spectra	  at	  195.4	  nm	  (left)	  and	  at	  the	  ending	  negative	  maximum	  at	  202.0	  nm	  (right).	  The	  curves	  were	  
recorded	   for	   the	   formulated	  samples	   that	  were	  diluted	   in	   two	  steps:	   to	  a	  concentration	  of	  1	  mg/mL	  
with	  PBS,	  and	  a	  concentration	  of	  0.1	  mg/mL	  with	  water.	  The	  0.1	  cm	  fixed	  path	  length	  cuvette	  was	  used.	  
Near-UV 
Near-UV CD spectra of etanercept were recorded at the provided concentrations (~0.9 
mg/mL) using a 1 cm cuvette. The raw data of the samples and the buffer are shown in 
Appendix B, Figure B13 (replicates and averaged data), while the processed spectra 
are presented in Figure 4.13. All samples present CD spectra of similar shape, while 
sample 1 presents a slightly higher intensity and a somewhat different shape especially 
in the tyrosine region (peak at 275 nm). The well-defined CD spectrum in the near-UV 
region is similar to previously published data66 and confirms that etanercept presents 
ordered structure. All six samples appear to have similar tertiary structure within 
experimental error, with sample 1 being slightly different from the rest in the 
environment of its tyrosine residues. 
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Figure	  4.13:	  Near-­‐UV	  CD	  data	  (Δε	  units)	  of	  the	  six	  etanercept	  samples	  in	  their	  original	  concentrations	  
(~0.9	  mg/mL)	  using	  a	  1	  cm	  cuvette.	  
Secondary structure estimation for etanercept 
In order to have a “reference” secondary structure of the protein for comparison with 
the obtained results from the analysis with CDSSTR, SELCON3 and SSNN 
(following), the secondary structure of etanercept was calculated by combination of the 
PDB crystal structures for TNFR2 and the Fc fragment of human IgG1, as described 
above (Section 4.1.4), and gave the following results: 
 
Table	  4.7:	  Secondary	  structure	  percentages	  of	  etanercept	  as	  calculated	  by	  the	  PDB	  entries	  for	  TNFR2	  
and	   the	   Fc	   fragment	   of	   human	   IgG1	   (as	   discussed	   in	   introduction	   for	   etanercept,	   Section	   4.1.4).	  
According	  to	  68,	   for	  the	  α -­‐helix	  content,	  310-­‐helix	  was	  added	  to	  α -­‐helix;	  β -­‐strand	  gave	  β -­‐sheet;	  turns	  
content	  was	  the	  sum	  of	  turns	  and	  bends;	  β -­‐bridge	  conformation	  and	  residues	  that	  were	  not	  assigned	  
any	  secondary	  structure	  were	  summed	  to	  give	  other.	  
 
 
Similarly to what was applied to protein A (secondary structure estimation, Section 
4.5.1 in Vol. 2), 310-helix (G) was added to α-helix (H), β-strand (E) gave the β-sheet 
content, bend (S) was added to turn (T), and the sum of β-bridge (B) and not assigned 
(NA) structure gave other. 
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The CD spectra of the etanercept samples were analysed for their secondary 
structure content using CDSSTR and SELCON3 with reference sets 1–7, and SSNN, 
which uses reference set 7. The results from all performed analyses are presented in 
Table B13 (Appendix B), where a large variation was apparent among estimates from 
different software and reference sets, especially for the random coil content. The 
analyses that gave results close to the calculated values from the PDB crystal structures 
(≤10% deviation) are presented in Table 4.8. CDSSTR with reference sets 3 and 4, and 
SELCON3 with reference set 4 fulfilled the structure criterion, with CDSSTR showing 
similarity for all 6 samples, namely 2–3% α-helix, 33–37% β-sheet, 24–27% turn and 
35–39% other, while SELCON3 showed some variation among samples estimating a 
higher α-helix (~10%) and other content (35–47%) and lower sheet (~27%) and turns 
(~22%). 
 
Table	  4.8:	  Results	  from	  the	  secondary	  structure	  analysis	  of	  the	  CD	  spectra	  of	  etanercept	  with	  different	  
software	   and	   reference	   sets.	   Only	   the	   programs/reference	   sets	   that	   gave	   results	   close	   (deviation	  
≤10%)	   to	   the	  calculated	  ones	   from	  the	  crystal	   structures	  are	  shown.	  CDSSTR	  rs3,	  4	  and	  SELCON3	  rs4	  
fulfilled	  the	  structure	  criterion.	  
 
 
Table 4.9 shows the overall means and standard deviations for each structure, 
from the analyses with all software and reference sets. All six samples presented 
similar secondary structure contents consisting of: 2–3% α-helix, 21–23% β-sheet, 20–
21% turn and 54–57% other. Deviations with a 95% confidence interval were 
Program' Sample' Helix' Sheet' Turns' Other'
CDSSTR'rs3'
TNFR2:Fc'1' 0.03$ 0.37$ 0.24$ 0.37$
TNFR2:Fc'2' 0.02$ 0.35$ 0.24$ 0.38$
TNFR2:Fc'3' 0.02$ 0.33$ 0.26$ 0.39$
TNFR2:Fc'4' 0.02$ 0.37$ 0.24$ 0.37$
TNFR2:Fc'5' 0.02$ 0.36$ 0.24$ 0.38$
TNFR2:Fc'6' 0.02$ 0.34$ 0.25$ 0.39$
CDSSTR'rs4'
TNFR2:Fc'1' 0.03$ 0.35$ 0.27$ 0.35$
TNFR2:Fc'2' 0.03$ 0.34$ 0.26$ 0.37$
TNFR2:Fc'3' 0.03$ 0.33$ 0.26$ 0.39$
TNFR2:Fc'4' 0.03$ 0.35$ 0.27$ 0.36$
TNFR2:Fc'5' 0.02$ 0.35$ 0.26$ 0.37$
TNFR2:Fc'6' 0.03$ 0.33$ 0.26$ 0.38$
SELCON3'rs4'
TNFR2:Fc'1' 0.02$ 0.27$ 0.25$ 0.47$
TNFR2:Fc'2' 0.11$ 0.33$ 0.21$ 0.35$
TNFR2:Fc'3' 0.10$ 0.27$ 0.22$ 0.41$
TNFR2:Fc'4' 0.10$ 0.24$ 0.20$ 0.46$
TNFR2:Fc'5' 0.10$ 0.27$ 0.22$ 0.41$
TNFR2:Fc'6' 0.12$ 0.28$ 0.21$ 0.39$
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relatively small for the helix estimates (±6%), sheet and turns showed a deviation of 
±18% and ±14% on average respectively, while other content presented the largest 
deviation of ±27% on average. 
 
Table	  4.9:	  Overall	  means	  and	   standard	  deviations	  with	  a	  95%	  confidence	   interval	   from	   the	  analyses	  
with	  all	   different	   software	  programs	  and	   reference	   sets	   for	  each	  etanercept	   sample.	   The	   results	  are	  
the	  average	  of	  15	  analyses.	  
 
 
The original CD spectra of the etanercept samples and the calculated spectra, 
after the analysis with programs and reference sets that gave results close to the crystal 
structure estimates for at least one of the samples, are shown in Figure 4.14. Fits for 
CDSSTR rs2–4 and SELCON3 rs2–4 are presented, and as can be observed fits of 
SELCON3 rs4 were of the poorest quality in most of the cases, SELCON3 rs3 
estimated the second feature of the etanercept CD spectrum (at 230 nm), but shifted at 
around 215–220 nm, while the fits from SELCON3 rs2 varied from poor (for samples 
1, 2 and 6) to acceptable quality (for samples 3, 4 and 5). CDSSTR presented improved 
spectral fits, which is generally expected as described for protein H in Vol. 2 (see 
secondary structure estimation for protein H Section 4.3.1). 
 
Helix& Sheet& Turns& Other&
TNFR2:Fc&1& 0.02±0.05& 0.21±0.17& 0.20±0.16& 0.57±0.30&
TNFR2:Fc&2& 0.02±0.07& 0.23±0.16& 0.20±0.13& 0.55±0.25&
TNFR2:Fc&3& 0.02±0.06& 0.22±0.20& 0.21±0.15& 0.54±0.28&
TNFR2:Fc&4& 0.02±0.06& 0.23±0.21& 0.21±0.15& 0.54±0.29&
TNFR2:Fc&5& 0.02±0.06& 0.23±0.20& 0.21±0.14& 0.54±0.28&
TNFR2:Fc&6& 0.03±0.07& 0.21±0.16& 0.20±0.13& 0.57±0.23&
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Figure	  4.14:	  Original	   (experimentally	  measured)	   and	   fitted	  CD	   spectra	  of	   the	   six	   etanercept	   samples	  
after	   analysis	   with	   different	   software	   and	   reference	   sets.	   Spectral	   fits	   of	   programs	   that	   presented	  
≤10%	  deviation	  from	  the	  PDB-­‐calculated	  secondary	  structure	  for	  at	  least	  one	  of	  the	  samples	  are	  shown.	  
In conclusion, the far-UV CD spectra for all six samples of etanercept look 
identical in shape, dominated by random coil and β-sheet conformation, suggesting 
similarity in their secondary structure. The average from analyses of the CD spectra 
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with various software and reference sets confirmed similarity in secondary structure 
contents among samples, however the results are probably not representative of the 
actual structure of etanercept due to the large variation among estimates from different 
software and reference sets. Melting curves recorded at two wavelengths presented 
similar transitions for all six samples, indicating that the samples were of equal thermal 
stability. Onset of protein unfolding was observed at around 50 °C, the structure 
seemed to reach its fully unfolded conformation at approximately 80 °C, while all six 
samples displayed partial reversibility of unfolding and similar spectra at the end of the 
temperature experiment when cooled down to 20 °C. The near-UV CD spectra 
appeared to be of similar shape, suggesting that all six samples had similar tertiary 
structure with sample 1 being slightly different from the rest. 
4.6.3. FT-IR spectroscopy of etanercept 
FT-IR spectra of etanercept were recorded at the provided concentrations (~0.9 
mg/mL) in ammonium bicarbonate buffer (1st analysis). The processed data (corrected 
for the buffer/water vapour and zeroed) for all replicates are shown in Figure B14 
(Appendix B). The apparent replicate-to-replicate variation, more obvious for samples 
1 and 6, was probably induced during buffer correction, while raw data (not shown) 
appeared more consistent (but dominated by liquid water). The buffer was recorded 
once, in the beginning of the measurements, therefore it is likely that small changes in 
humidity during the rest of the measurements have affected correction of the spectra 
and were reflected in the processed data, while the small concentration of the samples 
(10 mg/mL is deemed to be appropriate for FT-IR) contributed to exaggeration of these 
variations. The averaged data (over three replicates) for the six samples are shown in 
Figure 4.15 (left). The features of the spectra are almost identical for the six samples, 
presenting the amide I band at around 1638 cm−1 and the amide II at ~1548 cm−1. The 
amide I band was normalised to unity for all samples (Figure 4.15, bottom right), and 
was subsequently resolved with the second derivative (top right) in order to aid peak 
positioning. The second derivative revealed the main feature of the etanercept 
spectrum at 1638 cm−1, which in combination with the peak at 1685 cm−1 is 
characteristic of antiparallel β-sheet structure, indicating that the main conformation of 
the protein is indeed β-sheet. Additional second derivative peaks appeared at 1654 
cm−1, denoting presence of α-helix or random coil, at 1662 cm−1 and 1672 cm−1, which 
are typical of turns and loops.69,70 For all six samples the normalised amide I band was 
input to the IR-reference set retrained version of the SSNN software (as described in 
Chapter 2) in order to provide estimates of the secondary structure contents. 
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Figure	  4.15:	  Left:	  ATR-­‐FTIR	  spectra	  of	  the	  six	  etanercept	  samples	  (~0.9	  mg/mL)	  after	  buffer	  subtraction,	  
water	  vapour	  correction	  and	  zeroing.	  The	  spectra	  are	  presented	  as	  an	  average	  over	  three	  replicates	  in	  
absolute	   absorbance	   units.	   Right:	   The	   amide	   I	   band	   was	   normalised	   to	   unity	   (bottom).	   Second	  
derivative	  amide	  I	  spectra	  (top)	  were	  used	  to	  aid	  peak	  positioning.	  
Secondary structure analysis for etanercept 
Table 4.10 shows the results from the secondary structure analysis of the six etanercept 
samples and the NRMSD values, which indicate a reasonable fit between the measured 
and the modelled spectrum. The estimates indicate that there are no significant 
differences between the secondary structures of the samples. Sheet content was 
estimated as approximately 33%, which was close to the value that was calculated 
from the PDB crystal structures and also to the CDSSTR rs3 and 4 results from the CD 
spectra analysis. Turn was estimated as 24% (sum of turn and bend), which was similar 
to the CDSSTR (rs3, 4) estimates, while helix was overestimated (20%) with a 
consequent underestimation of the random coil content (22%). This confusion in FT-IR 
spectra analysis is due to the fact that the average maxima for both α-helix and random 
coil bands are at 1654 cm−1, with their extremes differing only slightly: 1648–1657 
cm−1 and 1642–1657 cm−1 respectively.71 Therefore differentiation between the two 
structures is challenging in most of the cases. The small deviations that appeared in 
samples 1 and 6 (~5% and ~3% in sheet content respectively) were probably the result 
of the variation in their replicates. 
In conclusion, the FT-IR spectra of all six etanercept samples appeared similar 
within experimental and processing error. As discussed in Chapter 2, the results from 
the quantitative analysis of the spectra with the use of SSNN should be regarded as an 
approximation, as overlap of different bands (such as α-helix and random coil) can 
confuse the algorithm and disrupt the estimation. 
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Table	   4.10:	   Secondary	   structure	   assignment	   for	   the	   FT-­‐IR	   spectra	   of	   etanercept	   using	   the	   IR	   trained	  
version	  of	  SSNN.	  
 
4.6.4. Fluorescence spectroscopy of etanercept 
Fluorescence emission spectra for the etanercept samples were recorded for two 
excitation wavelengths: 280 nm (where tyrosine and tryptophan residues fluoresce) and 
295 nm (only tryptophans fluoresce). Two analyses were conducted in different buffers. 
 
For the 1st analysis, the samples were provided as buffer exchanged into 
ammonium bicarbonate buffer and were recorded as such at the provided 
concentrations (~0.9 mg/mL). Raw fluorescence data (in three replicates) for the 
samples and the buffer are shown in Appendix B, Figure B15–Figure B16 for both 
excitation wavelengths (280 nm and 295 nm). The data following subtraction of the 
ammonium bicarbonate signal are shown in Figure 4.16 (top). A prominent difference 
between the emission spectra of the biosimilar and the innovator samples was the 
observed additional peak at around 460 nm for the biosimilar samples, perhaps 
suggesting the presence of an aromatic compound. All six samples presented their 
maxima at ~334.8 nm and ~336.5 nm for excitation wavelengths 280 nm and 295 nm 
respectively (Table 4.11). The similarity of the emission wavelengths for 280 nm and 
295 nm excitation indicates dominance of tryptophan fluorescence with both excitation 
wavelengths. The observed differences in intensity among samples suggest either 
differences in the environment of the aromatic (Tyr/Trp) residues or differences in 
concentration. A decrease in the fluorescence intensity is usually indicative of Tyr/Trp 
residues that are exposed to the solvent.45 However, significant changes in the 
environment such as exposure to the more polar environment of the solvent would 
have also caused a shift in the maximum wavelength towards higher wavelengths 
(closer to the maximum for Trp in water, at 353 nm),46 which was not observed in this 
case for any of the samples. The intensity of fluorescence of Trp and Tyr residues can 
also be affected by complicated quenching mechanisms that arise from neighbouring 
amino acids in the folded state of the protein, causing a signal decrease.72 It is likely 
Helix& Sheet& Bend& Turn& Other&
TNFR2:Fc&1& 0.24% 0.28% 0.11% 0.14% 0.23%
TNFR2:Fc&2& 0.20% 0.34% 0.11% 0.13% 0.22%
TNFR2:Fc&3& 0.20% 0.33% 0.11% 0.13% 0.22%
TNFR2:Fc&4& 0.20% 0.34% 0.11% 0.13% 0.22%
TNFR2:Fc&5& 0.20% 0.33% 0.11% 0.13% 0.22%
TNFR2:Fc&6& 0.23% 0.30% 0.11% 0.14% 0.23%
NRMSD&
0.024%
0.030%
0.037%
0.032%
0.050%
0.055%
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therefore, that either such quenching mechanisms or a mis-calculation of the 
concentrations was responsible for the intensity variation. 
The fluorescence intensities were divided by the molar protein concentration to 
account for variation in the protein concentration between samples. These data are 
shown in Figure B17 (Appendix B). Sample 1 presented much higher intensity than the 
rest, from which it can probably be inferred that either its concentration was 
underestimated or sample 1 indeed differed in the aromatic residues environment. 
Referring back to the near-UV CD spectra of the six samples (Figure 4.13), sample 1 
presented somewhat different shape in the near-UV wavelength (250–280 nm), in the 
tyrosine area. Moreover, by looking at the far-UV CD spectra (Figure 4.11, left) a 
higher intensity for sample 1 was apparent. Consequently, the variation in the 
fluorescence intensity of sample 1 probably results from the combination of both 
factors. 
 
 
Figure	  4.16:	  Baseline	  corrected	  and	  averaged	  (over	  three	  replicates)	  fluorescence	  emission	  spectra	  of	  
the	  etanercept	  samples	   for	  excitation	  wavelengths	  280	  nm	  (left)	  and	  295	  nm	  (right).	  Top:	  data	   from	  
the	  1st	  analysis	  of	  the	  samples	  in	  ammonium	  bicarbonate	  buffer,	  at	  the	  received	  concentrations	  (~0.9	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mg/mL).	  Bottom:	  data	   from	   the	  2nd	  analysis,	   after	  50-­‐	  and	  25-­‐fold	  dilution	  of	   the	  biosimilar	  and	   the	  
innovator	  samples	  respectively	  in	  PBS	  buffer,	  to	  a	  final	  concentration	  of	  1	  mg/mL.	  
The 2nd analysis was aiming to assess whether the observed response at 
around 460 nm for the biosimilar samples 1–3 was still observed following dilution of 
the original formulations with PBS buffer. Raw fluorescence data (in three replicates) 
for the samples and the buffer are shown in Appendix B, Figure B18–Figure B19 for 
both excitation wavelengths (280 nm and 295 nm). The data following subtraction of 
the PBS signal are shown in Figure 4.16 (bottom). All six samples presented similarly 
shaped curves and none of them showed an additional peak at 460 nm. The maxima 
appeared at approximately 335.5 nm and 337.1 nm for excitation wavelengths 280 nm 
and 295 nm respectively (Table 4.11). The slightly shifted maxima (+0.6 nm) 
compared to the 1st analysis, especially with excitation at 280 nm, was complemented 
by the change in the calculated ratio of the intensities at 330 nm and 350 nm, which 
was decreased from 1.12 (1st analysis) to 1.11 (2nd analysis). This minor shift in the 
repeat analysis could perhaps have resulted from interactions of the protein with 
arginine, which was found to cause an expansion of the etanercept structure in the DLS 
results (Section 4.6.1) and could potentially have led to exposure of some of the 
Tyr/Trp residues to the solvent. The variation in the fluorescence intensities in PBS 
was within experimental error of the dilution.  
 
Table	  4.11:	  Key	  features	  of	   fluorescence	  emission	  spectra	  at	  excitation	  wavelengths	  280	  nm	  and	  295	  
nm.	  The	  maxima	  wavelengths	  and	  the	   intensity	  ratio	  at	  330:350	  nm	  are	  given	  for	  the	  1st	  and	  the	  2nd	  
analysis	  of	  the	  etanercept	  samples.	  
 
 
Excita'on*at*280*nm* Excita'on*at*295*nm*
Max*(nm)* Intensity*ra'o*330:350*nm* Max*(nm)*
Intensity*ra'o*
330:350*nm*
Sample* 1
st*
Analysis*
2nd*
Analysis*
1st*
Analysis*
2nd*
Analysis*
1st*
Analysis*
2nd*
Analysis*
1st*
Analysis*
2nd*
Analysis*
TNFR2:Fc(1( 334.8( 335.2( 1.12( 1.11( 336.6( 336.6( 1.08( 1.08(
TNFR2:Fc(2( 334.6( 334.9( 1.12( 1.11( 336.4( 336.8( 1.08( 1.08(
TNFR2:Fc(3( 334.6( 335.4( 1.12( 1.11( 336.8( 336.9( 1.08( 1.08(
TNFR2:Fc(4( 335.2( 335.8( 1.12( 1.11( 337.0( 337.1( 1.07( 1.08(
TNFR2:Fc(5( 335.2( 335.6( 1.12( 1.11( 336.6( 337.1( 1.07( 1.08(
TNFR2:Fc(6( 334.6( 335.4( 1.12( 1.11( 336.4( 337.2( 1.08( 1.08(
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In conclusion, the observed response at 460 nm in the biosimilar samples from 
the 1st analysis was probably created during buffer exchange. The variation in the 
fluorescence intensities among samples in the 1st analysis was probably due to 
inaccuracy in the initially assigned concentrations, while the variation following 
dilution (for the 2nd analysis) was within the experimental error of the dilution. 
However, the key feature for assessing similarity in the environment of the aromatic 
residues is the emission wavelength at which the fluorescence intensity is maximal. 
This wavelength was consistent between samples within each analysis for both 
excitation wavelengths, while a small shift (+0.6 nm) was evident for the 2nd analysis 
with excitation at 280 nm, perhaps indicating changes in the environment of some 
Tyr/Trp residues due to interaction with buffer excipients (arginine). In all cases, the 
similarity of the emission wavelengths (334.6–337.2 nm) after exciting either at 280 
nm or 295 nm, indicated dominance of tryptophan fluorescence even with excitation at 
280 nm. 
Taking into account the results from all four techniques applied, the etanercept 
samples appeared to be similar in the 1st analysis (far-/near-UV CD data at room 
temperature, FT-IR data and fluorescence collected for samples in ammonium 
bicarbonate buffer at the received concentration of ~0.9 mg/mL), with sample 1 
showing some differences from the others for all techniques. However, the 2nd 
analysis—which included far-UV CD spectra before and after the melting curves, CD 
melting curves, all DLS data and repeat fluorescence, recorded for the samples diluted 
with PBS to 0.1 mg/mL (for far-UV CD) or 1 mg/mL (all other techniques)—showed 
all six samples to be the same within experimental error and equally stable upon 
heating. This led to the conclusion that the observed variation for sample 1 during the 
1st analysis probably resulted from a concentration inaccuracy. DLS showed the 
presence of some larger particles in the biosimilar samples, but of insignificant 
population. During the temperature experiment, 55 °C seemed to be a key temperature, 
while at the end of the temperature experiment (cooled to 20 °C), etanercept appeared 
partially unfolded yet no aggregation was observed, perhaps due to the protective 
effect of ArgHCl against aggregation.65 The CD melting curves showed similar paths 
of unfolding for all six samples and were in agreement with DLS showing that Tm1 
was at 53 °C. The CD temperature experiment (recorded only for sample 1) showed 
that the fully unfolded conformation was reached at 80 °C. CD spectra recorded after 
cooling the samples down to 25 °C (following the melting curves) showed 
predominantly random coil structure and perhaps partial refolding of the protein, while 
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the respective HT spectra (before, during and following the melting curves) showed 
only insignificant signs of aggregation. 
Overall, DLS showed similar sizes and stability for all six samples. The far- 
and near-UV CD spectra suggested that the samples had similar secondary and tertiary 
structure, within experimental and analysis error. The secondary structure analysis 
from the CD spectra of etanercept showed a large variation due to the unusual 
spectrum of the protein. However, the averaged values from all the performed analyses 
showed similar secondary structure contents between the biosimilar and the innovator 
samples, but probably not quantitatively representative of the actual structure. The CD 
melting curves suggested equal thermal stability of all samples. The FT-IR spectra 
were similar for all six samples, within experimental and data processing error. 
Analysis of the amide I IR band suggested similar secondary structure conformation, 
though the results from SSNN should be seen with caution (especially for α-helix and 
random coil). Finally, fluorescence showed similar environment for the Tyr/Trp 
residues of all six samples, within the experimental error of the dilution. 
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4.7. MONOCLONAL ANTIBODY IN PHASE 3 
4.7.1. DLS spectroscopy of a monoclonal antibody 
DLS data for the four monoclonal antibodies were collected by Dr. Claire E. 
Broughton. The samples were diluted to 5 mg/mL, using a buffer that was the same as 
the formulation buffer but omitting Tween 80. The hydrodynamic diameter of the 
samples was measured as 10.3–11.0 nm (Z-average value as calculated by the 
Zetasizer software, based on intensity values), with sample 1 presenting the smallest 
size and sample 4 the largest. Intensity values are usually closer to the absolute size of 
the particles, however, the presence of larger particles can affect the estimated size, as 
seems to be the case here. In fact, sample 4 presented a narrower averaged distribution 
(over 8 measurements), with higher intensity and a slightly smaller size than the other 
three samples, as can be observed from the intensity distributions (Figure 4.17, left). 
However, a larger variation was evident over the course of measurements for sample 4, 
suggesting a mixture of particles with different sizes (Figure B22, Appendix B). In all 
four samples, some large particles were present with a size of ~6000 nm (probably not 
related to the protein), which seemed to have a greater impact on the calculated Z-
average value of sample 4, in which they appeared with a slightly higher intensity. All 
four samples showed moderate polydispersity with a PDI value of 0.2, therefore for the 
comparability purpose of this study the number values were used. 
 
 
Figure	  4.17:	  Left:	  Size	  distributions	  (nm)	  presented	  in	  intensity	  values	  for	  the	  four	  monoclonal	  antibody	  
samples.	  Right:	  Size	  distributions	  (nm)	  of	  the	  four	  samples	  presented	  in	  number	  values.	  The	  presented	  
data	  were	  recorded	  for	  the	  diluted	  samples	  to	  5	  mg/mL	  and	  are	  averaged	  over	  8	  measurements.	  
The distributions of the samples in number values (Figure 4.17, right) showed 
that the population of the large particles (~6000 nm) was not reproducible, samples 1–
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3 presented identical distributions and sizes of 7.0–7.1 nm, while sample 4 presented a 
slightly larger average size of 7.5 nm and a peak with two maxima (at 6.5 and 7.5 nm). 
The mean sizes and standard deviations were calculated from the mean number values 
of each measurement (as calculated by the Zetasizer software) and are shown in Figure 
4.18, with the exact values in the attached table. 
 
 
Figure	   4.18:	   Left:	   Overall	   mean	   particle	   diameters	   (nm)	   of	   the	   four	   monoclonal	   antibody	   samples	  
indicated	  as	  solid	  circles.	  For	  each	  sample,	  the	  overall	  mean	  was	  calculated	  over	  8	  measurements	  using	  
the	  number	  mean	  values	  as	  estimated	  by	  the	  Zetasizer	  software.	  The	  error	  bars	  indicate	  the	  standard	  
deviation	  with	  a	  95%	  confidence	  interval.	  The	  values	  of	  the	  overall	  means	  and	  the	  standard	  deviations	  
for	  each	  sample	  are	  shown	  in	  the	  attached	  table	  (right).	  
In conclusion, DLS showed similarly sized particles for samples 1–3, while 
sample 4 appeared somewhat different. The large variation throughout the 
measurements (intensity distributions), the two maxima and the slightly larger mean 
size (number values) of sample 4, probably suggest the presence of particles with 
different sizes. 
4.7.2. CD spectra of a monoclonal antibody 
CD spectra of the monoclonal antibody samples were recorded for the diluted samples 
at a concentration of ~0.1 mg/mL in 10 mM sodium phosphate buffer (pH ~7.0) using 
a 0.1 cm fixed path length cuvette. The four recorded baselines of the formulation 
buffer showed significant intensity signals at ~198 nm, probably due to arginine and 
citric acid excipients in the original formulation, even after 1000-fold dilution (Figure 
B23, Appendix B). The processed data (baseline-corrected and zeroed) are shown in 
Figure 4.19 (left). As already seen for trastuzumab in Chapter 3, all four samples 
presented the typical CD spectrum of an immunoglobulin with zero intensity at 208.2 
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nm and the typical shape of a β-sheet protein with a positive peak at 201 nm, a 
negative peak at 216 nm and a shoulder at 228 nm. Samples 1–3 appeared quite similar, 
indicating similarity in their secondary structure, while sample 4 appeared somewhat 
different in intensity but still of comparable secondary structure. 
Spectra recorded at the end of the melting curves, after cooling down the 
samples to 25 °C (Figure 4.19, right), showed a broad negative peak at ~210 nm for all 
four samples, with sample 4 presenting a wider and slightly shifted peak, at ~212 nm. 
In all cases the spectra after returning to room temperature indicate a mixture of 
partially unfolded and completely unfolded molecules, as they seem to be a 
combination of a β-sheet and a random coil spectrum. Thermal denaturation, therefore, 
led to irreversibility due to the “off-pathway” events in the energy funnel, in the effort 
of the protein to obtain a conformation located in one of the neighbouring minima (see 
Section 1.2 and as described in Section 3.5.1). One of these minima was also 
represented by structures stabilised by hydrophobic clustering (aggregation) between 
the partially unfolded conformations. Looking back to Chapter 3 (Figure 3.30, bottom) 
the partially unfolded spectrum could be represented by the spectra of the native 
antibodies (mAbs) at 78 °C and the completely unfolded state illustrated by the spectra 
at 83 °C. The fact that sample 4 presents a significantly larger signal after cooling 
down is not completely related to its initially larger signal (at 25 °C), but is mostly due 
to dominance of the random coil spectrum (as this usually presents a stronger negative 
signal than β-sheet) and therefore the presence of a larger fraction of completely 
unfolded molecules compared to samples 1–3. This observation is in agreement with 
the DLS data which indicated the presence of differently sized particles in sample 4, 
perhaps suggesting that a fraction of the protein molecules was in a partially unfolded 
conformation from the beginning. 
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Figure	   4.19:	   Comparison	  of	   the	  CD	   spectra	   (mdeg)	   of	   the	  diluted	  monoclonal	   antibody	   samples	   at	   a	  
concentration	  of	  ~0.1	  mg/mL	  using	  a	  0.1	  cm	  fixed	  path	  length	  cuvette.	  Spectra	  were	  acquired	  before	  
recording	   the	  melting	   curves	   (25	   °C,	   left),	   and	   at	   the	   end	   of	   the	   temperature	   experiment	   after	   the	  
samples	  were	  cooled	  down	  to	  25	  °C	  (right).	  
Melting curves 
The signals of the maximum at 200.0 nm and of the minimum at 217.0 nm were 
followed for all four samples throughout a range of temperatures from 25 °C to 100 °C 
resulting in the melting curves shown in Figure 4.20 (left and right respectively). All 
four samples presented a common path of unfolding at 200 nm, obtaining their 
completely unfolded conformation at ~78 °C, while sample 4 showed the largest 
change in the intensity of its signal and sample 1 the smallest, which were also related 
to their respective intensities for their 25 °C spectra. Decrease of the intensity at 200 
nm indicates either an increase in the random coil content or a decrease in α-helix 
content, as the wavelength 200 nm is affected by the characteristic spectra of both 
conformations. The curves at 217 nm were very similar for samples 1–3 presenting the 
onset of loss of β-sheet structure at around 58 °C, while at ~73 °C β-sheet appeared to 
increase and was stabilised at ~78 °C. Increase in the β-sheet content perhaps suggests 
that aggregation took place, as aggregation usually occurs for partially unfolded 
proteins after interaction of their β-sheet segments.73,74 Sample 4 appeared significantly 
different than the rest, showing the lowest β-sheet content, at which it was stabilised at 
~75 °C. Visual inspection of all samples at the end of the melting curves measurements 
and after cooling down to room temperature, confirmed the presence of solid particles 
in all samples confirming aggregation, perhaps favoured at the used pH, as neutral pH 
conditions have been found in literature to increase aggregation of antibodies.75,76 The 
raw melting curves for both wavelengths are shown in Figure B24 (Appendix B). 
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Figure	  4.20:	  Offset	  (as	  described	  in	  materials	  and	  methods,	  Section	  4.2.4)	  melting	  curves	  (mdeg)	  of	  the	  
monoclonal	  antibody	  samples	  at	  200.0	  nm	  (left)	  and	  217.0	  nm	  (right).	  The	  curves	  were	   recorded	   for	  
the	  samples	  diluted	  with	  sodium	  phosphate	  buffer,	  resulting	  in	  a	  final	  solution	  of	  ~0.1	  mg/mL	  protein	  
in	  10	  mM	  sodium	  phosphate	  buffer.	  The	  0.1	  cm	  fixed	  path	  length	  cuvette	  was	  used.	  
In conclusion, samples 1–3 presented quite similar spectra, and therefore 
secondary structure, while sample 4 appeared to be of comparable secondary structure 
based on its CD spectrum compared to the spectra of samples 1–3. All four samples 
were stable up to 58 °C. Samples 1–3 were of equal stability perhaps showing signs of 
aggregation of a partially unfolded conformation at increased temperature, while 
sample 4 presented lower β-sheet content and a completely unfolded conformation at 
75 °C. After cooling down, the samples presented a mixture of partially unfolded and 
completely unfolded molecules, with sample 4 appearing slightly different, perhaps 
due to the presence of a larger fraction of completely unfolded molecules compared to 
samples 1–3. Solid particles, and consequently aggregation, were obvious in all 
samples following visual inspection at the end of the measurements. 
4.7.3. 1D 1H-NMR spectroscopy of a monoclonal antibody 
1D 1H-NMR spectra for the four monoclonal antibodies were recorded at 45 °C, after 
the samples had been buffer exchanged into sodium phosphate buffer at pH 5.4—as the 
protein is more stable at pH 4.5–5.5 and the original formulation was at pH 5.0—and at 
concentrations of approximately 30–45 mg/mL. The used temperature (45 °C) has been 
previously mentioned in the literature to enhance homogeneity of the samples,77,78 
while the secondary structure of the protein is not expected to be affected since 
antibodies are usually stable at least up to 50 °C, which was also indicated by the CD 
melting curves. In order to improve the quality of the spectra, the experimental time 
was significantly longer compared to the one required for insulin (2 h compared to 5 
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min), as the molar concentration of the antibody was smaller (~200 µM compared to 1 
mM for insulin). Exhaustive buffer exchange was necessary as the signals of the 
formulation excipients were very strong in the original samples, covering the protein 
signals. Care was required in order to ensure the same conditions for all samples, as 
small variations in pH can result in major spectral differences and mislead the 
conclusions. Absence of stabilising excipients, and especially the surfactant Tween 80, 
in such high concentrations might favour formation of aggregates. However, this did 
not seem to be the case here, as further widening of the peaks would have been 
expected given the size of the protein. This is also supported by the 1D 1H-NMR 
spectra recorded in sodium phosphate buffer at neutral pH (7.0), which presented 
broadening in their line widths compared to the spectra of the samples at pH 5.4 
(Figure B25, Appendix B). The fact that the 1D 1H-NMR spectra at neutral pH were 
recorded before the spectra at pH 5.4 perhaps suggests that reversible aggregation was 
favoured at neutral pH and absence of stabilising excipients. 
The 1D NMR spectra for the four samples and the formulation buffer on its 
own are shown in Figure 4.21, where it is obvious that only insignificant traces of the 
formulation buffer were present in the samples. However, a few sharp peaks appeared, 
that were probably impurities induced during sample preparation, and were removed 
from the spectra for clarity, as well as the water peak. An overall look at the four 
antibody spectra does not disclose any distinct differences among the samples, except 
for a slightly weaker intensity of sample 4 compared to the rest. 
 
 
Figure	  4.21:	  1D	  1H-­‐NMR	  spectra	  of	  the	  four	  monoclonal	  antibody	  samples,	  after	  buffer	  exchange	  into	  
20	  mM	  sodium	  phosphate	  buffer,	  at	  a	  protein	  concentration	  of	  approximately	  30–45	  mg/mL	  and	  pH	  
5.4.	   Samples	   1–4	   are	   shown	   in	   purple,	   green,	   red	   and	   blue	   respectively.	   In	   black	   is	   the	   formulation	  
buffer	  spectrum.	  All	  spectra	  were	  recorded	  at	  45	  °C.	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Subtracting sample 2 from sample 1 (Figure 4.22) indicated a few differences 
in the regions 6.0–8.0 ppm (sidechain HN, aromatic protons and backbone HN), 4.0–4.3 
ppm (Hα resonances), 2.7–3.5 ppm and 0.3–1.3 ppm (aliphatic protons). Samples 2 
and 3 appeared almost identical (Figure 4.23), with only minor differences in the Hα 
and aliphatic region, at 4.0–4.3 ppm and 2.7–3.5 ppm respectively. Samples 2 and 4 
(Figure 4.24) presented some variation in the aromatic/HN area (6.0–9.0 ppm), in the 
Hα region (4.0–4.3 ppm) and in the aliphatic region (2.5–3.5 ppm and 1.2–1.5 ppm). 
Finally, samples 1 and 4 (Figure 4.25) varied in the aromatic/HN (6.3–9.0 ppm), Hα 
(4.0–4.3 ppm) and aliphatic region (2.7–3.5 ppm and 0.3–1.3 ppm). Variation in the 
regions 4.0–4.3 ppm and 2.7–3.5 ppm, that was present in all subtractions, might result 
from heterogeneity in glycosylation, as usually glycan signals appear at around 3.0–5.0 
ppm. Therefore, it cannot be inferred with certainty whether differences in these areas 
are due to lack of similarity in the higher-order structure of the samples or associated 
with the present glycan patterns. 
 
 
Figure	  4.22:	  Residual	  1H-­‐NMR	  spectrum	  (black)	  after	  subtracting	  the	  spectrum	  of	  sample	  2	  (green)	  from	  
sample	   1	   (purple).	   A	   scaling	   factor	   of	   0.9	   was	   used	   for	   the	   subtraction.	   Red	   brackets	   indicate	   the	  
regions	  of	  the	  spectra	  that	  appeared	  to	  vary	  after	  subtraction.	  
 
Figure	  4.23:	  Residual	  1H-­‐NMR	  spectrum	  (black)	  following	  subtraction	  of	  sample	  3	  (red)	  from	  sample	  2	  
(green).	  A	  scaling	  factor	  of	  0.92	  was	  used	  for	  the	  subtraction.	  Red	  brackets	  indicate	  the	  regions	  of	  the	  
spectra	  that	  appeared	  to	  vary	  after	  subtraction.	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Figure	  4.24:	  Residual	  1H-­‐NMR	  spectrum	  (black)	  following	  subtraction	  of	  sample	  4	  (blue)	  from	  sample	  2	  
(green).	   A	   scaling	   factor	   of	   1.6	   was	   used.	   Red	   brackets	   indicate	   the	   regions	   of	   the	   spectra	   that	  
appeared	  to	  vary	  after	  subtraction.	  
 
Figure	  4.25:	  Residual	  1H-­‐NMR	  spectrum	  (black)	  following	  subtraction	  of	  sample	  4	  (blue)	  from	  sample	  1	  
(purple).	   A	   scaling	   factor	   of	   1.5	   was	   used.	   Red	   brackets	   indicate	   the	   regions	   of	   the	   spectra	   that	  
appeared	  to	  vary	  after	  subtraction.	  
In conclusion, the 1D 1H-NMR spectra of the four monoclonal antibody 
samples showed similarity between samples 2 and 3, while samples 1 and 4 appeared 
somewhat different from each other and from samples 2 and 3. Overall, all three 
techniques (CD, DLS and NMR) agreed on similarity of samples 2 and 3 and variation 
of sample 4, while differences in sample 1 were only evident in the NMR spectra, as its 
particles size, secondary structure and thermal stability were found to be almost 
identical to samples 2 and 3. However, it should be kept in mind that the different 
concentrations used in each technique and the varied pH ranges (7.0 or 5.0–5.4) and 
buffer conditions (presence or absence of excipients) might have induced various 
structural changes, to which NMR is very sensitive. 
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4.8. CONCLUSIONS 
In the cases of protein H and hGH, only far-UV CD was conducted for comparability 
studies and investigation of their secondary structure respectively. Though CD is 
sufficient and the most direct technique for probing the secondary structure of proteins, 
it cannot show with certainty variation in particle populations and is not sensitive to 
differences at amino acid level. For these purposes, complementarity with DLS and 
near-UV CD or fluorescence spectroscopy is necessary. Protein A has an unusual far-
UV CD spectrum of βII type, which is hard to differentiate from a random coil 
spectrum. Near-UV CD was therefore conducted in addition, in order to prove the 
presence of ordered structure in the protein. Etanercept has also an unusual far-UV CD 
spectrum, with predominant random coil and β-sheet conformation. The study in this 
case was complemented by FT-IR for additional confirmation on the secondary 
structure of the protein; near-UV CD and fluorescence looked into the tertiary structure 
and orientation of the aromatic amino acids, while DLS revealed that the innovator 
samples were of higher purity due to the presence of some larger particles in the 
biosimilar samples. Moreover, coupling of DLS with temperature-dependent 
measurements and the CD melting curves showed similar stability for all etanercept 
samples under stressed conditions. For the monoclonal antibody study (mAb), DLS 
already indicated particle size variation in one of the samples (sample 4), which 
perhaps could also explain for the different far-UV CD spectrum compared to samples 
1–3. CD melting curves showed differences in stability of sample 4 compared to the 
remaining three samples. In addition, 1D 1H-NMR confirmed the observed variation of 
sample 4, while it also revealed some differences for sample 1, which were not obvious 
from CD or DLS. However, since NMR is quite sensitive to differences in atom level, 
all four samples showed some variation in the area 3.0–5.0 ppm, which might result 
from the glycosylation patterns and not from actual changes in the higher-order 
structure of the protein. 
As far as the encountered challenges are concerned, secondary structure 
analysis of the far-UV CD spectra using different algorithms and reference sets 
appeared to vary significantly in some cases, because of two reasons: unusual spectrum 
of the examined protein and intensity error accumulated from different sources. 
Combination of analyses with various software and reference sets usually offers an 
improved representation of the under-analysis protein, while comparison of the results 
with literature or the DSSP assignment for the PDB crystal structure is advisable when 
more accurate structure percentages are required. The studies in the present chapter 
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showed that an intensity error may occur mainly due to high viscosity of concentrated 
samples, which can result in a path length increase up to 50% when a demountable 
cuvette is used. Concentration errors (e.g. due to solvent evaporation or human error at 
sample dilution) and intensity calibration deviation can contribute up to ~5% and ~8% 
respectively, and can either cancel out or add up to a path length error. However, the 
often significant path length error was addressed to a satisfactory level by using a fixed 
cuvette, the instrument calibration error can be eliminated by applying a scaling factor, 
while concentration errors are harder to control. Finally, additional sample preparation 
such as dilution of highly concentrated samples (e.g. for CD) or buffer exchange due to 
the unsuitable formulation buffer, depending on the used analytical method (e.g. CD or 
NMR) is occasionally necessary (e.g. mAb study), though not ideal as it might induce 
changes in the secondary structure of the protein or impurities. If dilution is not with 
the formulation buffer errors in buffer component concentrations can cause further 
errors. Such was potentially the case for protein A, where the secondary structure of 
the protein changed upon dilution and the mAb study, where buffer exchange caused 
induction of impurities in the samples. However, as long as all samples were treated 
similarly, sample-to-sample comparison was still possible within each technique and 
combination of the results confirmed similarity or variation for protein A and mAb 
respectively. Complementarity of the used techniques in order to draw conclusions on 
similarity among samples is discussed in Chapter 5. 
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Chapter 5 
Conclusion 
Seven studies were completed in total in the present work, each one to a different 
extent, but with the same purpose: structural and physical characterisation of protein 
biotherapeutics. Such complex molecules require a series of tests in order to support 
comparability between a follow-on version (biosimilar) and the original (innovator) 
product, as well as batch-to-batch similarity. Changes in the used conditions in any 
step of the manufacturing process can induce heterogeneity, which can affect the 
stability, potency and immunogenicity of the final product. Full control of the 
manufacturing process is therefore of utmost importance, and accordingly significant is 
the inspection of the structural similarity and the amount of impurities or degradation 
products among samples. Far-UV CD spectroscopy was the common technique in all 
studies, while a number of analytical techniques such as: near-UV CD, DLS, FT-IR, 
fluorescence, 1D 1H-NMR and MS were used in different combinations in each study, 
in order to identify what information can be extracted and how they complement each 
other. Temperature-dependent measurements were applied in some of the studies, for 
further investigations on the thermal stability of the protein. 
 
What information does each technique offer and which are the 
challenges? 
Mass spectrometry (MS) includes a number of sophisticated experiments for protein 
characterisation and is probably the most robust technique and currently the method of 
choice in comparability studies for biopharmaceutical products. In this work, MS was 
used as a tool to confirm the primary structure (amino acid sequence) of the antibody 
samples (mAb-ADC study, Chapter 3) and also in order to look at post-translational 
modifications, such as carbohydrate structure and position, and degradation products 
(asparagine deamidation and methionine oxidation), while relative quantitation of the 
toxin molecules on each one of the conjugated samples was also applied. However, MS 
is a very expensive technique both because of the cost of the instrument itself, as this 
also needs to be coupled with an HPLC separation system, and due to the pricey 
reagents (e.g. enzymes) that are usually required for treatment of the samples prior to 
analysis. Furthermore, MS experiments produce a very large amount of data, which is 
time-consuming to analyse even with the use of the available automated libraries. 
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The rest of the techniques that were used in these studies are in their majority 
non-invasive. They can usually be applied to the provided sample in its original 
solution, without requiring any additional sample preparation, with some exceptions 
for high-concentrated samples (50–100 mg/mL) or in cases where the formulation 
buffer is unsuitable for the chosen method. CD, DLS, FT-IR, fluorescence and 1D 1H-
NMR spectroscopies all offer the convenience of speed as far as acquiring, processing 
and interpretation of the results are concerned, while all of them apart from NMR have 
the additional advantage of being significantly cheaper techniques compared to MS. 
Far-UV CD is the most direct technique for providing information on the 
secondary structure of a protein. However, often-encountered challenges might include 
intensity errors resulting from high viscosity of concentrated samples when used with a 
demountable cuvette, especially in the absence of stabilising excipients such as 
surfactants and salts which change the ionic strength of the solution and therefore 
decrease viscosity. In such cases, dilution of the samples might be necessary, however 
it should be made sure that the secondary structure of the protein is not affected by 
changes in concentration. An alternative solution to variations in the path length of a 
demountable cuvette due to high viscosity of the samples would be either the 
manufacturing of a sealed holder that will allow assembly of the cell ensuring a stable 
path length and also heating of the cell without the possibility of solvent evaporation or 
leakage, or the use of a sealed circular cell of the same path length as the demountable 
cuvette—both already in use by Prof. Bonnie Wallace. Visual inspection of the CD 
spectra is usually the first step to assess any observed differences or errors, while 
quantitation of the results can be achieved by the use of secondary structure analysis 
software. Combination of various programs and reference sets often offers better 
comparison, especially when comparing results from the same software/reference set 
for each sample, as in many cases different algorithms and reference sets present 
significant variation. This variation usually results from differences in the performance 
of each algorithm (e.g. CDSSTR consistently shows smaller spectral error than 
SELCON3, without this meaning that the quality of the analysis is always better) or 
from an unusual CD spectrum or even from accumulation of an intensity error. SSNN 
provided good comparative results for the temperature-dependent experiments for 
insulin (Chapter 2) and mAb-ADC (Chapter 3) studies. 
FT-IR is also a useful technique for investigating the secondary structure of 
proteins, as an alternative to CD, while it is probably the most effective spectroscopic 
method when it comes to fibrillation studies. However, processing of the FT-IR spectra 
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and more specifically buffer and water vapour corrections can result in variability in 
the shape of the amide I band when dealing with small concentrations (~1 mg/mL). 
Higher concentrations (≥10 mg/mL) are preferable when this is feasible, while the 
great flexibility of the technique allows for the analysis of solid samples and deposited 
layers of liquid samples after they dry out (as applied in the case of insulin). 
Nevertheless, the latter might not be always desirable as in most cases the structure of 
the protein in solution is of main interest. 
DLS is the most straightforward technique to provide information on the purity 
and homogeneity of the analysed sample. Particle size is a fundamental physical 
characteristic of a globular protein, while variation in size can indicate the presence of 
different populations and therefore changes in conformation, oligomerisation and 
aggregation state. It is one of the most versatile techniques as it can deal with a wide 
variety of concentrations as well as formulation buffers. 
Near-UV CD provides additional information on protein folding, looking at 
the tertiary structure of the molecule and more specifically at conformational changes 
in the environment of the aromatic amino acid side chains and disulfide bonds. Each 
protein has a unique near-UV CD spectrum, characteristic for the specific molecule as 
this can differ even among the same protein from different species. Weakening of the 
CD signal in the near-UV region usually indicates loss of ordered structure. Its 
sensitivity makes it a very useful tool in comparability studies and a reliable 
complement to far-UV CD data. 
Fluorescence emission spectra are also sensitive to changes in tertiary 
structure and orientation of the aromatic amino acids, especially tryptophan and 
tyrosine. Changes in intensity occur due to conformational changes that alter 
interactions between the aromatic amino acid side chains and nearby quenchers, while 
shift of the maximum towards longer wavelengths indicates unfolding of the structure. 
NMR is useful when dealing with high concentrated samples. It offers more 
detailed information compared to the above-mentioned techniques, and is able to point 
out subtle changes in the higher-order structure of the protein that might be missed by 
the rest of the methods. However, the exact same conditions should be ensured for all 
samples, as slight changes in pH can result in different chemical shifts. Furthermore, 
the formulation buffer is an additional limiting factor as the commonly used excipients 
overlap with the protein signals. In such cases buffer exchange might be necessary, 
though not desirable, as it can cause conformational and stability changes to the protein 
as well as induce impurities. NMR spectra are somewhat hard to interpret due to the 
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difficulty in specifying whether the observed variation results from intrinsic protein 
heterogeneity (such as glycan patterns) or from differences in the higher-order 
structure of the protein. 
 
Solving the puzzle: Complementarity of Techniques in drawing 
conclusions for the probed proteins 
Application of different spectroscopic techniques as complementary to each other 
provides undoubtedly a more complete idea on the similarity of the assessed samples, 
since each of the selected methods investigates different biophysical phenomena. 
However, some of the techniques provide answers to similar questions. Far-UV CD 
and FT-IR, for example, both examine the secondary structure of the molecule, and 
similarly near-UV CD and fluorescence both provide information on tertiary structure 
and orientation of the aromatic amino acid side chains. Combination of the correct 
techniques is, therefore, not a matter of which technique can be de facto omitted or 
replaced by another, but what information is required in each case. The flexibility of 
each method, as far as the used concentration or formulation buffer are concerned, can 
be used in favour of the scientist, provided that the experiments are planned 
accordingly and depending on the under-analysis protein and its formulation. 
In any study, the academic way imposes the importance that the researcher 
should be informed on literature, when published data are available. However, industry 
works in much shorter time-scales and is therefore interested in obtaining results as fast 
as possible, ideally performing a series of “blind experiments” that would however 
ensure that the desired conclusions will be reached. The conducted studies in the 
present work have provided empirical experience, which can offer practical advice 
when decisions should be made on which of the above biophysical techniques should 
be used and in which cases. A potential “SOP” would suggest the following: 
 
Given the fact that MS is the only technique to provide detailed information on 
the primary structure, post-translational modifications and degradation 
products, it is still the basis of the quality control tests. 
 
DLS, likewise, provides fundamental information on particle size, 
oligomerisation, aggregation state and purity of the samples. It is quick, cheap, 
easy and versatile as far as the range of concentration and formulation buffers 
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are concerned. It is therefore advisable that DLS measurements are performed 
in all cases. 
 
Inaccurate concentration estimation can often be an issue as was observed in 
a few of the examined case studies, especially those included in the 
confidential Vol. 2. Concentration should therefore be checked and 
standardised for all samples (different batches of a protein), ideally as received 
on arrival, by UV-Vis spectroscopy. In the case that the excipients of the used 
formulation present high absorbance, resulting in low quality far-UV CD data, 
a diluted sample of each batch should be used for measuring the UV-Vis 
absorbance and estimating the concentration prior to all experiments. 
 
For investigation of the secondary structure, either CD or FT-IR data should 
be acquired, depending on the protein concentration in the provided 
preparation. Namely, CD is recommended for relatively low concentrations 
(ideally 0.1–1 mg/mL and an upper extreme of 3 mg/mL), while FT-IR 
performs better at higher concentrations (ideally ≥10 mg/mL and a lower end 
at 1 mg/mL). Selecting between the two techniques should also be determined 
by the structure of the examined protein. As already seen in Chapter 4, certain 
protein structures can result in spectra that are indistinguishable from the 
spectrum of a completely different structure. Such was the case of protein A, 
where similarity of its unusual CD spectrum (of βII type) with the typical 
random coil spectrum could raise doubts, while this issue could have probably 
been clarified by the position of the FT-IR amide I band if an FT-IR spectrum 
had been acquired. Vice versa, in the case of α-helix or random coil structure, 
which present overlapping amide I bands in FT-IR, CD can be used instead as 
the CD spectra for α-helix and random coil are fairly distinct. In principle, 
either CD or FT-IR should be sufficient for probing the secondary structure of 
a protein, while when in doubt both techniques can be used as complementary 
to each other. 
 
For the tertiary structure, near-UV CD is probably sufficient for 
comparability purposes and can be easily recorded as an additional spectrum 
when far-UV CD data are recorded. However, in cases where major 
differences are apparent in the near-UV CD spectra or where changes in the 
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conformation of the protein are suspected, fluorescence is a useful tool, as shift 
in the maximum would directly address the question of any conformational 
change present. Fluorescence data would have probably been useful as an 
additional experiment in the case of the monoclonal antibody study (Section 
4.7), where one of the samples (sample 4) appeared to be significantly 
different to the remaining three, and the reason of this variation was not clear. 
In addition, fluorescence is undoubtedly an advantageous technique for 
molecules with only a few aromatic amino acids (especially tyrosines and 
tryptophans) or even one tryptophan, as in such cases the emission spectrum 
will provide very specific information, or in cases where aromatic amino acids 
are located in regions that are important for binding and activity of the 
molecule. 
 
For investigation of the higher-order structure as a whole of a protein 
molecule, namely secondary, tertiary and quaternary structure, the use of 1D 
1H-NMR spectroscopy seems to be promising. Acquisition of NMR spectra 
should be considered when dealing with high concentrations (≥200 µM), as the 
provided data can offer complementary information to the rest of the 
techniques. NMR can contribute to quantitation of the observed differences 
when used in combination with statistical analysis. However, it is probably not 
sufficient yet as a stand-alone technique for this purpose, and further 
experience and data are needed in order to define the amount of variation 
among samples and the significance of such differences. 
 
Overall, MS, DLS and far-UV CD or FT-IR (depending on protein structure- 
and preparation/concentration-specific experiment planning) are the most important 
techniques for assessing batch-to-batch or biosimilar-to-innovator similarity of 
biotherapeutic molecules. The rest of the techniques can provide additional and 
supporting information according to the manufacturer’s requirements, in order to point 
out differences or confirm similarity among samples, and also clarify any unclear 
results. Concentrations should be checked for all samples upon arrival and prior to all 
experiments, either for the samples as received or following dilution. When dilution or 
buffer exchange is unavoidable, it should ideally be confirmed that the protein 
conformation does not change upon dilution (with an FT-IR or far-/near-UV CD 
experiment for example). Coupling with temperature provides additional information 
 238 
on thermal stability evaluation and shows which samples are more prone to 
conformational changes under the stress of high temperature. 
 
Future Aspects and Improvements 
Even though exposing a protein to forced stress (such as high temperature) provides a 
valid comparability study on the susceptibility of each of the examined samples to 
conformational changes, it does not necessarily reflect changes that might occur to the 
molecule under the everyday-life stress conditions that a biopharmaceutical product 
can undergo during shipping, handling and storage processes. Long-term stability 
studies under relatively moderate stress and real-time storage conditions such as 
exposure to: direct sunlight, air (e.g. using a permeable vial), temperatures up to 45–
60 °C (useful for countries with high environmental temperatures), high humidity, 
shaking, freeze-thaw cycles, long shelf-storage (e.g. ≥2 years), will probably be more 
indicative of the actual changes that might take place and the resulting degradation 
products. Temperature ramps that do not go as high as 75 °C or 100 °C will help in 
probing whether stability and folding are compromised at lower temperatures (e.g. 50–
60 °C), if the protein returns to its native fold when cooled down to 20 °C and which is 
the upper temperature that represents the point of no return. 
Finally, further NMR work in the direction of studying the glycan patterns 
following deglycosylation of a protein is probably an interesting complement to MS 
data, while statistical analysis of consistent NMR data and quantitation of the observed 
variation is an attractive addition to the rest of the analytical techniques. 
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Appendix A 
MASS SPECTROMETRY 
 
Figure	  A1:	  Overall	  coverage	  map	  for	  the	  trastuzumab	  sequence	  after	  tryptic	  digestion.	  The	   identified	  
residues	   for	   the	   heavy	   (top)	   and	   the	   light	   (bottom)	   chain	   are	   marked	   in	   orange,	   and	   the	   missing	  
peptides	  appear	  in	  white.	  Coverage	  was	  94.90%	  for	  the	  heavy	  chain	  and	  100.00%	  for	  the	  light	  chain.	  
 
Mapped& 427&
Residues& 450&
Coverage( 94.90%(
Mapped& 214&
Residues& 214&
Coverage( 100.00%(
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Table	  A1:	  Peptide	  mapping	  table	  resulting	  from	  digestion	  with	  trypsin	  for	  the	  native	  antibody	  (sample	  
mAb	  (S)).	  Calc.	  MW	  is	  the	  monoisotopic	  mass	  calculated	  from	  the	  m/z	  mass	  and	  the	  charge	  state.	  Exp.	  
MW	  is	  the	  expected	  monoisotopic	  mass	  of	  the	  cleaved	  peptide.	  
 
RT m/z Charge,
state
Calc.,MW,
(Da)
Chain Possible,
Assignment
Exp.,MW,
(Da)
Comments
10.70 939.94 2 1877.88 LC 1–18 1877.88
8.13 947.96 2 1893.92 LC 1–18 1893.88 Oxidised
4.72 750.38 1 749.38 LC 19–24 749.37
9.91 1161.55 1 1160.55 LC 25–35 1160.55 Cleaved8at8W
1.43 572.83 2 1143.66 LC 36–45 1143.64 Missed8cleavage
16.96 886.98 2 1771.96 LC 46–61 1771.95
0.55 553.28 1 552.28 LC 62–66 552.27
19.42 1396.97 3 4187.91 LC 67–103 4187.89
2.01 488.31 1 487.31 LC 104–107 487.30
2.33 545.34 1 544.34 LC 105–108 544.33 Missed8cleavage
16.69 973.52 2 1945.04 LC 109–126 1945.02
13.99 752.39 3 2254.17 LC 126–145 2254.14 Missed8cleavage
18.40 899.94 2 1797.88 LC 127–142 1797.87
3.11 560.32 1 559.32 LC 146–149 559.31
6.43 1068.49 2 2134.98 LC 150–169 2134.96
12.04 751.88 2 1501.76 LC 170–183 1501.75
0.47 625.28 1 624.28 LC 184–188 624.28
8.14 714.68 3 2141.04 LC 189–207 2141.06 Missed8cleavage
9.55 938.96 2 1875.92 LC 191–207 1875.90
0.72 523.27 1 522.27 LC 208–211 522.26
3.01 870.33 1 869.33 LC 208–214 869.33 Missed8cleavage
12.55 941.51 2 1881.02 HC 1–19 1881.00
9.52 584.78 2 1167.56 HC 20–30 1167.56
15.52 661.98 3 1982.94 HC 20–36 1982.92 Missed8cleavage,8cleaved8at8W
14.63 747.04 3 2238.12 HC 20–38 2238.09 Missed8cleavage
9.45 545.28 2 1088.56 HC 31–38 1088.54
14.16 755.43 1 754.43 HC 37–43 754.44 Tentative
8.57 830.45 1 829.45 HC 44–50 829.44
5.92 1084.54 1 1083.54 HC 51–59 1083.53
6.11 1085.54 1 1084.54 HC 51–59 1084.53 Deamidated
2.04 682.34 1 681.34 HC 60–65 681.33
6.07 591.80 2 1181.60 HC 66–76 1181.60 Missed8cleavage
6.69 969.49 1 968.49 HC 68–76 968.48
9.87 655.83 2 1309.66 HC 77–87 1309.64
6.49 668.28 2 1334.56 HC 88–98 1334.54
18.58 1392.62 2 2783.24 HC 99–124 2783.25
11.04 593.83 2 1185.66 HC 125–136 1185.64
10.21 661.84 2 1321.68 HC 137–150 1321.65
22.47 1343.67 5 6713.35 HC 151–213 6713.29 Missed8cleavage
12.33 726.86 4 2903.44 HC 192–217 2903.44 Missed8cleavage
2.99 361.21 1 360.21 HC 214–216 360.20 Weak
13.06 472.28 1 471.28 HC 218–221 471.27
15.89 844.04 3 2529.12 HC 222–244 2529.09 Missed8cleavage,8cleaved8at8F
16.52 1019.96 2 2037.92 HC 226–244 2037.92 Cleaved8at8F
6.07 826.52 1 825.52 HC 245–251 825.51 Missed8cleavage
6.96 835.44 1 834.44 HC 252–258 834.43
5.89 851.42 1 850.42 HC 252–258 850.43 Oxidised
13.06 714.01 3 2139.03 HC 259–277 2139.00
16.04 763.03 3 2286.09 HC 259–278 2286.07 Missed8cleavage,8cleaved8at8F
11.79 839.40 2 1676.80 HC 278–291 1676.79
4.31 1317.54 2 2633.08 HC 296–304 2633.00 G0F81444.50
4.31 1398.55 2 2795.10 HC 296–304 2795.08 G1F81606.58
4.31 1479.57 2 2957.14 HC 296–304 2957.13 G2F81768.63
17.37 904.50 2 1807.00 HC 305–320 1807.00
17.75 904.98 2 1807.96 HC 305–320 1808.00 Deamidated
16.50 743.41 3 2227.23 HC 305–323 2227.20 Missed8cleavage
16.74 743.73 3 2228.19 HC 305–323 2228.20 Missed8cleavage8deamidated
6.09 578.79 2 1155.58 HC 321–329 1155.56 Tentative,8missed8cleavage
7.30 838.50 1 837.50 HC 330–337 837.50
0.36 448.27 1 447.27 HC 338–341 447.27
12.82 656.37 1 655.37 HC 342–347 655.38 Tentative,8missed8cleavage
16.72 884.45 2 1766.90 HC 342–357 1766.93 Tentative,8missed8cleavage
10.21 643.82 2 1285.64 HC 348–358 1285.67
0.47 637.29 1 636.29 HC 359–363 636.28 Very8weak
11.43 581.81 2 1161.62 HC 364–373 1161.61
14.87 1272.56 2 2543.12 HC 374–395 2543.12
15.11 1273.06 2 2544.12 HC 374–395 2544.12 Deamidated
15.70 937.47 2 1872.94 HC 396–412 1872.91
2.99 575.34 1 574.34 HC 413–417 574.33
12.82 1201.24 3 3600.72 HC 413–442 3600.70 Tentative,8missed8cleavage
12.69 701.31 4 2801.24 HC 420–442 2801.24
9.55 788.46 1 787.46 HC 443–450 787.44 Very8weak
7.55 660.36 1 659.36 HC 443–450 659.35 K8missing
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Table	  A2:	  Peptide	  mapping	  table	  resulting	  from	  digestion	  with	  trypsin	  for	  the	  native	  antibody	  (sample	  
mAb	  (LR)).	  Calc.	  MW	  is	  the	  monoisotopic	  mass	  calculated	  from	  the	  m/z	  mass	  and	  the	  charge	  state.	  Exp.	  
MW	  is	  the	  expected	  monoisotopic	  mass	  of	  the	  cleaved	  peptide.	  
 
 
RT m/z Charge,
state
Calc.,MW,
(Da)
Chain Possible,
Assignment
Exp.,MW,
(Da)
Comments
10.70 939.94 2 1877.88 LC 1–18 1877.88
8.14 947.94 2 1893.88 LC 1–18 1893.88 Oxidised
4.72 750.38 1 749.38 LC 19–24 749.37
9.01 763.07 3 2286.21 LC 25–45 2286.18 Missed6cleavage
16.96 886.98 2 1771.96 LC 46–61 1771.95
0.55 553.27 1 552.27 LC 62–66 552.27
19.43 1396.98 3 4187.94 LC 67–103 4187.89
2.01 488.31 1 487.31 LC 104–107 487.30
2.31 644.41 1 643.41 LC 104–108 643.40 Missed6cleavage
16.72 973.52 2 1945.04 LC 109–126 1945.02
14.00 752.39 3 2254.17 LC 126–145 2254.14 Missed6cleavage
18.40 899.94 2 1797.88 LC 127–142 1797.87
3.96 888.48 1 887.48 LC 143–149 887.49 Missed6cleavage
3.12 560.32 1 559.32 LC 146–149 559.31
6.43 1068.49 2 2134.98 LC 150–169 2134.96
12.04 751.88 2 1501.76 LC 170–183 1501.75
0.48 625.29 1 624.29 LC 184–188 624.28
8.14 714.69 3 2141.07 LC 189–207 2141.06 Missed6cleavage
9.55 938.96 2 1875.92 LC 191–207 1875.90
0.70 523.27 1 522.27 LC 208–211 522.26
3.01 870.35 1 869.35 LC 208–214 869.33 Missed6cleavage
12.55 941.50 2 1881.00 HC 1–19 1881.00
9.52 584.78 2 1167.56 HC 20–30 1167.56
15.55 661.98 3 1982.94 HC 20–36 1982.92 Missed6cleavage,6cleaved6at6W
14.65 747.04 3 2238.12 HC 20–38 2238.09 Missed6cleavage
9.43 545.28 2 1088.56 HC 31–38 1088.54
14.16 755.44 1 754.44 HC 37–43 754.44 Tentative
0.33 500.28 1 499.28 HC 39–43 499.28 Tentative
8.57 830.45 1 829.45 HC 44–50 829.44
5.93 1084.54 1 1083.54 HC 51–59 1083.53
6.09 1085.53 1 1084.53 HC 51–59 1084.53 Deamidated
2.04 682.34 1 681.34 HC 60–65 681.33
6.07 591.80 2 1181.60 HC 66–76 1181.60 Missed6cleavage
6.70 969.49 1 968.49 HC 68–76 968.48
9.89 655.83 2 1309.66 HC 77–87 1309.64
6.49 1335.56 1 1334.56 HC 88–98 1334.54
18.57 1392.63 2 2783.26 HC 99–124 2783.25
11.04 593.83 2 1185.66 HC 125–136 1185.64
10.21 661.84 2 1321.68 HC 137–150 1321.65
22.49 1343.65 5 6713.25 HC 151–213 6713.29 Missed6cleavage
12.35 968.82 3 2903.46 HC 192–217 2903.44 Missed6cleavage
9.33 765.87 2 1529.74 HC 213–225 1529.78 Missed6cleavage,6weak
13.07 472.28 1 471.28 HC 218–221 471.27 Weak
15.91 1265.55 2 2529.10 HC 222–244 2529.09 Missed6cleavage,6cleaved6at6F
16.55 1019.96 2 2037.92 HC 226–244 2037.92 Cleaved6at6F
5.91 826.52 1 825.52 HC 245–251 825.51 Missed6cleavage
5.89 566.37 1 565.37 HC 247–251 565.36 Missed6cleavage
6.96 835.43 1 834.43 HC 252–258 834.43
5.89 851.42 1 850.42 HC 252–258 850.43 Oxidised
13.07 714.01 3 2139.03 HC 259–277 2139.00
16.00 763.03 3 2286.09 HC 259–278 2286.07 Missed6cleavage,6cleaved6at6F
11.79 839.40 2 1676.80 HC 278–291 1676.79
10.37 595.31 2 1188.62 HC 296–304 1188.50 Very6weak
4.31 1317.51 2 2633.02 HC 296–304 2633.00 G0F61444.50
4.31 1398.55 2 2795.10 HC 296–304 2795.08 G1F61606.58
4.31 1479.58 2 2957.16 HC 296–304 2957.13 G2F61768.63
17.37 904.51 2 1807.02 HC 305–320 1807.00
17.74 905.00 2 1808.00 HC 305–320 1808.00 Deamidated
16.55 743.40 3 2227.20 HC 305–323 2227.20 Missed6cleavage
16.75 743.74 3 2228.22 HC 305–323 2228.20 Missed6cleavage6deamidated
6.11 1156.58 1 1155.58 HC 321–329 1155.56 Tentative,6missed6cleavage
0.36 736.37 1 735.37 HC 324–329 735.36 Missed6cleavage,6weak
7.31 838.50 1 837.50 HC 330–337 837.50
0.36 448.28 1 447.28 HC 338–341 447.27
12.86 656.37 1 655.37 HC 342–347 655.38 Tentative,6missed6cleavage
16.67 884.45 2 1766.90 HC 342–357 1766.93 Tentative,6missed6cleavage
10.21 643.82 2 1285.64 HC 348–358 1285.67
0.50 637.28 1 636.28 HC 359–363 636.28 Very6weak
11.43 581.82 2 1161.64 HC 364–373 1161.61
14.87 1272.57 2 2543.14 HC 374–395 2543.12
15.06 1273.07 2 2544.14 HC 374–395 2544.12 Deamidated
15.69 937.47 2 1872.94 HC 396–412 1872.91
2.99 575.34 1 574.34 HC 413–417 574.33
12.84 901.19 4 3600.76 HC 413–442 3600.70 Tentative,6missed6cleavage
12.69 934.76 3 2801.28 HC 420–442 2801.24
8.14 788.45 1 787.45 HC 443–450 787.44
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Table	  A3:	  Peptide	  mapping	  table	  resulting	  from	  digestion	  with	  trypsin	  for	  the	  antibody	  drug	  conjugate	  
produced	  with	  the	  solution	  method	  (sample	  ADC	  (S)).	  Calc.	  MW	  is	  the	  monoisotopic	  mass	  calculated	  
from	  the	  m/z	  mass	  and	  the	  charge	  state.	  Exp.	  MW	  is	  the	  expected	  monoisotopic	  mass	  of	  the	  cleaved	  
peptide.	  
 
RT m/z Charge,
state
Calc.,MW,
(Da)
Chain Possible,
Assignment
Exp.,MW,
(Da)
Comments
10.74 939.95 2 1877.90 LC 1–18 1877.88
8.18 947.94 2 1893.88 LC 1–18 1893.88 Oxidised
4.75 750.38 1 749.38 LC 19–24 749.37
9.94 1161.54 1 1160.54 LC 25–35 1160.55 Cleaved8at8W
1.50 572.83 2 1143.66 LC 36–45 1143.64 Missed8cleavage
16.96 886.98 2 1771.96 LC 46–61 1771.95
0.55 553.27 1 552.27 LC 62–66 552.27
19.47 1396.97 3 4187.91 LC 67–103 4187.89
2.04 488.31 1 487.31 LC 104–107 487.30
9.30 947.54 1 946.54 LC 108–116 946.52 Cleaved8at8F
16.64 973.52 2 1945.04 LC 109–126 1945.02
9.04 457.24 2 912.48 LC 119–126 912.46
14.00 752.39 3 2254.17 LC 126–145 2254.14 Missed8cleavage
18.44 899.95 2 1797.90 LC 127–142 1797.87
3.14 560.32 1 559.32 LC 146–149 559.31
6.45 1068.49 2 2134.98 LC 150–169 2134.96
12.06 751.88 2 1501.76 LC 170–183 1501.75
0.47 625.28 1 624.28 LC 184–188 624.28
8.19 714.69 3 2141.07 LC 189–207 2141.06 Missed8cleavage
9.58 938.95 2 1875.90 LC 191–207 1875.90
0.70 523.26 1 522.26 LC 208–211 522.26
3.04 870.34 1 869.34 LC 208–214 869.33 Missed8cleavage,8unconjugated
23.47 1064.56 2 2127.12 LC 208–214 2127.12 Missed8cleavage,8drug8peptide
25.09 812.44 2 1622.88 LC 212–214 1622.87 Drug8peptide
12.57 941.50 2 1881.00 HC 1–19 1881.00
9.57 584.79 2 1167.58 HC 20–30 1167.56
15.55 661.98 3 1982.94 HC 20–36 1982.92 Missed8cleavage,8cleaved8at8W
14.69 747.04 3 2238.12 HC 20–38 2238.09 Missed8cleavage
14.16 755.42 1 754.42 HC 37–43 754.44 Tentative
8.62 830.45 1 829.45 HC 44–50 829.44
5.94 1084.55 1 1083.55 HC 51–59 1083.53
6.13 1085.56 1 1084.56 HC 51–59 1084.53 Deamidated
2.09 682.35 1 681.35 HC 60–65 681.33
6.13 591.81 2 1181.62 HC 66–76 1181.60 Missed8cleavage
6.74 969.48 1 968.48 HC 68–76 968.48
9.96 655.83 2 1309.66 HC 77–87 1309.64
6.50 668.29 2 1334.58 HC 88–98 1334.54
18.57 1392.64 2 2783.28 HC 99–124 2783.25
11.07 593.83 2 1185.66 HC 125–136 1185.64
10.26 661.83 2 1321.66 HC 137–150 1321.65
21.95 1176.22 3 3525.66 HC 151–183 3525.71 Cleaved8at8F
22.50 1343.66 5 6713.30 HC 151–213 6713.29 Missed8cleavage
12.88 887.96 4 3547.84 HC 184–216 3547.78 Missed8cleavage
12.38 726.86 4 2903.44 HC 192–217 2903.44 Missed8cleavage
13.11 472.28 1 471.28 HC 218–221 471.27
22.84 884.48 2 1766.96 HC 222–225 1766.96 Drug8peptide
15.98 844.04 3 2529.12 HC 222–244 2529.09
Missed8cleavage,8cleaved8at8F,8
unconjugated
25.65 1263.29 3 3786.87 HC 222–244 3786.87 Missed8cleavage,8drug8peptide
16.57 1019.96 2 2037.92 HC 226–244 2037.92 Cleaved8at8F
5.94 826.52 1 825.52 HC 245–251 825.51 Missed8cleavage
6.99 835.43 1 834.43 HC 252–258 834.43
5.93 851.45 1 850.45 HC 252–258 850.43 Oxidised
13.11 714.01 3 2139.03 HC 259–277 2139.00
16.08 763.03 3 2286.09 HC 259–278 2286.07 Missed8cleavage,8cleaved8at8F
11.84 839.40 2 1676.80 HC 278–291 1676.79
10.42 595.30 2 1188.60 HC 296–304 1188.50 Very8weak
4.33 1317.51 2 2633.02 HC 296–304 2633.00 G0F81444.50
4.33 1398.55 2 2795.10 HC 296–304 2795.08 G1F81606.58
4.33 1479.58 2 2957.16 HC 296–304 2957.13 G2F81768.63
17.42 904.51 2 1807.02 HC 305–320 1807.00
17.77 905.00 2 1808.00 HC 305–320 1808.00 Deamidated
16.57 743.41 3 2227.23 HC 305–323 2227.20 Missed8cleavage
16.81 743.73 3 2228.19 HC 305–323 2228.20 Missed8cleavage,8deamidated
6.16 578.78 2 1155.56 HC 321–329 1155.56 Tentative,8missed8cleavage
7.35 838.50 1 837.50 HC 330–337 837.50
0.36 448.28 1 447.28 HC 338–341 447.27
16.69 884.44 2 1766.88 HC 342–357 1766.93 Tentative,8missed8cleavage
10.26 643.83 2 1285.66 HC 348–358 1285.67
0.50 637.29 1 636.29 HC 359–363 636.28 Very8weak
11.47 581.81 2 1161.62 HC 364–373 1161.61
14.89 1272.56 2 2543.12 HC 374–395 2543.12
15.06 1273.08 2 2544.16 HC 374–395 2544.12 Deamidated
15.69 937.47 2 1872.94 HC 396–412 1872.91
2.99 575.34 1 574.34 HC 413–417 574.33
12.86 901.18 4 3600.72 HC 413–442 3600.70 Tentative,8missed8cleavage
12.72 934.75 3 2801.25 HC 420–442 2801.24
8.19 788.45 1 787.45 HC 443–450 787.44 Very8weak
7.58 660.36 1 659.36 HC 443–450 659.35 K8missing
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Table	  A4:	  Peptide	  mapping	  table	  resulting	  from	  digestion	  with	  trypsin	  for	  the	  antibody	  drug	  conjugate	  
produced	   with	   the	   lock-­‐release	   method	   (sample	   ADC	   (LR)).	   Calc.	   MW	   is	   the	   monoisotopic	   mass	  
calculated	  from	  the	  m/z	  mass	  and	  the	  charge	  state.	  Exp.	  MW	  is	  the	  expected	  monoisotopic	  mass	  of	  the	  
cleaved	  peptide.	  
 
RT m/z Charge,
state
Calc.,MW,
(Da)
Chain Possible,
Assignment
Exp.,MW,
(Da)
Comments
10.72 939.95 2 1877.90 LC 1–18 1877.88
8.16 947.94 2 1893.88 LC 1–18 1893.88 Oxidised
4.74 750.38 1 749.38 LC 19–24 749.37
9.93 1161.55 1 1160.55 LC 25–35 1160.55 Cleaved8at8W
1.47 572.83 2 1143.66 LC 36–45 1143.64 Missed8cleavage
16.98 886.98 2 1771.96 LC 46–61 1771.95
0.55 553.27 1 552.27 LC 62–66 552.27
19.43 1396.97 3 4187.91 LC 67–103 4187.89
21.93 1183.58 3 3547.74 LC 78–107 3547.66 Missed8cleavage
2.04 488.31 1 487.31 LC 104–107 487.30
2.31 545.34 1 544.34 LC 105–108 544.33 Missed8cleavage
16.74 973.52 2 1945.04 LC 109–126 1945.02
13.99 752.39 3 2254.17 LC 126–145 2254.14 Missed8cleavage
18.42 899.94 2 1797.88 LC 127–142 1797.87
10.72 347.17 1 346.17 LC 143–145 346.19 Very8weak
3.14 560.32 1 559.32 LC 146–149 559.31
6.43 1068.48 2 2134.96 LC 150–169 2134.96
12.06 751.88 2 1501.76 LC 170–183 1501.75
0.47 625.28 1 624.28 LC 184–188 624.28
8.16 714.69 3 2141.07 LC 189–207 2141.06 Missed8cleavage
9.57 938.96 2 1875.92 LC 191–207 1875.90
0.70 523.26 1 522.26 LC 208–211 522.26
3.04 870.34 1 869.34 LC 208–214 869.33 Missed8cleavage,8unconjugated
23.45 1064.56 2 2127.12 LC 208–214 2127.12 Missed8cleavage,8drug8peptide
25.11 812.43 2 1622.86 LC 212–214 1622.87 Drug8peptide
12.55 941.50 2 1881.00 HC 1–19 1881.00
9.55 584.78 2 1167.56 HC 20–30 1167.56
15.57 661.98 3 1982.94 HC 20–36 1982.92 Missed8cleavage,8cleaved8at8W
14.67 747.04 3 2238.12 HC 20–38 2238.09 Missed8cleavage
9.47 545.28 2 1088.56 HC 31–38 1088.54
14.16 755.43 1 754.43 HC 37–43 754.44 Tentative
8.58 830.46 1 829.46 HC 44–50 829.44
5.93 1084.54 1 1083.54 HC 51–59 1083.53
6.13 1085.54 1 1084.54 HC 51–59 1084.53 Deamidated
2.04 682.34 1 681.34 HC 60–65 681.33
6.09 591.80 2 1181.60 HC 66–76 1181.60 Missed8cleavage
6.70 969.49 1 968.49 HC 68–76 968.48
9.93 655.83 2 1309.66 HC 77–87 1309.64
6.50 668.27 2 1334.54 HC 88–98 1334.54
18.57 1392.63 2 2783.26 HC 99–124 2783.25
11.04 593.83 2 1185.66 HC 125–136 1185.64
10.23 661.84 2 1321.68 HC 137–150 1321.65
22.49 1343.66 5 6713.30 HC 151–213 6713.29 Missed8cleavage
12.35 726.87 4 2903.48 HC 192–217 2903.44 Missed8cleavage
2.99 361.21 1 360.21 HC 214–216 360.20 Weak
13.09 472.28 1 471.28 HC 218–221 471.27
22.79 884.49 2 1766.98 HC 222–225 1766.96 Drug8peptide
15.96 844.03 3 2529.09 HC 222–244 2529.09
Missed8cleavage,8cleaved8at8F,8
unconjugated
25.67 1263.29 3 3786.87 HC 222–244 3786.87 Missed8cleavage,8drug8peptide
16.55 1019.95 2 2037.90 HC 226–244 2037.92 Cleaved8at8F
6.07 826.51 1 825.51 HC 245–251 825.51 Missed8cleavage
6.96 835.44 1 834.44 HC 252–258 834.43
5.93 851.43 1 850.43 HC 252–258 850.43 Oxidised
13.09 714.01 3 2139.03 HC 259–277 2139.00
16.04 763.03 3 2286.09 HC 259–278 2286.07 Missed8cleavage,8cleaved8at8F
11.82 839.40 2 1676.80 HC 278–291 1676.79
4.33 1317.52 2 2633.04 HC 296–304 2633.00 G0F81444.50
4.31 1398.54 2 2795.08 HC 296–304 2795.08 G1F81606.58
4.33 1479.58 2 2957.16 HC 296–304 2957.13 G2F81768.63
17.40 904.51 2 1807.02 HC 305–320 1807.00
17.77 905.01 2 1808.02 HC 305–320 1808.00 Deamidated
16.55 743.41 3 2227.23 HC 305–323 2227.20 Missed8cleavage
16.77 743.73 3 2228.19 HC 305–323 2228.20 Missed8cleavage,8deamidated
7.33 838.50 1 837.50 HC 330–337 837.50
0.36 448.28 1 447.28 HC 338–341 447.27
16.60 884.45 2 1766.90 HC 342–357 1766.93 Tentative,8missed8cleavage
10.21 643.82 2 1285.64 HC 348–358 1285.67
0.47 637.28 1 636.28 HC 359–363 636.28
11.45 581.82 2 1161.64 HC 364–373 1161.61
14.87 1272.56 2 2543.12 HC 374–395 2543.12
15.06 1273.06 2 2544.12 HC 374–395 2544.12 Deamidated
15.69 937.47 2 1872.94 HC 396–412 1872.91
3.01 575.34 1 574.34 HC 413–417 574.33
12.86 901.17 4 3600.68 HC 413–442 3600.70 Weak
12.72 701.32 4 2801.28 HC 420–442 2801.24
8.16 788.44 1 787.44 HC 443–450 787.44
7.57 660.36 1 659.36 HC 443–450 659.35 K8missing
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Figure	  A2:	  Comparison	  of	  the	  MS	  spectra	  of	  the	  glycosylated	  peptide	  HC296–304	  for	  all	  four	  samples	  
(top).	  The	  same	  peaks	  corresponding	  to	  the	  glycosylated	  peptide	  and	  glycan	  fragments	  (as	  described	  in	  
Figure	  3.2)	  were	  found	  in	  all	  cases	  as	  shown	  in	  the	  zoom-­‐in	  image	  (bottom).	  
 
Figure	  A3:	  Spectrum	  of	   the	  drug-­‐conjugated	  peptide	  HC222–225	  (RT	  22.81	  min)	   for	   the	  ADC	  (S)	   (top,	  
red)	  and	  ADC	  (LR)	   (bottom,	  orange)	  samples.	  The	  drug	  molecule	   is	  attached	  to	  Cys	   (223)	   resulting	   in	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m/z	  884.48	  for	  the	  [M+2H]2+	  state.	  Signature	  fragment	  ions	  from	  vcMMAE	  are	  present	  as	  [M+H]+,	  with	  
m/z	  718.51	  (MMAE	  molecule)	  and	  506.36.	  The	  extracted	  chromatograms	  on	  the	  left	  show	  the	  absence	  
of	   the	   peak	   at	   ~22.80	  min	   for	   the	  mAb	   samples	   (blue,	   green)	   in	   contrast	   to	   the	   ADC	   samples	   (red,	  
orange).	  
 
Figure	  A4:	  Spectrum	  of	   the	  drug-­‐conjugated	  peptide	  LC212–214	   (RT	  25.11	  min)	   for	   the	  ADC	   (S)	   (top,	  
red)	  and	  ADC	  (LR)	   (bottom,	  orange)	  samples.	  The	  drug	  molecule	   is	  attached	  to	  Cys	   (214)	   resulting	   in	  
m/z	  812.44	  for	  the	  [M+2H]2+	  state.	  Signature	  fragment	  ions	  from	  vcMMAE	  are	  present	  as	  [M+H]+,	  with	  
m/z	  718.51	  (MMAE	  molecule)	  and	  506.36.	  The	  extracted	  chromatograms	  on	  the	  left	  show	  the	  absence	  
of	   the	   peak	   at	   ~25.10	  min	   for	   the	  mAb	   samples	   (blue,	   green)	   in	   contrast	   to	   the	   ADC	   samples	   (red,	  
orange).	  
 
Figure	  A5:	  Comparison	  of	  the	  spectra	  of	  the	  non-­‐conjugated	  peptide	  HC222–244	  (RT	  ~16	  min)	  for	  the	  
four	   samples	   (mAb	   (S):	   blue,	   mAb	   (LR):	   green,	   ADC	   (S):	   red,	   ADC	   (LR):	   orange).	   All	   cysteines	   are	  
carboxymethylated	   (Cmc)	   resulting	   in	   m/z	   844.04	   for	   the	   [M+3H]3+	   state.	   The	   extracted	  
chromatograms	  on	  the	  left	  show	  the	  presence	  of	  the	  peak	  at	  ~16	  min	  for	  all	  samples.	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Figure	  A6:	  Comparison	  of	   the	   spectra	  of	   the	  non-­‐conjugated	  peptide	   LC208–214	   (RT	  ~3	  min)	   for	   the	  
four	   samples	   (mAb	   (S):	   blue,	   mAb	   (LR):	   green,	   ADC	   (S):	   red,	   ADC	   (LR):	   orange).	   Cys	   (214)	   is	  
carboxymethylated	  (Cmc)	  resulting	  in	  m/z	  870.34	  for	  the	  [M+H]+	  state.	  The	  extracted	  chromatograms	  
on	  the	  left	  show	  the	  presence	  of	  the	  peak	  at	  ~3	  min	  in	  all	  samples.	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Figure	  A8:	  Spectra	  of	  the	  native	  (bottom)	  and	  deamidated	  (centre	  and	  top)	  peptide	  HC51–59	  with	  RT	  
5.94	  min,	  6.12	  min	  and	  6.45	  min	  respectively	  are	  shown	  for	  the	  ADC	  (S)	  sample.	  The	  two	  deamidated	  
forms	  of	  N55	  probably	  correspond	  to	  Asp	  and	  isoAsp	  formation.	  The	  weak	  intensities	  though,	  make	  it	  
hard	  to	  differentiate	  between	  the	  two	  structures	  by	  looking	  at	  the	  fragment	  ions.	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Figure	  A10:	   Spectra	  of	   the	  native	   (bottom)	  and	  deamidated	   (top)	  peptide	  HC305–323	  with	  RT	  16.57	  
min	  and	  16.77	  min	  respectively	  are	  shown	  for	   the	  ADC	  (S)	  sample.	  N318	   is	  modified	  to	  aspartic	  acid	  
resulting	  in	  a	  mass	  increase	  of	  1	  Da	  and	  m/z	  743.74	  for	  the	  [M+3H]3+	  state.	  The	  observed	  y’’	  fragment	  
ions	  are	  assigned.	  A	  comparison	  of	  all	  four	  samples	  can	  be	  found	  in	  Figure	  A11.	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Table	  A5:	  Deamidation	  and	  oxidation	  sites	  for	  mAb	  (S).	  The	  peptides	  in	  their	  observed	  charge	  states,	  
the	  intensities	  for	  the	  MS	  peaks	  at	  full	  width	  half	  maximum	  (FWHM)	  and	  the	  integrated	  areas	  of	  the	  
chromatogram	  peaks	  on	  the	  extracted	  chromatograms	  are	  given,	  with	  the	  peak	  start,	  end	  and	  top.	  The	  
succinimidyl	  intermediate	  is	  shown	  where	  observed.	  Table	  3.8	  (main	  text)	  shows	  the	  relative	  amounts	  
for	  each	  modification.	  
	  
	  
Table	  A6:	  Similarly	  for	  mAb	  (LR).
	  
Site% Pep(de% m/z% Charge%state% Comment% RT%
Intensity%
at%FWHM%
Integrated%
area%
Peak%
start%
Peak%
end%
Peak%
top%
M4% LC1–18& 947.96& 2& Oxida2on& 8.14& 428& 127.85& 8.04& 8.27& 8.11&
939.94& 2& No&oxida2on& 10.70& 62900& 19148.70& 10.60& 10.83& 10.68&
M255% HC252–258& 851.42& 1& Oxida2on& 5.91& 596& 167.48& 5.80& 6.02& 5.87&
835.44& 1& No&oxida2on& 6.96& 33400& 8838.33& 6.86& 7.08& 6.94&
N55% HC51–59& 1085.54& 1& Deamida2on& 6.09& 1370& 322.90& 6.02& 6.17& 6.09&
1084.54& 1& No&deamida2on& 5.91& 4810& 1490.49& 5.82& 5.99& 5.90&
1067.52& 1& Succinimidyl& 6.68& 750& 94.30& 6.60& 6.79& 6.68&
N318% HC305–320& 904.98& 2& Deamida2on& 17.72& 4790& 988.64& 17.65& 17.87& 17.73&
904.50& 2& No&deamida2on& 17.37& 52600& 16559.49& 17.24& 17.53& 17.35&
603.67& 3& Deamida2on& 17.72& 339& 114.02& 17.61& 17.89& 17.79&
603.35& 3& No&deamida2on& 17.37& 3210& 1162.41& 17.26& 17.53& 17.36&
597.67& 3& Succinimidyl& 17.72& 692& 211.46& 17.61& 17.91& 17.75&
HC305–323& 743.73& 3& Deamida2on& 16.72& 19900& 4362.58& 16.65& 16.82& 16.72&
743.41& 3& No&deamida2on& 16.52& 49300& 18563.58& 16.40& 16.63& 16.48&
737.73& 3& Succinimidyl& 16.93& 1740& 610.02& 16.81& 17.05& 16.91&
1115.10& 2& Deamida2on& 16.72& 3090& 397.40& 16.65& 16.80& 16.70&
1114.61& 2& No&deamida2on& 16.52& 8220& 2995.68& 16.40& 16.66& 16.50&
1106.09& 2& Succinimidyl& 16.93& 416& 104.91& 16.80& 17.04& 16.89&
N387% HC374–395& 1273.06& 2& Deamida2on& 15.09& 412& 145.18& 15.03& 15.10& 15.05&
1272.56& 2& No&deamida2on& 14.87& 6580& 1822.10& 14.74& 14.99& 14.85&
tenta2ve& 831.69& 3& Succinimidyl& 15.93& 845& 192.12& 15.79& 16.07& 15.87&
mAb$(S)$
Site% Pep(de% m/z% Charge%state% Comment% RT%
Intensity%
at%FWHM%
Integrated%
Area%
Peak%
start%
Peak%
end%
Peak%
top%
M4% LC1–18& 947.94& 2& Oxida1on& 8.14& 314& 99.26& 8.03& 8.24& 8.12&
939.94& 2& No&oxida1on& 10.70& 78100& 23027.62& 10.60& 10.82& 10.68&
M255% HC252–258& 851.42& 1& Oxida1on& 5.91& 909& 245.98& 5.79& 6.00& 5.87&
835.43& 1& No&oxida1on& 6.96& 30000& 7229.66& 6.86& 7.08& 6.94&
N55% HC51–59& 1085.53& 1& Deamida1on& 6.09& 1310& 329.36& 6.02& 6.17& 6.07&
1084.54& 1& No&deamida1on& 5.91& 4600& 1199.33& 5.82& 5.99& 5.91&
1067.52& 1& Succinimidyl& 6.70& 774& 93.65& 6.59& 6.78& 6.68&
N318% HC305–320& 905.00& 2& Deamida1on& 17.74& 4150& 1385.58& 17.62& 17.90& 17.73&
904.51& 2& No&deamida1on& 17.37& 54800& 18799.74& 17.25& 17.53& 17.35&
603.65& 3& Deamida1on& 361& 112.63& 17.62& 17.84& 17.72&
603.35& 3& No&deamida1on& 3460& 1239.52& 17.26& 17.53& 17.36&
597.67& 3& Succinimidyl& 17.74& 726& 263.97& 17.62& 17.85& 17.75&
HC305–323& 743.74& 3& Deamida1on& 16.76& 16900& 4012.60& 16.67& 16.92& 16.73&
743.40& 3& No&deamida1on& 16.55& 26400& 10267.26& 16.43& 16.66& 16.53&
737.73& 3& Succinimidyl& 16.94& 1330& 394.87& 16.84& 17.07& 16.92&
1115.09& 2& Deamida1on& 2460& 994.07& 16.67& 16.96& 16.72&
1114.61& 2& No&deamida1on& 4790& 1400.65& 16.43& 16.67& 16.53&
1106.09& 2& Succinimidyl& 16.94& 212& 73.13& 16.95& 17.04& 16.87&
N387% HC374–395& 1273.07& 2& Deamida1on& 15.08& 337& 272.19& 14.97& 15.07& 15.05&
1272.57& 2& No&deamida1on& 14.88& 6100& 2047.53& 14.73& 15.05& 14.85&
mAb$(LR)$
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Table	  A7:	  Similarly	  for	  ADC	  (S).	  
 
	  
Table	  A8:	  Similarly	  for	  ADC	  (LR).	  
 
 
Site% Pep(de% m/z% Charge%state% Comment% RT%
Intensity%
at%FWHM%
Integrated%
Area%
Peak%
start%
Peak%
end%
Peak%
top%
M4% LC1–18& 947.94& 2& Oxida1on& 8.19& 102& 46.41& 7.96& 8.33& 8.14&
939.95& 2& No&oxida1on& 10.72& 13000& 4487.58& 10.65& 10.84& 10.72&
M255% HC252–258& 851.46& 1& Oxida1on& 5.94& 175& 48.84& 5.82& 6.02& 5.91&
835.43& 1& No&oxida1on& 6.99& 6430& 1370.73& 6.92& 7.09& 6.97&
N55% HC51–59& 1085.56& 1& Deamida1on& 6.12& 269& 78.85& 6.04& 6.19& 6.11&
1084.55& 1& No&deamida1on& 5.94& 725& 189.03& 5.87& 6.04& 5.92&
1067.54& 1& Succinimidyl& 6.72& 86& 25.11& 6.61& 6.84& 6.72&
N318% HC305–320& 905.00& 2& Deamida1on& 17.72& 1360& 316.24& 17.67& 17.89& 17.75&
904.51& 2& No&deamida1on& 17.42& 12000& 4709.07& 17.27& 17.63& 17.40&
603.68& 3& Deamida1on& 143& 31.22& 17.68& 17.84& 17.74&
603.35& 3& No&deamida1on& 882& 320.73& 17.30& 17.56& 17.40&
597.67& 3& Succinimidyl& 17.72& 281& 62.45& 17.62& 17.86& 17.74&
HC305–323& 743.73& 3& Deamida1on& 16.77& 4420& 702.68& 16.70& 16.84& 16.75&
743.41& 3& No&deamida1on& 16.57& 9720& 3468.06& 16.46& 16.70& 16.55&
tenta1ve& 737.73& 3& Succinimidyl& 16.93& 500& 153.70& 16.86& 17.07& 16.91&
1115.09& 2& Deamida1on& 678& 291.60& 16.73& 16.84& 16.77&
1114.61& 2& No&deamida1on& 1240& 644.26& 16.47& 16.75& 16.55&
N387% HC374–395& 1273.08& 2& Deamida1on& 15.09& 139& 58.96& 15.02& 15.10& 15.05&
1272.56& 2& No&deamida1on& 14.89& 1520& 457.09& 14.77& 15.02& 14.87&
ADC$(S)$
Site% Pep(de% m/z% Charge%state% Comment% RT%
Intensity%
at%FWHM%
Integrated%
Area%
Peak%
start%
Peak%
end%
Peak%
top%
M4% LC1–18& 947.94& 2& Oxida1on& 8.16& 291& 52.41& 8.04& 8.21& 8.16&
939.95& 2& No&oxida1on& 10.72& 38800& 12942.43& 10.62& 10.83& 10.70&
M255% HC252–258& 851.43& 1& Oxida1on& 5.92& 352& 96.90& 5.81& 5.97& 5.91&
835.44& 1& No&oxida1on& 6.98& 17700& 4755.08& 6.84& 7.16& 6.96&
N55% HC51–59& 1085.54& 1& Deamida1on& 6.11& 885& 206.11& 6.02& 6.19& 6.09&
1084.54& 1& No&deamida1on& 5.92& 2910& 797.92& 5.84& 6.02& 5.91&
1067.52& 1& Succinimidyl& 6.70& 580& 68.67& 6.60& 6.80& 6.70&
N318% HC305–320& 905.01& 2& Deamida1on& 17.74& 2510& 628.85& 17.66& 17.92& 17.75&
904.51& 2& No&deamida1on& 17.40& 28900& 10091.38& 17.25& 17.58& 17.38&
603.66& 3& Deamida1on& 231& 51.70& 17.67& 17.81& 17.79&
603.34& 3& No&deamida1on& 1950& 656.24& 17.28& 17.54& 17.36&
597.67& 3& Succinimidyl& 17.74& 429& 104.23& 17.68& 17.87& 17.73&
HC305–323& 743.73& 3& Deamida1on& 16.77& 10800& 2486.53& 16.68& 16.85& 16.75&
743.41& 3& No&deamida1on& 16.55& 30100& 11372.43& 16.43& 16.67& 16.53&
737.73& 3& Succinimidyl& 16.94& 1590& 376.22& 16.82& 17.05& 16.92&
1115.10& 2& Deamida1on& 1220& 647.83& 16.70& 16.82& 16.75&
1114.62& 2& No&deamida1on& 4300& 1948.07& 16.43& 16.73& 16.53&
1106.09& 2& Succinimidyl& 16.94& 214& 58.67& 16.86& 16.99& 16.92&
N387% HC374–395& 1273.06& 2& Deamida1on& 15.11& 244& 184.32& 15.06& 15.14& 15.11&
1272.56& 2& No&deamida1on& 14.89& 4220& 1311.89& 14.75& 15.03& 14.87&
ADC$(LR)$
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Table	   A9:	   Integrated	   areas	   for	   each	   one	   of	   the	  monitored	   transitions	   for	   the	  marker	   and	   the	   drug-­‐
conjugated	  peptides	  for	  the	  ADC	  samples.	  The	  peaks	  from	  the	  TIC	  plot	  of	  the	  TQ-­‐S	  data	  were	  used.	  The	  
relative	  abundance	  of	  the	  drug-­‐conjugated	  peptides,	   for	  each	  sample,	  was	  calculated	  by	  dividing	  the	  
sum	  of	   the	  areas	   from	  the	  two	  transitions	  by	   the	  marker	  peptide	  area.	  The	  resulting	  plot	   is	  given	   in	  
Figure	  3.15.	  	  
 
  
ADC$(S)$
Pep+de$ Property$ Transi+on$ 1$ 2$ 3$ 4$ 5$ 6$
LC46%61' marker' 886.99'>'359.20' 256912.33' 223243.03' 271722.06' 257371.81' 329028.44' 361112.22'
LC212%214' with'drug' 812.44'>'686.50' 134498.75' 206610.17' 301530.78' 290352.97' 343596.25' 373547.75'
812.44'>'718.50' 191451.77' 308971.25' 462551.19' 460773.38' 549256.44' 621008.00'
HC222%225' with'drug' 884.48'>'686.50' 73861.38' 89975.53' 106234.76' 106264.66' 115188.71' 122080.96'
884.48'>'718.50' 118017.12' 151571.92' 194995.38' 190655.17' 211164.73' 236677.61'
ADC$(LR)$
Pep+de$ Property$ Transi+on$ 1$ 2$ 3$ 4$ 5$ 6$
LC46%61' marker' 886.99'>'359.20' 1572686.13' 416346.19' 369991.47' 376137.81' 343868.13' 328005.53'
LC212%214' with'drug' 812.44'>'686.50' 888619.00' 300738.09' 267279.31' 279121.19' 246631.67' 225018.91'
812.44'>'718.50' 1338262.00' 628304.25' 594221.13' 643845.50' 579126.56' 518342.16'
HC222%225' with'drug' 884.48'>'686.50' 166576.53' 49744.11' 45056.84' 44440.23' 39547.89' 36154.06'
884.48'>'718.50' 289689.78' 123203.20' 116556.29' 118799.48' 105760.67' 103411.59'
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Figure	  A17:	  Size	  distribution	  (presented	  in	  intensity	  values,	  nm)	  for	  mAb	  (S)	  at	  a	  temperature	  range	  of	  
20–75°C	  and	  after	  the	  sample	  was	  cooled	  down	  to	  20°C.	  The	  distribution	  becomes	  wider	  and	  slightly	  
shifts	  to	  larger	  values	  at	  the	  end	  of	  the	  experiment.	  The	  presented	  data	  are	  averaged	  over	  6	  replicates.	  
 
 
Figure	  A18:	  Size	  distribution	  (presented	  in	  intensity	  values,	  nm)	  for	  mAb	  (LR)	  at	  a	  temperature	  range	  of	  
20–75°C	  and	  after	  the	  sample	  was	  cooled	  down	  to	  20°C.	  The	  distribution	  becomes	  wider	  and	  slightly	  
shifts	  to	  larger	  values	  at	  the	  end	  of	  the	  experiment.	  The	  presented	  data	  are	  averaged	  over	  6	  replicates.	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Figure	  A19:	  Size	  distribution	  (presented	  in	  intensity	  values,	  nm)	  for	  ADC	  (S)	  at	  a	  temperature	  range	  of	  
20–75°C	  and	  after	  the	  sample	  was	  cooled	  down	  to	  20°C.	  The	  increased	  width,	  the	  shift	  to	  larger	  values	  
and	  the	  loss	   in	  intensity	  of	  the	  distribution	  at	  the	  end	  of	  the	  experiment,	   indicate	  the	  appearance	  of	  
larger	  particles.	  The	  presented	  data	  are	  averaged	  over	  6	  replicates.	  
 
 
Figure	  A20:	  Size	  distribution	  (presented	  in	  intensity	  values,	  nm)	  for	  ADC	  (LR)	  at	  a	  temperature	  range	  of	  
20–75°C	  and	  after	  the	  sample	  was	  cooled	  down	  to	  20°C.	  The	  increased	  width,	  the	  shift	  to	  larger	  values	  
and	  the	  loss	   in	  intensity	  of	  the	  distribution	  at	  the	  end	  of	  the	  experiment,	   indicate	  the	  appearance	  of	  
larger	  particles.	  The	  presented	  data	  are	  averaged	  over	  6	  replicates.	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Table	  A10:	  Overall	  mean	  particle	   sizes	   presented	   in	   terms	   of	   number	   values	   (nm)	   and	   the	   standard	  
deviations	   (over	   six	   replicates)	   with	   a	   95%	   confidence	   interval	   are	   shown	   for	   each	   sample	   at	   a	  
temperature	  range	  of	  20–75°C	  and	  after	  the	  samples	  were	  cooled	  down	  to	  20°C.	  
 
  
Sample' 20°C' 25°C' 30°C' 35°C' 40°C' 45°C' 50°C' 55°C' 60°C' 65°C' 70°C' 75°C' Cooled'to'20°C'
mAb'(S)! 6.8±0.5! 6.8±0.9! 6.9±0.6! 7.0±1.1! 6.9±1.5! 6.9±0.6! 6.9±1.5! 7.1±2.3! 7.1±1.3! 6.9±0.7! 7.1±1.3! 7.3±1.6! 7.1±0.7!
mAb'(LR)! 6.7±0.6! 6.5±0.5! 7.0±2.3! 7.3±2.8! 7.4±3.4! 7.5±2.7! 7.0±2.1! 7.1±1.9! 7.0±1.7! 7.3±1.2! 7.4±0.7! 7.5±0.7! 7.1±0.9!
ADC'(S)! 7.2±1.1! 6.9±0.9! 6.9±1.2! 7.3±1.4! 7.0±1.6! 7.1±1.3! 7.2±1.1! 7.0±1.4! 7.5±2.0! 7.5±2.1! 8.1±1.4! 8.3±1.0! 8.9±0.6!
ADC'(LR)! 6.6±0.9! 7.0±1.7! 7.0±1.8! 7.1±1.8! 6.8±1.0! 7.1±1.9! 7.3±2.3! 7.4±2.4! 7.8±2.6! 7.9±2.3! 7.9±2.1! 7.9±1.7! 8.5±1.1!
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Figure	   A21:	   Comparison	   of	   the	   CD	   spectra	   of	   the	   four	   trastuzumab	   samples	   at	   their	   original	  
concentration	   (1	  mg/mL)	  using	  a	  0.01	  cm	  demountable	   cuvette	   (blue)	  and	  after	  10-­‐fold	  dilution	   (0.1	  
mg/mL)	   using	   a	   0.1	   cm	   fixed	   cuvette	   (red).	   All	   data	  were	   acquired	   at	   20	   °C.	   The	  high	   concentration	  
spectra	  are	   the	  average	  of	  5	   replicates	   (16	   scans	  each),	  and	   the	  diluted	  spectra	  are	  averaged	  over	  6	  
replicates	  (16	  scans	  each).	  The	  1	  mg/mL	  spectra	  were	  recorded	  on	  a	  J-­‐815	  spectrophotometer,	  while	  J-­‐
1500	   was	   used	   for	   the	   data	   at	   0.1	   mg/mL.	   In	   order	   to	   correct	   for	   the	   variance	   in	   the	   calibration	  
between	  the	  two	  instruments,	  the	  high	  concentration	  spectra	  were	  shifted	  by	  −3	  nm.	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Table	  A11:	  Maximum,	  zero-­‐crossing	  and	  minimum	  points/values	  of	  the	  normalised	  CD	  spectra	  for	  the	  6	  
replicates.	   The	   samples	  were	   10-­‐fold	   diluted	   and	   a	   0.1	   cm	   fixed	   path	   length	   cuvette	  was	   used.	   The	  
spectra	  were	  recorded	  at	  20	  °C	  and	  each	  spectrum	  is	  the	  accumulation	  of	  16	  scans.	  
 
  
Sample' Rep' Max'(nm)'
Max'
value'
(Δε)'
Zero5
crossing'
(nm)'
Min'
(nm)'
Min'
value'
(Δε)'
mAb'(S)'
1" 201.0" 2.00" 208.4" 215.6" −1.12"2" 200.8" 1.97" 208.4" 216.8" −1.04"3" 201.0" 2.11" 208.8" 216.8" −1.02"4" 200.4" 2.02" 208.2" 214.4" −0.96"5" 201.6" 2.02" 208.2" 216.4" −1.04"6" 202.0" 1.98" 208.4" 216.8" −1.05"
' " " " " " "
mAb'(LR)'
1" 200.8" 1.97" 209.0" 216.8" −0.86"2" 201.8" 2.01" 209.2" 216.4" −0.78"3" 201.6" 2.04" 209.4" 216.0" −0.80"4" 201.2" 1.94" 208.8" 216.6" −0.85"5" 200.6" 1.96" 208.6" 217.8" −0.87"6" 201.2" 1.99" 208.8" 216.8" −0.87"
' " " " " " "
ADC'(S)'
1" 201.0" 1.94" 209.2" 218.2" −0.79"2" 201.4" 1.93" 209.8" 217.6" −0.70"3" 201.2" 1.85" 209.6" 216.6" −0.76"4" 200.4" 1.85" 209.2" 216.8" −0.77"5" 201.0" 1.84" 209.4" 216.6" −0.77"6" 201.4" 1.83" 208.8" 215.8" −0.86"
' " " " " " "
ADC'(LR)'
1" 201.0" 1.96" 209.0" 217.2" −0.90"2" 201.0" 1.94" 209.2" 217.0" −0.89"3" 201.0" 2.04" 209.0" 216.0" −0.83"4" 201.0" 2.08" 209.0" 215.8" −0.81"5" 201.4" 1.97" 209.0" 217.0" −0.77"6" 202.0" 1.99" 208.8" 216.4" −0.91""
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Figure	  A22:	   Left:	   CD	   spectra	  of	   the	   formulation	  after	  10-­‐fold	  dilution	  at	   a	   temperature	   range	  of	   20–
100	  °C,	  per	  1	  °C.	  The	  spectra	  were	  recorded	  on	  a	  J-­‐1500	  spectrophotometer,	  using	  a	  0.1	  cm	  fixed	  path	  
length	   cuvette	   according	   to	   the	   temperature	   experiment	   for	   the	   samples.	   The	   red	   arrows	   show	   the	  
direction	  of	  the	  decreasing	  signal	  intensities	  at	  195	  nm	  and	  212	  nm	  with	  increasing	  temperature.	  Right:	  
Comparison	  of	  the	  formulation	  spectra	  at	  20	  °C	  and	  at	  the	  end	  of	  the	  temperature	  experiment,	  after	  
the	  cuvette	  was	  cooled	  down	  to	  20	  °C.	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Table	  A12:	  Unfolding	  temperatures	  for	  the	  trastuzumab	  samples	  extracted	  from	  the	  CD	  spectra	  of	  each	  
replicate.	  The	  averaged	  temperatures	  for	  the	  first	  and	  the	  last	  three	  replicates	  are	  given	  as	  well	  as	  the	  
total	  averages	  for	  each	  sample,	  also	  described	  in	  the	  text.	  
 
 
Sample' Replicate' Unfolding'Temperature' Average! '
mAb'(S)'
1! 82!°C! ! !2! 80!°C! rep!1–3! 82!°C!3! 82!°C! ! !4! 82!°C! ! !5! 82!°C! rep!4–6! 82!°C!6! 82!°C! ! !! ! Total! 82!°C!
mAb'(LR)'
1! 83!°C! ! !2! 81!°C! rep!1–3! 82!°C!3! 82!°C! ! !4! 82!°C! ! !5! 83!°C! rep!4–6! 83!°C!6! 82!°C! ! !! ! Total! 82!°C!
ADC'(S)!
1! 80!°C! ! !2! 78!°C! rep!1–3! 79!°C!3! 78!°C! ! !4! 80!°C! ! !5! 80!°C! rep!4–6! 81!°C!6! 81!°C! ! !! ! Total! 80!°C!
ADC'(LR)!
1! 82!°C! ! !2! 80!°C! rep!1–3! 80!°C!3! 79!°C! ! !4! 78!°C! ! !5! 82!°C! rep!4–6! 81!°C!6! 82!°C! ! !! ! Total! 80!°C!!
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Figure	  A23:	  Comparison	  of	  the	  HT	  spectra	  of	  the	  four	  trastuzumab	  samples	  at	  20	  °C	  and	  at	  the	  end	  of	  
the	  experiment,	  after	  the	  samples	  were	  cooled	  down	  to	  20	  °C.	  Only	  the	  last	  3	  replicates	  were	  used	  for	  
calculating	  the	  average.	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Figure	   A24:	   SSNN	   output	   from	   the	   analysis	   of	   the	   averaged	   trastuzumab	   spectra	   at	   a	   temperature	  
range	  20–100	  °C,	  per	  1	  °C.	  The	  spectral	  fits	  with	  the	  NRMSD	  values	  at	  80	  °C	  and	  81	  °C	  are	  shown	  for	  the	  
native	   and	   the	   conjugated	   antibodies	   respectively.	   The	   incorrectly	   estimated	   feature	   at	   228	   nm	  
accounts	  for	  the	  misleading	  increase	  in	  α-­‐helix.	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Appendix B 
PROTEIN H 
Table	   B1:	   Target	   wavelengths	   for	   the	   HT	   maxima	   for	   each	   one	   of	   the	   calibration	   tests,	   measured	  
wavelengths	   at	   the	   beginning	   of	   the	   experiment	   and	   the	   respective	   deviations	   are	   presented.	   The	  
measured	  values	  should	  be	  ±0.8	  nm	  from	  the	  target	  values.	  
 
 
Table	  B2:	  The	  maximum	  target	  intensity	  values	  (mdeg)	  at	  the	  specific	  wavelengths	  and	  the	  measured	  
intensities	  before	  the	  experiment	  are	  shown	  for	  the	  performed	  tests.	  The	  measured	  values	  should	  be	  
±1	  mdeg	  from	  the	  target	  values.	  Values	  that	  did	  not	  meet	  the	  criterion	  are	  noted	  in	  red.	  
 
Test% Target%Wavelength%(nm)% Wavelength%(nm)% Devia3on%(nm)%
Neodymium)ﬁlter) 586.0) 585.4) −0.6)
Holmium)ﬁlter)
637.5) 637.6) 0.1)
536.6) 536.0) −0.6)
460.2) 459.8) −0.4)
453.7) 453.6) −0.1)
445.7) 445.4) −0.3)
360.9) 360.8) −0.1)
333.9) 333.8) −0.1)
287.6) 287.4) −0.2)
279.4) 279.2) −0.2)
Benzene)vapour)
259.0) 258.9) −0.1)
253.0) 252.8) −0.2)
247.2) 247.0) −0.2)
241.7) 241.4) −0.3)
Ammonia)vapour)
208.6) 208.1) −0.5)
204.8) 204.2) −0.6)
201.1) 200.4) −0.7)
197.5) 196.8) −0.7)
194.0) 193.4) −0.6)
190.6) 190.1) −0.5)
187.2) 186.7) −0.5)
Test% Wavelength%(nm)%
Target%Intensity%
(mdeg)%
Intensity%
(mdeg)%
ACS$solu)on$(1$cm$
cuve1e)$ 291$ 188.0$
189.5$
ACS$solu)on$(1$mm$
cuve1e)$
291$ 18.8$ 19.2$
193$ −39.1$ −39.9$
(R,R);Na[CoIII(EDDS)]$ 211.5$ −50.0$ −52.3$
(S,S);Na[CoIII(EDDS)]$ 211.5$ 50.0$ 51.9$
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SOMATROPIN (RECOMBINANT HUMAN GROWTH HORMONE) 
Table	   B3:	   Target	   wavelengths	   for	   the	   HT	   maxima	   for	   each	   one	   of	   the	   calibration	   tests,	   measured	  
wavelengths	   at	   the	   beginning	   of	   the	   experiment	   and	   the	   respective	   deviations	   are	   presented.	   The	  
measured	  values	  should	  be	  ±0.8	  nm	  from	  the	  target	  values.	  Values	  that	  did	  not	  meet	  the	  criterion	  are	  
marked	  in	  red.	  
 
 
Table	  B4:	  The	  maximum	  target	  intensity	  values	  (mdeg)	  at	  the	  specific	  wavelengths	  and	  the	  measured	  
intensities	  before	  the	  experiment	  are	  shown	  for	  the	  performed	  tests.	  The	  measured	  values	  should	  be	  
±1	  mdeg	  from	  the	  target	  values.	  Values	  that	  did	  not	  meet	  the	  criterion	  are	  noted	  in	  red.	  
 
 
Test% Target%Wavelength%(nm)% Wavelength%(nm)% Devia3on%(nm)%
Neodymium)ﬁlter) 586.0) 585.1) −0.9)
Holmium)ﬁlter)
637.5) 637.0) −0.5)
536.6) 535.6) −1.0)
460.2) 459.4) −0.8)
453.7) 453.2) −0.5)
445.7) 445.2) −0.5)
360.9) 360.6) −0.3)
333.9) 333.8) −0.1)
287.6) 287.4) −0.2)
279.4) 279.2) −0.2)
Benzene)vapour)
259.0) 258.8) −0.2)
253.0) 252.8) −0.2)
247.2) 247.0) −0.2)
241.7) 241.4) −0.3)
Ammonia)vapour)
208.6) 208.0) −0.6)
204.8) 204.2) −0.6)
201.1) 200.4) −0.7)
197.5) 196.8) −0.7)
194.0) 193.4) −0.6)
190.6) 190.1) −0.5)
187.2) 186.6) −0.6)
Test% Wavelength%(nm)%
Target%Intensity%
(mdeg)%
Intensity%
(mdeg)%
ACS$solu)on$(1$cm$
cuve1e)$ 291$ 188.0$
188.1$
ACS$solu)on$(1$mm$
cuve1e)$
291$ 18.8$ 19.2$
193$ −39.1$ −40.5$
(R,R)<Na[CoIII(EDDS)]$ 211.5$ −50.0$ −49.5$
(S,S)<Na[CoIII(EDDS)]$ 211.5$ 50.0$ 51.4$
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Figure	  B1:	  Raw	  CD	  data	  (mdeg)	  of	  hGH	  and	  reference	  buffer	   in	  the	  original	  concentration	  (nominally	  
3.56	  mg/mL,	  top	  left),	  after	  2-­‐fold	  dilution	  (top	  right),	  4-­‐fold	  dilution	  (bottom	  left)	  and	  30-­‐fold	  dilution	  
(bottom	   right).	   The	   three	   replicates	   (in	   black),	   the	   averaged	   spectra	   (in	   red)	   of	   the	   sample	   and	   the	  
respective	  buffer	  spectrum	  (in	  blue)	  are	  shown.	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Table	  B5:	  Maximum,	  zero-­‐crossing	  and	  minimum	  points/values	  of	  the	  normalised	  CD	  spectra	  (Δε	  units)	  
for	  the	  3	  replicates	  of	  hGH	  in	  different	  dilutions	  and	  after	  the	  path	  length	  correction	  was	  applied.	  
 
 
Sample' Rep' Max'(nm)'
Max'
value'
(Δε)'
Zero5
crossing'
(nm)'
Min'
(nm)'
Min'
value'
(Δε)'
Min'
(nm)'
Min'
value'
(Δε)'
hGH'
1" 192.2" 12.59" 200.4" 208.2" −6.33" 221.0" −5.75"2" 192.2" 12.19" 200.4" 208.2" −6.15" 220.2" −5.54"3" 192.2" 13.08" 200.6" 208.2" −6.31" 218.6" −5.72"
' " " " " " " " "
hGH'
df2'
1" 192.0" 12.09" 200.4" 208.4" −6.22" 219.4" −5.69"2" 192.2" 13.57" 200.4" 208.6" −6.43" 219.8" −5.86"3" 192.0" 13.30" 200.4" 208.4" −6.38" 219.4" −5.80"
' " " " " " " " "
hGH'
df4'
1" 192.0" 11.56" 200.4" 208.4" −5.78" 220.2" −5.27"2" 192.2" 12.51" 200.4" 208.4" −6.30" 218.2" −5.73"3" 192.0" 12.94" 200.4" 208.2" −6.36" 219.2" −5.77"
' " " " " " " " "
hGH'
df30'
1" 192.0" 13.31" 200.4" 208.2" −6.29" 220.0" −5.72"2" 191.8" 13.12" 200.4" 208.2" −6.23" 220.0" −5.63"3" 192.0" 13.13" 200.4" 208.4" −6.21" 219.2" −5.63""
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Table	   B6:	   Secondary	  
structure	   estimates	   and	  
NRMSD	   values	   from	  
analysis	   of	   the	   CD	   spectra	  
of	   hGH	   in	   different	  
concentrations.	  The	  results	  
from	   CDSSTR,	   SELCON3	  
(using	   reference	   sets	   1–7)	  
and	  SSNN	  (reference	  set	  7)	  
are	   compared.	   All	  
programs	   and	   reference	  
sets	   presented	   very	   close	  
values	   for	  hGH	   in	  different	  
concentrations,	  resulting	  in	  
an	   overall	   accurate	  
estimation.	   The	   averaged	  
values	   and	   standard	  
deviations	   from	   the	   15	  
analyses	   were	   calculated	  
for	   each	   sample	   and	   are	  
presented	   in	   Table	   4.8	   in	  
the	  main	  text.	  
	  
 
Sample' Program' Ref.'set' Helix' Sheet' Turns' Other'
hGH'
CDSSTR& 1& 0.61& 0.09& 0.12& 0.19&SELCON3& 0.57& 0.07& 0.16& 0.21&
CDSSTR& 2& 0.62& 0.03& 0.11& 0.24&SELCON3& 0.62& 0.06& 0.11& 0.21&
CDSSTR& 3& 0.63& 0.09& 0.09& 0.19&SELCON3& 0.58& 0.07& 0.14& 0.22&
CDSSTR& 4& 0.61& 0.07& 0.09& 0.23&SELCON3& 0.56& 0.06& 0.13& 0.25&
CDSSTR& 5& 0.61& 0.06& 0.11& 0.22&SELCON3& 0.58& 0.07& 0.09& 0.27&
CDSSTR& 6& 0.65& 0.10& 0.12& 0.14&SELCON3& 0.59& 0.18& 0.22& 0.01&
CDSSTR&
7&
0.61& 0.07& 0.09& 0.23&
SELCON3& 0.59& 0.16& 0.25& 0.01&
SSNN& 0.54& 0.07& 0.15& 0.24&
hGH'df2'
CDSSTR& 1& 0.62& 0.09& 0.12& 0.17&SELCON3& 0.60& 0.15& 0.22& 0.03&
CDSSTR& 2& 0.65& 0.03& 0.11& 0.21&SELCON3& 0.64& 0.13& 0.15& 0.08&
CDSSTR& 3& 0.66& 0.07& 0.10& 0.18&SELCON3& 0.61& 0.17& 0.22& 0.00&
CDSSTR& 4& 0.61& 0.08& 0.09& 0.22&SELCON3& 0.59& 0.16& 0.25& 0.00&
CDSSTR& 5& 0.64& 0.05& 0.10& 0.22&SELCON3& 0.59& 0.07& 0.09& 0.26&
CDSSTR& 6& 0.65& 0.08& 0.10& 0.17&SELCON3& 0.60& 0.17& 0.22& 0.00&
CDSSTR&
7&
0.62& 0.06& 0.08& 0.24&
SELCON3& 0.60& 0.16& 0.25& 0.00&
SSNN& 0.57& 0.06& 0.14& 0.23&
hGH'df4'
CDSSTR& 1& 0.61& 0.09& 0.13& 0.18&SELCON3& 0.57& 0.17& 0.23& 0.03&
CDSSTR& 2& 0.61& 0.03& 0.12& 0.24&SELCON3& 0.62& 0.14& 0.16& 0.08&
CDSSTR& 3& 0.65& 0.07& 0.11& 0.18&SELCON3& 0.58& 0.18& 0.23& 0.01&
CDSSTR& 4& 0.59& 0.08& 0.10& 0.23&SELCON3& 0.57& 0.16& 0.25& 0.02&
CDSSTR& 5& 0.65& 0.03& 0.10& 0.22&SELCON3& 0.57& 0.07& 0.09& 0.27&
CDSSTR& 6& 0.63& 0.07& 0.14& 0.16&SELCON3& 0.58& 0.18& 0.22& 0.02&
CDSSTR&
7&
0.60& 0.07& 0.09& 0.25&
SELCON3& 0.57& 0.16& 0.25& 0.02&
SSNN& 0.53& 0.07& 0.16& 0.23&
hGH'df30'
CDSSTR& 1& 0.62& 0.09& 0.13& 0.17&SELCON3& 0.59& 0.16& 0.22& 0.03&
CDSSTR& 2& 0.62& 0.04& 0.10& 0.25&SELCON3& 0.64& 0.13& 0.15& 0.09&
CDSSTR& 3& 0.63& 0.09& 0.09& 0.19&SELCON3& 0.60& 0.17& 0.22& 0.00&
CDSSTR& 4& 0.61& 0.08& 0.09& 0.22&SELCON3& 0.58& 0.17& 0.25& 0.01&
CDSSTR& 5& 0.63& 0.06& 0.10& 0.21&SELCON3& 0.59& 0.07& 0.09& 0.26&
CDSSTR& 6& 0.65& 0.08& 0.11& 0.16&SELCON3& 0.60& 0.17& 0.22& 0.00&
CDSSTR&
7&
0.61& 0.07& 0.09& 0.23&
SELCON3& 0.59& 0.16& 0.25& 0.00&
SSNN& 0.57& 0.06& 0.14& 0.23&
NRMSD'
0.027&
0.151&
0.025&
0.078&
0.025&
0.147&
0.034&
0.169&
0.036&
0.153&
0.026&
0.142&
0.034&
0.148&
0.020&
0.036&
0.149&
0.019&
0.092&
0.029&
0.143&
0.040&
0.151&
0.029&
0.139&
0.025&
0.150&
0.032&
0.157&
0.021&
0.037&
0.147&
0.023&
0.089&
0.030&
0.130&
0.044&
0.147&
0.033&
0.144&
0.031&
0.141&
0.035&
0.155&
0.020&
0.032&
0.145&
0.023&
0.096&
0.019&
0.151&
0.043&
0.151&
0.045&
0.146&
0.023&
0.159&
0.035&
0.156&
0.023&
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Figure	  B2:	  Original	  and	  calculated	  CD	  spectra	  from	  the	  analysis	  of	  hGH	  after	  2-­‐	  (left)	  and	  4-­‐fold	  dilution	  
(right)	   with	   different	   software	   and	   reference	   sets.	   Spectral	   fits	   of	   the	   calculated	   spectra	   are	   in	  
agreement	  with	   each	   other	   and	  with	   the	   respective	   original	   spectra,	   suggesting	   an	   overall	   accurate	  
secondary	  structure	  analysis.	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PROTEIN A 
Table	   B7:	   Target	   wavelengths	   for	   the	   HT	   maxima	   for	   each	   one	   of	   the	   calibration	   tests,	   measured	  
wavelengths	   at	   the	   beginning	   of	   the	   experiment	   and	   the	   respective	   deviations	   are	   presented.	   The	  
measured	  values	  should	  be	  ±0.8	  nm	  from	  the	  target	  values.	  
 
 
Table	  B8:	  The	  maximum	  target	  intensity	  values	  (mdeg)	  at	  the	  specific	  wavelengths	  and	  the	  measured	  
intensities	  before	  the	  experiment	  are	  shown	  for	  the	  performed	  tests.	  The	  measured	  values	  should	  be	  
±1	  mdeg	  from	  the	  target	  values.	  Values	  that	  did	  not	  meet	  the	  criterion	  are	  noted	  in	  red.	  
 
  
Test% Target%Wavelength%(nm)% Wavelength%(nm)% Devia3on%(nm)%
Neodymium)ﬁlter) 586.0) 585.5) −0.5)
Holmium)ﬁlter)
637.5) 638.0) 0.5)
536.6) 536.2) −0.4)
460.2) 459.8) −0.4)
453.7) 453.6) −0.1)
445.7) 445.4) −0.3)
360.9) 360.8) −0.1)
333.9) 333.8) −0.1)
287.6) 287.4) −0.2)
279.4) 279.0) −0.4)
Benzene)vapour)
259.0) 258.8) −0.2)
253.0) 252.8) −0.2)
247.2) 246.9) −0.3)
241.7) 241.4) −0.3)
Ammonia)vapour)
208.6) 208.0) −0.6)
204.8) 204.1) −0.7)
201.1) 200.3) −0.8)
197.5) 196.8) −0.7)
194.0) 193.3) −0.7)
190.6) 190.0) −0.6)
187.2) 186.6) −0.6)
Test% Wavelength%(nm)%
Target%Intensity%
(mdeg)%
Intensity%
(mdeg)%
ACS$solu)on$(1$cm$
cuve1e)$ 291$ 188.0$
179.6$
ACS$solu)on$(1$mm$
cuve1e)$
291$ 18.8$ 17.9$
193$ −39.1$ −37.5$
(R,R)=Na[CoIII(EDDS)]$ 211.5$ −50.0$ −48.0$
(S,S)=Na[CoIII(EDDS)]$ 211.5$ 50.0$ 49.4$
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Figure	   B3:	   Left:	   Particle	   distribution	   by	   intensity	   of	   100	   nm	   latex	   spheres	  measured	   in	   10	  mM	  NaCl	  
solution.	   Right:	   Particle	   distribution	   by	   intensity	   of	   100	   nm	   latex	   spheres	   measured	   in	   PBS	   buffer	  
solution.	  Individual	  measurements	  are	  shown	  in	  grey,	  replicates	  (averaged	  over	  6	  measurements)	  are	  
shown	  in	  red	  and	  overall	  average	  over	  three	  replicates	  is	  shown	  in	  blue.	  
 
 
Figure	  B4:	  Average	  particle	  distributions	  by	  intensity	  of	  100	  nm	  latex	  spheres	  in	  NaCl	  (black)	  and	  PBS	  
replicates	   1–3	   (red,	   green	   and	   blue)	   solutions	   averaged	   over	   6	  measurements.	   The	   overall	   average	  
distribution	  for	  PBS	  over	  3	  replicates	  (18	  measurements	  in	  total)	  is	  shown	  in	  cyan.	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Table	   B9:	   Target	   wavelengths	   for	   the	   HT	   maxima	   for	   each	   one	   of	   the	   calibration	   tests,	   measured	  
wavelengths	   at	   the	   beginning	   of	   the	   experiment	   and	   the	   respective	   deviations	   are	   presented.	   The	  
measured	  values	  should	  be	  ±0.8	  nm	  from	  the	  target	  values.	  Values	  that	  did	  not	  meet	  the	  criterion	  are	  
marked	  in	  red.	  
 
 
Table	  B10:	  The	  maximum	  target	  intensity	  values	  (mdeg)	  at	  the	  specific	  wavelengths	  and	  the	  measured	  
intensities	  before	  the	  experiment	  are	  shown	  for	  the	  performed	  tests.	  The	  measured	  values	  should	  be	  
±1	  mdeg	  from	  the	  target	  values.	  Values	  that	  did	  not	  meet	  the	  criterion	  are	  noted	  in	  red.	  
 
  
Test% Target%Wavelength%(nm)% Wavelength%(nm)% Devia3on%(nm)%
Neodymium)ﬁlter) 586.0) 584.4) −1.6)
Holmium)ﬁlter)
637.5) 637.8) 0.3)
536.6) 535.4) −1.2)
460.2) 459.3) −0.9)
453.7) 453.0) −0.7)
445.7) 444.8) −0.9)
360.9) 360.1) −0.8)
333.9) 333.1) −0.8)
287.6) 287.0) −0.6)
279.4) 278.9) −0.5)
Benzene)vapour)
259.0) 258.6) −0.4)
253.0) 252.5) −0.5)
247.2) 246.7) −0.5)
241.7) 241.2) −0.5)
Ammonia)vapour)
208.6) 207.6) −1.0)
204.8) 203.7) −1.1)
201.1) 200.0) −1.1)
197.5) 196.4) −1.1)
194.0) 193.0) −1.0)
190.6) 189.6) −1.0)
187.2) 186.4) −0.8)
Test% Wavelength%(nm)%
Target%Intensity%
(mdeg)%
Intensity%
(mdeg)%
ACS$solu)on$(1$cm$
cuve1e)$ 291$ 188.0$
192.5$
ACS$solu)on$(1$mm$
cuve1e)$
291$ 18.8$ 19.1$
193$ −39.1$ −39.3$
(R,R);Na[CoIII(EDDS)]$ 211.5$ −50.0$ −53.3$
(S,S);Na[CoIII(EDDS)]$ 211.5$ 50.0$ 54.1$
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Figure	   B5:	   DLS	   measurements	   showing	   the	   particle	   size	   distributions	   (intensity	   values)	   of	   the	   six	  
etanercept	  samples	  diluted	  to	  1	  mg/mL	  with	  PBS.	  The	  three	  biosimilars	  (samples	  1–3)	  are	  presented	  on	  
the	   left	   and	   the	   three	   innovator	   samples	   (4–6)	   are	   shown	   on	   the	   right.	   Samples	   were	   recorded	   in	  
triplicate	  with	  six	  measurements	  for	  each	  replicate.	  All	  18	  measurements	  are	  shown	  in	  grey,	  averages	  
of	  6	  measurements	  for	  each	  replicate	  are	  shown	  in	  red	  and	  total	  average	  in	  blue.	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Figure	   B6:	   Size	   distributions	   (presented	   in	   intensity	   values,	   nm)	   for	   the	   six	   etanercept	   samples	   at	   a	  
temperature	   range	   of	   25–75°C	   and	   after	   the	   samples	   were	   cooled	   down	   to	   20°C.	   The	   distribution	  
becomes	  wider	  and	  shifts	  to	   larger	  values	  at	  the	  end	  of	  the	  experiment	  (in	  red	  the	  distribution	  after	  
the	   samples	  were	   cooled	   down	   to	   20	   °C).	   The	   insets	   show	   the	   distributions	   in	   number	   values.	   The	  
three	  biosimilars	   (samples	  1–3)	  are	  presented	  on	   the	   left	  and	   the	   three	   innovator	  samples	   (4–6)	  are	  
shown	  on	  the	  right.	  The	  presented	  data	  were	  averaged	  over	  6	  measurements.	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Figure	  B7:	  Size	  distributions	  presented	  in	  intensity	  values	  (nm)	  for	  the	  six	  samples	  at	  25	  °C	  (left),	  and	  
after	  the	  samples	  were	  cooled	  down	  to	  20	  °C	  (right).	  The	  distributions	  become	  wider	  at	  the	  end	  of	  the	  
experiment	   and	   the	   size	   of	   the	   protein	   shifts	   to	   larger	   values.	   Both	   observations	   indicate	   the	  
appearance	  of	  larger	  particles.	  The	  presented	  data	  are	  averaged	  over	  6	  measurements.	  
 
Table	   B11:	  Overall	  mean	   particle	   sizes	   presented	   in	   terms	   of	   number	   values	   (nm)	   and	   the	   standard	  
deviations	   (over	   six	  measurements)	  with	   a	   95%	   confidence	   interval	   are	   shown	   for	   each	   sample	   at	   a	  
temperature	  range	  of	  25–75°C	  and	  after	  the	  samples	  were	  cooled	  down	  to	  20°C.	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Figure	  B8:	  Raw	  far-­‐UV	  CD	  data	  (mdeg)	  of	  the	  six	  etanercept	  samples	  and	  the	  reference	  buffer	  at	  the	  
received	  concentrations	   (~0.9	  mg/mL).	  The	  three	  biosimilars	   (samples	  1–3)	  are	  presented	  on	  the	   left	  
and	  the	  three	   innovator	  samples	  (4–6)	  are	  shown	  on	  the	  right.	  Samples	  and	  buffer	  were	  recorded	  in	  
triplicate	  (black	  and	  grey	  respectively).	  The	  averaged	  data	  for	  the	  buffer	  and	  the	  samples	  are	  shown	  in	  
blue	  and	  red	  respectively.	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Table	  B12:	  Minima	  (wavelength	  and	  Δε	  values)	  of	  the	  CD	  spectra	  for	  the	  6	  etanercept	  samples	  in	  their	  
original	  concentrations	  (~0.9	  mg/mL)	  using	  a	  0.01	  cm	  demountable	  cuvette.	  The	  averaged	  values	  over	  
three	  replicates	  are	  presented	  for	  each	  sample,	  as	  replicates	  appeared	  relatively	  noisy.	  
 
 
 
Figure	  B9:	  CD	  spectra	  of	  the	  diluted	  etanercept	  sample	  1	  at	  a	  temperature	  range	  of	  20–100	  °C,	  per	  5	  °C.	  
The	  spectra	  were	  recorded	  at	  a	  concentration	  of	  0.1	  mg/mL,	  using	  a	  0.1	  cm	  fixed	  path	  length	  cuvette.	  
The	  multiple	  crossing-­‐points	  of	  the	  spectra	  at	  around	  195	  nm	  indicate	  that	  etanercept	  has	  more	  than	  
one	  transition	  melting	  temperatures.	  The	  fully	  unfolded	  structure	  was	  observed	  at	  around	  80	  °C,	  while	  
the	  spectrum	  after	  the	  sample	  was	  cooled	  down	  to	  20	  °C	  (black	  line)	  presented	  a	  somewhat	  different	  
shape	  than	  the	  spectra	  at	  high	  temperatures	  (80–100	  °C),	  slightly	  shifted	  towards	  a	  lower	  wavelength.	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Figure	  B10:	  Melting	  curves	  recorded	  for	  the	  formulated	  etanercept	  samples	  that	  were	  diluted	  in	  two	  
steps:	  to	  a	  concentration	  of	  1	  mg/mL	  with	  PBS,	  and	  a	  concentration	  of	  0.1	  mg/mL	  with	  water.	  The	  0.1	  
cm	  fixed	  path	  length	  cuvette	  was	  used.	  Top:	  raw	  melting	  curves	  (mdeg)	  of	  the	  etanercept	  samples	  at	  
195.4	  nm	   (left)	  and	  at	  202.0	  nm	   (right).	  Bottom:	   the	   respective	  HT	   (V)	  values,	   recorded	  at	   the	   same	  
time	  as	  the	  melting	  curves,	  at	  195.4	  nm	  (left)	  and	  at	  202.0	  nm	  (right).	  The	  observed	  “dips”	  in	  the	  HT	  
values	  for	  samples	  2,	  3,	  4	  and	  6	  can	  result	  from	  aggregated	  particles	  that	  settle	  at	  the	  bottom	  of	  the	  
cuvette	  with	   time.	  However,	   the	   changes	  were	   very	   small,	   perhaps	   indicating	   that	   aggregation	   took	  
place	  only	  to	  a	  limited	  extent.	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Figure	  B11:	  Comparison	  of	  the	  CD	  spectra	  of	  the	  diluted	  etanercept	  samples	  at	  a	  concentration	  of	  0.1	  
mg/mL	  using	  a	  0.1	  cm	  fixed	  path	  length	  cuvette.	  Spectra	  were	  acquired	  before	  recording	  the	  melting	  
curves	  (25	  °C,	  left),	  and	  at	  the	  end	  of	  the	  temperature	  experiment	  after	  the	  samples	  were	  cooled	  down	  
to	  25	  °C	  (right).	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Figure	  B12:	  Comparison	  of	  the	  HT	  spectra	  of	  the	  diluted	  etanercept	  samples	  at	  a	  concentration	  of	  0.1	  
mg/mL	  using	  a	  0.1	   cm	   fixed	  path	   length	  cuvette,	   recorded	  at	   the	   same	   time	  as	   the	  CD	  spectra	   from	  
Figure	  B11.	  The	  HT	  spectra	  at	  25	  °C	  (before	  recording	  the	  melting	  curves,	  black)	  and	  at	  the	  end	  of	  the	  
temperature	  experiment	  after	  the	  samples	  were	  cooled	  down	  to	  25	  °C	  (red)	  are	  identical,	  suggesting	  
that	  no	  significant	  aggregation	  took	  place.	  The	  three	  biosimilar	  samples	  (1–3)	  are	  presented	  on	  the	  left	  
and	  the	  three	  innovator	  samples	  (4–6)	  are	  shown	  on	  the	  right.	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Figure	  B13:	  Raw	  near-­‐UV	  CD	  data	  (mdeg)	  of	  the	  six	  etanercept	  samples	  and	  the	  reference	  buffer	  in	  the	  
received	  concentrations	   (~0.9	  mg/mL).	  The	  three	  biosimilars	   (samples	  1–3)	  are	  presented	  on	  the	   left	  
and	  the	  three	   innovator	  samples	  (4–6)	  are	  shown	  on	  the	  right.	  Samples	  and	  buffer	  were	  recorded	  in	  
triplicate	  (black	  and	  grey	  respectively).	  The	  averaged	  data	  for	  the	  buffer	  and	  the	  samples	  are	  shown	  in	  
blue	  and	  red	  respectively.	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Table	   B13:	   Secondary	   structure	   estimates	   and	   NRMSD	   values	   from	   analysis	   of	   the	   CD	   spectra	   of	  
etanercept.	  The	  results	  from	  CDSSTR,	  SELCON3	  (using	  reference	  sets	  1–7)	  and	  SSNN	  (reference	  set	  7)	  
showed	   a	   large	   variation	   due	   to	   the	   unique	   spectrum	   of	   the	   protein.	   Results	   that	   presented	   ≤10%	  
deviation	   from	   the	   secondary	   structure	   that	   was	   calculated	   by	   combination	   of	   the	   PDB	   crystal	  
structures	  are	  highlighted	  in	  pale	  green.	  
 
Sample' Program' Ref.'set' Helix' Sheet' Turns' Other'
TNFR2:Fc'1'
CDSSTR& 1& (0.02& 0.26& 0.31& 0.46&SELCON3& (0.03& 0.14& 0.30& 0.59&
CDSSTR& 2& 0.05& 0.25& 0.24& 0.46&SELCON3& 0.07& 0.19& 0.16& 0.58&
CDSSTR& 3& 0.03& 0.37& 0.24& 0.37&SELCON3& 0.01& 0.26& 0.26& 0.47&
CDSSTR& 4& 0.03& 0.35& 0.27& 0.35&SELCON3& 0.02& 0.27& 0.25& 0.47&
CDSSTR& 5& 0.03& 0.25& 0.15& 0.58&SELCON3& 0.02& 0.17& 0.10& 0.71&
CDSSTR& 6& 0.00& 0.23& 0.14& 0.63&SELCON3& (0.02& 0.14& 0.26& 0.61&
CDSSTR&
7&
0.02& 0.18& 0.14& 0.66&
SELCON3& 0.00& 0.04& 0.07& 0.90&
SSNN& 0.04& 0.10& 0.07& 0.79&
TNFR2:Fc'2'
CDSSTR& 1& (0.02& 0.28& 0.28& 0.46&SELCON3& (0.03& 0.22& 0.31& 0.50&
CDSSTR& 2& 0.04& 0.24& 0.22& 0.50&SELCON3& 0.06& 0.30& 0.17& 0.47&
CDSSTR& 3& 0.02& 0.35& 0.24& 0.38&SELCON3& 0.01& 0.08& 0.27& 0.64&
CDSSTR& 4& 0.03& 0.34& 0.26& 0.37&SELCON3& 0.11& 0.33& 0.21& 0.35&
CDSSTR& 5& 0.02& 0.26& 0.15& 0.57&SELCON3& 0.01& 0.18& 0.09& 0.72&
CDSSTR& 6& 0.00& 0.22& 0.15& 0.63&SELCON3& (0.01& 0.11& 0.23& 0.68&
CDSSTR&
7&
0.02& 0.21& 0.14& 0.63&
SELCON3& 0.02& 0.21& 0.18& 0.59&
SSNN& 0.05& 0.11& 0.09& 0.76&
TNFR2:Fc'3'
CDSSTR& 1& (0.02& 0.24& 0.30& 0.48&SELCON3& (0.02& 0.16& 0.30& 0.56&
CDSSTR& 2& 0.05& 0.20& 0.26& 0.48&SELCON3& 0.01& 0.46& 0.29& 0.24&
CDSSTR& 3& 0.02& 0.33& 0.26& 0.39&SELCON3& 0.01& 0.05& 0.27& 0.67&
CDSSTR& 4& 0.03& 0.33& 0.26& 0.39&SELCON3& 0.10& 0.27& 0.22& 0.41&
CDSSTR& 5& 0.03& 0.24& 0.16& 0.58&SELCON3& 0.01& 0.18& 0.10& 0.72&
CDSSTR& 6& 0.00& 0.27& 0.15& 0.58&SELCON3& (0.01& 0.11& 0.24& 0.67&
CDSSTR&
7&
0.02& 0.21& 0.15& 0.62&
SELCON3& 0.03& 0.20& 0.17& 0.60&
SSNN& 0.05& 0.11& 0.08& 0.76&
NRMSD'
0.098&
0.214&
0.102&
0.514&
0.140&
0.453&
0.222&
0.467&
0.220&
0.608&
0.165&
0.347&
0.075&
0.683&
0.158&
0.118&
0.342&
0.091&
0.450&
0.171&
0.208&
0.179&
0.204&
0.235&
0.597&
0.119&
0.393&
0.109&
0.700&
0.160&
0.123&
0.274&
0.069&
0.079&
0.122&
0.159&
0.168&
0.448&
0.218&
0.591&
0.138&
0.353&
0.104&
0.642&
0.159&
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Sample' Program' Ref.'set' Helix' Sheet' Turns' Other'
TNFR2:Fc'4'
CDSSTR& 1& (0.03& 0.30& 0.33& 0.40&SELCON3& (0.02& 0.14& 0.30& 0.57&
CDSSTR& 2& 0.05& 0.22& 0.22& 0.51&SELCON3& 0.01& 0.45& 0.30& 0.25&
CDSSTR& 3& 0.02& 0.37& 0.24& 0.37&SELCON3& 0.00& 0.06& 0.28& 0.67&
CDSSTR& 4& 0.03& 0.35& 0.27& 0.36&SELCON3& 0.10& 0.24& 0.20& 0.46&
CDSSTR& 5& 0.02& 0.23& 0.15& 0.60&SELCON3& 0.01& 0.18& 0.10& 0.72&
CDSSTR& 6& 0.01& 0.25& 0.15& 0.59&SELCON3& (0.01& 0.11& 0.23& 0.67&
CDSSTR&
7&
0.02& 0.19& 0.13& 0.66&
SELCON3& 0.03& 0.20& 0.17& 0.60&
SSNN& 0.05& 0.11& 0.08& 0.76&
TNFR2:Fc'5'
CDSSTR& 1& (0.03& 0.25& 0.29& 0.49&SELCON3& (0.02& 0.13& 0.30& 0.59&
CDSSTR& 2& 0.04& 0.21& 0.23& 0.52&SELCON3& 0.02& 0.46& 0.29& 0.24&
CDSSTR& 3& 0.02& 0.36& 0.24& 0.38&SELCON3& 0.00& 0.10& 0.29& 0.61&
CDSSTR& 4& 0.02& 0.35& 0.26& 0.37&SELCON3& 0.10& 0.27& 0.22& 0.41&
CDSSTR& 5& 0.02& 0.26& 0.15& 0.57&SELCON3& 0.00& 0.19& 0.10& 0.72&
CDSSTR& 6& 0.00& 0.26& 0.18& 0.56&SELCON3& (0.01& 0.10& 0.23& 0.68&
CDSSTR&
7&
0.01& 0.20& 0.14& 0.64&
SELCON3& 0.02& 0.19& 0.16& 0.63&
SSNN& 0.05& 0.11& 0.08& 0.76&
TNFR2:Fc'6'
CDSSTR& 1& (0.02& 0.23& 0.29& 0.51&SELCON3& (0.03& 0.11& 0.29& 0.63&
CDSSTR& 2& 0.04& 0.22& 0.22& 0.53&SELCON3& 0.10& 0.22& 0.15& 0.53&
CDSSTR& 3& 0.02& 0.34& 0.25& 0.39&SELCON3& 0.04& 0.11& 0.27& 0.58&
CDSSTR& 4& 0.03& 0.33& 0.26& 0.38&SELCON3& 0.12& 0.28& 0.21& 0.39&
CDSSTR& 5& 0.02& 0.25& 0.15& 0.58&SELCON3& 0.01& 0.19& 0.10& 0.70&
CDSSTR& 6& 0.00& 0.25& 0.16& 0.59&SELCON3& (0.01& 0.08& 0.22& 0.71&
CDSSTR&
7&
0.01& 0.23& 0.15& 0.62&
SELCON3& 0.03& 0.15& 0.13& 0.69&
SSNN& 0.05& 0.11& 0.09& 0.75&
NRMSD'
0.131&
0.250&
0.064&
0.074&
0.164&
0.168&
0.158&
0.361&
0.222&
0.598&
0.123&
0.360&
0.097&
0.664&
0.158&
0.142&
0.216&
0.071&
0.087&
0.147&
0.211&
0.143&
0.488&
0.251&
0.593&
0.131&
0.344&
0.109&
0.670&
0.161&
0.109&
0.178&
0.072&
0.451&
0.185&
0.170&
0.165&
0.292&
0.232&
0.622&
0.127&
0.314&
0.118&
0.410&
0.155&
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Figure	  B14:	  FT-­‐IR	  data	   (absorbance	  units)	  of	   triplicate	  measurement	  of	   the	  etanercept	  samples	   (~0.9	  
mg/mL)	  following	  baseline	  subtraction	  and	  zeroing.	  The	  three	  biosimilars	  (samples	  1–3)	  are	  presented	  
on	  the	  left	  and	  the	  three	  innovator	  samples	  (4–6)	  are	  shown	  on	  the	  right.	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Figure	   B15:	   Raw	   fluorescence	   data	   (1st	   analysis)	   of	   the	  biosimilar	   etanercept	   samples	   (samples	   1–3)	  
and	  the	  reference	  buffer	  (ammonium	  bicarbonate)	  at	  the	  received	  concentrations	  (~0.9	  mg/mL).	  Data	  
for	   excitation	   wavelengths	   280	   nm	   (left)	   and	   295	   nm	   (right)	   are	   shown.	   Samples	   and	   buffer	   were	  
recorded	  in	  triplicate	  (black	  and	  grey	  respectively).	  The	  averaged	  data	  for	  the	  buffer	  and	  the	  samples	  
are	  shown	  in	  blue	  and	  red	  respectively.	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Figure	  B16:	  Raw	  fluorescence	  data	  (1st	  analysis)	  of	  the	  innovator	  etanercept	  samples	  (samples	  4–6)	  and	  
the	  reference	  buffer	  (ammonium	  bicarbonate)	  at	  the	  received	  concentrations	  (~0.9	  mg/mL).	  Data	  for	  
excitation	  wavelengths	  280	  nm	  (left)	  and	  295	  nm	  (right)	  are	  shown.	  Samples	  and	  buffer	  were	  recorded	  
in	  triplicate	  (black	  and	  grey	  respectively).	  The	  averaged	  data	  for	  the	  buffer	  and	  the	  samples	  are	  shown	  
in	  blue	  and	  red	  respectively.	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Figure	   B17:	   Averaged	   fluorescence	   emission	   spectra	   of	   the	   etanercept	   samples	   for	   excitation	  
wavelengths	  280	  nm	  (left)	  and	  295	  nm	  (right),	  after	  correcting	  for	  the	  concentration	  variation	  among	  
samples.	   The	  data	  are	   from	   the	  1st	   analysis	  of	   the	   samples	   in	  ammonium	  bicarbonate	  buffer,	   at	   the	  
received	  concentrations	  (~0.9	  mg/mL).	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Figure	  B18:	  Raw	   fluorescence	  data	   (2nd	   analysis)	   of	   the	  biosimilar	   etanercept	   samples	   (samples	  1–3)	  
diluted	  to	  a	  concentration	  of	  1	  mg/mL	  and	  the	  reference	  buffer	  (PBS).	  Data	  for	  excitation	  wavelengths	  
280	  nm	  (left)	  and	  295	  nm	  (right)	  are	  shown.	  Samples	  and	  buffer	  were	  recorded	  in	  triplicate	  (black	  and	  
grey	   respectively).	   The	   averaged	   data	   for	   the	   buffer	   and	   the	   samples	   are	   shown	   in	   blue	   and	   red	  
respectively.	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Figure	  B19:	  Raw	   fluorescence	  data	   (2nd	   analysis)	   of	   the	   innovator	   etanercept	   samples	   (samples	   4–6)	  
diluted	  to	  a	  concentration	  of	  1	  mg/mL	  and	  the	  reference	  buffer	  (PBS).	  Data	  for	  excitation	  wavelengths	  
280	  nm	  (left)	  and	  295	  nm	  (right)	  are	  shown.	  Samples	  and	  buffer	  were	  recorded	  in	  triplicate	  (black	  and	  
grey	   respectively).	   The	   averaged	   data	   for	   the	   buffer	   and	   the	   samples	   are	   shown	   in	   blue	   and	   red	  
respectively.	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Figure	  B20:	  Top:	  Particle	  distribution	  by	   intensity	  of	  100	  nm	   latex	   spheres	  measured	   in	  10	  mM	  NaCl	  
solution.	  Middle/Bottom:	  Particle	  distribution	  by	  intensity	  of	  100	  nm	  latex	  spheres	  measured	  in	  each	  
one	   of	   the	   four	   buffers,	   prepared	   according	   to	   dilution	   of	   the	   respective	   samples.	   Individual	  
measurements	  are	  shown	   in	  grey	  and	  average	  over	  5	  measurements	   is	   shown	   in	   red.	  The	  Z-­‐Average	  
values	  as	  calculated	  by	  the	  software	  are	  given,	  as	  an	  average	  over	  5	  measurements.	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Figure	  B21:	  Average	  particle	  distributions	  by	   intensity	  of	  100	  nm	  latex	  spheres	   in	  NaCl	   (black)	  and	   in	  
each	  one	  of	  the	  buffer	  1–4	  (purple,	  green,	  red	  and	  blue)	  solutions,	  prepared	  according	  to	  the	  dilution	  
of	  the	  respective	  samples.	  All	  data	  are	  averaged	  over	  5	  measurements.	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Figure	   B22:	   DLS	  measurements	   showing	   the	   particle	   size	   distributions	   (intensity	   values)	   of	   the	   four	  
mAb	   samples	   diluted	   to	   5	  mg/mL	  with	   the	   provided	   formulation	   buffer	   (omitting	   Tween	   80).	   All	   8	  
measurements	  are	  shown	  in	  grey,	  average	  over	  8	  measurements	  is	  shown	  in	  red.	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Figure	  B23:	  Recorded	  baselines	  before	  each	  one	  of	  the	  monoclonal	  antibody	  samples,	  after	  1000-­‐fold	  
dilution	  of	   the	  original	   formulation	  with	  water	  and	  100	  mM	  sodium	  phosphate	  buffer,	   resulting	   in	  a	  
final	   solution	  of	   10	  mM	  sodium	  phosphate	  buffer,	   50	  µM	  citric	   acid,	   110	  µM	  L-­‐arginine,	   240	  µM	  L-­‐
arginine	  HCl	  and	  0.00005%	  w/v	  Tween	  80.	  A	  0.1	  cm	  fixed	  path	  length	  cuvette	  was	  used.	  
 
 
Figure	   B24:	   Raw	  melting	   curves	   (mdeg)	   of	   the	  monoclonal	   antibody	   samples	   at	   200.0	   nm	   (left)	   and	  
217.0	   nm	   (right).	   The	   curves	  were	   recorded	   for	   the	   diluted	  with	   sodium	  phosphate	   buffer	   samples,	  
resulting	   to	   a	   final	   solution	   of	   ~0.1	  mg/mL	  protein	   in	   10	  mM	   sodium	  phosphate	   buffer.	   The	   0.1	   cm	  
fixed	  path	  length	  cuvette	  was	  used.	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Figure	   B25:	   Comparison	   of	   the	   1D	   1H-­‐NMR	   spectra	   of	   the	   four	   monoclonal	   antibodies	   in	   sodium	  
phosphate	  buffer	  at	  pH	  5.4	  (in	  colour)	  and	  pH	  7.0	  (in	  black).	  From	  top	  to	  bottom:	  mAb	  1	  is	  shown	  in	  
purple	   (pH	   5.4)	   and	   black	   (pH	   7.0),	  mAb	   2	   is	   shown	   in	   green	   (pH	   5.4)	   and	   black	   (pH	   7.0),	  mAb	   3	   is	  
shown	  in	  red	  (pH	  5.4)	  and	  black	  (pH	  7.0)	  and	  mAb	  4	  is	  shown	  in	  blue	  (pH	  5.4)	  and	  black	  (pH	  7.0).	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1. Document!history!
Document! Date!of!Issue! Reason!for!Issue!
SOP48.1! 30th!October!2002! First!Issue!
SOP48.2! 7th!January!2013! Inclusion!of!Na[Co(EDDS)]!calibration!
SOP48.3! 22nd!March!2016! Inclusion! of! Benzene! and! Ammonia!
solution!calibration!
!
2. Objective!
The! objective! of! this! Standard!Operating! Procedure! (SOP)! is! to! describe! the!
calibration!of!the!Jasco!instrument!and!the!measurement!and!analysis!of!near&
UV!and!far&UV!circular!dichroism!(CD)!spectra!of!proteins.!
!
3. Introduction!
This!SOP!details!the!procedure,!with!reference!to!existing!SOP’s,!for!analysing!
the! secondary! structure! of! the! protein! samples! using! circular! dichroism!
spectroscopy! and! Curtis! Johnson’s! fitting! program! CDsstr! as! downloaded,!
saved!to!disk!and!modified!in!our!laboratory!for!data!collected!from!260!nm!to!
190! nm! or! 195! nm.! The! program! (CDsstr)! for! the! SOP! has! been! saved! and!
archived!for!this!purpose!and!will!not!be!updated!with!any!new!versions!that!
are! released.! It! also! contains! instructions! for! running! near! UV! CD! spectra! if!
required.!
!
4. Safety!
A!full!risk!assessment!must!be!completed!prior!to!the!delivery!of!the!samples.!!
!
5. Responsibility!
Any!group!member!trained! in! the! implementation!of! this!SOP!may!carry!out!
the!!required!work.!
!
6. Associated!Documents!
None 
!
7. Equipment!
Jasco!V&660!UV/Vis!spectrometer!
Jasco!J&720!Spectropolarimeter!
Jasco!J&815!Spectropolarimeter!
Jasco!J&1500!Spectropolarimeter!
Mettler!Toledo!XP2U!balance!
Oxford!A1204!Analytical!balance!!
Sartorius!S4!balance!!
CDsstr!Original!Version!!
0.01!mm!rectangular!demountable!cuvette!(Starna!Ltd)!
0.1 mm!rectangular!demountable!cuvette!(Starna!Ltd)!
1!mm!rectangular!cuvette!(Starna!Ltd)!
1 cm rectangular cuvette (Starna Ltd) 
!
8. Materials!
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Potassium!Hydroxide!AnalaR!BDH!102104V!
Potassium!Chromate!Aldrich!21,661&5,!99%!ACS!reagent!!
Ammonium!d&camphor&10&sulphonate!Katayama!Chemical!Co!05&1251!
Na[Co(S,S&EDDS)]!and!Na[Co(R,R&EDDS)]!University!of!Warwick!
Ammonia!solution!35%!FSA,!Analytical!Reagent!A/3280/PB17!Batch!22044111!
Benzene!Aldrich!40,176&5,!99.8%!
Ethanol!‘absolute’!AnalaR!BDH!10107EP!
De&ionised!water!18.2!MΩ!Elga!MaximaMillipore!MilliQ!
Buffers!as!required!!
Protein samples as supplied 
 
9. Procedure!
1. On!receipt!store!the!samples!at!5!±!3oC!or!as!specified!by!the!supplier.!
!
2. To#assign#the#path#length#of#the#demountable#0.#01#mm#cuvette#proceed#
as#follows:#
2.1 Prepare! a! 0.2!M! potassium! chromate! solution! by! accurately!weighing!
0.971g! potassium! chromate! and! transferring! it! to! a! 25!mL! volumetric!
flask.! Add! approximately! 20! mL! water! and! 1! pellet! of! potassium!
hydroxide.!Make!up!to!volume.!Mix!well.#
2.2 Fill! the! demountable! cell! with! the! potassium! chromate! solution! and!
measure! the! UV/vis! absorption! spectrum! following! the! SOP! for! the!
spectrometer!used.!Note:!it!is!important!to!always!assemble!the!cell!the!
same!way.!Calculate!the!pathlength!of!the!cell!using!the!Beer!Lambert!
law! A=εcl! where! A! is! the! absorbance,! c! is! the! exact! concentration! of!
potassium! chromate! solution! in! moles! dm−3,! ε! is! the! extinction!
coefficient! (4830!mol−1!dm3!cm−1!at!372!nm),!and! l! is! the!pathlength! in!
cm.!
2.3 Repeat! step! 2.2! twice.! Calculate! the! average! value! and! record! this! as!
the!nominal!path!length!of!the!cuvette.!
#
3. To#assign#the#pathlength#of#the#demountable#0.1#mm#cuvette#proceed#as#
follows:#
3.1 Prepare!a!0.02!M!potassium!chromate!solution!by!accurately!weighing!
0.0971g!potassium!chromate!and!transferring! it! to!a!25!mL!volumetric!
flask.! Add! approximately! 20! mL! water! and! 1! pellet! of! potassium!
hydroxide.!Make!up!to!volume.!Mix!well.!Alternatively!accurately!dilute!
the!solution!made!in!step!2!by!a!factor!of!10.#
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3.2 Fill! the! demountable! cell! with! the! potassium! chromate! solution! and!
measure! the! UV/vis! absorption! spectrum! following! the! SOP! for! the!
spectrometer!used.!Note:!it!is!important!to!always!assemble!the!cell!the!
same!way.!Calculate!the!pathlength!of!the!cell!using!the!Beer!Lambert!
law! A=εcl! where! A! is! the! absorbance,! c! is! the! exact! concentration! of!
potassium! chromate! solution! in! moles! dm−3,! ε! is! the! extinction!
coefficient! (4830!mol−1!dm3!cm−1!at!372!nm),!and! l! is! the!pathlength! in!
cm.!
3.3 Repeat! step! 3.2! twice.! Calculate! the! average! value! and! record! this! as!
the!nominal!path!length!of!the!cuvette.!
!
4. To#calibrate# the#wavelength#accuracy#of# the#spectropolarimeter#proceed#
as#follows:!
4.1 Create!a!new!folder!for!the!current!date!within!the!instrument!
folder!01!Calibration!on!the!network!drive.!
4.2 After! the! instrument! has! been! on! for! more! than! 30! minutes!
measure! the! spectrum! of! the! neodymium! filter! with! the!
following! parameters:!
!
Channels:! ! CD/HT/Abs!
DIT:! ! ! 0.25!s!
Band!width:! ! 1.0!nm!
Wavelength!range:! 610!nm!to!560!nm!
Data!pitch:! ! 0.025!nm!
Scan!speed:! ! 20!nm/min!
Accumulations:! 1!
!
4.3 Save!the!file!as!“01!Neodymium!Filter.jws”.!Note!the!maximum!
HT! value! for! the!peak! and! the!wavelength! at!which! the!HT! is!
maximal,! which! should! be! 586! ±! 0.8! nm.! Select! Processing! >!
Common!Options!>!Channel!Conversion.!Select!Channel!2,!click!
Add!>!OK.!Select!Processing!>!Peak!Processing!>!Peak!Find.!Save!
the!file!as!“01!Neodymium!Filter!Peaks.jws”.!If!the!wavelength!
accuracy!is!not!within!specification,!ensure!the!shift!is!constant!
across!the!wavelength!range!by!checking!with!ACS!as!below.!If!
the!shift!is!constant!recalibrate!the!spectrum!accordingly.!If!it!is!
not!consult!Professor!Rodger!who!will!call!in!an!engineer.!
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4.4 Measure!the!spectrum!of!the!holmium!filter!with!the!following!
parameters:!
!
Channels:! ! CD/HT/Abs!
DIT:! ! ! 0.125!s!
Band!width:! ! 1.0!nm!
Wavelength!range:! 700!nm!to!230!nm!
Data!pitch:! ! 0.1!nm!
Scan!speed:! ! 200!nm/min!
Accumulations:! 1!
!
4.5 Save!the!file!as!“02!Holmium!Filter.jws”.!Note!the!maximum!HT!
value! for! the! peaks! and! compare! to! the!manufacturer! notes.!
The!wavelength!at!which!the!HT!is!maximal!should!be!within!±!
0.8! nm! of! the! reported! value.! Select! Processing! >! Common!
Options!>!Channel!Conversion.!Select!Channel!2,!click!Add!>!OK.!
Select!Processing!>!Peak!Processing!>!Peak!Find.!Save!the!file!as!
“01! Holmium! Filter! Peaks.jws”.! If! the! wavelength! accuracy! is!
not!within!specification,!ensure!the!shift!is!constant!across!the!
wavelength!range!by!checking!with!ACS!as!below.!If!the!shift!is!
constant! recalibrate! the! spectrum! accordingly.! If! it! is! not!
consult!Professor!Rodger!who!will!call!in!an!engineer.!
4.6 Place!100!uL!benzene!in!a!1!cm!cuvette.!Leave!open!in!the!fume!
hood! for! 10! mins,! seal! with! a! suitable! lid! and! measure! the!
benzene!vapour!spectrum!with!the!following!parameters:!
!
! ! ! Channels:! ! CD/HT/Abs!
DIT:! ! ! ! 0.125!s!
Band!width:! ! 0.2!nm!
Wavelength!range:! 265!nm!to!240!nm!
Data!pitch:! ! 0.05!nm!
Scan!speed:! ! 50!nm/min!
! ! ! Accumulations:! 1!
!
4.7 Save! the! file!as!“03!Benzene!Vapour.jws”.!Note! the!maximum!
HT!value! for! the!peaks.!The!HT!maxima!should!be!at!259!nm,!
253! nm,! 247.2! nm! and! 241.7! nm! within! 0.8! nm.! Select!
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Processing! >! Common! Options! >! Channel! Conversion.! Select!
Channel!2,!click!Add!>!OK.!Select!Processing!>!Peak!Processing!>!
Peak! Find.! Save! the! file! as! “03!Benzene!Vapour! Peaks.jws”.! If!
the!wavelength!accuracy!is!not!within!specification,!ensure!the!
shift!is!constant!across!the!wavelength!range!by!checking!with!
ACS!as!below.! If! the!shift! is! constant! recalibrate! the!spectrum!
accordingly.!If!it!is!not!consult!Professor!Rodger!who!will!call!in!
an!engineer.!
4.8 Place!10!uL!ammonia!solution!in!a!1!mm!cuvette.!Leave!open!in!
the!fume!hood!for!10!mins.!Seal!the!cuvetter!with!a!suitable!lid!
and!measure!the!ammonia!vapour!spectrum!with!the!following!
parameters:!
!
Channels:! ! CD/HT/Abs!
DIT:! ! ! 0.25!s!
Band!width:! ! 0.5!nm!
Wavelength!range:! 210!nm!to!180!nm!
Data!pitch:! ! 0.05!nm!
Scan!speed:! ! 100!nm/min!
Accumulations:! 1!
!
Save!the!file!as!“04!Ammonia!Vapour.jws”.!Note!the!maximum!
HT!value!for!the!peaks.!The!HT!maxima!should!be!at!208.6!nm,!
204.8!nm,!201.1!nm,!197.5!nm,!194.0!nm,!190.6!nm!and!187.2!
nm! within! 0.8! nm.! Select! Processing! >! Common! Options! >!
Channel! Conversion.! Select! Channel! 2,! click! Add! >! OK.! Select!
Processing!>!Peak!Processing!>!Peak!Find.!Save! the! file!as! “04!
Ammonia!Vapour!Peaks.jws”.!If!the!wavelength!accuracy!is!not!
within! specification,! ensure! the! shift! is! constant! across! the!
wavelength!range!by!checking!with!ACS!as!below.!If!the!shift!is!
constant! recalibrate! the! spectrum! accordingly.! If! it! is! not!
consult!Professor!Rodger!who!will!call!in!an!engineer.!
!
5. To#determine#the#scaling#factor#for#the#CD#intensity#proceed#as#follows:!
5.1 Measure!a!spectrum!of!0.06%!(w/v)!aqueous!ammonium!d&10&
camphor!sulfonate!(ACS)!in!a!1!cm!pathlength!cuvette.!Subtract!
a! water! baseline! run!with! the! same! cuvette! and! parameters.!
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The!ACS!sample!may!be!stored!in!a!sealed!glass!container!in!the!
refrigerator.!The!instrument!parameters!are!as!follows:!!
!
Channels:! ! CD/HT/Abs!
DIT:! ! ! 0.5!s!
Band!width:! ! 1!nm!
Wavelength!range:! 350!nm!to!250!nm!
Data!pitch:! ! 0.05!nm!
Scan!speed:! ! 50!nm/min!
Accumulations:! 1!
!
Save! the! file! as! “05! 0.06%! ACS! 1! cm! cuvette.jws”.! The!
wavelength!and! intensity!of! the!CD!peak! should!be!190.4!±! 1!
mdeg!at!291.0!nm.!If!the!intensity!is!not!within!stated!limits!use!
an! independently! made! ACS! standard! and! repeat! the!
calibration!test.!If!the!value!is!reproducible,!all!subsequent!data!
should!be!scaled!to!bring!the!intensity!to!the!correct!value.!
5.2 Test! the! performance! of! the! instrument! below! 200! nm! by!
placing!the!above!ACS!solution!in!a!1!mm!cuvette!and!collecting!
a!spectrum!from!350!nm!to!180!nm.!Save!the!data!as!“05!0.06%!
ACS!1!mm!cuvette.jws”.!The!ratio!of! the!maxima!of! the!291.0!
nm!peak!and!the!193!nm!should!be!1:2.1.!
5.3 Measure! a! spectrum! of! all! three! Na[Co(EDDS)]! standards!
(blank,!RR!and!SS)! in!the!supplied!Na[Co(EDDS)]!calibration!kit!
using!the!following!parameters:!!
!
Channels:! ! CD/HT/Abs!
DIT:! ! ! 1!s!
Band!width:! ! 1!nm!
Wavelength!range:! 350!nm!to!190!nm!
Data!pitch:! ! 0.5!nm!
Scan!speed:! ! 100!nm/min!
Accumulations:! 4!
!
Save! the! files!as!“06!NaCoEDDS!Blank/RR/SS.jws”!Subtract! the!
blank! from! the! RR! and! SS! samples.! The! wavelength! and!
intensity!of!the!main!peak!should!be!+50!±!1!mdeg!at!211.5!nm!
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for! the! SS! and! –50! ±! 1! mdeg! for! the! RR! sample.! Record! the!
values! in! the! instrument! log!as!well! as! in! the! laboratory!book!
for!this!assay.!
!
6. To#measure#the#sample#CD#far>UV#spectra#proceed#as#follows:!
6.1 Remove! the! samples! and! appropriate! buffers! from! the! cold!
store!and!allow!to!reach!room!temperature!prior!to!analysis.!!
6.2 Follow! SOP28:! Jasco# J>715# circular# dichroism#
spectropolarimeter#wavelength# scans!modified! to! run!with! 10!
L/min!N2!flow!and!to!account!for!revised!software.!
6.3 Determine! the! required!path! length! for! the!protein!backbone!
region!spectrum!(from!260!nm!to!190!nm)!on!the!basis!that!a!1!
mm!cuvette!probably!requires!a!0.1!mg/mL!protein!solution.!!
6.4 Clean!the!cuvette!at!each!stage!as!follows.!Rinse!it!well!at!least!
three! times! with! de&ionised! water! followed! by! ethanol! or!
acetone.!Dry!with!a!tissue,!wipe!with!a! lens!cloth!and!remove!
any!fibres!with!a!nitrogen!line!prior!to!filling!and!reassembly!for!
the! demountable! cuvettes.! Dry! with! nitrogen! for! the! non&
demountable! cuvettes.! If! the! cuvette! shows! traces! of! protein!
residue,!wash!well!with!detergent,!rinse!with!de&ionised!water.!
If! the! residue! still! remains,!place! cuvette! in! a! solution!of!6!M!
nitric! acid! or! Hellmanex.! Allow! the! quartz! to! stand! for! ten!
minutes! or! longer! if! necessary! before! removing! and! rinsing!
thoroughly!with!water.!!
6.5 Fill! the!clean!cuvette!of! the!appropriate!path! length!with!high!
purity! (18!MΩ)!water!and! run!a!water! spectrum!on! the! J&715!
following! the! instrument! SOP! and! using! the! following!
parameter! set:! 0.2! nm! (or! other! choice)! data! pitch,! 100!
nm/min,! 8! accumulations! (or! the! number! required! for!
satisfactory! signal! to! noise! levels),! 1! s! response,! 1.0! nm!band!
width.!Save!the!data!both!in!Jasco!file!format!and!as!a!text!file.!
This! spectrum! is! solely! to! check! that! the! cuvette! has! been!
properly!cleaned!and!does!not!have!any!protein!residues!stuck!
to!it!(as!shown!by!the!absence!of!a!protein!CD!spectrum).!!
6.6 If!the!cuvette!is!not!clean,!repeat!6.4!and!6.5!until!it!is.!
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6.7 Repeat!steps!6.4!and!6.5!but!filling!the!cuvette!with!the!buffer!
as!supplied.!This!spectrum!will!henceforth!be!referred!to!as!the!
baseline.!
6.8 Repeat!steps!6.3!and!6.4!but!filling!the!cuvette!with!the!protein!
reference!standard!or!test!sample(s).!
!
7. To#measure#the#sample#CD#near>UV#spectra#proceed#as#follows:!
7.1 Remove! the! samples! and! appropriate! buffers! from! the! cold!
store!and!allow!to!reach!room!temperature!prior!to!analysis.!!
7.2 Follow! SOP28:! Jasco# J>715# circular# dichroism#
spectropolarimeter#wavelength# scans!modified!as! required! for!
new!software!and!collect!data!from!320!nm!to!250!nm.!
7.3 Determine! the! required!path! length! for! the!protein! ‘aromatic’!
region!spectrum!(from!320!nm!to!250!nm)!on!the!basis!that!a!1!
cm!cuvette!probably!requires!a!1!mg/mL!protein!solution.!This!
value!varies! significantly! from!protein! to!protein!depending! in!
particular!on!the!percentage!of!tryptophans!present.!The!ideal!
sample!will!have!an!A280!nm!of!approximately!1.!!
7.4 Clean!the!cuvette!at!each!stage!as!follows.!Rinse!it!well!at!least!
three! times! with! de&ionised! water! followed! by! ethanol! or!
acetone.! Dry! with! nitrogen! gas! or! a! tissue,! wipe! with! a! lens!
cloth! and! remove! any! fibres.! If! the! cuvette! shows! traces! of!
protein! residue,! wash! well! with! detergent,! rinse! with! de&
ionised! water.! If! the! residue! still! remains,! place! cuvette! in! a!
solution! of! 6!M! nitric! acid! of! Hellmanex.! Allow! the! quartz! to!
stand! for! ten!minutes! or! longer! if! necessary! before! removing!
and!rinsing!thoroughly!with!water!and!drying!as!above.!
7.5 Fill! the!clean!cuvette!of! the!appropriate!path! length!with!high!
purity! (18!MΩ)!water!and! run!a!water! spectrum!on! the! J&715!
following! the! instrument! SOP! and! using! the! following!
parameter! set:! 0.5! nm! data! pitch,! 100! nm/min,! 8!
accumulations!(in!the!first!instance),!1!s!response,!1.0!nm!band!
width,!and!20!mdeg.!Save!the!data!both!in!Jasco!file!format!and!
as!a!text!file.!This!spectrum!is!solely!to!check!that!the!cuvette!
has! been! properly! cleaned! and! does! not! have! any! protein!
residues! stuck! to! it! (as! shown!by! the!absence!of!a!protein!CD!
spectrum).!!
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7.6 If!the!cuvette!is!not!clean,!repeat!7.4!and!7.5!until!it!is.!
7.7 Repeat!steps!7.4!and!7.5!but!filling!the!cuvette!with!the!buffer!
as!supplied.!This!spectrum!will!henceforth!be!referred!to!as!the!
baseline.!
7.8 Repeat!steps!7.3!and!7.4!but!filling!the!cuvette!with!the!protein!
reference!standard!or!test!sample(s).!
!
8. Preliminary#data#analysis!
8.1 Either!within!the!Jasco!software!or!a!spreadsheet!program!such!
as!Excel!or!a!graph!plotting!one!such!as!Kaleidagraph!subtract!
the!baseline#spectrum!from!each!sample!spectrum.!If!necessary!
zero! the! spectra! in! the! 250! −! 260! nm! region! for! the! far! UV!
spectra! and! in! the!310!nm! to!320!nm! region! for! the!near!UV!
spectra.!Plot! the! resulting! spectrum.! If! this! is!done!within! the!
Jasco!software!save!the!final!spectrum!as!a!text! file.!Filter!the!
data!so!that!it!is!in!1!nm!increments.!
8.2 If! the!molar! amino! acid! residue! concentration! is! known,! plot!
the! spectra! as! Δε! by! first! converting! the! CD! spectra! from!
millidegrees!to!absorbance!units!by!dividing!by!32980!and!then!
converting!from!absorbance!units!to!Δε!using!the!Beer!Lamber!
Law!(A!=!ε!c! l,!where!c! is!concentration!of!amino!acids! in!mol!
dm−3! for! the! far&UV! and!molar! protein! concentration! for! near!
UV,!and!l!is!path!length!in!cm).#
#
9. # CD#structure#fitting#data#analysis#for#far#UV#spectra!
9.1 For! each! sample! that! has! been! measured! for! which! CD!
structure! fitting! is! required,! take! the! text! file! for! the!baseline!
subtracted!and!zeroed!spectrum!and!edit!it!in!Excel!or!another!
piece! of! software! to! produce! the! data! in! the! following! form.!
One! title! line! containing! anything! followed! by! 71! lines!
(assuming!fitting!is!being!undertaken!from!260!nm!to!190!nm)!
of!numbers!corresponding!to!the!CD!spectrum!in!units!of!moles!
of! (amino!acids)−1!dm3!cm−1!with!only! two!decimal!places.!This!
will! require! taking! the! second! column! of! numbers! from! the!
original! text! file! dividing! each! entry! by! (l*32980)! (to! convert!
from! mdeg! to! absorbance! units! and! from! l! cm! to! 1! cm!
pathlength)! and! also! dividing! by! the! molar! concentration! of!
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amino!acid!residues! in!the!sample.!For!example,! if!the!protein!
sample!is!18!mg/mL,!then!the!molar!concentration!is!(18×(#!of!
residues! per! molecule))/! (MW! of! protein).! If! you! have! more!
than! one! data! set,! the! second! set! starts! on! the! line! directly!
below!the!first.!
9.2 Ensure! that! the! CDsstr! program! and! the! required! associated!
files!are! located! in!a!directory!on!the!C!drive!of! the!computer!
you! are! using.! The! files! include:! procd190.tst;! readme.cd;!
secstr.dta;!bascd.dta;!Cdsstr.exe.!procd190.tst!is!a!data!file!that!
can!be!used!to!test!the!program;!it!has!three!data!sets!in!it.!
9.3 To! run! the! program,! proceed! as! follows.! Delete,! rename,! or!
move!any! file!with!a! .out! filename!extension!remaining! in! the!
cdsstr!folder.!
9.4 Delete! any! previously! used! file! named! proCD.dta! unless! you!
wish!to!use!it!in!the!current!run.!
9.5 If! it! is! not! already! available,! prepare! an! input! file! called!
procd.dta! containing! the! CD! data! of! the! protein(s)! to! be!
analyzed.! Save! the! file! as! c:\cdsstr\proCD.dta! in! the! required!
format.!
9.6 Begin! the!analysis!by!opening!a!DOS!window!within!windows.!
Type! ‘c:’.!Then!type! ‘cd\cdsstr’!at! the!command!prompt.!Type!
‘CDsstr’!to!run!the!program!assuming!the!program!is!in!the!top!
directory.!!
9.7 Enter!values!for!the!program!variables!as!prompted.!NbasCD!=!
22;! Nwave! =! 71;! Npro! =! number! of! data! sets! in! procd.dta;!
ncomb!=!100;!icombf!=!100000.!
9.8 When!the!command!prompt!reappears,!view,!print!and!record!
in!the!laboratory!book!the!results!of!the!analysis!by!inspecting!
the!output!files!anal.out!and!reconCD.out.!
!
10. Sample#analysis#
The!samples!should!be!analyzed!in!the!following!order:!
Current!analytical!reference!standard!(if!available)!
Test!samples!
Current!Analytical!reference!standard!(if!available)!
!
11. Acceptance#Criteria#
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11.1 All! instrument! calibration! criteria! must! be! met! prior! to! assay! of!
first!samples.#
11.2 The! initial! and! final! spectra! if! collected! on! a! standard! sample!
should!be!comparable!with!each!other,!and!if!appropriate,!comparable!
with!previous!analyses!of!the!reference!standard.#
#
12. Report#preparation#
! ! Prepare! the! report! to! include! the! following:! assay! acceptance!
criteria,!data,!path! length!used! for! analysis,! sample,!buffer! and!
reference! IDs,! the! final! spectra! from! the! samples,! Δε! plots! if!
required,!a!numerical!table!of!the!CD!values!against!wavelength!
for!each!sample,!and!the!results!of! the!protein! fitting!program.!
Results! are! to! be! reported! relative! to! the! current! analytical!
reference!standard!where!possible.!The!results!must!be!checked!
and!countersigned!prior!to!release.!!
